Drug Interaction ID	Drug 1 Name	Drug 1 RxCUI	Drug 1 Class Name	Drug 1 Code	Drug 2 Name	Drug 2 RxCUI	Drug 2 Class Name	Drug 2 Code	Clinical Source	Source File	Description	Severity	Comment
0			BRADYCARIA INDUCING DRUGS	C0N0S0			OTHER BRADYCARIA INDUCING DRUGS	C0N0S0	ANSM	100-BRADYCARIA-INDUCING-DRUGS.html	Risk of excessive bradycardia (addition of the effects)	Take into account	
1			BRADYCARIA INDUCING DRUGS	C0N0S0	FINGOLIMOD	1012892			ANSM	100-BRADYCARIA-INDUCING-DRUGS.html	Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms	Not recommended	
2			BRADYCARIA INDUCING DRUGS	C0N0S0			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	100-BRADYCARIA-INDUCING-DRUGS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
3	BRENTUXIMAB	1147320			BLEOMYCIN	1622			ANSM	101-BRENTUXIMAB.html	Risk of increase of pulmonary toxicity	CONTRAINDICATION	
4	BRENTUXIMAB	1147320					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	101-BRENTUXIMAB.html	Increase of the concentrations of the active metabolite of the brentuximab, with risk of neutropenia	Take into account	
5	BUPRENORPHINE	1819			ATAZANAVIR	343047			ANSM	102-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
6	BUPRENORPHINE	1819					BENZODIAZEPINES AND RELATED	N05-001	ANSM	102-BUPRENORPHINE.html	With the buprenorphine used in opioid replacement therapy: increased risk of respiratory depression which could be fatal.	Take into account	
7	BUPRENORPHINE	1819			FOSAMPRENAVIR	358262			ANSM	102-BUPRENORPHINE.html	Risk of increase or of decrease of the effects of the A to take into account buprenorphine [sic], simultaneously by inhibition and acceleration of its metabolism by the protease inhibitor.	Take into account	
8	BUPRENORPHINE	1819					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	102-BUPRENORPHINE.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
9	BUPRENORPHINE	1819			ITRACONAZOLE	28031			ANSM	102-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	
10	BUPRENORPHINE	1819			KETOCONAZOLE	6135			ANSM	102-BUPRENORPHINE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	
11	BUPROPION	42347			CLOMIPRAMINE	2597			ANSM	103-BUPROPION.html	Risk of increase of the undesirable effects of the cloripramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
12	BUPROPION	42347			DESIPRAMINE	3247			ANSM	103-BUPROPION.html	Risk of increase of the undesirable effects of the desipramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
13	BUPROPION	42347			FLECAINIDE	4441			ANSM	103-BUPROPION.html	Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
14	BUPROPION	42347					MAOI-B	N04BD0-001	ANSM	103-BUPROPION.html	Risk of hypertensive crises	CONTRAINDICATION	
15	BUPROPION	42347			MEQUITAZINE	29528			ANSM	103-BUPROPION.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
16	BUPROPION	42347			METOPROLOL	6918			ANSM	103-BUPROPION.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
17	BUPROPION	42347			NORTRIPTYLINE	7531			ANSM	103-BUPROPION.html	Risk of increase of the undesirable effects of the nortriptyline due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
18	BUPROPION	42347			PROPAFENONE	8754			ANSM	103-BUPROPION.html	Risk of increase of the undesirable effects of the propafenone due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
19	BUPROPION	42347			TAMOXIFEN	10324			ANSM	103-BUPROPION.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine [sic]	Not recommended	
20	BUPROPION	42347			TRAMADOL	10689			ANSM	103-BUPROPION.html	Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications	Take into account	
21	BUPROPION	42347			VEMURAFENIB	1147220			ANSM	103-BUPROPION.html	Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity	Take into account	
22	BUSPIRONE	1827			DIAZEPAM	3322			ANSM	104-BUSPIRONE.html	Risk of increase of the undesirable effects of the buspirone	Take into account	
23	BUSPIRONE	1827			DILTIAZEM	3443			ANSM	104-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the diltiazem, with increase of its undesirable effects	Precaution for use	
24	BUSPIRONE	1827			ERYTHROMYCIN	4053			ANSM	104-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
25	BUSPIRONE	1827			ITRACONAZOLE	28031			ANSM	104-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
26	BUSPIRONE	1827			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	104-BUSPIRONE.html	Rick of increase of the undesirable effects of the buspirone due to decrease of its metabolism by the grapefruit	Take into account	
27	BUSPIRONE	1827			RIFAMPICIN	9384			ANSM	104-BUSPIRONE.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
28	BUSPIRONE	1827			VERAPAMIL	11170			ANSM	104-BUSPIRONE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects.	Precaution for use	
29	BUSULFAN	1828			DEFERASIROX	614373			ANSM	105-BUSULFAN.html	Risk of increase of the toxicity of the busulfan due to decrease of its clearance by the deferasirox	Take into account	
30	BUSULFAN	1828			ITRACONAZOLE	28031			ANSM	105-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the itraconazole	Not recommended	
31	BUSULFAN	1828			METRONIDAZOLE	6922			ANSM	105-BUSULFAN.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
32	CABAZITAXEL	996051					ENZYMATIC INDUCERS	N03-J05-001	ANSM	106-CABAZITAXEL.html	Decrease of the concentrations of the cytotoxic by increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
33	CABAZITAXEL	996051					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	106-CABAZITAXEL.html	Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzymatic inducer	Precaution for use	
34	CAFFEINE	1886			CIPROFLOXACIN	2551			ANSM	107-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
35	CAFFEINE	1886			DIPYRIDAMOLE	3521			ANSM	107-CAFFEINE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine	Precaution for use	
36	CAFFEINE	1886			ENOXACIN	3925			ANSM	107-CAFFEINE.html	Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism	Not recommended	
37	CAFFEINE	1886			LITHIUM	6448			ANSM	107-CAFFEINE.html	In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the plasma concentrations of lithium	Take into account	
38	CAFFEINE	1886			MEXILETINE	6926			ANSM	107-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine	Take into account	
39	CAFFEINE	1886			NORFLOXACINE	7517			ANSM	107-CAFFEINE.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
40	CAFFEINE	1886			STIRIPENTOL	37119			ANSM	107-CAFFEINE.html	Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	
41	CALCITONIN	36118			LITHIUM	6448			ANSM	108-CALCITONIN.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	
42	CALCIUM	1428011					BISPHOSPHONATES	M05B-001	ANSM	109-CALCIUM.html	For the calcium salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	
43	CALCIUM	1428011					TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	109-CALCIUM.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	
44	CALCIUM	1428011			DIGOXIN	3407			ANSM	109-CALCIUM.html	Risk of serious arrhythmias, even lethal ones, with the calcium salts administered by IV route.	Contraindication	
45	CALCIUM	1428011					THIAZIDE DIURETICS AND RELATED	C03-003	ANSM	109-CALCIUM.html	Risk of hypercalcemia due to decrease of the urinary elimination of the calcium.	Take into account	
46	CALCIUM	1428011			ESTRAMUSTINE	4089			ANSM	109-CALCIUM.html	Decrease of the digestive absorption of the estramustine	Precaution for use	
47	CALCIUM	1428011			IRON	1431589			ANSM	109-CALCIUM.html	With the iron salts by oral route: decrease of the digestive absorption of the iron salts	Precaution for use	
48	CALCIUM	1428011					THYROID HORMONES	H03AA	ANSM	109-CALCIUM.html	Decrease of the absorption of the thyroid hormones	Precaution for use	
49	CALCIUM	1428011			STRONTIUM	81638			ANSM	109-CALCIUM.html	With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium	Precaution for use	
50	CALCIUM	1428011			ZINC				ANSM	109-CALCIUM.html	Decrease of the digestive absorption of the zinc by the calcium	Precaution for use	
51	FUSIDIC ACID	4608					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	10-FUSIDIC-ACID.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type.	CONTRAINDICATION	
52	FUSIDIC ACID	4608					OMBITASVIR + PARITAPEVIR	OMPA	ANSM	10-FUSIDIC-ACID.html	Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir	CONTRAINDICATION	
53	CANAKINUMAB	853491					ANTI-TNF ALPHA	4ABO	ANSM	110-CANAKINUMAB.html	Risk of increase of serious infections	Not recommended	
54	CARBAMAZEPINE	2002			ACETAZOLAMIDE	167			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose.	Precaution for use	
55	CARBAMAZEPINE	2002			CIMETIDINE	2541			ANSM	111-CARBAMAZEPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	
56	CARBAMAZEPINE	2002			CLARITHROMYCIN	21212			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	
57	CARBAMAZEPINE	2002			CLONAZEPAM	2598			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of the clonazepam due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
58	CARBAMAZEPINE	2002			CLOZAPINE	2626			ANSM	111-CARBAMAZEPINE.html	Risk of increase of the serious hematological effects	Not recommended	
59	CARBAMAZEPINE	2002			DANAZOL	3102			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine, with signs of overdose	Precaution for use	
60	CARBAMAZEPINE	2002			DIGOXIN	3407			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine and decrease of the digoxinemia	Precaution for use	
61	CARBAMAZEPINE	2002					POTASSIUM LOWERING DIURETICS	C03	ANSM	111-CARBAMAZEPINE.html	Risk of symptomatic hyponatremia	Precaution for use	
62	CARBAMAZEPINE	2002			ERYTHROMYCIN	4053			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	
63	CARBAMAZEPINE	2002			ETHOSUXIMIDE	4135			ANSM	111-CARBAMAZEPINE.html	Decrease of the plasma concentrations of ethosuximide	Precaution for use	
64	CARBAMAZEPINE	2002			FELBAMATE	24812			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of felbamate due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
65	CARBAMAZEPINE	2002			FLUCONAZOLE	4450			ANSM	111-CARBAMAZEPINE.html	For doses of fluconazole >=200 mg per day: possible increase of the undesirable effects of the carbamazepine	Precaution for use	
66	CARBAMAZEPINE	2002			FLUOXETINE	4493			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	
67	CARBAMAZEPINE	2002			FLUVOXAMINE	42355			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	
68	CARBAMAZEPINE	2002			ISONIAZID	6038			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
69	CARBAMAZEPINE	2002			JOSAMYCIN	6084			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to decrease of its hepatic metabolism	Precaution for use	
70	CARBAMAZEPINE	2002			LAMOTRIGINE	28439			ANSM	111-CARBAMAZEPINE.html	Risk of increase of the neurological effects (vertigo, ataxia, diplopia) of the carbamazepine when the lamotrigine is introduced	Precaution for use	
71	CARBAMAZEPINE	2002			LITHIUM	6448			ANSM	111-CARBAMAZEPINE.html	Risk of neurotoxicity manifesting as disorders of the cerebellum, confusion, drowsiness, ataxia. These disorders are reversible when the treatment with the lithium is stopped.	Not recommended	
72	CARBAMAZEPINE	2002			ST JOHN'S WORT	258326			ANSM	111-CARBAMAZEPINE.html	Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine	Not recommended	
73	CARBAMAZEPINE	2002			NINTEDANIB	1592737			ANSM	111-CARBAMAZEPINE.html	Decrease of the plasma concentrations of nintedanib due to decrease of its absorption by the carbamazepine	Precaution for use	
74	CARBAMAZEPINE	2002			OLANZAPINE	61381			ANSM	111-CARBAMAZEPINE.html	Risk of decrease of the plasma concentrations of the olanzapine and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
75	CARBAMAZEPINE	2002			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine, with risk of overdose, due to inhibition of its metabolism by the grapefruit	Not recommended	
76	CARBAMAZEPINE	2002			PAROXETINE	32937			ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	
77	CARBAMAZEPINE	2002					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	111-CARBAMAZEPINE.html	Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness	Take into account	
78	CARBAMAZEPINE	2002					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	111-CARBAMAZEPINE.html	Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)	Take into account	
79	CARBAMAZEPINE	2002			RIFAMPICIN	9384			ANSM	111-CARBAMAZEPINE.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
80	CARBAMAZEPINE	2002			RISPERIDONE	35636			ANSM	111-CARBAMAZEPINE.html	Risk of decrease of the active fraction of the risperidone and of its therapeutic effectiveness due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
81	CARBAMAZEPINE	2002			SIMVASTATIN	36567			ANSM	111-CARBAMAZEPINE.html	Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism	Not recommended	
82	CARBAMAZEPINE	2002			TOPIRAMATE	38404			ANSM	111-CARBAMAZEPINE.html	Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
83	CARBAMAZEPINE	2002					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	111-CARBAMAZEPINE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
84	CARMUSTINE	2105			CIMETIDINE	2541			ANSM	112-CARMUSTINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine)	Not recommended	
85	CARVEDILOL	20352			CIMETIDINE	2541			ANSM	113-CARVEDILOL.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine	CONTRAINDICATION	
86	CARVEDILOL	20352			RIFAMPICIN	9384			ANSM	113-CARVEDILOL.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
87	CALCIUM POLYSTYRENE SULFONATE	47630			SORBITOL	9945			ANSM	114-CALCIUM-POLYSTYRENE-SULFONATE.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal	CONTRAINDICATION	
88	SODIUM POLYSTYRENE SULFONATE	56512			SORBITOL	9945			ANSM	115-SODIUM-POLYSTYRENE-SULFONATE.html	With the resin administered by oral and rectal routes: risk of colonic necrosis, possibly fatal	Not recommended	
89	CEFALOTIN	2236					AMINOGLYCOSIDES	J01GB-001	ANSM	116-CEFALOTIN.html	Increase of the nephrotoxicity of the aminoglycosides by the cefalotin is under discussion	Precaution for use	
90	CEFAMANDOLE	2178					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	117-CEFAMANDOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
91	CEFOPERAZONE	2184					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	118-CEFOPERAZONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
92	CEFOTETAN	2187					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	119-CEFOTETAN.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
93	NICOTINIC ACID	446722			ALCOHOL (DRINK OR INGREDIENT)				ANSM	11-NICOTINIC-ACID.html	Risk of rash, redness, and heat linked to an increase of the vasodilator effect	Take into account	
94	CEFTRIAXONE	2193					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	120-CEFTRIAXONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
95	CHLORDIAZEPOXIDE	2356			CIMETIDINE	2541			ANSM	121-CHLORDIAZEPOXIDE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	
96	CHLOROQUINE	2393			CICLOSPORIN	3008			ANSM	122-CHLOROQUINE.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	
97	CHLOROQUINE	2393			CIMETIDINE	2541			ANSM	122-CHLOROQUINE.html	Slowing of the elimination of the chloroquine and risk of overdose	Take into account	
98	CHLOROQUINE	2393					THYROID HORMONES	H03AA	ANSM	122-CHLOROQUINE.html	Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy	Precaution for use	
99	CHLORPROMAZINE	2403			INSULIN				ANSM	123-CHLORPROMAZINE.html	With strong doses (100 mg per day of chlorpromazine): elevation of glycemia (decrease of the freeing of insulin)	Precaution for use	
100	CHLORPROMAZINE	2403					BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	123-CHLORPROMAZINE.html	With strong doses (100 mg per day of chlorpromazine): elevation of glycemia (decrease of the freeing of insulin)	Precaution for use	
101	CICLOSPORIN	3008			URSODEOXYCHOLIC ACID				ANSM	124-CICLOSPORIN.html	Risk of variation of the blood concentrations of ciclosporin	Take into account	
102	CICLOSPORIN	3008			AFATINIB	1430438			ANSM	124-CICLOSPORIN.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the ciclosporin	Precaution for use	
103	CICLOSPORIN	3008			ALISKIREN	325646			ANSM	124-CICLOSPORIN.html	Increase by nearly 5 times of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	CONTRAINDICATION	
104	CICLOSPORIN	3008			AMBRISENTAN	358274			ANSM	124-CICLOSPORIN.html	Doubling of the concentrations of ambrisentan, with increase of the vasodilator effect (severe headaches )	Take into account	
105	CICLOSPORIN	3008					AMINOGLYCOSIDES	J01GB-001	ANSM	124-CICLOSPORIN.html	Larger increase of the creatinemia than with ciclosporin alone, with increase of the nephrotoxic risk	Take into account	
106	CICLOSPORIN	3008			AMIODARONE	703			ANSM	124-CICLOSPORIN.html	Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects	Not recommended	
107	CICLOSPORIN	3008			AMPHOTERICIN B	732			ANSM	124-CICLOSPORIN.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
108	CICLOSPORIN	3008					SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	124-CICLOSPORIN.html	With the ciclosporin administered orally:reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).	Precaution for use	
109	CICLOSPORIN	3008					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	124-CICLOSPORIN.html	Risk of addition of the nephrotoxic effects, especially with older patients.	Precaution for use	
110	CICLOSPORIN	3008			ATORVASTATIN	83367			ANSM	124-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the intestinal absorption of the cholesterol lowering medication)	Precaution for use	
111	CICLOSPORIN	3008			AZITHROMYCIN	18631			ANSM	124-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	
112	CICLOSPORIN	3008			BOSENTAN	75207			ANSM	124-CICLOSPORIN.html	Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan	CONTRAINDICATION	
113	CICLOSPORIN	3008			CHLOROQUINE	2393			ANSM	124-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	
114	CICLOSPORIN	3008			CIMETIDINE	2541			ANSM	124-CICLOSPORIN.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
115	CICLOSPORIN	3008			CLINDAMYCIN	2582			ANSM	124-CICLOSPORIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	
116	CICLOSPORIN	3008			COLCHICINE	2683			ANSM	124-CICLOSPORIN.html	Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, especially in cases of pre-existing renal insufficiency	Not recommended	
117	CICLOSPORIN	3008			DABIGATRAN				ANSM	124-CICLOSPORIN.html	Increase by more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
118	CICLOSPORIN	3008			DANAZOL	3102			ANSM	124-CICLOSPORIN.html	Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism	Precaution for use	
119	CICLOSPORIN	3008					POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	124-CICLOSPORIN.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
120	CICLOSPORIN	3008					POTASSIUM LOWERING DIURETICS	C03	ANSM	124-CICLOSPORIN.html	Risk of increase of the creatinemia without modification of the blood concentrations of ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout	Tale into account	
121	CICLOSPORIN	3008			ERIBULINE	1045453			ANSM	124-CICLOSPORIN.html	Increase of the plasma concentrations of eribuline by the ciclosporin	Not recommended	
122	CICLOSPORIN	3008			EVEROLIMUS	141704			ANSM	124-CICLOSPORIN.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together	Precaution for use	
123	CICLOSPORIN	3008			EZETIMIBE	341248			ANSM	124-CICLOSPORIN.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
124	CICLOSPORIN	3008			FENOFIBRATE	8703			ANSM	124-CICLOSPORIN.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	
125	CICLOSPORIN	3008			FIDAXOMICIN	1111103			ANSM	124-CICLOSPORIN.html	Increase of the plasma concentrations of the fidaxomicin.	Not recommended	
126	CICLOSPORIN	3008			JOSAMYCIN	6084			ANSM	124-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	
127	CICLOSPORIN	3008			LERCANIDIPINE	135056			ANSM	124-CICLOSPORIN.html	Moderate increase of the blood concentrations of the immunosuppressant and larger increase of the concentrations of the lercanidipine	Precaution for use	
128	CICLOSPORIN	3008			METHOTREXATE	6851			ANSM	124-CICLOSPORIN.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	
129	CICLOSPORIN	3008			METHYLPREDNISOLONE	6902			ANSM	124-CICLOSPORIN.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia. Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
130	CICLOSPORIN	3008			MIDECAMYCIN	30005			ANSM	124-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	
131	CICLOSPORIN	3008			MODAFINIL	30125			ANSM	124-CICLOSPORIN.html	Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant	Not recommended	
132	CICLOSPORIN	3008			NIFEDIPINE	7417			ANSM	124-CICLOSPORIN.html	Risk of addition of undesirable effects of the gum disorders type.	Not recommended	
133	CICLOSPORIN	3008			NINTEDANIB	1592737			ANSM	124-CICLOSPORIN.html	Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the ciclosporin	Precaution for use	
134	CICLOSPORIN	3008			ORLISTAT	37925			ANSM	124-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity	Not recommended	
135	CICLOSPORIN	3008			PITAVASTATIN	861634			ANSM	124-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin	CONTRAINDICATION	
136	CICLOSPORIN	3008			POTASSIUM	8588			ANSM	124-CICLOSPORIN.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
137	CICLOSPORIN	3008			PREDNISOLONE	8638			ANSM	124-CICLOSPORIN.html	Increase of the effects of the prednisolone: characteristic Cushings appearance, reduction of tolerance of carbohydrates (decrease of clearance of the prednisolone)	Take into account	
138	CICLOSPORIN	3008			REPAGLINIDE	73044			ANSM	124-CICLOSPORIN.html	Increase of more than double of the concentrations of the repaglinide due to increase of its absorption	Not recommended	
139	CICLOSPORIN	3008			ROSUVASTATIN	301542			ANSM	124-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin	CONTRAINDICATION	
140	CICLOSPORIN	3008			ROXITHROMYCIN	9478			ANSM	124-CICLOSPORIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	
141	CICLOSPORIN	3008			SIMVASTATIN	36567			ANSM	124-CICLOSPORIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolosis type due to decrease of the metabolism of the simvastatin	CONTRAINDICATION	
142	CICLOSPORIN	3008			SIROLIMUS	35302			ANSM	124-CICLOSPORIN.html	Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together	Precaution for use	
143	CICLOSPORIN	3008			SULFINPYRAZONE	10205			ANSM	124-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone	Precaution for use	
144	CICLOSPORIN	3008			TENEFOVIR ALAFENAMIDE	1721603			ANSM	124-CICLOSPORIN.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	
145	CICLOSPORIN	3008			TERBINAFINE	37801			ANSM	124-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	
146	CICLOSPORIN	3008			TICLOPIDINE	10594			ANSM	124-CICLOSPORIN.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	
147	CICLOSPORIN	3008			TRIMETHOPRIM	10829			ANSM	124-CICLOSPORIN.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith the trimethoprim (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large, with possible loss of immunosuppressant capacity	Take into account	
148	CICLOSPORIN	3008			VERAPAMIL	11170			ANSM	124-CICLOSPORIN.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders	Precaution for use	
149	CIMETIDINE	2541			ALFENTANIL	480			ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	
150	CIMETIDINE	2541					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	
151	CIMETIDINE	2541			CARBAMAZEPINE	2002			ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: at the beginning of treatment, increase of the plasma concentrations of carbamazepine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	
152	CIMETIDINE	2541			CARMUSTINE	2105			ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the carmustine)	Not recommended	
153	CIMETIDINE	2541			CARVEDILOL	20352			ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the carvedilol, which can be dangerous in the case of treatment for heart failure due to decrease of its hepatic metabolism by the cimetidine	CONTRAINDICATION	
154	CIMETIDINE	2541			CHLORDIAZEPOXIDE	2356			ANSM	125-CIMETIDINE.html	With the cemitidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	
155	CIMETIDINE	2541			CHLOROQUINE	2393			ANSM	125-CIMETIDINE.html	Slowing of the elimination of the chloroquine and risk of overdose	Take into account	
156	CIMETIDINE	2541			CICLOSPORIN	3008			ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the blood concentrations of ciclosporin	Take into account	
157	CIMETIDINE	2541			DIAZEPAM	3322			ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased risk of drowsiness	Precaution for use	
158	CIMETIDINE	2541			LIDOCAINE	6387			ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	
159	CIMETIDINE	2541			LOMUSTINE	6466			ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)	Not recommended	
160	CIMETIDINE	2541			METHADONE	6813			ANSM	125-CIMETIDINE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	
161	CIMETIDINE	2541			METOPROLOL	6918			ANSM	125-CIMETIDINE.html	With the metoprolol used for heart failure, and the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Precaution for use	
162	CIMETIDINE	2541			MOCLOBEMIDE	30121			ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism	Precaution for use	
163	CIMETIDINE	2541			NIFEDIPINE	7417			ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	
164	CIMETIDINE	2541					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with possibility of appearance of the usual signs of overdose	Not recommended	
165	CIMETIDINE	2541					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	125-CIMETIDINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	
166	CINACALCET	407990			DEXTROMETHORPHAN	3289			ANSM	126-CINACALCET.html	Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	CONTRAINDICATION	
167	CINACALCET	407990			FLECAINIDE	4441			ANSM	126-CINACALCET.html	Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	
168	CINACALCET	407990			MEQUITAZINE	29528			ANSM	126-CINACALCET.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
169	CINACALCET	407990			METOPROLOL	6918			ANSM	126-CINACALCET.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	
170	CINACALCET	407990			PROPAFENONE	8754			ANSM	126-CINACALCET.html	Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	
171	CINACALCET	407990			VORTIOXETINE	1455099			ANSM	126-CINACALCET.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	
172	CIPROFLOXACIN	2551			AGOMELATINE	306718			ANSM	127-CIPROFLOXACIN.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects.	Not recommended	
173	CIPROFLOXACIN	2551			CAFFEINE	1886			ANSM	127-CIPROFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of its hepatic metabolism	Take into account	
174	CIPROFLOXACIN	2551			CLOZAPINE	2626			ANSM	127-CIPROFLOXACIN.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	
175	CIPROFLOXACIN	2551			METHOTREXATE	6851			ANSM	127-CIPROFLOXACIN.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
176	CIPROFLOXACIN	2551					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	127-CIPROFLOXACIN.html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with ciprofloxacin	Precaution for use	
177	CIPROFLOXACIN	2551			ROPINIROLE	72302			ANSM	127-CIPROFLOXACIN.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	
178	CIPROFLOXACIN	2551					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	127-CIPROFLOXACIN.html	Increased risk of ventricular arrythmias, especially of torsades de pointes.	Precaution for use	
179	CIPROFLOXACIN	2551					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	127-CIPROFLOXACIN.html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	
180			CITRATES	V09HX			ALUMINUM (SALTS)	A02AD0-001	ANSM	128-CITRATES.html	Risk of facilitation of systemic uptake of the aluminum, especially in case of altered renal function.	Precaution for use	
181	CLADRIBINE	44157			LAMIVUDINE	68244			ANSM	129-CLADRIBINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
182	URSODEOXYCHOLIC ACID				CICLOSPORIN	3008			ANSM	12-URSODEOXYCHOLIC-ACID.html	Risk of variation of blood concentrations of ciclosporin	Take into account	
183	CLARITHROMYCIN	21212			ATAZANAVIR	343047			ANSM	130-CLARITHROMYCIN.html	Increase of the plasma concentrations of clarithyromycin and inhibition of the formation of its active metabolite	Precaution for use	
184	CLARITHROMYCIN	21212			ATORVASTATIN	83367			ANSM	130-CLARITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	
185	CLARITHROMYCIN	21212			CARBAMAZEPINE	2002			ANSM	130-CLARITHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Precaution for use	
186	CLARITHROMYCIN	21212			DEXAMETHASONE	3264			ANSM	130-CLARITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of CushingÂ’s syndrome	Take into account	
187	CLARITHROMYCIN	21212			DIGOXIN	3407			ANSM	130-CLARITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	
188	CLARITHROMYCIN	21212			EBASTINE	23796			ANSM	130-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed subjects (congenital long QT syndrome)	Not recommended	
189	CLARITHROMYCIN	21212			ERIBULINE	1045453			ANSM	130-CLARITHROMYCIN.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
190	CLARITHROMYCIN	21212			ETRAVIRINE	475969			ANSM	130-CLARITHROMYCIN.html	In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine	Take into account	
191	CLARITHROMYCIN	21212			FIDAXOMICIN	1111103			ANSM	130-CLARITHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
192	CLARITHROMYCIN	21212			GLIBENCLAMIDE	4815			ANSM	130-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	
193	CLARITHROMYCIN	21212			GLIMEPIRIDE	25789			ANSM	130-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic.	Precaution for use	
194	CLARITHROMYCIN	21212					IMMUNOSUPPRESSANTS	L04A	ANSM	130-CLARITHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
195	CLARITHROMYCIN	21212					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	130-CLARITHROMYCIN.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	
196	CLARITHROMYCIN	21212			LINEZOLIDE	190376			ANSM	130-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the linezolide by the clarithromycin due to increase of its absorption	Take into account	
197	CLARITHROMYCIN	21212			LUMEFANTRINE	847728			ANSM	130-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
198	CLARITHROMYCIN	21212			MIZOLASTINE	61455			ANSM	130-CLARITHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
199	CLARITHROMYCIN	21212			PRAVASTATIN	42463			ANSM	130-CLARITHROMYCIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	
200	CLARITHROMYCIN	21212			REPAGLINIDE	73044			ANSM	130-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	
201	CLARITHROMYCIN	21212			RIFABUTIN	55672			ANSM	130-CLARITHROMYCIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	
202	CLARITHROMYCIN	21212			RIFAMPICIN	9384			ANSM	130-CLARITHROMYCIN.html	Decrease of the plasma concentrations and risk of lower effectiveness of the clarithromycin, especially with the HIV patient, due to increase of its hepatic metabolism by the rifampacin	Precaution for use	
203	CLARITHROMYCIN	21212			SIMVASTATIN	36567			ANSM	130-CLARITHROMYCIN.html	Increased risk of undesirable effects (contentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	CONTRAINDICATION	
204	CLARITHROMYCIN	21212					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	130-CLARITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de points	Precaution for use	
205	CLARITHROMYCIN	21212					BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	130-CLARITHROMYCIN.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetic	Precaution for use	
206	CLARITHROMYCIN	21212					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	130-CLARITHROMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
207	CLARITHROMYCIN	21212			VENLAFAXINE	39786			ANSM	130-CLARITHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
208	CLARITHROMYCIN	21212					VINCA ALKALOIDS	L01CA	ANSM	130-CLARITHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin.	Precaution for use	
209	CLINDAMYCIN	2582					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	131-CLINDAMYCIN.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage.	Precaution for use	
210	CLINDAMYCIN	2582			CICLOSPORIN	3008			ANSM	131-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	
211	CLINDAMYCIN	2582			TACROLIMUS	42316			ANSM	131-CLINDAMYCIN.html	Decrease of the blood concentrations of the immunosuppressant with risk of loss of immunosuppressive activity	Precaution for use	
212	CLOBAZAM	21241			STIRIPENTOL	37119			ANSM	132-CLOBAZAM.html	Increase of the plasma concentrations of these anticonvulsants, with risk of overdose, due to inhibition of their hepatic metabolism	Precaution for use	
213	CLOMIPRAMINE	2597			BUPROPION	42347			ANSM	133-CLOMIPRAMINE.html	Risk of increase of the undesirable effects of the clomipramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
214	CLONAZEPAM	2598			CARBAMAZEPINE	2002			ANSM	134-CLONAZEPAM.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of the clonazepam due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
215	CLONIDINE	2599					TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	135-CLONIDINE.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
216	CLONIDINE	2599			DILTIAZEM	3443			ANSM	135-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
217	CLONIDINE	2599			VERAPAMIL	11170			ANSM	135-CLONIDINE.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
218	CLONIDINE	2599			YOHIMBINE	220982			ANSM	135-CLONIDINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
219	CLOPIDOGREL	32968			ACETYLSALICYLIC ACID	1191			ANSM	136-CLOPIDOGREL.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	
220	CLOPIDOGREL	32968			PACLITAXEL	56946			ANSM	136-CLOPIDOGREL.html	Increase of the concentrations of the paclitaxel by the clopidogrel, with risk of increase of the undesirable effects.	Take into account	
221	CLOPIDOGREL	32968					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	136-CLOPIDOGREL.html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)	Precaution for use	
222	CLOPIDOGREL	32968			REPAGLINIDE	73044			ANSM	136-CLOPIDOGREL.html	Increase of the concentrations of the repaglinide by the clopidogrel, with risk of increase of the undesirable effects.	Take into account	
223	CLOZAPINE	2626					BENZODIAZEPINES AND RELATED	N05-001	ANSM	137-CLOZAPINE.html	Accrued risk of drop in blood pressure with respiratory and/or cardiac arrest.	Take into account	
224	CLOZAPINE	2626			CARBAMAZEPINE	2002			ANSM	137-CLOZAPINE.html	Risk of increase of the serious hematological effects	Not recommended	
225	CLOZAPINE	2626			CIPROFLOXACIN	2551			ANSM	137-CLOZAPINE.html	Increase of the concentrations of clozapine with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	
226	CLOZAPINE	2626			FLUVOXAMINE	42355			ANSM	137-CLOZAPINE.html	Increase of the plasma concentrations of clozapine with signs of overdose	Precaution for use	
227	CLOZAPINE	2626					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	137-CLOZAPINE.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	
228	CLOZAPINE	2626			RIFAMPICIN	9384			ANSM	137-CLOZAPINE.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	
229	COBICISTAT	1306284			AMIODARONE	703			ANSM	138-COBICISTAT.html	Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat	CONTRAINDICATION	
230	COBICISTAT	1306284					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	138-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to the increase of its metabolism by the inducer	CONTRAINDICATION	
231	COBICISTAT	1306284					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	138-COBICISTAT.html	Risk of increase of the plasma concentratons of the cobicistat or of the inhibitor of CYP3A4	Take into account	
232	COBICISTAT	1306284			ITRACONAZOLE	28031			ANSM	138-COBICISTAT.html	Risk of increase of the concentrations of itraconazole by the cobicistat	Precaution for use	
233	COBICISTAT	1306284			ST JOHNS WORT	258326			ANSM	138-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	CONTRAINDICATION	
234	COBICISTAT	1306284			QUINIDINE	9068			ANSM	138-COBICISTAT.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	CONTRAINDICATION	
235	COBICISTAT	1306284			RIFABUTIN	55672			ANSM	138-COBICISTAT.html	Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat	Precaution for use	
236	COBICISTAT	1306284			RIFAMPICIN	9384			ANSM	138-COBICISTAT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	CONTRAINDICATION	
237	COBICISTAT	1306284			TENEFOVIR ALAFENAMIDE	1721603			ANSM	138-COBICISTAT.html	With the atazanavir, the darunavir or the lopinavir boosted by cobicistat, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption.	Precaution for use	
238	COBICISTAT	1306284					VINCA ALKALOIDS	L01CA	ANSM	138-COBICISTAT.html	Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat	Precaution for use	
239	COCAINE	2653			DISULFIRAM	3554			ANSM	139-COCAINE.html	Increase of the concentrations of cocaine due to decrease of its metabolism by the disulfiram, with increased risk of torsades de pointes	Take into account	
240	ACITRETIN	16818			ALCOHOL (DRINK OR INGREDIENT)				ANSM	13-ACITRETIN.html	With women of child bearing age, risk of transformation of the acitretin into etretinate, a powerful agent of birth defects and malformations with a very prolonged half life (120 days), exposing the woman to a major risk of these birth defects and malformations of the child in case of pregnancy, during the treatment and two months after it ends.	CONTRAINDICATION	
241	ACITRETIN	16818			METHOTREXATE	6851			ANSM	13-ACITRETIN.html	Risk of increase of the hepatotoxicity of the methotrexate	Not recommended	
242	COLCHICINE	2683					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	140-COLCHICINE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
243	COLCHICINE	2683			CICLOSPORIN	3008			ANSM	140-COLCHICINE.html	Risk of addition of the undesirable neuromuscular effects and increase of the toxicity of the colchicine with risk of overdose due to inhibition of its elimination by the ciclosporin, espceially in cases of pre-existing renal insufficiency	Not recommended	
244	COLCHICINE	2683					FIBRATES	C01AB-001	ANSM	140-COLCHICINE.html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis	Precaution for use	
245	COLCHICINE	2683			FLUCONAZOLE	4450			ANSM	140-COLCHICINE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Not recommended	
246	COLCHICINE	2683					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	140-COLCHICINE.html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis	Precaution for use	
247	COLCHICINE	2683					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	140-COLCHICINE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Contraindication:	
248	COLCHICINE	2683					MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	140-COLCHICINE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	CONTRAINDICATION	
249	COLCHICINE	2683					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	140-COLCHICINE.html	Increase od the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the therapy with ombitasvir + paritaprevir	CONTRAINDICATION	
250	COLCHICINE	2683			PRISTINAMYCIN	66958			ANSM	140-COLCHICINE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	CONTRAINDICATION	
251	COLCHICINE	2683			VERAPAMIL	11170			ANSM	140-COLCHICINE.html	Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil	Not recommended	
252	COLISTIN	2709					CURARES	M03A-001	ANSM	141-COLISTIN.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	
253			CURARES	M03A-001			AMINOGLYCOSIDES	J01GB-001	ANSM	141-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	
254			CURARES	M03A-001	COLISTIN	2709			ANSM	141-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	
255			CURARES	M03A-001			LINCOSANIDES	J01FF0	ANSM	141-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	
256			CURARES	M03A-001	POLYMYXIN B	8536			ANSM	141-CURARES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	
257	CRIZOTINIB	1148495					SUBSTRATES AT RISK OF CYP3A4	L01N01	ANSM	142-CRIZOTINIB.html	Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib	Not recommended	
258			NON-DEPOLARIZING CURARES	M03A-002			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	144-NON-DEPOLARIZING-CURARES.html	With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).	Take into account	
259	CYANOCOBALAMIN	11248					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	145-CYANOCOBALAMIN.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12	Take into account	
260	CYANOCOBALAMIN	11248					PROTON PUMP INHIBITORS	A02BC-001	ANSM	145-CYANOCOBALAMIN.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.	Take into account	
261			TETRACYCLINE ANTIBIOTICS	J01AA			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	146-TETRACYCLINE-ANTIBIOTICS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
262			TETRACYCLINE ANTIBIOTICS	J01AA	CALCIUM	1428011			ANSM	146-TETRACYCLINE-ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	
263			TETRACYCLINE ANTIBIOTICS	J01AA	IRON	1431589			ANSM	146-TETRACYCLINE-ANTIBIOTICS.html	With the tetracycline antibiotics administered by oral route: decrease of the digestive absorption of the tetracycline antibiotics (formation of complexes)	Precaution for use	
264			TETRACYCLINE ANTIBIOTICS	J01AA			RETINOIDS	D05-D10	ANSM	146-TETRACYCLINE-ANTIBIOTICS.html	Risk of intracranial hypertension	CONTRAINDICATION	
265			TETRACYCLINE ANTIBIOTICS	J01AA	STRONTIUM	81638			ANSM	146-TETRACYCLINE-ANTIBIOTICS.html	Decrease of the digestive absorption of the strontium	Precaution for use	
266			TETRACYCLINE ANTIBIOTICS	J01AA	VITAMIN A	11246			ANSM	146-TETRACYCLINE-ANTIBIOTICS.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension	CONTRAINDICATION	
267			TETRACYCLINE ANTIBIOTICS	J01AA	ZINC	11416			ANSM	146-TETRACYCLINE-ANTIBIOTICS.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	
268	CYCLOPHOSPHAMIDE	3002			PENTOSTATIN	8011			ANSM	147-CYCLOPHOSPHAMIDE.html	Increase of the risk of pulmonary toxicity which could be fatal	Not recommended	
269	CYPROHEPTADINE	3013					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	148-CYPROHEPTADINE.html	Risk of decrease of the effectiveness of the antidepressant	Take into account	
270	CYPROTERONE	3014			APREPITANT	358255			ANSM	149-CYPROTERONE.html	Risk of decrease of the concentrations of cyproterone with risk of lower contraceptive effectiveness	Precaution for use	
271	CYPROTERONE	3014			BOSENTAN	75207			ANSM	149-CYPROTERONE.html	Risk of decrease of the effectiveness of the cyproterone	Precaution for use	
272	CYPROTERONE	3014					ENZYMATIC INDUCERS	N03-J05-001	ANSM	149-CYPROTERONE.html	Risk of decrease of the effectiveness of the cyproterone	Not recommended:	
273	CYPROTERONE	3014					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	149-CYPROTERONE.html	Risk of decrease of the effectiveness of the cyproterone	Not recommended	
274	CYPROTERONE	3014			ST JOHNS WORT	258326			ANSM	149-CYPROTERONE.html	Risk of decrease of the effectiveness of the cyproterone, due to increase of its hepatic metabolism by the St Johns Wort	CONTRAINDICATION	
275	CYPROTERONE	3014			PERAMPANEL	1356552			ANSM	149-CYPROTERONE.html	For doses of perampenel >or = to 12 mg/day, risk of decrease of the effectiveness of the cyproterone.	Not recommended	
276	CYPROTERONE	3014			ULIPRISTAL	1005921			ANSM	149-CYPROTERONE.html	Risk of antagonism of the effects of the progestin	Not recommended	
277	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992					HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precautions for use	
278	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992					TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	
279	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	
280	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	3992					MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	14-ADRENALINE-(ORAL-DENTAL-OR-SUB-CUTANEOUS).html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	
281			CYTOTOXICS	L01			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	150-CYTOTOXICS.html	Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy	Precaution for use	
282			CYTOTOXICS	L01			IMMUNOSUPPRESSANTS	L04A	ANSM	150-CYTOTOXICS.html	Excessive immunodepression with risk of lymphoproliferative syndrome	Take into account	
283			CYTOTOXICS	L01			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	150-CYTOTOXICS.html	Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only by the cytotoxic, or risk of increase of the toxicity or loss of effectiveness of the cytotoxic due to the increase of its hepatic metabolism by the phenytoin or the fosphenytoin	Not recommended	
284			CYTOTOXICS	L01			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	150-CYTOTOXICS.html	Risk of general vaccine disease, possibly fatal	Contraindication	
285	DABIGATRAN				AMIODARONE	703			ANSM	151-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	
286	DABIGATRAN						ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	151-DABIGATRAN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
287	DABIGATRAN				CICLOSPORIN	3008			ANSM	151-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
288	DABIGATRAN				DRONEDARONE	233698			ANSM	151-DABIGATRAN.html	Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
289	DABIGATRAN				ITRACONAZOLE	28031			ANSM	151-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
290	DABIGATRAN				KETOCONAZOLE	6135			ANSM	151-DABIGATRAN.html	Increase of more than double the plasma concentrations of dabagitan, with increase of the risk of bleeding	CONTRAINDICATION	
291	DABIGATRAN				QUINIDINE	9068			ANSM	151-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	
292	DABIGATRAN				RIFAMPICIN	9384			ANSM	151-DABIGATRAN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
293	DABIGATRAN				TACROLIMUS	42316			ANSM	151-DABIGATRAN.html	Risk of increase of the plasma concentrations of dabigatran	Not recommended	
294	DABIGATRAN				TICAGRELOR	1116632			ANSM	151-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Take into account	
295	DABIGATRAN				VERAPAMIL	11170			ANSM	151-DABIGATRAN.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	
296	DACARBAZINE	3098			FOTEMUSTINE	25287			ANSM	152-DACARBAZINE.html	With the dacarbazine in large doses: risk of pulmonary toxicity (adult respiratory distress syndrome).	Precaution for use	
297	DACLATASVIR	1606218			AMIODARONE	703			ANSM	153-DACLATASVIR.html	Only in the combination daclatasvir/sofosbuvir:Possibly abrupt onset of bradycardia, that can have fatal consequences	Not recommended	
298	DACLATASVIR	1606218			DEXAMETHASONE	3264			ANSM	153-DACLATASVIR.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	CONTRAINDICATION	
299	DACLATASVIR	1606218					ENZYMATIC INDUCERS	N03-J05-001	ANSM	153-DACLATASVIR.html	Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer.	Contraindication:	
300	DACLATASVIR	1606218					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	153-DACLATASVIR.html	Increase of the concentrations of daclatasvir by the inhibitor.	Precaution for use	
301	DACLATASVIR	1606218			ST JOHNS WORT	258326			ANSM	153-DACLATASVIR.html	Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns Wort	CONTRAINDICATION	
302	DALFOPRISTIN	229369			DIHYDROERGOTAMINE	3418			ANSM	154-DALFOPRISTIN.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
303	DALFOPRISTIN	229369			ERGOTAMINE	4025			ANSM	154-DALFOPRISTIN.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
304	DALFOPRISTIN	229369					IMMUNOSUPPRESSANTS	L04A	ANSM	154-DALFOPRISTIN.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Precaution for use	
305	DALFOPRISTIN	229369			PIMOZIDE	8331			ANSM	154-DALFOPRISTIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes.	Not recommended	
306	DANAZOL	3102					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	155-DANAZOL.html	Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.	Precaution for use	
307	DANAZOL	3102			CARBAMAZEPINE	2002			ANSM	155-DANAZOL.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	
308	DANAZOL	3102			CICLOSPORIN	3008			ANSM	155-DANAZOL.html	Increase of the blood concentrations of ciclosporin due to inhibition of its hepatic metabolism	Precaution for use	
309	DANAZOL	3102			INSULIN	5856			ANSM	155-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	
310	DANAZOL	3102			SIMVASTATIN	36567			ANSM	155-DANAZOL.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin	CONTRAINDICATION	
311	DANAZOL	3102					BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	155-DANAZOL.html	Diabetes inducing effect of the danazol	Not recommended	
312	DANAZOL	3102			TACROLIMUS	42316			ANSM	155-DANAZOL.html	Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism	Precaution for use	
313	DANTROLENE	3105					DIHYDROPYRIDINES	C08CA-002	ANSM	156-DANTROLENE.html	With the dantrolene administered via IV: cases of fatal ventricular fibrillations are constantly observed in animals when verapamil and dantrolene are administered via IV. The administration of a calcium channel blocker and dantrolene is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	Not recommended	
314	DANTROLENE	3105			DILTIAZEM	3443			ANSM	156-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	CONTRAINDICATION	
315	DANTROLENE	3105			VERAPAMIL	11170			ANSM	156-DANTROLENE.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident	CONTRAINDICATION	
316	DAPOXETINE	69394					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	157-DAPOXETINE.html	Risk of increase of the undesirable effects, especially of the vertigo or fainting type	CONTRAINDICATION	
317	DAPOXETINE	69394					MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION	N05AA-001	ANSM	157-DAPOXETINE.html	Risk of increase of the undesirable effects, especially of the vertigo and fainting type	Nor recommended	
318	DAPSONE	3108			ZIDOVUDINE	11413			ANSM	158-DAPSONE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	
319	DAPTOMYCIN	22299					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	159-DAPTOMYCIN.html	Risk of addition of undesirable effects (dose dependent) of the rhabdomyolysis type.	Not recommended	
320	AFATINIB	1430438			AMIODARONE	703			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the amiodarone.	Precaution for use	
321	AFATINIB	1430438					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	15-AFATINIB.html	Decrease of the plasma concentrations of afatinib due to increase of its metabolisn by these substances	Precaution for use	
322	AFATINIB	1430438			CICLOSPORIN	3008			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the ciclosporin	Precaution for use	
323	AFATINIB	1430438			ERYTHROMYCIN	4053			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin.	Precaution for use	
324	AFATINIB	1430438					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the protease inhibiter.	Precaution for use	
325	AFATINIB	1430438			ITRACONAZOLE	28031			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the itraconazole.	Precaution for use	
326	AFATINIB	1430438			KETOCONAZOLE	6135			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the ketoconazole.	Precaution for use	
327	AFATINIB	1430438			PRIMIDONE	8691			ANSM	15-AFATINIB.html	Decrease of the plasma concentrations of the afatinib due to the increase of its metabolism by the primidone	Precaution for use	
328	AFATINIB	1430438			RIFAMPICIN	9384			ANSM	15-AFATINIB.html	Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the rifampicin	Precaution for use	
329	AFATINIB	1430438			VERAPAMIL	11170			ANSM	15-AFATINIB.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the verapamil.	Precaution for use	
330	DARIFENACIN	136198			FLECAINIDE	4441			ANSM	160-DARIFENACIN.html	Increase of the plasma concentrations of felcainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	
331	DARIFENACIN	136198			METOPROLOL	6918			ANSM	160-DARIFENACIN.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	
332	DARIFENACIN	136198			PROPAFENONE	8754			ANSM	160-DARIFENACIN.html	Increase of the plasma concentrations of propafenone, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	
333	DASABUVIR	1597381			ETHINYLESTRADIOL	4124			ANSM	161-DASABUVIR.html	Increase of the hepatoxicity	CONTRAINDICATION	
334	DASABUVIR	1597381			GEMFIBROZIL	4719			ANSM	161-DASABUVIR.html	Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil	CONTRAINDICATION	
335	DASABUVIR	1597381					ENZYMATIC INDUCERS	N03-J05-001	ANSM	161-DASABUVIR.html	Risk of reduction of the plasma concentrations of the dasabuvir by the inducer.	CONTRAINDICATION	
336	DASABUVIR	1597381			ST JOHNS WORT	258326			ANSM	161-DASABUVIR.html	Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort	CONTRAINDICATION	
337	DASABUVIR	1597381			MITOTANE	7004			ANSM	161-DASABUVIR.html	Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane	CONTRAINDICATION	
338	DEFERASIROX	614373			ACETYLSALICYLIC ACID	1191			ANSM	162-DEFERASIROX.html	With acetylsalicyclic acid in anti-inflammatory doses (>=1 gr per dose and/or >= 3 gr per day) or for antalgic or antipyretic doses (>=500 mg per dose and/or <3 gr per day): increase of the risk of digestive ulceration and hemorrhage	Take into account	
339	DEFERASIROX	614373					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	162-DEFERASIROX.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	
340	DEFERASIROX	614373					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	162-DEFERASIROX.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
341	DEFERASIROX	614373					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	162-DEFERASIROX.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
342	DEFERASIROX	614373			BUSULFAN	1828			ANSM	162-DEFERASIROX.html	Risk of increase of the toxocity of the bufulfan by decrease of its clearance by the deferasirox.	Take into account	
343	DEFERASIROX	614373			DEFERIPRONE	11645			ANSM	162-DEFERASIROX.html	Risk of hyperchelation	CONTRAINDICATION	
344	DEFERASIROX	614373			DEFEROXAMINE	3131			ANSM	162-DEFERASIROX.html	Risk of hyperchelation	CONTRAINDICATION	
345	DEFERASIROX	614373			REPAGLINIDE	73044			ANSM	162-DEFERASIROX.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the deferasirox	Not recommended	
346	DEFERASIROX	614373			RIFAMPICIN	9384			ANSM	162-DEFERASIROX.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	
347	DEFERIPRONE	11645			DEFERASIROX	614373			ANSM	163-DEFERIPRONE.html	Risk of hyperchelation	CONTRAINDICATION	
348	DEFEROXAMINE	3131			ASCORBIC ACID	1151			ANSM	164-DEFEROXAMINE.html	With large doses of the ascorbic acid and by intravenous route: cardiac function anomalies, even acute heart failure (generally reversible by ending administration of the Vitamin C).	Precaution for use:	
349	DEFEROXAMINE	3131			DEFERASIROX	614373			ANSM	164-DEFEROXAMINE.html	Risk of hyperchelation	CONTRAINDICATION	
350	DEFIBROTIDE	1311089					PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	165-DEFIBROTIDE.html	Increased risk of hemorrhage	Not recommended	
351	DEFIBROTIDE	1311089					ORAL ANTICOAGULANTS	B01A-001	ANSM	165-DEFIBROTIDE.html	Increased risk of hemorrhage.	Not recommended	
352	DEFIBROTIDE	1311089					HEPARINS	B01AB	ANSM	165-DEFIBROTIDE.html	Increased risk of hemorrhage.	Not recommended	
353	DEFIBROTIDE	1311089					THROMBOLYTICS	B01AD	ANSM	165-DEFIBROTIDE.html	Increased risk of hemorrhage.	CONTRAINDICATION	
354	DELAMANID	1344662					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	166-DELAMANID.html	Decrease of the plasma concentrations de delamanid due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
355	DELAMANID	1344662			RIFAMPICIN	9384			ANSM	166-DELAMANID.html	Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
356			DERIVATIVES OF AMINOSALICYLIC ACID (ASA)	A07EC-001			ANTIPURINES	ANTIPUR	ANSM	167-DERIVATIVES-OF-AMINOSALICYLIC-ACID-(ASA).html	Risk of increase of the myelosuppression effect of the immunomodulator by inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TMPT)	Take into account	
357			NITRATE DERIVATIVES AND RELATED	C01D-001			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	168-NITRATE-DERIVATIVES-AND-RELATED.html	Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and especially provoking an acute coronary accident	CONTRAINDICATION	
358			NITRATE DERIVATIVES AND RELATED	C01D-001			MEDICATIONS THAT LOWER BLOOD PRESSURE	MLBP	ANSM	168-NITRATE-DERIVATIVES-AND-RELATED.html	Increase of the risk of hypotension, especially orthostatic.	Take into account	
359			NITRATE DERIVATIVES AND RELATED	C01D-001	RIOCIGUAT	1439816			ANSM	168-NITRATE-DERIVATIVES-AND-RELATED.html	Risk of significant hypotension (synergic effect).	CONTRAINDICATION	
360	DESIPRAMINE	3247			BUPROPION	42347			ANSM	169-DESIPRAMINE.html	Risk of increase of the undesirable effects of the desipramine due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
361	AGOMELATINE	306718			CIPROFLOXACIN	2551			ANSM	16-AGOMELATINE.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects.	Not Recommended	
362	AGOMELATINE	306718			FLUVOXAMINE	42355			ANSM	16-AGOMELATINE.html	Increase of the concentrations of agomelatine, with risk of increase of its undesirable effects.	CONTRAINDICATION	
363	DEXAMETHASONE	3264			AMINOGLUTETHIMIDE	677			ANSM	170-DEXAMETHASONE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	
364	DEXAMETHASONE	3264			CLARITHROMYCIN	21212			ANSM	170-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
365	DEXAMETHASONE	3264			DACLATASVIR	1606218			ANSM	170-DEXAMETHASONE.html	With the dexamethasone for systemic use, risk of significant decrease of the plasma concentrations of daclatasvir due to increase of it hepatic metabolism by the inducer	CONTRAINDICATION	
366	DEXAMETHASONE	3264			ERYTHROMYCIN	4053			ANSM	170-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
367	DEXAMETHASONE	3264					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	170-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
368	DEXAMETHASONE	3264			ITRACONAZOLE	28031			ANSM	170-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
369	DEXAMETHASONE	3264			KETOCONAZOLE	6135			ANSM	170-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
370	DEXAMETHASONE	3264			POSACONAZOLE	282446			ANSM	170-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
371	DEXAMETHASONE	3264			PRAZIQUANTEL	8628			ANSM	170-DEXAMETHASONE.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	
372	DEXAMETHASONE	3264			RILPIVIRINE	1102270			ANSM	170-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metaolism by the dexamethasone	CONTRAINDICATION	
373	DEXAMETHASONE	3264			SIMEPREVIR	1482790			ANSM	170-DEXAMETHASONE.html	With the dexmethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir by increase of its hepatic metabolism by the dexamethasone	Not recommended	
374	DEXAMETHASONE	3264			TELITHROMYCIN	274786			ANSM	170-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
375	DEXAMETHASONE	3264			VORICONAZOLE	121243			ANSM	170-DEXAMETHASONE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzymatic inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
376	DEXTRAN 40	42635					LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	171-DEXTRAN-40.html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
377	DEXTRAN 40	42635					UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-003	ANSM	171-DEXTRAN-40.html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
378	DEXTROMETHORPHAN	3289			CINACALCET	407990			ANSM	172-DEXTROMETHORPHAN.html	Very large increase of the plasma concentrations of dextromethorphan with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	CONTRAINDICATION	
379	DEXTROMETHORPHAN	3289					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	172-DEXTROMETHORPHAN.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
380	DEXTROMETHORPHAN	3289					REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	172-DEXTROMETHORPHAN.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not recommended	
381	DIAZEPAM	3322			BUSPIRONE	1827			ANSM	173-DIAZEPAM.html	Risk of increase of the undesirable effects of the buspirone	Take into account	
382	DIAZEPAM	3322			CIMETIDINE	2541			ANSM	173-DIAZEPAM.html	With the cimetidine used in doses greater than or equal to 800 mg/day: accrued risk of drowsiness	Precaution for use	
383	DIAZEPAM	3322					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	173-DIAZEPAM.html	Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.	Precaution for use	
384	DIAZEPAM	3322			STIRIPENTOL	37119			ANSM	173-DIAZEPAM.html	Increase of the plasma concentrations of the diazepam, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	
385	DIDANOSINE	3364			ALLOPURINOL	519			ANSM	174-DIDANOSINE.html	Increase of the plasma concentrations of didanosine and of its undesirable effects	Not recommended	
386	DIDANOSINE	3364			GANCICLOVIR	4678			ANSM	174-DIDANOSINE.html	Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours	Not recommended	
387	DIDANOSINE	3364			PENTAMIDINE	7994			ANSM	174-DIDANOSINE.html	Increased risk of onset of pancreatitis due to addition of undesirable effects	Precaution for use	
388	DIDANOSINE	3364			RIBAVIRIN	9344			ANSM	174-DIDANOSINE.html	Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite	Not recommended	
389	DIDANOSINE	3364			TENOFOVIR DISOPROXIL	300195			ANSM	174-DIDANOSINE.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitchondrial toxicity of the didanosine	Not recommended	
390	DIDANOSINE	3364			THALIDOMIDE	10432			ANSM	174-DIDANOSINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
391	DIDANOSINE	3364			ZALCITABINE	3363			ANSM	174-DIDANOSINE.html	Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
392	DIGOXIN	3407			AMIODARONE	703			ANSM	175-DIGOXIN.html	Depression of self-regulation (excessive bradycardia) and difficulties with atrioventricular conduction. In addition, increase of the digoninemia due to decrease of the clearance of digoxin	Precaution for use	
393	DIGOXIN	3407			AZITHROMYCIN	18631			ANSM	175-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	
394	DIGOXIN	3407					BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	175-DIGOXIN.html	Difficulties with autoregulation (bradycardia, sinus arrest) and difficulties with sinoauricular and atrioventricular conduction	Take into account	
395	DIGOXIN	3407			CALCIUM				ANSM	175-DIGOXIN.html	Risk of serious arrhythmias, even lethal ones with the calcium salts administered via IV	Contraindication	
396	DIGOXIN	3407			CARBAMAZEPINE	2002			ANSM	175-DIGOXIN.html	Increase of the plasma concentrations of carbamazepine and decrease of the digoxinemia	Precaution for use	
397	DIGOXIN	3407			CLARITHROMYCIN	21212			ANSM	175-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	
398	DIGOXIN	3407			DRONEDARONE	233698			ANSM	175-DIGOXIN.html	Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. In addition, increase of the digoxinemia due to decrease of the metabolism of the digoxin. Clinical monitoring and EKG.	Not recommended	
399	DIGOXIN	3407			ERYTHROMYCIN	4053			ANSM	175-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	
400	DIGOXIN	3407			HYDROQUINIDINE	27220			ANSM	175-DIGOXIN.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction).	Precaution for use	
401	DIGOXIN	3407					POTASSIUM LOWERING AGENTS	C03-001	ANSM	175-DIGOXIN.html	Hypokaliemia producing toxic effects of the digitalics	Precaution for use	
402	DIGOXIN	3407					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	175-DIGOXIN.html	Increase of the digoxinemia, more marked for IV route, due to increase of the absorption of the digoxin or decrease of its renal clearance.	Precaution for use	
403	DIGOXIN	3407			ITRACONAZOLE	28031			ANSM	175-DIGOXIN.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias.	Precaution for use	
404	DIGOXIN	3407			MIDODRINE	6963			ANSM	175-DIGOXIN.html	Difficulties with autoregulation (increase of the bradycardia inducing effect of the midodrine) and difficulties with atrioventricular conduction.	Not recommended	
405	DIGOXIN	3407			ST JOHNS WORT	258326			ANSM	175-DIGOXIN.html	Decrease of the digoxinemia, by reason of the enzyme inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure).	CONTRAINDICATION	
406	DIGOXIN	3407			OMEPRAZOLE	7646			ANSM	175-DIGOXIN.html	Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole	Precaution for use	
407	DIGOXIN	3407			POSACONAZOLE	282446			ANSM	175-DIGOXIN.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias.	Precaution for use	
408	DIGOXIN	3407			PROPAFENONE	8754			ANSM	175-DIGOXIN.html	Risk of increase of the digoxinemia, especially with older patients	Precaution for use	
409	DIGOXIN	3407			QUINIDINE	9068			ANSM	175-DIGOXIN.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)	Precaution for use	
410	DIGOXIN	3407			QUININE	9071			ANSM	175-DIGOXIN.html	Moderate increase of the digoxinemia	Precaution for use	
411	DIGOXIN	3407			RANOLAZINE	35829			ANSM	175-DIGOXIN.html	Increase of the digoxinemia	Precaution for use	
412	DIGOXIN	3407			SUCRALFATE	10156			ANSM	175-DIGOXIN.html	Decrease of the digestive absorption of the digoxin	Precaution for use	
413	DIGOXIN	3407			SULFASALAZINE	9524			ANSM	175-DIGOXIN.html	Decrease of the digoxinemia that can reach 50%	Precaution for use	
414	DIGOXIN	3407			TELAPREVIR	1102261			ANSM	175-DIGOXIN.html	Increase of the digoxinemia	Precaution for use	
415	DIGOXIN	3407			TELITHROMYCIN	274786			ANSM	175-DIGOXIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	
416	DIGOXIN	3407			VERAPAMIL	11170			ANSM	175-DIGOXIN.html	Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extra-renal elimination of the digoxin	Precaution for use	
417	DIHYDROERGOTAMINE	3418			DALFOPRISTIN	229369			ANSM	176-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
418	DIHYDROERGOTAMINE	3418			DILTIAZEM	3443			ANSM	176-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
419	DIHYDROERGOTAMINE	3418			EFAVIRENZ	195085			ANSM	176-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
420	DIHYDROERGOTAMINE	3418					MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	176-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).	CONTRAINDICATION	
421	DIHYDROERGOTAMINE	3418			QUINUPRISTINE	135098			ANSM	176-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
422	DIHYDROERGOTAMINE	3418			STIRIPENTOL	37119			ANSM	176-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).	CONTRAINDICATION	
423	DIHYDROERGOTAMINE	3418			TRICLABENDAZOLE	38608			ANSM	176-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
424	DIHYDROERGOTAMINE	3418			VORICONAZOLE	121243			ANSM	176-DIHYDROERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
425			DIHYDROPYRIDINES	C08CA-002			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	177-DIHYDROPYRIDINES.html	Hypotension, heart failure with patients having latent or uncontrolled cardiac insufficiency (addition of the negative inotropic effects). The beta blocking agent can furthermore minimize the sympathetic reflex reaction brought into play in the case of excessive hemodynamic repercussion	Take into account	
426			DIHYDROPYRIDINES	C08CA-002			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	177-DIHYDROPYRIDINES.html	Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative inotropic effect of the dihydropyridines in vitro, more or less marked, and susceptible of adding to the negative inotropic effects of the beta blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion.	Take into account	
427			DIHYDROPYRIDINES	C08CA-002	DANTROLENE	3105			ANSM	177-DIHYDROPYRIDINES.html	With the dantrolene administered via IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered via IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.	Not recommended	
428	DILTIAZEM	3443			ALFENTANIL	480			ANSM	178-DILTIAZEM.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	
429	DILTIAZEM	3443			AMIODARONE	703			ANSM	178-DILTIAZEM.html	For diltiazem by injection: risk of bradycardia and of atrioventricular blockFor diltiazem by mouth: risk of bradycardia or of atrioventricular block, especially in older persons.	Not recommended	
430	DILTIAZEM	3443			ATORVASTATIN	83367			ANSM	178-DILTIAZEM.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	
431	DILTIAZEM	3443					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	178-DILTIAZEM.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	
432	DILTIAZEM	3443					BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	178-DILTIAZEM.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction	CONTRAINDICATION	
433	DILTIAZEM	3443			BUSPIRONE	1827			ANSM	178-DILTIAZEM.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the diltiazem, with increase of its undesirable effects	Precaution for use	
434	DILTIAZEM	3443			CLONIDINE	2599			ANSM	178-DILTIAZEM.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
435	DILTIAZEM	3443			DANTROLENE	3105			ANSM	178-DILTIAZEM.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantolene together is thus potentially dangerous. However, some patients have received nifedipine and dantolene together without incident	CONTRAINDICATION	
436	DILTIAZEM	3443			DIHYDROERGOTAMINE	3418			ANSM	178-DILTIAZEM.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
437	DILTIAZEM	3443			DRONEDARONE	233698			ANSM	178-DILTIAZEM.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	
438	DILTIAZEM	3443			ERGOTAMINE	4025			ANSM	178-DILTIAZEM.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	CONTRAINDICATION	
439	DILTIAZEM	3443			ESMOLOL	49737			ANSM	178-DILTIAZEM.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac arrest.	Not recommended	
440	DILTIAZEM	3443			IBRUTINIB	1442981			ANSM	178-DILTIAZEM.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the diltiazem	Precaution for use	
441	DILTIAZEM	3443					IMMUNOSUPPRESSANTS	L04A	ANSM	178-DILTIAZEM.html	Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Precaution for use	
442	DILTIAZEM	3443			IVABRADINE	77417			ANSM	178-DILTIAZEM.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules.	CONTRAINDICATION	
443	DILTIAZEM	3443			MIDAZOLAM	6960			ANSM	178-DILTIAZEM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use	
444	DILTIAZEM	3443			NIFEDIPINE	7417			ANSM	178-DILTIAZEM.html	Large increase of the concentrations of nefidipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	CONTRAINDICATION	
445	DILTIAZEM	3443			OLAPARIB				ANSM	178-DILTIAZEM.html	Increase of the plasma concentrations of olaparib by the diltiazem	Not recommended	
446	DILTIAZEM	3443			PIMOZIDE	8331			ANSM	178-DILTIAZEM.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
447	DILTIAZEM	3443			SIMVASTATIN	36567			ANSM	178-DILTIAZEM.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	
448	DILTIAZEM	3443			TAMSULOSIN	77492			ANSM	178-DILTIAZEM.html	Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism	Precaution for use	
449	DILTIAZEM	3443			TICAGRELOR	1116632			ANSM	178-DILTIAZEM.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolsim	Take into account	
450	DIMETHYL FUMARATE	1373478					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	179-DIMETHYL-FUMARATE.html	Possible increase of the risk of infection	Take into account	
451	ALBENDAZOLE	430					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	17-ALBENDAZOLE.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of lower effectiveness.	Precaution for use	
452	ALBENDAZOLE	430					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	17-ALBENDAZOLE.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of lower effectiveness.	Precaution for use	
453	ALBENDAZOLE	430			RIFAMPICIN	9384			ANSM	17-ALBENDAZOLE.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of lower effectiveness.	Precaution for use	
454	DIPROPHYLLINE	3714			PROBENECID	8698			ANSM	180-DIPROPHYLLINE.html	Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)	Precaution for use	
455	DIPYRIDAMOLE	3521			THEINE				ANSM	181-DIPYRIDAMOLE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theine	Precaution for use	
456	DIPYRIDAMOLE	3521					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	181-DIPYRIDAMOLE.html	With the dipyridamole by injection: increase of the antihypertensive effect	Take into account	
457	DIPYRIDAMOLE	3521			CAFFEINE	1886			ANSM	181-DIPYRIDAMOLE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the caffeine	Precaution for use	
458	DIPYRIDAMOLE	3521					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	181-DIPYRIDAMOLE.html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theophylline	Precaution for use	
459	DISOPYRAMIDE	3541					ENZYMATIC INDUCERS	N03-J05-001	ANSM	182-DISOPYRAMIDE.html	Risk of decrease of the concentrations of the disopyramide by the inducer.	Precaution for use	
460	DISOPYRAMIDE	3541					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	182-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide due to decrease of its metabolism.	Precaution for use	
461	DISOPYRAMIDE	3541			JOSAMYCIN	6084			ANSM	182-DISOPYRAMIDE.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglycemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsade de pointes type.	Precaution for use	
462	DISULFIRAM	3554					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	183-DISULFIRAM.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
463	DISULFIRAM	3554			COCAINE	2653			ANSM	183-DISULFIRAM.html	Increase of the concentrations of cocaine due to decrease of its metabolism by the disulfirame, with increased risk of the onset of torsades de pointes	Take into account	
464	DISULFIRAM	3554			ISONIAZID	6038			ANSM	183-DISULFIRAM.html	Disorders of behavior and of coordination	Not recommended	
465	DISULFIRAM	3554			METRONIDAZOLE	6922			ANSM	183-DISULFIRAM.html	Risk of episodes of acute psychosis or confused state, reversible upon stopping the administration of the two substances together	Not recommended	
466	DISULFIRAM	3554					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	183-DISULFIRAM.html	Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)	Not recommended	
467			DIURETICS	C0E-001	ACETYLSALICYLIC ACID	1191			ANSM	184-DIURETICS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the anti-hypertensive effect.	Precaution for use	
468			DIURETICS	C0E-001			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	184-DIURETICS.html	Acute renal insufficiency with the patient at risk (older patient and/or dehydrated one) due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the NSAIs). Furthermore, reduction of the antihypertensive effect	Precaution for use	
469			DIURETICS	C0E-001			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	184-DIURETICS.html	In case of dehydration caused by the diuretics, increased risk of acute functional renal insufficiency, in particular when large doses of the contrast media are used.	Precaution for use	
470			LOOP DIURETICS	C03CA-001			AMINOGLYCOSIDES	J01GB-001	ANSM	185-LOOP-DIURETICS.html	Increase of the nephrotoxic and ototoxic risks of the aminoglycoside (functional renal insufficiency linked to the dehydration caused by the diuretic)	Precaution for use	
471			LOOP DIURETICS	C03CA-001	LITHIUM	6448			ANSM	185-LOOP-DIURETICS.html	Increase of the plas ma concentrations of lithium with signs of overdose of lithium as with a low sodium regimen (decrease of the urinary excretion of the lithium)		
472			LOOP DIURETICS	C03CA-001	METFORMIN	6809			ANSM	185-LOOP-DIURETICS.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics		
473			LOOP DIURETICS	C03CA-001			PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS	L01XA	ANSM	185-LOOP-DIURETICS.html	Risk of addition of the ototoxic and/or nephrotoxic effects		
474									ANSM	185-LOOP-DIURETICS.html			
475			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004			OTHER POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	CONTRAINDICATION	
476			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Risk of hyperkalemia (possibly lethal) especially when there is renal insufficiency (addition of the effects of the hyperkalemia inducing substances)	Not recommended	
477			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	CICLOSPORIN	3008			ANSM	186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
478			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004			POTASSIUM LOWERING DIURETICS	C03	ANSM	186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	The rational choice of these two medications, useful for some patients, does not exclude the onset of hypokalemia or, in particular with patients having renal insufficiency and diabetes, of hyperkalemia	Precaution for use	
479			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Risk of hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia producing effects)	Not recommended	
480			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	LITHIUM	6448			ANSM	186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Increase of the plasma concentrations of lithium with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)	Precaution for use	
481			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	POTASSIUM	8588			ANSM	186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially with renal insufficiency (addition of the hyperkalemia producing effects)	Contraindication	
482			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	TACROLIMUS	42316			ANSM	186-POTASSIUM-SPARING-DIURETICS-(ALONE-OR-IN-COMBINATION).html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
483			POTASSIUM LOWERING DIURETICS	C03			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	187-POTASSIUM-LOWERING-DIURETICS.html	Risk of abrupt arterial hypotension and/or acute renal insufficiency at the beginning of or at an increase in the dosage of a treatment with an angiotensin II antagonist where there is pre-existing fluid depletion.	Precaution for use	
484			POTASSIUM LOWERING DIURETICS	C03	CARBAMAZEPINE	2002			ANSM	187-POTASSIUM-LOWERING-DIURETICS.html	Risk of symptomatic hyponatremia	Precaution for use	
485			POTASSIUM LOWERING DIURETICS	C03	CICLOSPORIN	3008			ANSM	187-POTASSIUM-LOWERING-DIURETICS.html	Risk of increase of the creatinemia without modification of the blood concentrations of the ciclosporin, even in the absence of fluid depletion. Also risk of hyperuricemia and of complications such as gout	Take into account	
486			POTASSIUM LOWERING DIURETICS	C03			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	187-POTASSIUM-LOWERING-DIURETICS.html	The rational choice of these medications, useful for some patients, does not exclude the onset of hypokalemia or, in particular with patients having renal insufficiency and diabetes, of hyperkalemia	Precaution for use	
487			POTASSIUM LOWERING DIURETICS	C03			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	187-POTASSIUM-LOWERING-DIURETICS.html	Risk of abrupt arterial hypotension and/or renal insufficiency at the start of or when there is an increase of the dosage of the treatment with the ACE inhibitor in cases of pre-existing fluid depletion	Precaution for use	
488			THIAZIDE DIURETICS AND RELATED	C03-003	CALCIUM	1428011			ANSM	188-THIAZIDE-DIURETICS-AND-RELATED.html	Risk of hypercalcemia due to decrease of the urinary elimination of the calcium.	Take into account	
489			THIAZIDE DIURETICS AND RELATED	C03-003	LITHIUM	6448			ANSM	188-THIAZIDE-DIURETICS-AND-RELATED.html	Increase of the plasma concentrations of lithium with signs of overdose of lithium, as with a reduced sodium regimen (decrease of the urinary excretion of the lithium)	Not recommended	
490	DOCETAXEL	72962			DRONEDARONE	233698			ANSM	189-DOCETAXEL.html	Risk of increase of the toxicity of the docetaxel due to decrease of its metabolism	Precaution for use	
491	DOCETAXEL	72962					ENZYMATIC INDUCERS	N03-J05-001	ANSM	189-DOCETAXEL.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
492	DOCETAXEL	72962					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	189-DOCETAXEL.html	Risk of increase of the undesirable dose-dependent effects of the docetaxel due to inhibition of its metabolism by the enzymatic inhibitor	Precaution for use	
493			URINARY ALKALIZERS	B05-001	HYDROQUINIDINE	27220			ANSM	18-URINARY-ALKALIZERS.html	Increase of the plasma concentrations of the hydroquinidine and risk of overdose (decrease of the renal excretion of the hydroquinidine by alkalinizing of the urine)	Precaution for use	
494			URINARY ALKALIZERS	B05-001	QUINIDINE	9068			ANSM	18-URINARY-ALKALIZERS.html	Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).	Precaution for use	
495	DOLUTEGRAVIR	1433868					ENZYMATIC INDUCERS	N03-J05-001	ANSM	190-DOLUTEGRAVIR.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer	Not recommended	
496	DOLUTEGRAVIR	1433868			METFORMIN	6809			ANSM	190-DOLUTEGRAVIR.html	Increase of the plasma concentrations of metformin by the dolutegravir and of its undesirable effects of the lactic acidosis type	Precaution for use	
497	DOLUTEGRAVIR	1433868			ST JOHNS WORT	258326			ANSM	190-DOLUTEGRAVIR.html	Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort.	Not recommended	
498	DOMPERIDONE	3626			FLUCONAZOLE	4450			ANSM	191-DOMPERIDONE.html	Risk of problems with ventricular rhythm, especially of torsades de pointes	CONTRAINDICATION	
499	DOMPERIDONE	3626					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	191-DOMPERIDONE.html	Increase of the plasma concentrations of domperidone due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
500			DOPAMINERGICS	N04B-002			ANTIEMITIC NEUROLEPTICS	A03FA-001	ANSM	192-DOPAMINERGICS.html	Reciprocal antagonism between the dopaminergic and the neuropleptic	CONTRAINDICATION	
501			DOPAMINERGICS	N04B-002	TETRABENAZINE	10390			ANSM	192-DOPAMINERGICS.html	Reciprocal antagonism between the dopaminergic and the tetrabenazine	Not recommended	
502			DOPAMINERGICS, EXCEPT PARKINSON	G02CB-002			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	193-DOPAMINERGICS,-EXCEPT-PARKINSON.html	Reciprocal antagonism of the dopamine agonist and the neuroleptics	CONTRAINDICATION	
503	DOXORUBICIN	3639			VERAPAMIL	11170			ANSM	194-DOXORUBICIN.html	Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations	Take into account	
504	DOXYCYCLINE	3640					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	195-DOXYCYCLINE.html	Decrease of the plasma concentations of the doxycycline due to increase of its hepatic metabolism by the inducer	Precaution for use	
505	DRONEDARONE	233698					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	196-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite	Not recommended	
506	DRONEDARONE	233698					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	196-DRONEDARONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
507	DRONEDARONE	233698			DABIGATRAN				ANSM	196-DRONEDARONE.html	Doubling of the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
508	DRONEDARONE	233698			DIGOXIN	3407			ANSM	196-DRONEDARONE.html	Depression of autoregulation (excessive bradycardia) and disorders of atrioventricular conduction. In addition, increase of the digoxinemia due to decrease of the metabolism of the digoxin. Clinical monitoring and EKG.	Not recommended	
509	DRONEDARONE	233698			DILTIAZEM	3443			ANSM	196-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	
510	DRONEDARONE	233698			DOCETAXEL	72962			ANSM	196-DRONEDARONE.html	Risk of increase of the toxicity of the docetaxel due to decrease of its metabolism.	Precaution for use	
511	DRONEDARONE	233698			FIDAXOMICIN	1111103			ANSM	196-DRONEDARONE.html	Increase of the plasma concentrations of the fidaxomicin.	Not recommended	
512	DRONEDARONE	233698					IMMUNOSUPPRESSANTS	L04A	ANSM	196-DRONEDARONE.html	Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Not recommended	
513	DRONEDARONE	233698					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	196-DRONEDARONE.html	Large increase of the concentrations of drodedarone due to decrease of its metabolism	CONTRAINDICATION	
514	DRONEDARONE	233698			ST JOHNS WORT	258326			ANSM	196-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite	Not recommended	
515	DRONEDARONE	233698			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	196-DRONEDARONE.html	Increase of the concentrations of dronedarone due to inhibition of its metabolism by the grapefruit	Not recommended	
516	DRONEDARONE	233698			QUINIDINE	9068			ANSM	196-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine	Precaution for use	
517	DRONEDARONE	233698			RIFAMPICIN	9384			ANSM	196-DRONEDARONE.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
518	DRONEDARONE	233698			SIMVASTATIN	36567			ANSM	196-DRONEDARONE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Not recommended	
519	DRONEDARONE	233698			VERAPAMIL	11170			ANSM	196-DRONEDARONE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	
520	DROSPIRENONE	840781			BOCEPREVIR	1102129			ANSM	197-DROSPIRENONE.html	Increase of more than double of the concentrations of drosperinone when taken with the boceprevir	Not recommended	
521	DULOXETINE	72625			ENOXACIN	3925			ANSM	198-DULOXETINE.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the enoxacin	CONTRAINDICATION	
522	DULOXETINE	72625			FLECAINIDE	4441			ANSM	198-DULOXETINE.html	Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	
523	DULOXETINE	72625			FLUVOXAMINE	42355			ANSM	198-DULOXETINE.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine	CONTRAINDICATION	
524	DULOXETINE	72625			MEQUITAZINE	29528			ANSM	198-DULOXETINE.html	Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
525	DULOXETINE	72625			METOPROLOL	6918			ANSM	198-DULOXETINE.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	
526	DULOXETINE	72625			PROPAFENONE	8754			ANSM	198-DULOXETINE.html	Increase of the plasma concentrations of propafenone with risk of overdose due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	
527	DULOXETINE	72625			TAMOXIFEN	10324			ANSM	198-DULOXETINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine	Not recommended	
528	EBASTINE	23796			CLARITHROMYCIN	21212			ANSM	199-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
529	EBASTINE	23796			ERYTHROMYCIN	4053			ANSM	199-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
530	EBASTINE	23796			ITRACONAZOLE	28031			ANSM	199-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
531	EBASTINE	23796			JOSAMYCIN	6084			ANSM	199-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
532	EBASTINE	23796			KETOCONAZOLE	6135			ANSM	199-EBASTINE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
533			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not Recommended	
534			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001			ANTIPARKINSONIAN ANTICHOLINERGICS	N04AA-001	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of increase of neuropsychological disorders	Precaution for use:	
535			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose.	Not recommended	
536			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001			ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)	R01AA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
537			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	19-DOPAMINERGIC-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
538	ABATACEPT	614391			ANTI-TNF ALPHA				ANSM	1-ABATACEPT.html	Increase of immunosupression	Not recommended	
539	ABATACEPT	614391					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	1-ABATACEPT.html	Risk of possibly fatal generalized vaccine disease	Not recommended	
540	ECONAZOLE	3743					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	200-ECONAZOLE.html	Regardless of the route of administration of the econazole:increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
541	EFAVIRENZ	195085					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	201-EFAVIRENZ.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	
542	EFAVIRENZ	195085			ATAZANAVIR	343047			ANSM	201-EFAVIRENZ.html	Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism	Not recommended	
543	EFAVIRENZ	195085			ATOVAQUONE	60212			ANSM	201-EFAVIRENZ.html	Decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Not recommended	
544	EFAVIRENZ	195085			DIHYDROERGOTAMINE	3418			ANSM	201-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
545	EFAVIRENZ	195085			ERGOTAMINE	4025			ANSM	201-EFAVIRENZ.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.)	CONTRAINDICATION	
546	EFAVIRENZ	195085			FOSAMPRENAVIR	358262			ANSM	201-EFAVIRENZ.html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	
547	EFAVIRENZ	195085			INDINAVIR	114289			ANSM	201-EFAVIRENZ.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	
548	EFAVIRENZ	195085			PIMOZIDE	8331			ANSM	201-EFAVIRENZ.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
549	EFAVIRENZ	195085			RIFABUTIN	55672			ANSM	201-EFAVIRENZ.html	Decrease by about half of the concentrations of rifabutin, due to increase of its hepatic metabolism by the efavirenz	Precaution for use	
550	EFAVIRENZ	195085			RIFAMPICIN	9384			ANSM	201-EFAVIRENZ.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
551	EFAVIRENZ	195085			VORICONAZOLE	121243			ANSM	201-EFAVIRENZ.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz	Not recommended	
552	ELTROMBOPAG	711942					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	202-ELTROMBOPAG.html	Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture	Precaution for use	
553	ELVITEGRAVIR	1306286					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	203-ELVITEGRAVIR.html	Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. Furthermore, increase of the concentrations of the progestin	Precaution for use	
554	ELVITEGRAVIR	1306286			ITRACONAZOLE	28031			ANSM	203-ELVITEGRAVIR.html	Increase pf the plasma concentrations of elvitegravir by decrease of its metabolism by the itraconazole	Precaution for use	
555	ELVITEGRAVIR	1306286			KETOCONAZOLE	6135			ANSM	203-ELVITEGRAVIR.html	Increase of the plasma concentrations of elvitegravir by decrease of its metabolism by the ketoconazole	Precaution for use	
556	ELVITEGRAVIR	1306286			RIFABUTIN	55672			ANSM	203-ELVITEGRAVIR.html	Decrease of the minimal concentrations of elvitegravir	Take into account	
557	ENOXACIN	3925			CAFFEINE	1886			ANSM	204-ENOXACIN.html	Increase of the plasma concentrations of caffeine, which can lead to agitation and hallucinations, due to decrease of its hepatic metabolism	Not recommended	
558	ENOXACIN	3925			DULOXETINE	72625			ANSM	204-ENOXACIN.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the enoxacin	CONTRAINDICATION	
559	ENOXACIN	3925			ROPINIROLE	72302			ANSM	204-ENOXACIN.html	Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism	Precaution for use	
560	ENOXACIN	3925					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	204-ENOXACIN.html	Overdose of theophylline due to substantial decrease of its metabolism	CONTRAINDICATION	
561	ENTACAPONE	60307			IRON	1431589			ANSM	205-ENTACAPONE.html	Decrease of the digestive absorption of the entacapone and of the iron due to chelation of the latter by the entacapone	Precaution for use	
562	ENZALUTAMIDE	1307298			GEMFIBROZIL	4719			ANSM	206-ENZALUTAMIDE.html	Increase of the active fraction of the enzalutamide	Precaution for use	
563	EPLERENONE	298869					ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	207-EPLERENONE.html	Increase of the risk of hyperkalemia, especially with older patients	Precaution for use	
564	EPLERENONE	298869					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	207-EPLERENONE.html	Increase of the risk of hyperkalemia, especially with older patients.	Precaution for use	
565	EPLERENONE	298869					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	207-EPLERENONE.html	Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia	CONTRAINDICATION	
566	ERGOTAMINE	4025			DALFOPRISTIN	229369			ANSM	208-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
567	ERGOTAMINE	4025			DILTIAZEM	3443			ANSM	208-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	CONTRAINDICATION	
568	ERGOTAMINE	4025			EFAVIRENZ	195085			ANSM	208-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye.).	CONTRAINDICATION	
569	ERGOTAMINE	4025					MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	208-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	CONTRAINDICATION	
570	ERGOTAMINE	4025			OXPRENOLOL	7801			ANSM	208-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	
571	ERGOTAMINE	4025			PROPRANOLOL	8787			ANSM	208-ERGOTAMINE.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	
572	ERGOTAMINE	4025			QUINUPRISTINE	135098			ANSM	208-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	CONTRAINDICATION	
573	ERGOTAMINE	4025			STIRIPENTOL	37119			ANSM	208-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of the ergot of rye).	CONTRAINDICATION	
574	ERGOTAMINE	4025			TRICLABENDAZOLE	38608			ANSM	208-ERGOTAMINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of the ergot of rye).	CONTRAINDICATION	
575	ERIBULINE	1045453			CICLOSPORIN	3008			ANSM	209-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the ciclosporin.	Not recommended	
576	ERIBULINE	1045453			CLARITHROMYCIN	21212			ANSM	209-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the clarithromycin.	Not recommended	
577	ERIBULINE	1045453					ENZYME INDUCERS	N03-J05-001	ANSM	209-ERIBULINE.html	Risk of decrease of the plasma concentrations of eribuline by the inducer	Not recommended	
578	ERIBULINE	1045453					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	209-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the ritonavir.	Not recommended	
579	ERIBULINE	1045453			ST JOHNS WORT	258326			ANSM	209-ERIBULINE.html	Risk of decrease of the plasma concentrations of eribuline by the St John's wort.	Not recommended	
580	ERIBULINE	1045453			VERAPAMIL	11170			ANSM	209-ERIBULINE.html	Increase of the plasma concentrations of eribuline by the verapamil.	Not recommended	
581			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
582			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of coronary blood vessels or of those of the extremities (ergotism), or of rapid elevation of blood pressure.	CONTRAINDICATION	
583			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of the coronary arteries or of those of the extremities (ergotism), or of rapid elevation of blood pressure.	CONTRAINDICATION	
584			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			OMBITASVIR + PARITAPEVIR	OMPA	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye by decrease of its hepatic metabolism by the therapy with the two medications.	CONTRAINDICATION	
585			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL)	R01AA	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure.	Not recommended	
586			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
587			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001			TRIPTANS	N02CC-001	ANSM	20-VASOCONSTRICTOR-ALKALOIDS-OF-ERGOT-OF-RYE.html	Risk of arterial hypertension, of constriction of coronary arteries	CONTRAINDICATION	
588	ERYTHROMYCIN	4053			AFATINIB	1430438			ANSM	210-ERYTHROMYCIN.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the erythromycin	Precaution for use	
589	ERYTHROMYCIN	4053			ALFENTANIL	480			ANSM	210-ERYTHROMYCIN.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	
590	ERYTHROMYCIN	4053			ATORVASTATIN	83367			ANSM	210-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	
591	ERYTHROMYCIN	4053			BUSPIRONE	1827			ANSM	210-ERYTHROMYCIN.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
592	ERYTHROMYCIN	4053			CARBAMAZEPINE	2002			ANSM	210-ERYTHROMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to inhibition of its hepatic metabolism	Not recommended	
593	ERYTHROMYCIN	4053			DEXAMETHASONE	3264			ANSM	210-ERYTHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
594	ERYTHROMYCIN	4053			DIGOXIN	3407			ANSM	210-ERYTHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	
595	ERYTHROMYCIN	4053			EBASTINE	23796			ANSM	210-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
596	ERYTHROMYCIN	4053			FIDAXOMICIN	1111103			ANSM	210-ERYTHROMYCIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
597	ERYTHROMYCIN	4053			GLIBENCLAMIDE	4815			ANSM	210-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	
598	ERYTHROMYCIN	4053			GLIMEPIRIDE	25789			ANSM	210-ERYTHROMYCIN.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	
599	ERYTHROMYCIN	4053					IMMUNOSUPPRESSANTS	L04A	ANSM	210-ERYTHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
600	ERYTHROMYCIN	4053			LUMEFANTRINE	847728			ANSM	210-ERYTHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
601	ERYTHROMYCIN	4053			MIZOLASTINE	61455			ANSM	210-ERYTHROMYCIN.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
602	ERYTHROMYCIN	4053			NINTEDANIB	1592737			ANSM	210-ERYTHROMYCIN.html	Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the erythromycin	Precaution for use	
603	ERYTHROMYCIN	4053			PRAVASTATIN	42463			ANSM	210-ERYTHROMYCIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	
604	ERYTHROMYCIN	4053			SIMVASTATIN	36567			ANSM	210-ERYTHROMYCIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent).	CONTRAINDICATION	
605	ERYTHROMYCIN	4053					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	210-ERYTHROMYCIN.html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous in children	Not recommended	
606	ERYTHROMYCIN	4053			VENLAFAXINE	39786			ANSM	210-ERYTHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
607	ERYTHROMYCIN	4053			VERAPAMIL	11170			ANSM	210-ERYTHROMYCIN.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	
608	ERYTHROMYCIN	4053					VINCA ALKALOIDS	L01CA	ANSM	210-ERYTHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin.	Precaution for use	
609	ESMOLOL	49737			AMIODARONE	703			ANSM	211-ESMOLOL.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
610	ESMOLOL	49737					CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	211-ESMOLOL.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
611	ESMOLOL	49737			DILTIAZEM	3443			ANSM	211-ESMOLOL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac arrest	Not recommended	
612	ESMOLOL	49737			PROPAFENONE	8754			ANSM	211-ESMOLOL.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
613	ESMOLOL	49737			VERAPAMIL	11170			ANSM	211-ESMOLOL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	
614	ESTRAMUSTINE	4089			CLODRONIC ACID	3350			ANSM	212-ESTRAMUSTINE.html	Risk of increase of the plasma concentrations of estramustine by the clodronate	Precaution for use	
615	ESTRAMUSTINE	4089			CALCIUM	1428011			ANSM	212-ESTRAMUSTINE.html	Decrease of the digestive absorption of the estramustine	Precaution for use	
616	ESTRAMUSTINE	4089					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	212-ESTRAMUSTINE.html	Risk of increase of the undesirable effects of the angioneurotic edema type (angioedema)	Not recommended	
617			NON-CONTRACEPTIVE ESTROGENS	G03C-001			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	213-NON-CONTRACEPTIVE-ESTROGENS.html	Decrease of the effectiveness of the estrogen .	Precaution for use	
618			NON-CONTRACEPTIVE ESTROGENS	G03C-001	BOCEPREVIR	1102129			ANSM	213-NON-CONTRACEPTIVE-ESTROGENS.html	Decrease of the effectiveness of the estrogen	Precaution for use	
619			NON-CONTRACEPTIVE ESTROGENS	G03C-001			THYROID HORMONES	H03AA	ANSM	213-NON-CONTRACEPTIVE-ESTROGENS.html	Risk of clinical hypothyroidism in cases of estrogen replacement therapy.	Precaution for use	
620			NON-CONTRACEPTIVE ESTROGENS	G03C-001	OXCARBAZEPINE	32624			ANSM	213-NON-CONTRACEPTIVE-ESTROGENS.html	Risk of decrease of the effectiveness of the hormonal treatment, due to increase of its hepatic metabolism by the oxcarbazepine.	Precaution for use	
621			NON-CONTRACEPTIVE ESTROGENS	G03C-001	TELAPREVIR	1102261			ANSM	213-NON-CONTRACEPTIVE-ESTROGENS.html	Decrease of the effectiveness of the estrogen.	Precaution for use	
622			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	APREPITANT	358255			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Decrease of the concentrations of the estrogen-progestin or of the progestatif, with risk of lower contraceptive effectiveness.	Precaution for use	
623			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	BOCEPREVIR	1102129			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Except for the combination with ethinylestradiol (0.035 mg)/norethisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir.	Precaution for use	
624			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	BOSENTAN	75207			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive	Precaution for use	
625			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ELVITEGRAVIR	1306286			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Decrease of the concentrations of ethinylestradiol, with risk of lower contraceptive effectiveness. In addition, increase of the concentrations of the progestin	Precaution for use	
626			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	GRISEOFULVIN	5021			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism	Precaution for use	
627			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001			ENZYMATIC INDUCERS	N03-J05-001	ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Decrease of the contraceptive effectiveness, due to increase of the hepatic metabolism of the hormonal contraceptive by the inducer	Not recommended	
628			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive due to the increase of its hepatic metabolism by the ritonavir.	Not recommended	
629			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	LAMOTRIGINE	28439			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism	Not recommended	
630			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ST JOHN'S WORT	258326			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, of the contraceptive, which can possibly have serious consequences (pregnancy).	CONTRAINDICATON	
631			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	MODAFINIL	30125			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential	Not recommended	
632			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	RUFINAMIDE	69036			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Moderate decrease of the concentrations of ethinylestradiol	Precaution for use	
633			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	TELAPREVIR	1102261			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the telaprevir	Precaution for use	
634			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	TOPIRAMATE	38404			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	For doses of topiramate >=200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of estrogen	Not recommended	
635			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ULIPRISTAL	1005921			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of antagonism of the effects of the estrogen-progestin contraceptive.	Not recommended	
636			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	VEMURAFENIB	1147220			ANSM	214-COMBINED-ESTROGEN-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness	Not recommended	
637	ETANERCEPT	214555			ANAKINRA	72435			ANSM	215-ETANERCEPT.html	Increased risk of serious infections and neutropenia	Not recommended	
638	ETHINYLESTRADIOL	4124			DASABUVIR	1597381			ANSM	216-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity	CONTRAINDICATION	
639	ETHINYLESTRADIOL	4124			ETORICOXIB	307296			ANSM	216-ETHINYLESTRADIOL.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
640	ETHINYLESTRADIOL	4124					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	216-ETHINYLESTRADIOL.html	Increase of the hepatotoxicity.	CONTRAINDICATION	
641	ETHOSUXIMIDE	4135			CARBAMAZEPINE	2002			ANSM	217-ETHOSUXIMIDE.html	Decrease of the plasma concentrations of ethosuximide	Precaution for use	
642	ETORICOXIB	307296			ETHINYLESTRADIOL	4124			ANSM	218-ETORICOXIB.html	Increase of the concentrations of ethinylestradiol by the etoricoxib	Take into account	
643	ETRAVIRINE	475969			CLARITHROMYCIN	21212			ANSM	219-ETRAVIRINE.html	In the treatment of infections with Mycobacterium avium complex, risk of decrease of the effectiveness of the clarithromycin due to increase of its hepatic metabolism by the etravirine	Take into account	
644	ALDESLEUKIN	70223					IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	21-ALDESLEUKIN.html	Increase of the risk of reaction to the contrast media in cases of previous treatment with interleukin2: skin rash or more rarely low blood pressure, oliguria, or even renal failure	Take into account	
645	EVEROLIMUS	141704			CICLOSPORIN	3008			ANSM	220-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus by the ciclosporin. The nephrotoxicity of the ciclosprorin is also increased when the two medications are administered together	Precaution for use	
646	EVEROLIMUS	141704					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	220-EVEROLIMUS.html	Increase of the risk of angioedema	Take into account	
647	EVEROLIMUS	141704			VERAPAMIL	11170			ANSM	220-EVEROLIMUS.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	
648	EXEMESTANE	258494			RIFAMPICIN	9384			ANSM	221-EXEMESTANE.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
649	EZETIMIBE	341248			CICLOSPORIN	3008			ANSM	222-EZETIMIBE.html	For one thing, increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to increase of the concentrations of ezetimibe; for another thing, possible increase of the concentrations of ciclosporin	Not recommended	
650	EZETIMIBE	341248			FENOFIBRATE	8703			ANSM	222-EZETIMIBE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
651	FELBAMATE	24812			CARBAMAZEPINE	2002			ANSM	223-FELBAMATE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine. In addition, decrease of the plasma concentrations of felbamate due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
652	FELBAMATE	24812					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	223-FELBAMATE.html	Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.	Precaution for use	
653	FELBAMATE	24812					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	223-FELBAMATE.html	Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate	Precaution for use	
654	FELBAMATE	24812					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	223-FELBAMATE.html	Increase of the plasma concentrations of the valproic acid, with risk of overdose	Precaution for use	
655	FENOFIBRATE	8703			CICLOSPORIN	3008			ANSM	224-FENOFIBRATE.html	Risk of increase of the nephrotoxicity of the ciclosporin	Precaution for use	
656	FENOFIBRATE	8703			EZETIMIBE	341248			ANSM	224-FENOFIBRATE.html	Risk of gallstones due to increase of the biliary excretion of cholesterol	Not recommended	
657	FENTANYL	4337					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	225-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant	Not recommended	
658	FENTANYL	4337					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	225-FENTANYL.html	Risk of increase of the opioid analgesic's effect of respiratory depression due to slight decrease of its hepatic metabolism	Precaution for use	
659	FENTANYL	4337			RIFAMPICIN	9384			ANSM	225-FENTANYL.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin	Not recommended	
660	IRON				INJECTABLE IRON SALTS	1431591			ANSM	226-IRON.html	Lypothymia, even loss of consciousness attributed to the rapid release of the iron in its complex form and to the saturation of the transferrin	Not recommended	
661	IRON				ACETOHYDROXAMIC ACID	16728			ANSM	226-IRON.html	Decrease of the digestive absorption of these two medications due to chelation of the iron	Take into account	
662	IRON						BISPHOSPHONATES	M05B-001	ANSM	226-IRON.html	For the iron salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	
663	IRON				CALCIUM	1428011			ANSM	226-IRON.html	With the iron salts by oral route: decrease of the digestive absorption of the iron salts	Precaution for use	
664	IRON						TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	226-IRON.html	With the tetracycline antibiotics administered by oral route: decrease of the digestive absorption of the tetracycline antibiotics (formation of complexes)	Precaution for use	
665	IRON				ENTACAPONE	60307			ANSM	226-IRON.html	Decrease of the digestive absorption of the entacapone and of the iron due to chelation of the latter by the entacapone	Precaution for use	
666	IRON						FLUOROQUINOLONES	J01MA-001	ANSM	226-IRON.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	
667	IRON						THYROID HORMONES	H03AA	ANSM	226-IRON.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	
668	IRON				LEVODOPA	6375			ANSM	226-IRON.html	Decrease of the digestive absorption of the levodopa	Precaution for use	
669	IRON				METHYLDOPA	6876			ANSM	226-IRON.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	
670	IRON				PENICILLAMINE	7975			ANSM	226-IRON.html	Decrease of the digestive absorption of the penicillamine	Precaution for use	
671	IRON				STRONTIUM	81638			ANSM	226-IRON.html	Decrease of the digestive absorption of the strontium.	Precaution for use	
672	IRON				ZINC	1431163			ANSM	226-IRON.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	
673			FIBRATES	C01AB-001			OTHER FIBRATES	C01AB-001	ANSM	227-FIBRATES.html	Increased risk of undesirable effects of the rhabdomyolosis type and of pharmacodynamic antagonism between the two molecules	CONTRAINDICATION	
674			FIBRATES	C01AB-001			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	227-FIBRATES.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
675			FIBRATES	C01AB-001	COLCHICINE	2683			ANSM	227-FIBRATES.html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolosis	Precaution for use	
676			FIBRATES	C01AB-001			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	227-FIBRATES.html	Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. Furthermore, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin	Contraindication	
677	FIDAXOMICIN	1111103			AMIODARONE	703			ANSM	228-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
678	FIDAXOMICIN	1111103			CICLOSPORIN	3008			ANSM	228-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
679	FIDAXOMICIN	1111103			CLARITHROMYCIN	21212			ANSM	228-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
680	FIDAXOMICIN	1111103			DRONEDARONE	233698			ANSM	228-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
681	FIDAXOMICIN	1111103			ERYTHROMYCIN	4053			ANSM	228-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
682	FIDAXOMICIN	1111103			KETOCONAZOLE	6135			ANSM	228-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
683	FIDAXOMICIN	1111103			VERAPAMIL	11170			ANSM	228-FIDAXOMICIN.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
684	FINGOLIMOD	1012892					BRADYCARDIA INDUCING DRUGS	C0N0S0	ANSM	229-FINGOLIMOD.html	Increase of the bradycardia inducing effects which can have fatal consequences. The beta-blocking agents are even more at risk since they inhibit the adrenergic compensation mechanisms	Not recommended	
685	ALFENTANIL	480			CIMETIDINE	2541			ANSM	22-ALFENTANIL.html	With cimetidine used in doses greater than or equal to 800mg/day: increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	
686	ALFENTANIL	480			DILTIAZEM	3443			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	
687	ALFENTANIL	480			ERYTHROMYCIN	4053			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	
688	ALFENTANIL	480			FLUCONAZOLE	4450			ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	
689	ALFENTANIL	480					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	22-ALFENTANIL.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism.	Precaution for use	
690	FLECAINIDE	4441			ABIRATERONE				ANSM	230-FLECAINIDE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone	Precautions for use	
691	FLECAINIDE	4441			BUPROPION	42347			ANSM	230-FLECAINIDE.html	Risk of increase of the undesirable effects of the flecainide due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
692	FLECAINIDE	4441			CINACALCET	407990			ANSM	230-FLECAINIDE.html	Increase of the plasma concentrations of flecanaide with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	
693	FLECAINIDE	4441			DARIFENACIN	136198			ANSM	230-FLECAINIDE.html	Increase of the plasma concentrations of flecainide, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	
694	FLECAINIDE	4441			DULOXETINE	72625			ANSM	230-FLECAINIDE.html	Increase of the plasma concentrations of flecainide with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	
695	FLECAINIDE	4441			MIRABEGRON	1300786			ANSM	230-FLECAINIDE.html	Increase of the plasma concentrations of the flecainide by decrease of its metabolism by the mirabegron	Precaution for use	
696	FLECAINIDE	4441			TERBINAFINE	37801			ANSM	230-FLECAINIDE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	
697	FLUCONAZOLE	4450			ALFENTANIL	480			ANSM	231-FLUCONAZOLE.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	
698	FLUCONAZOLE	4450			AMIODARONE	703			ANSM	231-FLUCONAZOLE.html	Risk of lengthening of the QT interval	Precaution for use	
699	FLUCONAZOLE	4450					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	231-FLUCONAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
700	FLUCONAZOLE	4450			APIXABAN	1364430			ANSM	231-FLUCONAZOLE.html	Increase of the plasma concentrations of the apixaban by the flucoonazole, with increase of the risk of bleeding	Not recommended	
701	FLUCONAZOLE	4450			CARBAMAZEPINE	2002			ANSM	231-FLUCONAZOLE.html	For doses of fluconazole >=200 mg per day: possible increase of the undesirable effects of the carbamazepine	Precaution for use	
702	FLUCONAZOLE	4450			COLCHICINE	2683			ANSM	231-FLUCONAZOLE.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Not Recommended	
703	FLUCONAZOLE	4450			DOMPERIDONE	3626			ANSM	231-FLUCONAZOLE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
704	FLUCONAZOLE	4450			HALOFANTRINE	50749			ANSM	231-FLUCONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
705	FLUCONAZOLE	4450					IMMUNOSUPPRESSANTS	L04A	ANSM	231-FLUCONAZOLE.html	Risk of increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism and of the creatinemia	Precaution for use	
706	FLUCONAZOLE	4450			IVACAFTOR	1243041			ANSM	231-FLUCONAZOLE.html	Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	
707	FLUCONAZOLE	4450			LOSARTAN	52175			ANSM	231-FLUCONAZOLE.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
708	FLUCONAZOLE	4450			MIDAZOLAM	6960			ANSM	231-FLUCONAZOLE.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation.	Not recommended	
709	FLUCONAZOLE	4450			NEVIRAPINE	53654			ANSM	231-FLUCONAZOLE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	
710	FLUCONAZOLE	4450			OLAPARIB	1597582			ANSM	231-FLUCONAZOLE.html	Increase of the plasma concentrations of olaparib by the fluconazole	Not recommended	
711	FLUCONAZOLE	4450			OXYCODONE	7804			ANSM	231-FLUCONAZOLE.html	Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the fluconazole.	Not recommended	
712	FLUCONAZOLE	4450					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	231-FLUCONAZOLE.html	Increase of the plasma oncentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin	Precaution for use	
713	FLUCONAZOLE	4450			PIMOZIDE	8331			ANSM	231-FLUCONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes.	CONTRAINDICATION	
714	FLUCONAZOLE	4450			RIFABUTIN	55672			ANSM	231-FLUCONAZOLE.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Precaution for use	
715	FLUCONAZOLE	4450			RIFAMPICIN	9384			ANSM	231-FLUCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the fluconazole by increase of its metabolism by the rifampacin	Not recommended	
716	FLUCONAZOLE	4450			RIVAROXABAN	1114195			ANSM	231-FLUCONAZOLE.html	Increase of the plasma concentrations of the rivaroxaban by the fluconazole, with increase of the risk of bleeding	Not recommeded	
717	FLUCONAZOLE	4450					BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	231-FLUCONAZOLE.html	Increase of the half life of the sulfonamide with possible onset of hypoglycemia	Precaution for use	
718	FLUCONAZOLE	4450					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	231-FLUCONAZOLE.html	Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)	Precaution for use	
719	FLUCYTOSINE	4451			ZIDOVUDINE (AZT)	11413			ANSM	232-FLUCYTOSINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	
720	FLUDARABINE	24698			PENTOSTATIN	8011			ANSM	233-FLUDARABINE.html	Increase of the risk of pulmonary toxicity that could be fatal.	Not recommended	
721			FLUOROQUINOLONES	J01MA-001			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	234-FLUOROQUINOLONES.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
722			FLUOROQUINOLONES	J01MA-001	IRON	1431589			ANSM	234-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	
723			FLUOROQUINOLONES	J01MA-001			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	234-FLUOROQUINOLONES.html	Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving prolonged corticotherapy	Take into account	
724			FLUOROQUINOLONES	J01MA-001	MYCOPHENOLATE MOFETIL				ANSM	234-FLUOROQUINOLONES.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness.	Take into account	
725			FLUOROQUINOLONES	J01MA-001	STRONTIUM	81638			ANSM	234-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the strontium	Precaution for use	
726			FLUOROQUINOLONES	J01MA-001	SUCRALFATE	10156			ANSM	234-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	
727			FLUOROQUINOLONES	J01MA-001	ZINC	1431163			ANSM	234-FLUOROQUINOLONES.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	
728			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	FOLINIC ACID	6313			ANSM	235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html	Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil.	Take into account	
729			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	
730			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	INTERFERON ALFA				ANSM	235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
731			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	METRONIDAZOLE	6922			ANSM	235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html	Increase of the toxicity of the fluourouracil due to decrease of its clearance	Take into account	
732			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ORNIDAZOLE	7701			ANSM	235-FLUOROURACIL-(AND,-BY-EXTRAPOLATION,-OTHER-FLUOROPYRIMIDINES).html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
733	FLUOXETINE	4493			CARBAMAZEPINE	2002			ANSM	236-FLUOXETINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	
734	FLUOXETINE	4493			MEQUITAZINE	29528			ANSM	236-FLUOXETINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzymatic inhibitor	Not recommended	
735	FLUOXETINE	4493			METOPROLOL	6918			ANSM	236-FLUOXETINE.html	Risk of increase of the undesirable effects of the metoprolol, especially with excessive bradycardia, due to inhibition of its metabolism by the fluoxetine.	Precaution for use	
736	FLUOXETINE	4493			NEBIVOLOL	31555			ANSM	236-FLUOXETINE.html	Risk of increase of the undesirable effects of the nebivolol, especially with excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	
737	FLUOXETINE	4493					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	236-FLUOXETINE.html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin	Precaution for use	
738	FLUOXETINE	4493			RISPERIDONE	35636			ANSM	236-FLUOXETINE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of its undesirable effects	Precaution for use	
739	FLUOXETINE	4493			TAMOXIFEN	10324			ANSM	236-FLUOXETINE.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine.	Not recommended	
740	FLUOXETINE	4493			VORTIOXETINE	1455099			ANSM	236-FLUOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to decrease of its hepatic metabolism	Precaution for use	
741	FLUVOXAMINE	42355			AGOMELATINE	306718			ANSM	237-FLUVOXAMINE.html	Increase of the concentrations of agomelatine, with risk of increase of the undesirable effects.	CONTRAINDICATION	
742	FLUVOXAMINE	42355			CARBAMAZEPINE	2002			ANSM	237-FLUVOXAMINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	
743	FLUVOXAMINE	42355			CLOZAPINE	2626			ANSM	237-FLUVOXAMINE.html	Increase of the plasma concentrations of clozapine with signs of overdose	Precaution for use	
744	FLUVOXAMINE	42355			DULOXETINE	72625			ANSM	237-FLUVOXAMINE.html	Risk of increase of the undesirable effects of the duloxetine due to decrease of its hepatic metabolism by the fluvoxamine	CONTRAINDICATION	
745	FLUVOXAMINE	42355			LIDOCAINE	6387			ANSM	237-FLUVOXAMINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	
746	FLUVOXAMINE	42355			METHADONE	6813			ANSM	237-FLUVOXAMINE.html	Increase of the plasma concentrations of methodone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
747	FLUVOXAMINE	42355			MEXILETINE	6926			ANSM	237-FLUVOXAMINE.html	Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine	Precaution for use	
748	FLUVOXAMINE	42355			OLANZAPINE	61381			ANSM	237-FLUVOXAMINE.html	Increase of the concentrations of the olanzapine, with risk of increase of the undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	
749	FLUVOXAMINE	42355					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	237-FLUVOXAMINE.html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	
750	FLUVOXAMINE	42355			PIRFENIDONE	88221			ANSM	237-FLUVOXAMINE.html	Increase of the plasma concentrations of pirfenidone with signs of overdose	CONTRAINDICATION	
751	FLUVOXAMINE	42355			PROPRANOLOL	8787			ANSM	237-FLUVOXAMINE.html	Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia	Precaution for use	
752	FLUVOXAMINE	42355			ROPINIROLE	72302			ANSM	237-FLUVOXAMINE.html	Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	
753	FLUVOXAMINE	42355					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	237-FLUVOXAMINE.html	Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	
754			FOLATES	V03-			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	238-FOLATES.html	Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	
755			FOLATES	V03-			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	238-FOLATES.html	Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	
756	FOSAMPRENAVIR	358262			BUPRENORPHINE	1819			ANSM	239-FOSAMPRENAVIR.html	Risk of increase or of decrease of the effects of the A to take into account buprenorphine [sic], simultaneously by inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
757	FOSAMPRENAVIR	358262			EFAVIRENZ	195085			ANSM	239-FOSAMPRENAVIR.html	Risk of lower effectiveness of the amprenavir.	Precaution for use	
758	FOSAMPRENAVIR	358262			MARAVIROC	620216			ANSM	239-FOSAMPRENAVIR.html	Significant decrease of the concentrations of amprenavir that can lead to a loss of viralogical response	Not recommended	
759	FOSAMPRENAVIR	358262			METHADONE	6813			ANSM	239-FOSAMPRENAVIR.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ampernavir	Precaution for use	
760	FOSAMPRENAVIR	358262			NEVIRAPINE	53654			ANSM	239-FOSAMPRENAVIR.html	Risk of lower effectiveness of the amprenavir	Precaution for use	
761	ALFUZOSIN	17300					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	23-ALFUZOSIN.html	Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects. .	CONTRAINDICATION	
762	ALFUZOSIN	17300					OMBITASVIR + PARITAPEVIR	OMPA	ANSM	23-ALFUZOSIN.html	Increase of the plasma concentrations of the alfuzosin by decrease of its hepatic metabolism by the therapy with the two medications.	CONTRAINDICATION	
763	FOSCARNET	33562			PENTAMIDINE	7994			ANSM	240-FOSCARNET.html	Risk of severe hypocalcemia	Precaution for use	
764	FOTEMUSTINE	25287			DACARBAZINE	3098			ANSM	241-FOTEMUSTINE.html	With the dacarbazine in large doses: risk of pulmonary toxicity (adult acute respiratory distress syndrome ).	Precaution for use	
765	FUROSEMIDE	460					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	242-FUROSEMIDE.html	Decrease of the diuretic effect which can reach 50%	Precaution for use	
766	GANCICLOVIR	4678			DIDANOSINE	3364			ANSM	243-GANCICLOVIR.html	Risk of increase of the undesirable effects of the didanosine, and especially the mitochondrial toxicity, due to substantial increase of its concentrations. In addition, risk of decrease of the effectiveness of the ganciclovir due to decrease of its concentrations, if the two medications are ingested in an interval of less than 2 hours	Not recommended	
767	GANCICLOVIR	4678			ZALCITABINE	3363			ANSM	243-GANCICLOVIR.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
768	GANCICLOVIR	4678			ZIDOVUDINE	11413			ANSM	243-GANCICLOVIR.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	
769	GEMFIBROZIL	4719			DASABUVIR	1597381			ANSM	244-GEMFIBROZIL.html	Risk of increase of the plasma concentrations of the dasabuvir by the gemfibrozil	CONTRAINDICATION	
770	GEMFIBROZIL	4719			ENZALUTAMIDE	130729			ANSM	244-GEMFIBROZIL.html	Increase of the active fraction of the enzalutamide	Precaution for use	
771	GEMFIBROZIL	4719			PIOGLITAZONE	33738			ANSM	244-GEMFIBROZIL.html	Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil	Not recommended	
772	GEMFIBROZIL	4719			REPAGLINIDE	73044			ANSM	244-GEMFIBROZIL.html	Risk of severe hypoglycemia, even coma, due to substantial increase of the plasma concentrations of repaglinide by the gemfiborzil	CONTRAINDICATION	
773	GLIBENCLAMIDE	4815			BOSENTAN	75207			ANSM	245-GLIBENCLAMIDE.html	Risk of reduced effectiveness of the glibenclamide due to decrease of its plasma concentrations, because of the inducer effect of the bosentan. Furthermore, cases of hepatoxicity have been reported with these substances administered together.	Precaution for use	
774	GLIBENCLAMIDE	4815			CLARITHROMYCIN	21212			ANSM	245-GLIBENCLAMIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	
775	GLIBENCLAMIDE	4815			ERYTHROMYCIN	4053			ANSM	245-GLIBENCLAMIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	
776	GLIMEPIRIDE	25789			CLARITHROMYCIN	21212			ANSM	246-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic.	Precaution for use	
777	GLIMEPIRIDE	25789			ERYTHROMYCIN	4053			ANSM	246-GLIMEPIRIDE.html	Risk of hypoglycemia due to increase of the absorption and of the plasma concentrations of the antidiabetic	Precaution for use	
778			GLINIDES	A10BX-001			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	247-GLINIDES.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
779			GLINIDES	A10BX-001			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	247-GLINIDES.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
780	GLIPIZIDE	4821			VORICONAZOLE	121243			ANSM	248-GLIPIZIDE.html	Risk of increase of the plasma concentrations of the glipizide at the origin of potentially severe hypoglycemia.	Precaution for use	
781			GLIPTINS	A10B-001			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	249-GLIPTINS.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
782			GLIPTINS	A10B-001			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	249-GLIPTINS.html	Increase of the risk of the onset of angioedema, due to the reduction of the activity of the enzyme dipetidyl peptidase-4 (DDP-4) by the gliptin, in patients treated with the angiotensin converting enzyme inhibitor	Take into account	
783	ALISKIREN	325646					ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	24-ALISKIREN.html	Risk of hyperkalemia, of renal insufficiency, of increase of cardiovascular mortality	Contraindication	
784	ALISKIREN	325646			CICLOSPORIN	3008			ANSM	24-ALISKIREN.html	The plasma concentrations of aliskiren increase by nearly 5 times and increase of the risk of its undesirable effects.	CONTRAINDICATION	
785	ALISKIREN	325646					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	24-ALISKIREN.html	Risk of hyperkalemia, of renal insufficiency, of increase of cardiovascular mortality	Contraindication	
786	ALISKIREN	325646			ITRACONAZOLE	28031			ANSM	24-ALISKIREN.html	The plasma concentrations of aliskiren increase by nearly 6 times and increase of the risk of its undesirable effects.	CONTRAINDICATION	
787	ALISKIREN	325646			GRAPEFRUIT				ANSM	24-ALISKIREN.html	Risk of decrease of the effectiveness of the aliskiren when grapefruit is consumed	Not recommended	
788	ALISKIREN	325646			QUINIDINE	9068			ANSM	24-ALISKIREN.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	CONTRAINDICATION	
789	ALISKIREN	325646			SACUBITRIL	1656328			ANSM	24-ALISKIREN.html	With diabetic patients or those with renal insufficiency, increase of the undesirable effects such as hypotension, hyperkaliemia	CONTRAINDICATION	
790	ALISKIREN	325646			VERAPAMIL	11170			ANSM	24-ALISKIREN.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	Precaution for use	
791			ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001			IMMUNOSUPPRESSANTS	L04A	ANSM	250-ANTI-LYMPHOCYTE-GLOBULINS.html	Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)	Take into account	
792			ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	250-ANTI-LYMPHOCYTE-GLOBULINS.html	Risk of possibly fatal general illness. This risk is increased in older patients already immunodepressed by the underlying disease.	Take into account	
793			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ACETYLSALICYLIC ACID	1191			ANSM	251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Increase of the risk of hemorrhage	Not recommended with:	
794			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			ORAL ANTICOAGULANTS	B01A-001	ANSM	251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the Vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) in large doses or in treatment prolonged beyond 10 days.	Precaution for use	
795			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have AddisonÂ’s disease treated with hydrocortisone and in cases of organ transplants	Precaution for use	
796			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Increase of the risk of ulceration and of gastrointestinal hemorrhage	Take into account	
797			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			NON-DEPOLARIZING CURARES	M03A-002	ANSM	251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	With the glucocorticoids by IV route: risk of severe myopathy, reversible after a possibly long period (several months).	Take into account	
798			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			FLUOROQUINOLONES	J01MA-001	ANSM	251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Possible increase of the risk of tendinitis, even of rupture of the tendon (exceptional), particularly in patients receiving corticotherapy for a prolonged period	Take into account	
799			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ISONIAZID	6038			ANSM	251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Described for prednisolone. Decrease of the plasma concentrations of the isoniazid. Mechanism proposed: increase of the hepatic metabolism of the isoniazid and decrease of that of the glucocorticoides	Precaution for use	
800			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	RIFAMPICIN	9384			ANSM	251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	
801			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	251-GLUCOCORTICOIDS-(EXCEPT-HYDROCORTISONE).html	With the exception of inhaled and local routes, and for doses greater than 10mg/day of prednisone-equivalent (or > 2mg/kg/day for a child or > 20mg/day for a child weighing more than 10 kg) during more than two weeks and for the "bolus" of corticoids: risk of possibly fatal general vaccine disease.	CONTRAINDICATION	
802	GLUCOSAMINE	4845					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	252-GLUCOSAMINE.html	Increase of the risk of hemorrhage	Precaution for use	
803	GLYCEROL	4910			LITHIUM	6448			ANSM	253-GLYCEROL.html	Decrease of the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness	Precaution for use	
804	GRISEOFULVIN	5021					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	254-GRISEOFULVIN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvin	Precaution for use	
805	GRISEOFULVIN	5021					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	254-GRISEOFULVIN.html	Risk of decrease of the contraceptive effectiveness due to increase of its hepatic metabolism	Precaution for use	
806	GRISEOFULVIN	5021					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	254-GRISEOFULVIN.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	
807	GUANETHIDINE	5036					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	255-GUANETHIDINE.html	With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension	CONTRAINDICATION	
808	HALOFANTRINE	50749			FLUCONAZOLE	4450			ANSM	256-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
809	HALOFANTRINE	50749					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	256-HALOFANTRINE.html	Increased risk of ventricular arryhthmias, especially of torsades de pointes	Not recommended	
810	HALOFANTRINE	50749			JOSAMYCIN	6084			ANSM	256-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
811	HALOFANTRINE	50749			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	256-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
812	HALOFANTRINE	50749			STIRIPENTOL	37119			ANSM	256-HALOFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
813	HALOPERIDOL	5093					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	257-HALOPERIDOL.html	NB: Carbamazepine is one of the Anticonvulsant Enzymatic InducersClinical monitoring and, if needed, adjustment of the dosage during the treatment with the carbamazepine and after it is stopped	Precaution for use	
814	HALOPERIDOL	5093			RIFAMPICIN	9384			ANSM	257-HALOPERIDOL.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
815	HALOTHANE	5095					BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	258-HALOTHANE.html	In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity	Not recommended	
816	HALOTHANE	5095					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	258-HALOTHANE.html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
817			HEPARINS	B01AB			PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	259-HEPARINS.html	Increased risk of hemorrhage	Take into account	
818			HEPARINS	B01AB	DEFIBROTIDE	1311089			ANSM	259-HEPARINS.html	Accrued risk of hemorrhage	Not recommended	
819	ALLOPURINOL	519					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	25-ALLOPURINOL.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	
820	ALLOPURINOL	519			DIDANOSINE	3364			ANSM	25-ALLOPURINOL.html	Increase of the plasma concentrations of didanosine and of its undesirable effects	Not recommended	
821	ALLOPURINOL	519					AMINOPENICILLINS	J01CA	ANSM	25-ALLOPURINOL.html	Increased risk of cutaneous reactions	Take into account	
822	ALLOPURINOL	519			VIDARABINE	11194			ANSM	25-ALLOPURINOL.html	Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral	Not recommended	
823			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ACETYLSALICYLIC ACID	1191			ANSM	260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	
824			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001			ORAL ANTICOAGULANTS	B01A-001	ANSM	260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage	Precaution for use	
825			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	
826			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	DEXTRAN 40	42635			ANSM	260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
827			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001			THROMBOLYTICS	B01AD	ANSM	260-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(CURATIVE-DOSES-AND-OR-OLDER-PATIENT).html	Increase of the risk of hemorrhage	Take into account	
828			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ACETYLSALICYLIC ACID	1191			ANSM	261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemeostasis increases the risk of bleeding. Thus, with patients under 65 years of age, adding heparin or similar substances in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical and possibly biological monitoring.	Take into account	
829			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	261-LOW-MOLECULAR-WEIGHT-HEPARINS-AND-RELATED-DRUGS-(PREVENTIVE-DOSES).html	Increase of the risk of hemorrhage	Take into account	
830			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ACETYLSALICYLIC ACID	1191			ANSM	262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastroduodenal mucosa by the acetylsalicylic acid)	Not recommended with	
831			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	
832			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage	Precaution for use	
833			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	DEXTRAN 40	42635			ANSM	262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage (inhibition of the platelet function by the dextran 40)	Not recommended	
834			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003			THROMBOLYTICS	B01AD	ANSM	262-UNFRACTIONATED-HEPARIN-(CURATIVE-DOSES-AND-OR-OLDER-PATIENTS).html	Increase of the risk of hemorrhage	Take into account	
835			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ACETYLSALICYLIC ACID	1191			ANSM	263-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
836			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	263-UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES).html	Increase of the risk of hemorrhage	Take into account	
837			THYROID HORMONES	H03AA			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	264-THYROID-HORMONES.html	Risk of clinically low thyroid in patients with hypothyroidism, due to increase of the metabolism of the T3 and of the T4	Precaution for use	
838			THYROID HORMONES	H03AA	CALCIUM	1428011			ANSM	264-THYROID-HORMONES.html	Decrease of absorption of the thyroid hormones	Precaution for use	
839			THYROID HORMONES	H03AA	CHLOROQUINE	2393			ANSM	264-THYROID-HORMONES.html	Risk of clinical hypothyroidism in patients taking thyroid hormones in substitution therapy	Precaution for use	
840			THYROID HORMONES	H03AA			NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	264-THYROID-HORMONES.html	Risk of clinical hypothyroidism in cases of estrogen substitution therapy	Precaution for use	
841			THYROID HORMONES	H03AA	IRON	1431589			ANSM	264-THYROID-HORMONES.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	
842			THYROID HORMONES	H03AA	IMATINIB	282388			ANSM	264-THYROID-HORMONES.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
843			THYROID HORMONES	H03AA			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	264-THYROID-HORMONES.html	Risk of reduction of the effectiveness of the thyroid hormones due to the increase of their hepatic metabolism by the ritonavir	Precaution for use	
844			THYROID HORMONES	H03AA	ORLISTAT	37925			ANSM	264-THYROID-HORMONES.html	Risk of disequilibrium of the thyroid replacement therapy in cases where there is treatment with orlistat	Take into account	
845			THYROID HORMONES	H03AA	PROGUANIL	2382			ANSM	264-THYROID-HORMONES.html	Risk of clinically low thyroid with patients having thyroid replacement therapy	Precaution for use	
846			THYROID HORMONES	H03AA			CHELATING RESINS	C10-V0	ANSM	264-THYROID-HORMONES.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	
847			THYROID HORMONES	H03AA	RIFABUTIN	55672			ANSM	264-THYROID-HORMONES.html	Described for phenytoin, rifampicin, and carbamazepine. [sic]Risk of clinical hypothyroidism in patients with low thyroid, due to increase of the metabolism of the T3 and T4	Precaution for use	
848			THYROID HORMONES	H03AA	RIFAMPICIN	9384			ANSM	264-THYROID-HORMONES.html	Risk of clinically low thyroid in patients with already low thyroid due to increase of the metabolism of the T3 and the T4.	Precaution for use	
849			THYROID HORMONES	H03AA	SUCRALFATE	10156			ANSM	264-THYROID-HORMONES.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	
850			THYROID HORMONES	H03AA	SUNITINIB	357977			ANSM	264-THYROID-HORMONES.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
851			MINERAL OILS	A06AA-	LATEX CONDOMS				ANSM	265-MINERAL-OILS.html	Risk of rupture of the condom when used with lubricants containing mineral oils (paraffin oil, silicone oil, etc...)	CONTRAINDICATION	
852	HYDROCORTISONE	5492					ENZYMATIC INDUCERS	N03-J05-001	ANSM	266-HYDROCORTISONE.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydrocortisone is administered in replacement therapy or in case of transplants	Precaution for use	
853	HYDROQUINIDINE	27220					URINARY ALKALIZERS	B05-001	ANSM	267-HYDROQUINIDINE.html	Increase of the plasma concentrations of the hydroquinidine and risk of overdose (decrease of the renal excretion of the hydroquinidine due to alkalinizing of the urine )	Precaution for use	
854	HYDROQUINIDINE	27220			DIGOXIN	3407			ANSM	267-HYDROQUINIDINE.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction).	Precaution for use	
855	HYDROQUINIDINE	27220			ITRACONAZOLE	28031			ANSM	267-HYDROQUINIDINE.html	Risk of tinnitis and/or loss of hearing acuity: cinchonism linked to a decrease of the hepatic metabolism of the antiarrythmic by the itraconazole	Precaution for use	
856	HYDROXYCARBAMIDE	5552					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	268-HYDROXYCARBAMIDE.html	When indicated for a patient with drepanocytosis (sickle cell anemia), theoretical risk of general fatal vaccine disease.	Not recommended	
857	HYDROXYCHLOROQUINE	5521			METOPROLOL	6918			ANSM	269-HYDROXYCHLOROQUINE.html	With the metoprolol used in heart failure: risk of increase of the undesirable effects of metoprolol due to decrease of its hepatic metabolism by the hydroxycloroquine	Precaution for use	
858	HYDROXYCHLOROQUINE	5521			RIFAMPICIN	9384			ANSM	269-HYDROXYCHLOROQUINE.html	Risk of decrease of the therapeutic effect of the hydroxychloroquine, due to increase of its metabolism by the rifampicin	Precaution for use	
859	HYDROXYCHLOROQUINE	5521					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	269-HYDROXYCHLOROQUINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
860			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001	ANSM	26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html	Increase of the hypotensive effect. Risk of severe orthostatic hypotension.	Not recommended	
861			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001			ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001	ANSM	26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html	Increase of the hypotensive effect. Increased risk of orthostatic hypotension	Take into account	
862			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	26-ALPHA-BLOCKERS-FOR-UROLOGICAL-USE.html	Risk of orthostatic hypotension, especially in older patients	Not recommended	
863			HYPERKALEMIA INDUCING MEDICATIONS	M01A-001			OTHER HYPERKALEMIA INDUCING MEDICATIONS	M01A-001	ANSM	270-HYPERKALEMIA-INDUCING-MEDICATIONS.html	Risk of increase of hyperkalemia, potentially lethal.	Take into account	
864			HYPNOTICS	N05-R06			OTHER HYPNOTICS	N05-R06	ANSM	271-HYPNOTICS.html	Increase of central nervous system depression	Take into account	
865			POTASSIUM LOWERING AGENTS	C03-001			OTHER POTASSIUM LOWERING AGENTS	C03-001	ANSM	272-POTASSIUM-LOWERING-MEDICATIONS.html	Increased risk of hypokalemia	Precaution for use	
866			POTASSIUM LOWERING AGENTS	C03-001	DIGOXIN	3407			ANSM	272-POTASSIUM-LOWERING-MEDICATIONS.html	Hypokaliemia that promotes the toxic effects of the digitalics.	Precaution for use	
867			POTASSIUM LOWERING AGENTS	C03-001			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	272-POTASSIUM-LOWERING-MEDICATIONS.html	Increased risk of ventricular arrhythmias, especially torsades de pointes	Precaution for use	
868			HYPONATREMIA INDUCING MEDICATIONS	C03EA			OTHER HYPONATREMIA INDUCING MEDICATIONS	C03EA	ANSM	273-HYPONATREMIA-INDUCING-MEDICATIONS.html	Increase of the risk of hyponatremia	Take into account	
869	IBRUTINIB	1442981			AMIODARONE	703			ANSM	274-IBRUTINIB.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the amiodarone	Precaution for use	
870	IBRUTINIB	1442981			DILTIAZEM	3443			ANSM	274-IBRUTINIB.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the diltiazem	Precaution for use	
871	IBRUTINIB	1442981			VERAPAMIL	11170			ANSM	274-IBRUTINIB.html	Increase of the plasma concentrations of irutinib due to decrease of its hepatic metabolism by the verapamil	Precaution for use	
872	IDELALISIB	1544460					CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	275-IDELALISIB.html	Increase of the undesirable effects of the calcium channel blocker, of the orthostatic hypotension sort, especially with older patients	Precaution for use	
873	IDELALISIB	1544460					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	275-IDELALISIB.html	Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer	Not recommended	
874	IDELALISIB	1544460					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	275-IDELALISIB.html	Increase of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor	Take into account	
875	IDELALISIB	1544460			ST JOHNS WORT	258326			ANSM	275-IDELALISIB.html	Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
876	IDELALISIB	1544460			RIFAMPICIN	9384			ANSM	275-IDELALISIB.html	Decease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer.	Not recommended	
877	IDELALISIB	1544460					SUBSTRATES AT RISK OF CYP3A4	L01N01	ANSM	275-IDELALISIB.html	Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idelalisib.	Not recommended	
878	IFOSFAMIDE	5657			APREPITANT	358255			ANSM	276-IFOSFAMIDE.html	Risk of increase of the neurotoxicity of the ifosfamide	Take into account	
879	IFOSFAMIDE	5657					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	276-IFOSFAMIDE.html	Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital	Not recommended	
880	IFOSFAMIDE	5657			VEMURAFENIB	1147220			ANSM	276-IFOSFAMIDE.html	Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity	Take into account	
881			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ALCOHOL (DRINK OR INGREDIENT)				ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Increase of the hypertensive and/or hyperthermic effects of the tyramine present in certain alcoholic drinks (chianti, certain beers, etc.)	Not recommended	
882			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	A01AD	ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	
883			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	DEXTROMETHORPHAN	3289			ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
884			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	GUANETHIDINE	5036			ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	With the guanethidine used by IV route: risk of unforeseeable vascular reactions, especially hypotension	CONTRAINDICATION	
885			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT)	COMT	ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Increase of the pharmacological effects, and especially increase in blood pressure and contraction of the blood vessels by the catecholamines due to the combined inhibition of their metabolism	CONTRAINDICATION	
886			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
887			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	CONTRAINDICATION	
888			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	MIDODRINE	6963			ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped.	CONTRAINDICATION	
889			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ST JOHNS WORT	258326			ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome	Precaution for use	
890			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	PETHIDINE	6754			ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
891			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	RESERPINE	9260			ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Psychomotor agitation, convulsions, hypertension	CONTRAINDICATION	
892			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			ALPHA SYMPATHOMIMETICS (ORAL AND/OR NASAL ROUTES)	R01AA	ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped	Not recommended	
893			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Increase of the pressor action of the sympathomimetic, most often moderate.	Precaution for use	
894			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Paroxysmal hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped	CONTRAINDICATION	
895			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	TETRABENAZINE	10390			ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of hypertensive crises. Because of the duration of the action of the MAOI, this interaction is still theoretically possible two weeks after the MAOI is stopped	CONTRAINDICATION	
896			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	TIANEPTINE	38252			ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of drop in blood pressure, paroxysmal hypertension, hyperthermia, convulsions, death	Not recommended	
897			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	TRAMADOL	10689			ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	CONTRAINDICATION	
898			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			TRIPTANS METABOLIZED BY THE MAO	N02CC-002	ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of arterial hypertension, of constriction of the coronary arteries	CONTRAINDICATION	
899			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003	ANSM	277-IRREVERSIBLE-MONOAMINE-OXIDASE-INHIBITORS-(MAOI).html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
900			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	DEXTROMETHORPHAN	3289			ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not Recommended	
901			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			MAOI-B	N04BD0-001	ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of rapid elevation of blood pressure, due to loss of selectivity on the monoamine oxydase, especially in case of eating food rich in tyramine (cheese, beer, ...)	CONTRAINDICATION	
902			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not recommended	
903			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, confusion, even coma	Not recommended	
904			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ST JOHN'S WORT	258326			ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome	Precaution for use	
905			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	PETHIDINE	6754			ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	CONTRAINDICATION	
906			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	By extrapolation from the non selective MAOIs: risk of increase of the pressor action.	Precaution for use	
907			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Contraindication:	
908			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	TRAMADOL	10689			ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	Not Recommended	
909			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			TRIPTANS METABOLIZED BY THE MAO	N02CC-002	ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of arterial hypertension, of constriction of coronary arteries	CONTRAINDICATION	
910			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003	ANSM	278-REVERSIBLE-MAOI-A,-INCLUDING-LINEZOLIDE-AND-METHYLENE-BLUE.html	Risk of arterial hypertension, of constriction of coronary arteries	Not Recommended	
911			MAOI-B	N04BD0-001	BUPROPION	42347			ANSM	279-MAOI-B.html	Risk of hypertensive crises	CONTRAINDICATION	
912			MAOI-B	N04BD0-001			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	279-MAOI-B.html	Risk of rapid elevation of blood pressure, due to loss of selectivity on the monamine oydase, especially in case of consuming food rich in tyramine (cheese, beer,Â…)	CONTRAINDICATION	
913			MAOI-B	N04BD0-001			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	279-MAOI-B.html	Risk of appearance of a serotonin syndrome	Take into account	
914			MAOI-B	N04BD0-001	LEVODOPA	6375			ANSM	279-MAOI-B.html	Increased risk of orthostatic hypotension	Take into account	
915			MAOI-B	N04BD0-001	PETHIDINE	6754			ANSM	279-MAOI-B.html	Symptoms of central nervous system excitability, evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
916			MAOI-B	N04BD0-001	TRAMADOL	10689			ANSM	279-MAOI-B.html	Risk of appearance of a serotonin syndrome	Take into account	
917			MAOI-B	N04BD0-001			TRIPTANS METABOLIZED BY THE MAO	N02CC-002	ANSM	279-MAOI-B.html	Risk of arterial hypertension, of constriction of the coronary arteries	CONTRAINDICATION	
918			MAOI-B	N04BD0-001			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003	ANSM	279-MAOI-B.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
919	ALPHA-TOCOPHEROL	11256					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	27-ALPHA-TOCOPHEROL.html	With the vitamin E used in doses greater than or equal to 500 mg per day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
920	IMATINIB	282388					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	280-IMATINIB.html	Increase of the risk of hemorrhage	Not recommended	
921	IMATINIB	282388					THYROID HORMONES	H03AA	ANSM	280-IMATINIB.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
922			IMMUNOSUPPRESSANTS	L04A	BOCEPREVIR	1102129			ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant (especially for the ciclosporin, extremely large for the tacrolimus)	Precaution for use	
923			IMMUNOSUPPRESSANTS	L04A	CLARITHROMYCIN	21212			ANSM	281-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
924			IMMUNOSUPPRESSANTS	L04A			CYTOTOXICS	L01	ANSM	281-IMMUNOSUPPRESSANTS.html	Excessive immunodepression with risk of lymphoproliferative syndrome	Take into account	
925			IMMUNOSUPPRESSANTS	L04A	DALFOPRISTIN	229369			ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Precaution for use	
926			IMMUNOSUPPRESSANTS	L04A	DILTIAZEM	3443			ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Precaution for use	
927			IMMUNOSUPPRESSANTS	L04A	DRONEDARONE	233698			ANSM	281-IMMUNOSUPPRESSANTS.html	Large increase of the blood concentrations of the immunosuppressant due to decrease of its metabolism	Not recommended	
928			IMMUNOSUPPRESSANTS	L04A	ERYTHROMYCIN	4053			ANSM	281-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
929			IMMUNOSUPPRESSANTS	L04A	FLUCONAZOLE	4450			ANSM	281-IMMUNOSUPPRESSANTS.html	Risk of increase of the blood concentrations of the immunosuppressant due to the inhibition of its metabolism and of the creatinemia	Precaution for use	
930			IMMUNOSUPPRESSANTS	L04A			ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001	ANSM	281-IMMUNOSUPPRESSANTS.html	Excessive immunodepression with risk of lymphoproliferative disorders (LPDs)	Take into account	
931			IMMUNOSUPPRESSANTS	L04A			ENZYMATIC INDUCERS	N03-J05-001	ANSM	281-IMMUNOSUPPRESSANTS.html	Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer	Precaution for use	
932			IMMUNOSUPPRESSANTS	L04A			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	281-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
933			IMMUNOSUPPRESSANTS	L04A	ITRACONAZOLE	28031			ANSM	281-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
934			IMMUNOSUPPRESSANTS	L04A	KETOCONAZOLE	6135			ANSM	281-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Not recommended	
935			IMMUNOSUPPRESSANTS	L04A	ST JOHNS WORT	258326			ANSM	281-IMMUNOSUPPRESSANTS.html	Decrease of the blood concentrations of the immunosuppressant, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect which can have possibly serious consequences (rejection of a graft).	CONTRAINDICATION	
936			IMMUNOSUPPRESSANTS	L04A	NICARDIPINE	7396			ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism	Precaution for use	
937			IMMUNOSUPPRESSANTS	L04A	GRAPEFRUIT (JUICE AND FRUIT)				ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the bioavailability of the immunosuppressant and as a result of its undesirable effects.	Not recommended	
938			IMMUNOSUPPRESSANTS	L04A	POSACONAZOLE	282446			ANSM	281-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
939			IMMUNOSUPPRESSANTS	L04A	PRISTINAMYCIN	66958			ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	
940			IMMUNOSUPPRESSANTS	L04A	QUINUPRISTINE	135098			ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	
941			IMMUNOSUPPRESSANTS	L04A	RANOLAZINE	35829			ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine	Precaution for use	
942			IMMUNOSUPPRESSANTS	L04A	STIRIPENTOL	37119			ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)	CONTRAINDICATION	
943			IMMUNOSUPPRESSANTS	L04A	TELAPREVIR	1102261			ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir	Precaution for use	
944			IMMUNOSUPPRESSANTS	L04A	TELITHROMYCIN	274786			ANSM	281-IMMUNOSUPPRESSANTS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
945			IMMUNOSUPPRESSANTS	L04A			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	281-IMMUNOSUPPRESSANTS.html	Risk of general vaccinal disease, possibly fatal.	CONTRAINDICATION	
946			IMMUNOSUPPRESSANTS	L04A	VEMURAFENIB	1147220			ANSM	281-IMMUNOSUPPRESSANTS.html	Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness	Not recommended	
947			IMMUNOSUPPRESSANTS	L04A	VORICONAZOLE	121243			ANSM	281-IMMUNOSUPPRESSANTS.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole	Not recommended	
948	INDINAVIR	114289			EFAVIRENZ	195085			ANSM	282-INDINAVIR.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	
949	INDINAVIR	114289			NEVIRAPINE	53654			ANSM	282-INDINAVIR.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	
950			ENZYMATIC INDUCERS	N03-J05-001			ANDROGENS	A14AA0	ANSM	283-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of the androgen and as a result of its effectiveness, due to increase of its hepatic metabolism by the inducer	Precaution for use	
951			ENZYMATIC INDUCERS	N03-J05-001	ARIPIPRAZOLE	89013			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the aripiprazole	Precaution for use	
952			ENZYMATIC INDUCERS	N03-J05-001	BEDAQUILINE	1364504			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
953			ENZYMATIC INDUCERS	N03-J05-001	BORTEZOMIB	358258			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
954			ENZYMATIC INDUCERS	N03-J05-001	CABAZITAXEL	996051			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
955			ENZYMATIC INDUCERS	N03-J05-001	CYPROTERONE	3014			ANSM	283-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the cyproterone	Not recommended	
956			ENZYMATIC INDUCERS	N03-J05-001	DACLATASVIR	1606218			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the inducer	Contraindication	
957			ENZYMATIC INDUCERS	N03-J05-001	DASABUVIR	1597381			ANSM	283-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of the dasabuvir by the inducer.	CONTRAINDICATION	
958			ENZYMATIC INDUCERS	N03-J05-001	DISOPYRAMIDE	3541			ANSM	283-ENZYMATIC-INDUCERS.html	Risk of decrease of the concentrations of the disopyramide by the inducer	Precaution for use	
959			ENZYMATIC INDUCERS	N03-J05-001	DOCETAXEL	72962			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
960			ENZYMATIC INDUCERS	N03-J05-001	DOLUTEGRAVIR	1433868			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the inducer	Not recommended	
961			ENZYMATIC INDUCERS	N03-J05-001	ERIBULINE	1045453			ANSM	283-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of eribuline by the inducer.	Not recommended	
962			ENZYMATIC INDUCERS	N03-J05-001			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the contraceptive effectiveness, due to increase of the hepatic metabolism of the hormonal contraceptive by the inducer	Not recommended	
963			ENZYMATIC INDUCERS	N03-J05-001	HYDROCORTISONE	5492			ANSM	283-ENZYMATIC-INDUCERS.html	Risk of decrease of the effectiveness of the hydrocortisone (increase of its metabolism); the consequences are serious when the hydorcortisone is administered in replacement therapy or in case of transplants	Precaution for use	
964			ENZYMATIC INDUCERS	N03-J05-001			IMMUNOSUPPRESSANTS	L04A	ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the blood concentrations and of the effectiveness of the immunosuppressant, due to increase of its hepatic metabolism by the inducer	Precaution for use	
965			ENZYMATIC INDUCERS	N03-J05-001	IRINOTECAN	51499			ANSM	283-ENZYMATIC-INDUCERS.html	Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	Not recommended	
966			ENZYMATIC INDUCERS	N03-J05-001	ISAVUCONAZOLE	1720882			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
967			ENZYMATIC INDUCERS	N03-J05-001	ITRACONAZOLE	28031			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the inducer	Not recommended	
968			ENZYMATIC INDUCERS	N03-J05-001	IVACAFTOR	1243041			ANSM	283-ENZYMATIC-INDUCERS.html	Large decrease of the concentrations of the ivacaftor, with risk of loss of effectiveness	Not recommended	
969			ENZYMATIC INDUCERS	N03-J05-001	LURASIDONE	1040028			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the inducer.	CONTRAINDICATION	
970			ENZYMATIC INDUCERS	N03-J05-001	MACITENTAN	1442132			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of macitentan due to increase of its metabolism by the inducer	Not recommended	
971			ENZYMATIC INDUCERS	N03-J05-001	MARAVIROC	620216			ANSM	283-ENZYMATIC-INDUCERS.html	In the absence of co-administration with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer.	Precaution for use	
972			ENZYMATIC INDUCERS	N03-J05-001	METHADONE	6813			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism	Precaution for use	
973			ENZYMATIC INDUCERS	N03-J05-001	MIANSERIN	6929			ANSM	283-ENZYMATIC-INDUCERS.html	Risk of ineffectiveness of the mianserin	Not recommended	
974			ENZYMATIC INDUCERS	N03-J05-001	OLAPARIB	1597582			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease, possibly very large depending on the inducer, of the plasma concentrations of the olaparib due to increase of its hepatic metabolism by the inducer	Not recommended	
975			ENZYMATIC INDUCERS	N03-J05-001			OMBITASVIR + PARITAPREVIR	OMPA	ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the bitherapy due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
976			ENZYMATIC INDUCERS	N03-J05-001	OXYCODONE	7804			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the inducer	Not recommended	
977			ENZYMATIC INDUCERS	N03-J05-001			PROGESTIN CONTRACEPTIVES	G03-001	ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer.	Not recommended	
978			ENZYMATIC INDUCERS	N03-J05-001			NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the effectiveness of the progestogen	Precaution for use	
979			ENZYMATIC INDUCERS	N03-J05-001	REGORAFENIB	1312397			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the inducer	Not recommended	
980			ENZYMATIC INDUCERS	N03-J05-001	RILPIVIRINE	1102270			ANSM	283-ENZYMATIC-INDUCERS.html	Significant decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
981			ENZYMATIC INDUCERS	N03-J05-001	SERTRALINE	36437			ANSM	283-ENZYMATIC-INDUCERS.html	Risk of ineffectiveness of the treatment by the antidepressant	Not recommended	
982			ENZYMATIC INDUCERS	N03-J05-001	SIMEPREVIR	1482790			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the inducer	Not recommended	
983			ENZYMATIC INDUCERS	N03-J05-001	SOFOSBUVIR				ANSM	283-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the inducer.	Contraindication	
984			ENZYMATIC INDUCERS	N03-J05-001	TENEFOVIR ALAFENAMIDE	1721603			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the inducer	Not recommended	
985			ENZYMATIC INDUCERS	N03-J05-001	VEMURAFENIB	1147220			ANSM	283-ENZYMATIC-INDUCERS.html	Risk of decrease of the concentrations of the vermurafenib, with lower effectiveness	Not recommended	
986			ENZYMATIC INDUCERS	N03-J05-001	VISMODEGIB	1242987			ANSM	283-ENZYMATIC-INDUCERS.html	Risk of decrease of the plasma concentrations of vismodegib due to increase of its hepatic metabolism by the inducer	Not recommended	
987			ENZYMATIC INDUCERS	N03-J05-001	VORTIOXETINE	1455099			ANSM	283-ENZYMATIC-INDUCERS.html	Decrease of the plasma concentrations of the vortioxetine	Precaution for use	
988			CATECHOL-O-METHYLTRANSFERASE INHIBITORS (COMT)	COMT			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	284-CATECHOL-O-METHYLTRANSFERASE-INHIBITORS-(COMT).html	Increase of the pharmacological effects, and especially increase in blood pressure and contraction of the blood vessels, by the catecholamines due to the combined inhibition of their metabolism	CONTRAINDICATION	
989			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001	ANSM	285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of orthostatic hypotension, especially with older patients	Not recommended	
990			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001	ANSM	285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of orthostatic hypotension, especially with older patients	Not recommended	
991			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE			NITRATE DERIVATIVES AND RELATED	C01D-001	ANSM	285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of significant hypotension (synergic effect) capable of aggravating the state of myocardial ischemia and provoking an acute cardiac accident	CONTRAINDICATION	
992			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Increase (very large for the avanafil and the vardenafil) of the plasma concentrations of the type 5 phosphodiesterase inhibitor, with risk of hypotension (severe with the vardenafil)	To know the risks and the levels of constraint for each Type 5 phosphodiesterase inhibitor with the strong inhibitors of CYP3A4, consult the AMM ["Authorisation de la mise au marche", a French document for all medications authorized to be marketed in France with information about them] specific for each one of them.	
993			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	RIOCIGUAT	1439816			ANSM	285-TYPE-5-PHOSPHODIESTERASE-INHIBITORS.html	Risk of large drop in blood pressure (synergic effect)	CONTRAINDICATION	
994			XANTHINE OXYDASE INHIBITORS	M04AA0			ANTIPURINES	ANTIPUR	ANSM	286-XANTHINE-OXYDASE-INHIBITORS.html	Possibly serious medullary insufficiency	CONTRAINDICATION	
995			XANTHINE OXYDASE INHIBITORS	M04AA0			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	286-XANTHINE-OXYDASE-INHIBITORS.html	With large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism.	Precaution for use	
996			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ACETYLSALICYLIC ACID	1191			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	For anti-inflammatory doses of acetylsalicylic acid (>=1gr per dose and/or >=3gr per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 gr per day):Acute renal insufficiency in dehydrated patients due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	
997			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ALISKIREN	325646			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease	Contraindication:	
998			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	In situations where the administration of these medications together is possible, increased risk of degradation of renal function, even acute renal insufficiency, and increase of the hyperkalemia as well as hypotension and fainting or loss of consciousness.	Take into account	
999			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Acute renal insufficiency with patients at risk (older patients, dehydrated ones, those taking diuretics, those having altered renal function) due to decrease of the glomerular filtration (inhibition of the vasodilating prostaglandins due to the NSAIs). These effects are generally reversible. Furthermore, reduction of the antihypertensive effect.	Precaution for use	
1000			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia producing effects)	Not recommended	
1001			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			POTASSIUM LOWERING DIURETICS	C03	ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of abrupt arterial hypotension and/or acute renal insufficiency at the start of or when there is an increase of the dosage of the treatment with the ACE inhibitor in cases of pre-existing fluid depletion	Precaution for use	
1002			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	EPLERENONE	298869			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the risk of hyperkalemia, especially with older patients.	Precaution for use	
1003			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ESTRAMUSTINE	4089			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of increase of the undesirable effects of the angioneurotic edema type (angioedema)	Not recommended	
1004			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	EVEROLIMUS	141704			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the risk of angioedema	Take into account	
1005			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			GLIPTINS	A10B-001	ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the risk of the onset of angioedema, due to reduction of the activity of the enzyme dipetidyl peptidase-4 (DDP-4) by the gliptin, in patients treated with the ACE inhibitor	Take into account	
1006			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	INSULIN	5856			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	
1007			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	LITHIUM	6448			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the plasma concentrations of lithium which can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	
1008			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	GOLD	1311190			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the gold salts administered by IV route: risk of Â“nitritoidÂ” reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly a drop in blood pressure)	Take into account	
1009			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	POTASSIUM	8588			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
1010			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	RACECADOTRIL	16738			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Risk of increase of the undesirable effects of the angioedema type.	Contraindication	
1011			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	SACUBITRIL	1656328			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	Increase of the risk of angiodema	Contraindication	
1012			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	SPIRONOLACTONE	9997			ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	With the spironolactone at dosages from 12.5 to 50 mg per day, and with low doses of ACE inhibitorsIn the treatment of class III or IV heart failure (NYHA) with an ejection fraction <35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescribed doses for this combination of medications.	Precaution for use	
1013			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	287-ANGIOTENSIN-CONVERTING-ENZYME-INHIBITORS-(ACE-INHIBITORS).html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in diabetic patients treated with glucose lowering sulfonamides. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for the glucose lowering sulfonamides)	Precaution for use	
1014			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	FUSIDIC ACID	4608			ANSM	288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type.	CONTRAINDICATION	
1015			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
1016			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	COLCHICINE	2683			ANSM	288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of increase of the undesirable muscular effects of these substances, and especially of rhabdomyolysis	Precaution for use	
1017			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	DAPTOMYCIN	22299			ANSM	288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of addition of the undesirable effects (dose dependent) of the rhabdomyolysis type.	Not recommended	
1018			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ELTROMBOPAG	711942			ANSM	288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of increase of the toxicity of the statins, due to inhibition of their hepatic recapture	Precaution for use	
1019			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA			FIBRATES	C01AB-001	ANSM	288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of addition of undesirable effects (dose-dependent) of the rhabdomyolosis type. Furthermore, with the gemfibrozil, decrease of the metabolism of the simvastatin and of the rosuvastatin, which increases the muscular risk, as well as the nephrotoxicity of the rosuvastatin	Contraindication	
1020			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	LEDIPASVIR	1591922			ANSM	288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolosis type.	Contraindication	
1021			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	LENALIDOMIDE	342369			ANSM	288-HMG-COA-REDUCTASE-INHIBITORS-(STATINS).html	Increased risk of the onset of rhabdomyolysis	Precaution for use	
1022			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	AFATINIB	1430438			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the protease inhibitor	Precaution for use	
1023			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ALBENDAZOLE	430			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the ritonavir, with risk of reduction of its effectiveness.	Precaution for use	
1024			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of constriction of coronary blood vessels or those of the extremities (ergotism), or of rapid elevation of blood pressure	CONTRAINDICATION	
1025			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer	Precaution for use	
1026			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Variation of the effect of the vitamin K antagonist, most often by decreasing it	Precaution for use	
1027			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ATORVASTATIN	83367			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Not recommended	
1028			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ATOVAQUONE	60212			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism	Not recommended	
1029			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome, even of adrenal insufficiency	Take into account	
1030			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	BOCEPREVIR	1102129			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure	Not recommended	
1031			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	BUPRENORPHINE	1819			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of increase or decrease of the effects of the buprenorphine, due to both inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
1032			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	CLARITHROMYCIN	21212			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of the clarithromycin and of its active metabolite due to decrease of its hepatic metabolism by the protease inhibitor	Precaution for use	
1033			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	CYPROTERONE	3014			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the effectiveness of the cyyproterone.	Not recommended	
1034			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	DEXAMETHASONE	3264			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushings syndrome	Take into account	
1035			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	DIGOXIN	3407			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the digoxinemia, more marked for intravenous route, due to increase of the absorption of the digoxin or decrease of its renal clearance.	Precaution for use	
1036			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ERIBULINE	1045453			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of eribuline by the ritonavir	Not recommended	
1037			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of the hormonal contraceptive, because of the increase of its hepatic metabolism by the ritonavir.	Not recommended	
1038			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			THYROID HORMONES	H03AA	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of reduction of the effectiveness of the thyroid hormones due to increase of their hepatic metabolism by the ritonavir	Precaution for use	
1039			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			IMMUNOSUPPRESSANTS	L04A	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
1040			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of increase of the plasma concentration of the ritonavir boosted protease inhibitor or of the CYP3A4 inhibitor.	Take into account	
1041			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ITRACONAZOLE	28031			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of increase of the concentrations of itraconazole by the protease inhibitor	Precaution for use	
1042			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	LAMOTRIGINE	28439			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir	Not recommended	
1043			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	LUMEFANTRINE	847728			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1044			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	METHADONE	6813			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir	Precaution for use	
1045			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ST JOHNS WORT	258326			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)	CONTRAINDICATION	
1046			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	MIZOLASTINE	61455			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1047			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	NINTEDANIB	1592737			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of nintedanib due to increase of its absorption by the ritonavir boosted protease inhibitor	Precaution for use	
1048			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			PROGESTIN CONTRACEPTIVES	G03-001	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir	Not recommended	
1049			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	QUINIDINE	9068			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1050			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	RIFABUTIN	55672			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin, for another thing.	Precaution for use	
1051			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	RIFAMPICIN	9384			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	CONTRAINDICATION	
1052			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ROSUVASTATIN	301542			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption	Precaution for use	
1053			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	SIMVASTATIN	36567			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metoblism of the simvastatin).	CONTRAINDICATION	
1054			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	TELAPREVIR	1102261			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure.	Not recommended	
1055			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	TENEFOVIR ALAFENAMIDE	1721603			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	With the atazanavir, the darunavir or the lopinavir, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	
1056			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism	Precaution for use	
1057			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ULIPRISTAL	1005921			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir	Not recommended	
1058			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	VENLAFAXINE	39786			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
1059			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002			VINCA ALKALOIDS	L01CA	ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor.	Precaution for use	
1060			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	VORICONAZOLE	121243			ANSM	289-RITONAVIR-BOOSTED-PROTEASE-INHIBITORS.html	Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment	Not recommended	
1061	ALPRAZOLAM	596					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	28-ALPRAZOLAM.html	Possible increase of the sedative effect of the alprazolam	Take into account	
1062			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the enzymatic inducer	Not recommended	
1063			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE			H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Risk of decrease of the bioavailability of the tyrosine-kinase inhibitor, by reason of its pH dependent absorption	Take into account	
1064			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE			PROTON PUMP INHIBITORS	A02BC-001	ANSM	290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Risk of decrease of the bioavailability of the tyrosine-kinase inhibitor, by reason of its pH dependent absorption	Take into account	
1065			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Risk of increase of the undesirable effects of the tyrosine kinase inhibitor due to decrease of its metabolism	Not recommeded:	
1066			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ST JOHNS WORT	258326			ANSM	290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns wort	CONTRAINDICATION	
1067			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	RIFAMPICIN	9384			ANSM	290-METABOLIZED-TYROSINE-KINASE-INHIBITORS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
1068			DIRECT THROMBIN INHIBITORS	BO1AE	OTHER MEDICATIONS ACTING ON HEMOSTASIS				ANSM	291-DIRECT-THROMBIN-INHIBITORS.html	Increase of the risk of hemorrhage	Take into account	
1069			STRONG INHIBITORS OF CYP3A4	J02-J05			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of constriction of the coronary arteries or of those of the extremities (ergotism), or of rapid elevation of blood pressure.	CONTRAINDICATION	
1070			STRONG INHIBITORS OF CYP3A4	J02-J05	ALFENTANIL	480			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism.	Precaution for use	
1071			STRONG INHIBITORS OF CYP3A4	J02-J05	ALFUZOSIN	17300			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the alfuzosin and of its undesirable effects	CONTRAINDICATION	
1072			STRONG INHIBITORS OF CYP3A4	J02-J05	ALRRAZOLAM	596			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Possible increase of the sedative effect of the alprazolam	Take into account	
1073			STRONG INHIBITORS OF CYP3A4	J02-J05			CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.	Precaution for use	
1074			STRONG INHIBITORS OF CYP3A4	J02-J05			URINARY ANTISPASMODICS	DFST	ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects	Contraindication	
1075			STRONG INHIBITORS OF CYP3A4	J02-J05	APIXABAN	1364430			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the apixaban by the inhibitor, with increased risk of bleeding	Not recommended	
1076			STRONG INHIBITORS OF CYP3A4	J02-J05	BEDAQUILINE	1364504			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor.	Not recommended	
1077			STRONG INHIBITORS OF CYP3A4	J02-J05	BORTEZOMIB	358258			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.	Precaution for use	
1078			STRONG INHIBITORS OF CYP3A4	J02-J05	BOSENTAN	75207			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increased risk of the undesirable effects of the bosentan, especially of hepatic attacks, due to decrease of its metabolism by the inhibitor	Precaution for use	
1079			STRONG INHIBITORS OF CYP3A4	J02-J05	BRENTUXIMAB	1147320			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of the active metabolite of the brentuximab, with risk of neutropenia	Take into account	
1080			STRONG INHIBITORS OF CYP3A4	J02-J05	CABAZITAXEL	996051			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable dose dependent effects of the cabazitaxel due to inhibition of its metabolism by the enzyme inhibitor	Precaution for use	
1081			STRONG INHIBITORS OF CYP3A4	J02-J05	COBICISTAT	1306284			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the cobicistat or of the inhibitor of CYP3A4	Take into account	
1082			STRONG INHIBITORS OF CYP3A4	J02-J05	COLCHICINE	2683			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	Contraindication	
1083			STRONG INHIBITORS OF CYP3A4	J02-J05	DACLATASVIR	1606218			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of daclatasvir by the inhibitor	Precaution for use	
1084			STRONG INHIBITORS OF CYP3A4	J02-J05	DAPOXETINE	69394			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects, especially of the vertigo or fainting type.	CONTRAINDICATION	
1085			STRONG INHIBITORS OF CYP3A4	J02-J05	DISOPYRAMIDE	3541			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the disopyramide due to decrease of its metabolism	Precaution for use	
1086			STRONG INHIBITORS OF CYP3A4	J02-J05	DOCETAXEL	72962			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable dose-dependent effects of the docetaxel due to inhibition of its metabolism by the enzyme inhibitor	Precaution for use	
1087			STRONG INHIBITORS OF CYP3A4	J02-J05	DOMPERIDONE	3626			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of domperidone due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1088			STRONG INHIBITORS OF CYP3A4	J02-J05	DRONEDARONE	233698			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Large increase of the concentrations of dronedarone due to decrease of its metabolism	CONTRAINDICATION	
1089			STRONG INHIBITORS OF CYP3A4	J02-J05	EPLERENONE	298869			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the eplerenone by the inhibitor and of its undesirable effects, especially hyperkalemia	CONTRAINDICATION	
1090			STRONG INHIBITORS OF CYP3A4	J02-J05	FENTANYL	4337			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the opioid analgesic's effect of respiratory depression due to slight decrease of its hepatic metabolism	Precaution for use	
1091			STRONG INHIBITORS OF CYP3A4	J02-J05	HALOFANTRINE	50749			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1092			STRONG INHIBITORS OF CYP3A4	J02-J05	IDELALISIB	1544460			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increaese of the plasma concentrations of idelalisib due to decrease of its hepatic metabolism by the inhibitor	Take into account	
1093			STRONG INHIBITORS OF CYP3A4	J02-J05			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase (very large for avanafil and vardenafil) of the plasma concentrations of the type 5 phospodiesterase inhibitor, with risk of hypotension (severe with vardenafil)	Contraindication - Not recommended - Precaution for use	
1094			STRONG INHIBITORS OF CYP3A4	J02-J05			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of the ritonavir boosted protease inhibitor or of the inhibitor of CYP3A4	Take into account	
1095			STRONG INHIBITORS OF CYP3A4	J02-J05			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the tyrosine kinase inhibitor due to decrease of its metabolism	Not recommended	
1096			STRONG INHIBITORS OF CYP3A4	J02-J05	IRINOTECAN	51499			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite	Not recommended	
1097			STRONG INHIBITORS OF CYP3A4	J02-J05	ISAVUCONAZOLE	1720882			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of isavuconazole due to decrease of its hepatic metabolism by the inhibitor	Contraindication	
1098			STRONG INHIBITORS OF CYP3A4	J02-J05	IVABRADINE	77417			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).	CONTRAINDICATION	
1099			STRONG INHIBITORS OF CYP3A4	J02-J05	IVACAFTOR	1243041			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Large increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	
1100			STRONG INHIBITORS OF CYP3A4	J02-J05	LOMITAPIDE	1364479			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the lomitapide due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1101			STRONG INHIBITORS OF CYP3A4	J02-J05	LURASIDONE	1040028			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the lurasidone due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1102			STRONG INHIBITORS OF CYP3A4	J02-J05	MARAVIROC	620216			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of maraviroc by the inhibitor.	Precaution for use	
1103			STRONG INHIBITORS OF CYP3A4	J02-J05	METHYLPREDNISOLONE	6902			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	In case of prolonged use, increase of the plasma concentration of the corticoid due to decrease of its hepatic metabolism by the in inhibitor, with risk of appearance of a cushings syndrome	Take into account	
1104			STRONG INHIBITORS OF CYP3A4	J02-J05	MIDAZOLAM	6960			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Not recommended	
1105			STRONG INHIBITORS OF CYP3A4	J02-J05	OLAPARIB	1597582			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the olaparib by the inhibitor	Not recommended	
1106			STRONG INHIBITORS OF CYP3A4	J02-J05			OMBITASVIR + PARITAPREVIR	OMPA	ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the ombitsavir + paritaprevir combination due to decrease of its hepatic metabolism by the inhibitor.	CONTRAINDICATION	
1107			STRONG INHIBITORS OF CYP3A4	J02-J05	OXYCODONE	7804			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the inhibitor	Not recommended	
1108			STRONG INHIBITORS OF CYP3A4	J02-J05	PANOBINOSTAT	1603350			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects, especially cardiac ones, of the panobinostat due to decrease of its metabolism by the inhibitor	Precaution for use	
1109			STRONG INHIBITORS OF CYP3A4	J02-J05	PIMOZIDE	8331			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk increase of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1110			STRONG INHIBITORS OF CYP3A4	J02-J05	QUETIAPINE	51272			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Large increase of the concentrations of quetiapine, with risk of overdose	CONTRAINDICATION	
1111			STRONG INHIBITORS OF CYP3A4	J02-J05	QUININE	9071			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory disorders (cinchonism).	Not recommended	
1112			STRONG INHIBITORS OF CYP3A	J02-J05	RANOLAZINE	35829			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the concentrations of ranolazine due to decrease of its metabolism by the inhibitor	CONTRAINDICATION	
1113			STRONG INHIBITORS OF CYP3A	J02-J05	REGORAFENIB	1312397			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
1114			STRONG INHIBITORS OF CYP3A4	J02-J05	RIOCIGUAT	1439816			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of riociquat due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
1115			STRONG INHIBITORS OF CYP3A4	J02-J05	RIVAROXABAN	1114195			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of rivaroxaban, with increase of the risk of bleeding	Not recommended	
1116			STRONG INHIBITORS OF CYP3A4	J02-J05	SIMEPREVIR	1482790			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the plasma concentrations of simeprevir due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
1117			STRONG INHIBITORS OF CYP3A4	J02-J05			SUBSTRATES AT RISK OF CYP3A4	L01N01	ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the undesirable effects specific to each substrate, with frequently severe consequences	Take into account	
1118			STRONG INHIBITORS OF CYP3A4	J02-J05	SUFENTANIL	56795			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the opioid analgesic's effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	
1119			STRONG INHIBITORS OF CYP3A4	J02-J05	TAMSULOSIN	77492			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism	Not recommended	
1120			STRONG INHIBITORS OF CYP3A4	J02-J05	TELITHROMYCIN	274786			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Risk of increase of the undesirable effects, especially of the cardiac arrhythmia type.	CONTRAINDICATION	
1121			STRONG INHIBITORS OF CYP3A4	J02-J05	TICAGRELOR	1116632			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1122			STRONG INHIBITORS OF CYP3A4	J02-J05	TRASTUZUMAB EMTANSINE				ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Increase of the plasma concentrations of the DM1, a componant element of the trastuzumab emtansine, due to inhibition of its metabolism by the inhibitor	Not recommended	
1123			STRONG INHIBITORS OF CYP3A4	J02-J05	VERAPAMIL	11170			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor	Precaution for use	
1124			STRONG INHIBITORS OF CYP3A4	J02-J05	ZOLPIDEM	39993			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Slight increase of the sedative effect of the zolpidem	Take into account	
1125			STRONG INHIBITORS OF CYP3A4	J02-J05	ZOPICLONE	40001			ANSM	292-STRONG-INHIBITORS-OF-CYP3A4.html	Slight increase of the sedative effect of the zopiclone	Take into account	
1126			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ACETYLSALICYLIC ACID	1191			ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
1127			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			ORAL ANTICOAGULANTS	B01A-001	ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Precaution for use	
1128			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects	Precaution for use	
1129			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Increase of the risk of hemorrhage	Take into account	
1130			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	CYPROHEPTADINE	3013			ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of decrease of the effectiveness of the antidepressant	Take into account	
1131			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
1132			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not recommended	
1133			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			MAOI-B	N04BD0-001	ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome	Take into account	
1134			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	LITHIUM	6448			ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome	Precaution for use	
1135			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ST JOHNS WORT	258326			ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome	Precaution for use	
1136			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ORLISTAT	37925			ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1137			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	TRAMADOL	10689			ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
1138			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB			TRIPTANS	N02CC-001	ANSM	293-SELECTIVE-SEROTONIN-REUPTAKE-INHIBITORS-(SSRIs).html	Risk of appearance of a serotonin syndrome	Take into account	
1139	INSULIN	5856			ALCOHOL (DRINK OR INGREDIENT)				ANSM	294-INSULIN.html	Increase of the hypoglycemic reaction (inhibition of the compensation reactions which can facilitate the onset of hypoglycemic coma)	Not recommended	
1140	INSULIN	5856					SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	294-INSULIN.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	
1141	INSULIN	5856					BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	ANSM	294-INSULIN.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	
1142	INSULIN	5856					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	294-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
1143	INSULIN	5856					BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	294-INSULIN.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
1144	INSULIN	5856			CHLORPROMAZINE	2403			ANSM	294-INSULIN.html	With large dosages (100 mg per day of chlorpromazine): elevation of the glycemia (decrease of the freeing of the insulin)	Precaution for use	
1145	INSULIN	5856			DANAZOL	3102			ANSM	294-INSULIN.html	Diabetes inducing effect of the danazol	Not recommended	
1146	INSULIN	5856					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	294-INSULIN.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in a diabetic treated with insulin. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for insulin).	Precaution for use	
1147	INTERFERON ALFA						FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ANSM	295-INTERFERON-ALFA.html	Increase of the gastrointestinal toxicity of the fluorouracil	Take into account	
1148	IPILIMUMAB	1094833					ORAL ANTICOAGULANTS	B01A-001	ANSM	296-IPILIMUMAB.html	Increase of the risk of digestive system hemorrhage	Precaution for use	
1149	IRINOTECAN	51499					ENZYMATIC INDUCERS	N03-J05-001	ANSM	297-IRINOTECAN.html	Probable decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	Not recommended	
1150	IRINOTECAN	51499					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	297-IRINOTECAN.html	Risk of increase of the undesirable effects of the irinotecan due to increase of the plasma concentrations of its active metabolite	Not recommended	
1151	IRINOTECAN	51499			ST JOHNS WORT	258326			ANSM	297-IRINOTECAN.html	Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	CONTRAINDICATION	
1152	ISAVUCONAZOLE	1720882					ENZYMATIC INDUCERS	N03-J05-001	ANSM	298-ISAVUCONAZOLE.html	Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
1153	ISAVUCONAZOLE	1720882					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	298-ISAVUCONAZOLE.html	Increase of the plasma concentrations of isavuconazole due to decrease of its hepatic metabolism by the inhibitor	Contraindication	
1154	ISAVUCONAZOLE	1720882			ST JOHN'S WORT	258326			ANSM	298-ISAVUCONAZOLE.html	Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1155	ISONIAZID	6038					HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	299-ISONIAZID.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	
1156	ISONIAZID	6038			CARBAMAZEPINE	2002			ANSM	299-ISONIAZID.html	Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism	Not recommended	
1157	ISONIAZID	6038			DISULFIRAM	3554			ANSM	299-ISONIAZID.html	Disorders of behavior and of coordination	Not recommended	
1158	ISONIAZID	6038					GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	299-ISONIAZID.html	Described for the prednisolone. Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides	Precaution for use	
1159	ISONIAZID	6038			KETOCONAZOLE	6135			ANSM	299-ISONIAZID.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	
1160	ISONIAZID	6038					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	299-ISONIAZID.html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	
1161	ISONIAZID	6038			PYRAZINAMIDE	8987			ANSM	299-ISONIAZID.html	Addition of the hepatotoxic effects.	Precaution for use	
1162	ISONIAZID	6038			RIFAMPICIN	9384			ANSM	299-ISONIAZID.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	
1163	ISONIAZID	6038			STAVUDINE	59763			ANSM	299-ISONIAZID.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	
1164			ALUMINUM (SALTS)	A02AD0-001			CITRATES	V09HX	ANSM	29-ALUMINUM-(SALTS).html	Risk of facilitating systemic uptake of the aluminum salts especially when there is altered renal function	Precaution for use	
1165	ABIRATERONE	1100072					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	2-ABIRATERONE.html	Notable decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
1166	ABIRATERONE	1100072			FLECAINIDE	4441			ANSM	2-ABIRATERONE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use	
1167	ABIRATERONE	1100072			METOPROLOL	6918			ANSM	2-ABIRATERONE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use	
1168	ABIRATERONE	1100072			PROPAFENONE	8754			ANSM	2-ABIRATERONE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone	Precaution for use	
1169	ABIRATERONE	1100072			RIFAMPICIN	9384			ANSM	2-ABIRATERONE.html	Substantial decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
1170	ISOPRENALINE	6054					HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	300-ISOPRENALINE.html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
1171	ITRACONAZOLE	28031			AFATINIB	1430438			ANSM	301-ITRACONAZOLE.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the itraconazole.	Precaution for use	
1172	ITRACONAZOLE	28031			ALISKIREN	325646			ANSM	301-ITRACONAZOLE.html	Increase by nearly six times of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	CONTRAINDICATION	
1173	ITRACONAZOLE	28031					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	301-ITRACONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
1174	ITRACONAZOLE	28031					PROTON PUMP INHIBITORS	A02BC-001	ANSM	301-ITRACONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the proton pump inhibitor	Take into account	
1175	ITRACONAZOLE	28031					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	301-ITRACONAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
1176	ITRACONAZOLE	28031			APREPITANT	358255			ANSM	301-ITRACONAZOLE.html	Increase of the concentrations of aprepitant due to decrease of its hepatic metabolism by the intraconazole.	Take into account	
1177	ITRACONAZOLE	28031			ATORVASTATIN	83367			ANSM	301-ITRACONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
1178	ITRACONAZOLE	28031					OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ANSM	301-ITRACONAZOLE.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the itraconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency	Take into account	
1179	ITRACONAZOLE	28031			BUPRENORPHINE	1819			ANSM	301-ITRACONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	
1180	ITRACONAZOLE	28031			BUSPIRONE	1827			ANSM	301-ITRACONAZOLE.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism, with substantial increase of sedation	Not recommended	
1181	ITRACONAZOLE	28031			BUSULFAN	1828			ANSM	301-ITRACONAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the itraconazole	Not recommended	
1182	ITRACONAZOLE	28031			COBICISTAT	1306284			ANSM	301-ITRACONAZOLE.html	Risk of increase of the concentrations of itraconazole by the cobicistat	Precaution for use	
1183	ITRACONAZOLE	28031			DABIGATRAN				ANSM	301-ITRACONAZOLE.html	Increase of more than double the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
1184	ITRACONAZOLE	28031			DEXAMETHASONE	3264			ANSM	301-ITRACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushing's syndrome	Take into account	
1185	ITRACONAZOLE	28031			DIGOXIN	3407			ANSM	301-ITRACONAZOLE.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias	Precaution for use	
1186	ITRACONAZOLE	28031			EBASTINE	23796			ANSM	301-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
1187	ITRACONAZOLE	28031			ELVITEGRAVIR	1306286			ANSM	301-ITRACONAZOLE.html	Increase of the plasma concentrations of elvitegravir due to decrease of its metabolism by the itraconazole	Precaution for use	
1188	ITRACONAZOLE	28031			HYDROQUINIDINE	27220			ANSM	301-ITRACONAZOLE.html	Risk of tinnitis and/or loss of hearing acuity: cinchonism linked to a decrease of the hepatic metabolism of the antiarrhythmic by the itraconazole	Precaution for use	
1189	ITRACONAZOLE	28031					IMMUNOSUPPRESSANTS	L04A	ANSM	301-ITRACONAZOLE.html	Very large increase of the blood concentrations of the immusuppressant due to inhibition of its hepatic metabolism	Not recommended	
1190	ITRACONAZOLE	28031					ENZYME INDUCERS	N03-J05-001	ANSM	301-ITRACONAZOLE.html	Decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the inducer.	Not recommended	
1191	ITRACONAZOLE	28031					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	301-ITRACONAZOLE.html	Risk of increase of the concentrations of itraconazole by the protease inhibitor	Precaution for use	
1192	ITRACONAZOLE	28031			LERCANIDIPINE	135056			ANSM	301-ITRACONAZOLE.html	Increased risk of undesirable effects, especially of edema, due to decrease of the hepatic metabolism of the dihydorpyridine	Not recommended	
1193	ITRACONAZOLE	28031			LUMEFANTRINE	847728			ANSM	301-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1194	ITRACONAZOLE	28031			ST JOHNS WORT	258326			ANSM	301-ITRACONAZOLE.html	Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1195	ITRACONAZOLE	28031			MIZOLASTINE	61455			ANSM	301-ITRACONAZOLE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1196	ITRACONAZOLE	28031			NINTEDANIB	1592737			ANSM	301-ITRACONAZOLE.html	Increase of the plasma concentrations of the nintedanib due to increase of its absorption by the itraconazole	Precaution for use	
1197	ITRACONAZOLE	28031			QUINIDINE	9068			ANSM	301-ITRACONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine	CONTRAINDICATION	
1198	ITRACONAZOLE	28031			SALMETEROL	36117			ANSM	301-ITRACONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole	Take into account	
1199	ITRACONAZOLE	28031			SIMVASTATIN	36567			ANSM	301-ITRACONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolosis type (decrease of the hepatic metabolism of the simvastatin)	CONTRAINDICATION	
1200	ITRACONAZOLE	28031			TELAPREVIR	1102261			ANSM	301-ITRACONAZOLE.html	Risk of increase of the plasma concentrations of telaprevir and of the itraconazole.	Precaution for use	
1201	ITRACONAZOLE	28031			TENEFOVIR ALAFENAMIDE	1721603			ANSM	301-ITRACONAZOLE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption.	Precaution for use	
1202	ITRACONAZOLE	28031			TRABECTEDIN	1716278			ANSM	301-ITRACONAZOLE.html	Risk of increase of the plasma concentrations of the trabectedin by the itraconazole	Not recommended	
1203	ITRACONAZOLE	28031			VENLAFAXINE	39786			ANSM	301-ITRACONAZOLE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
1204	ITRACONAZOLE	28031					VINCA ALKALOIDS	L01CA	ANSM	301-ITRACONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the itraconazole	Not recommended	
1205	IVABRADINE	77417					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	302-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer.	Precaution for use	
1206	IVABRADINE	77417			AZITHROMYCIN	18631			ANSM	302-IVABRADINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes. In addition, increase of the plasma concentrations of the ivabradine due to decrease of its metabolism by the azithromycin	Precaution for use	
1207	IVABRADINE	77417			DILTIAZEM	3443			ANSM	302-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the diltiazem), that add to the bradycardia inducing effects of these molecules	CONTRAINDICATION	
1208	IVABRADINE	77417					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	302-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the inhibitor).	CONTRAINDICATION	
1209	IVABRADINE	77417			JOSAMYCIN	6084			ANSM	302-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).	CONTRAINDICATION	
1210	IVABRADINE	77417			ST JOHNS WORT	258326			ANSM	302-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the St Johns wort	Not recommended	
1211	IVABRADINE	77417			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	302-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit).	Not recommended	
1212	IVABRADINE	77417			RIFAMPICIN	9384			ANSM	302-IVABRADINE.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin	Precaution for use	
1213	IVABRADINE	77417			VERAPAMIL	11170			ANSM	302-IVABRADINE.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules	CONTRAINDICATION	
1214	IVACAFTOR	1243041			FLUCONAZOLE	4450			ANSM	303-IVACAFTOR.html	Increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	
1215	IVACAFTOR	1243041					ENZYMATIC INDUCERS	N03-J05-001	ANSM	303-IVACAFTOR.html	Large decrease of the concentrations of the ivacaftor, with risk of loss of effectiveness	Not recommended	
1216	IVACAFTOR	1243041					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	303-IVACAFTOR.html	Large increase of the concentrations of ivacaftor, with risks of increase of its undesirable effects	Precaution for use	
1217	JOSAMYCIN	6084			CARBAMAZEPINE	2002			ANSM	304-JOSAMYCIN.html	Increase of the plasma concentrations of carbamazepine with signs of overdose, due to decrease of its hepatic metabolism	Precaution for use	
1218	JOSAMYCIN	6084			CICLOSPORIN	3008			ANSM	304-JOSAMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	
1219	JOSAMYCIN	6084			DISOPYRAMIDE	3541			ANSM	304-JOSAMYCIN.html	Risk of increase of the undesirable effects of the disopyramide: severe hypoglyclemia, lengthening of the QT interval, and serious ventricular arrhythmias, especially of the torsades de pointes type	Not recommended	
1220	JOSAMYCIN	6084			EBASTINE	23796			ANSM	304-JOSAMYCIN.html	Increased risk of ventricular arrhythmias in predisposed patients (congenital long QT syndrome)	Not recommended	
1221	JOSAMYCIN	6084			HALOFANTRINE	50749			ANSM	304-JOSAMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1222	JOSAMYCIN	6084			IVABRADINE	77417			ANSM	304-JOSAMYCIN.html	Increase of the plasma concentrations of the ivabradine and consequently of its undesirable effects (inhibition of its hepatic metabolism by the josamycin).	CONTRAINDICATION	
1223	JOSAMYCIN	6084			PIMOZIDE	8331			ANSM	304-JOSAMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1224	JOSAMYCIN	6084			SILDENAFIL	136411			ANSM	304-JOSAMYCIN.html	Increase of the plasma concentrations of sildenafil, with risk of hypotension	Precaution for use	
1225	JOSAMYCIN	6084			TACROLIMUS	42316			ANSM	304-JOSAMYCIN.html	Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin	Not recommended	
1226	JOSAMYCIN	6084					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	304-JOSAMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
1227	KETOCONAZOLE	6135			AFATINIB	1430438			ANSM	305-KETOCONAZOLE.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the ketoconazole.	Precaution for use	
1228	KETOCONAZOLE	6135					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	305-KETOCONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
1229	KETOCONAZOLE	6135					PROTON PUMP INHIBITORS	A02BC-001	ANSM	305-KETOCONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the anitsecretory	Take into account	
1230	KETOCONAZOLE	6135			ATORVASTATIN	83367			ANSM	305-KETOCONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
1231	KETOCONAZOLE	6135					OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ANSM	305-KETOCONAZOLE.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushings syndrome, even adrenal insufficiency	Take into account	
1232	KETOCONAZOLE	6135			BUPRENORPHINE	1819			ANSM	305-KETOCONAZOLE.html	Increase of the concentrations of buprenorphine due to decrease of its hepatic metabolism, with risk of increase of its undesirable effects	Precaution for use	
1233	KETOCONAZOLE	6135			DABIGATRAN				ANSM	305-KETOCONAZOLE.html	Increase of more than double of the plasma concentrations of dabigatran, with increase of the risk of bleeding	CONTRAINDICATION	
1234	KETOCONAZOLE	6135			DEXAMETHASONE	3264			ANSM	305-KETOCONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
1235	KETOCONAZOLE	6135			EBASTINE	23796			ANSM	305-KETOCONAZOLE.html	Increased risk of ventricular arrhythmias with predisposed patients (congenital long QT syndrome)	Not recommended	
1236	KETOCONAZOLE	6135			ELVITEGRAVIR	1306286			ANSM	305-KETOCONAZOLE.html	Increase of the plasma concentrations of elvitegravir due to decrease of its metabolism by the ketoconazole	Precaution for use	
1237	KETOCONAZOLE	6135			FIDAXOMICIN	1111103			ANSM	305-KETOCONAZOLE.html	Increase of the plasma concentrations of the fidaxomicine	Not recommended	
1238	KETOCONAZOLE	6135					IMMUNOSUPPRESSANTS	L04A	ANSM	305-KETOCONAZOLE.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism.	Not recommended	
1239	KETOCONAZOLE	6135			ISONIAZID	6038			ANSM	305-KETOCONAZOLE.html	Decrease of the plasma concentrations of ketoconazole	Precaution for use	
1240	KETOCONAZOLE	6135			LERCANIDIPINE	135056			ANSM	305-KETOCONAZOLE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
1241	KETOCONAZOLE	6135			LUMEFANTRINE	847728			ANSM	305-KETOCONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1242	KETOCONAZOLE	6135			MIZOLASTINE	61455			ANSM	305-KETOCONAZOLE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1243	KETOCONAZOLE	6135			NEVIRAPINE	53654			ANSM	305-KETOCONAZOLE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing	CONTRAINDICATION	
1244	KETOCONAZOLE	6135			NINTEDANIB	1592737			ANSM	305-KETOCONAZOLE.html	Increase of the plasma concentrations of nintedanib due to increase of its absorption by the ketoconazole	Precaution for use	
1245	KETOCONAZOLE	6135			RIFAMPICIN	9384			ANSM	305-KETOCONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
1246	KETOCONAZOLE	6135			SALMETEROL	36117			ANSM	305-KETOCONAZOLE.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
1247	KETOCONAZOLE	6135			SIMVASTATIN	36567			ANSM	305-KETOCONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolisis type (decrease of the hepatic metabolism of the cholesterol lowering substance)	CONTRAINDICATION	
1248	KETOCONAZOLE	6135			TENEFOVIR ALAFENAMIDE	1721603			ANSM	305-KETOCONAZOLE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	
1249	KETOCONAZOLE	6135			VENLAFAXINE	39786			ANSM	305-KETOCONAZOLE.html	Increase of the concentrations of vanlafaxine with risk of overdose	Take into account	
1250	KETOCONAZOLE	6135					VINCA ALKALOIDS	L01CA	ANSM	305-KETOCONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole	Not recommended	
1251	LAMIVUDINE	68244			CLADRIBINE	44157			ANSM	306-LAMIVUDINE.html	Risk of decrease of the effectiveness of the cladribine by the lamivudine	Not recommended	
1252	LAMIVUDINE	68244			ZALCITABINE	3363			ANSM	306-LAMIVUDINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
1253	LAMOTRIGINE	28439			CARBAMAZEPINE	2002			ANSM	307-LAMOTRIGINE.html	Risk of increase of the neurological effects (vertigo, ataxia, diplopia) of the carbamazepine when the lamotrigine is introduced	Precaution for use	
1254	LAMOTRIGINE	28439					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	307-LAMOTRIGINE.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism	Not recommended	
1255	LAMOTRIGINE	28439					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	307-LAMOTRIGINE.html	Risk of decrease of the concentrations and of the effectiveness of the lamotrigine due to increase of its hepatic metabolism by the ritonavir	Not recommended	
1256	LAMOTRIGINE	28439			OXCARBAZEPINE	32624			ANSM	307-LAMOTRIGINE.html	Decrease of the concentrations of the lamotrigine with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	
1257	LAMOTRIGINE	28439					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	307-LAMOTRIGINE.html	Increased risk of serious cutaneous reactions (Lyell's syndrome). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)	Not recommended	
1258	LANSOPRAZOLE	17128			TACROLIMUS	42316			ANSM	308-LANSOPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	
1259	LEDIPASVIR	1591922			AMIODARONE	703			ANSM	309-LEDIPASVIR.html	Only with the bitherapy ledipasvir/sofosbuvir, onset of bradycardia, possibly abruptly, which can have fatal consequences.	Not recommended	
1260	LEDIPASVIR	1591922					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	309-LEDIPASVIR.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzymatic inducer.	CONTRAINDICATION	
1261	LEDIPASVIR	1591922					PROTON PUMP INHIBITORS	A02BC-001	ANSM	309-LEDIPASVIR.html	Decrease of the concentrations of the ledipasvir when the proton pump inhibitor is administered before the ledipasvir	Precaution for use	
1262	LEDIPASVIR	1591922					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	309-LEDIPASVIR.html	Risk of increase of the plasma concentrations of the statin and of its undesirable effects of the rhabdomyolysis type	Contraindication	
1263	LEDIPASVIR	1591922			ST JOHNS WORT	258326			ANSM	309-LEDIPASVIR.html	Risk of large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1264	LEDIPASVIR	1591922			RIFAMPICIN	9384			ANSM	309-LEDIPASVIR.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the ripampicin	CONTRAINDICATION	
1265	LEDIPASVIR	1591922			TENOFOVIR DISOPROXIL	300195			ANSM	309-LEDIPASVIR.html	When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir	Precaution for use	
1266	AMBRISENTAN	358274			CICLOSPORIN	3008			ANSM	30-AMBRISENTAN.html	Doubling of the concentrations of ambrisentan, with increase of the vasodilator effect (severe headaches )	Take into account	
1267	LENALIDOMIDE	342369					HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	310-LENALIDOMIDE.html	Increased risk of onset of rhabdomyolysis	Precaution for use	
1268	LERCANIDIPINE	135056			CICLOSPORIN	3008			ANSM	311-LERCANIDIPINE.html	Moderate increase of the blood concentrations of the immunosuppressant and more notable increase of the concentrations of the lercanidipine	Precaution for use	
1269	LERCANIDIPINE	135056			ITRACONAZOLE	28031			ANSM	311-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydorpyridine	Not recommended	
1270	LERCANIDIPINE	135056			KETOCONAZOLE	6135			ANSM	311-LERCANIDIPINE.html	Increased risk of undesirable effects, especially edema, due to decrease of the hepatic metabolism of the dihydropyridine	Not recommended	
1271	LERCANIDIPINE	135056			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	311-LERCANIDIPINE.html	Increased risk of undesirable effects, especially of edema, due to decrease of the intestinal metabolism of the dihydropyridine	Take into account	
1272	LEVOCARNITINE	42955					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	312-LEVOCARNITINE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrage	Precaution for use	
1273	LEVODOPA	6375			BACLOFEN	1292			ANSM	313-LEVODOPA.html	Risk of aggravation of the Parkinsonian syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)	Take into account	
1274	LEVODOPA	6375			IRON	1431589			ANSM	313-LEVODOPA.html	Decrease of the digestive absorption of the levodopa	Precaution for use	
1275	LEVODOPA	6375					MAOI-B	N04BD0-001	ANSM	313-LEVODOPA.html	Increase of the risk of orthostatic hypotension	Take into account	
1276	LEVODOPA	6375			METHYLDOPA	6876			ANSM	313-LEVODOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	
1277	LEVODOPA	6375					ANTIEMITIC NEUROLEPTICS	A03FA-001	ANSM	313-LEVODOPA.html	Reciprocal antagonism between the levodopa and the neuroleptic	CONTRAINDICATION	
1278	LEVODOPA	6375					ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	313-LEVODOPA.html	Reciprocal antagonism between the levodopa and the neuroleptics	Not recommended	
1279	LEVODOPA	6375			RESERPINE	9260			ANSM	313-LEVODOPA.html	Inhibition of the effects of the levodopa	CONTRAINDICATION	
1280	LEVODOPA	6375			SPIRAMYCIN	9991			ANSM	313-LEVODOPA.html	When administered with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	
1281	LEVODOPA	6375			TETRABENAZINE	10390			ANSM	313-LEVODOPA.html	Reciprocal antagonism between the levodopa and the tetrabenazine	Not recommended	
1282	LEVOFLOXACINE	82122					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	314-LEVOFLOXACIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
1283	LIDOCAINE	6387			AMIODARONE	703			ANSM	315-LIDOCAINE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precautions for use	
1284	LIDOCAINE	6387					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	315-LIDOCAINE.html	With the lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	
1285	LIDOCAINE	6387					BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	315-LIDOCAINE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
1286	LIDOCAINE	6387			CIMETIDINE	2541			ANSM	315-LIDOCAINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of lidocaine with risk of undesirable neurological and cardiac effects (inhibition of the hepatic metabolism of the lidocaine)	Precaution for use	
1287	LIDOCAINE	6387			FLUVOXAMINE	42355			ANSM	315-LIDOCAINE.html	Increase of the plasma concentrations of the lidocaine with possibilities of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	
1288			LINCOSANIDES	J01FF0			CURARES	M03A-001	ANSM	316-LINCOSANIDES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent	Precaution for use	
1289	LINEZOLIDE	190376			CLARITHROMYCIN	21212			ANSM	317-LINEZOLIDE.html	Risk of increase of the undesirable effects of the linezolide by the clarithromycin, due to increase of its absorption	Take into account	
1290	LINEZOLIDE	190376			RIFAMPICIN	9384			ANSM	317-LINEZOLIDE.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	
1291	LITHIUM	6448			ACETAZOLAMIDE	167			ANSM	318-LITHIUM.html	Decrease of the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness	Precautions for use	
1292	LITHIUM	6448					ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	318-LITHIUM.html	Increase of the the plasma concentrations of lithium that can attain toxic values (decrease of the renal excretion of the lithium).	Not recommended	
1293	LITHIUM	6448					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	318-LITHIUM.html	Increase of the the plasma concentrations of lithium that can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	
1294	LITHIUM	6448			CAFFEINE	1886			ANSM	318-LITHIUM.html	In case of sudden discontinuation of consumption of coffee or of medications containing caffeine, risk of increase of the the plasma concentrations of lithium	Take into account	
1295	LITHIUM	6448			CALCITONIN	36118			ANSM	318-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the calcitonin	Precaution for use	
1296	LITHIUM	6448			CARBAMAZEPINE	2002			ANSM	318-LITHIUM.html	Risk of neurotoxicity manifesting as disorders of the cerebellum, confusion, drowsiness, ataxia. These disorders are reversible when the treatment with lithium is stopped	Not recommended	
1297	LITHIUM	6448					LOOP DIURETICS	C03CA-001	ANSM	318-LITHIUM.html	Increase of the the plasma concentrations of lithium with signs of overdose of lithium as with a low sodium regimen (decrease of the urinary excretion of the lithium)	Not recommended	
1298	LITHIUM	6448					POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	318-LITHIUM.html	Increase of the the plasma concentrations of lithium with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)	Precaution for use	
1299	LITHIUM	6448					THIAZIDE DIURETICS AND RELATED	C03-003	ANSM	318-LITHIUM.html	Increase of the the plasma concentrations of lithium with signs of overdose of lithium, as with a low sodium regimen (decrease of the urinary excretion of the lithium)	Not recommended	
1300	LITHIUM	6448			GLYCEROL	4910			ANSM	318-LITHIUM.html	Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness	Precaution for use	
1301	LITHIUM	6448					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	318-LITHIUM.html	Increase of the the plasma concentrations of lithium which can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	
1302	LITHIUM	6448					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	318-LITHIUM.html	Risk of appearance of a serotonin syndrome	Precaution for use	
1303	LITHIUM	6448			MANNITOL	6628			ANSM	318-LITHIUM.html	Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness	Precaution for use	
1304	LITHIUM	6448			METHYLDOPA	6876			ANSM	318-LITHIUM.html	Increase of the the plasma concentrations of lithium which can attain toxic values, with signs of overdose of lithium	Precaution for use	
1305	LITHIUM	6448			METRONIDAZOLE	6922			ANSM	318-LITHIUM.html	Increase of the the plasma concentrations of lithium which can attain toxic values with signs of overdose of lithium.	Precaution for use	
1306	LITHIUM	6448					NEUROLEPTICS	N05AA-003	ANSM	318-LITHIUM.html	Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning	Precaution for use	
1307	LITHIUM	6448			ORLISTAT	37925			ANSM	318-LITHIUM.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1308	LITHIUM	6448			SODIUM BICARBONATE				ANSM	318-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	
1309	LITHIUM	6448			SODIUM CHLORIDE	9863			ANSM	318-LITHIUM.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts.	Precaution for use	
1310	LITHIUM	6448			THEOPHYLLINE	10438			ANSM	318-LITHIUM.html	Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness	Precaution for use	
1311	LITHIUM	6448			TOPIRAMATE	38404			ANSM	318-LITHIUM.html	For doses of topiramate >= 200 mg/day: increase of the the plasma concentrations of lithium that can reach toxic values, with signs of overdose of lithium.	Precaution for use	
1312	LOMITAPIDE	1364479					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	319-LOMITAPIDE.html	Increase of the plasma concentrations of the lomitapide due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1313	LOMITAPIDE	1364479			ST JOHNS WORT	258326			ANSM	319-LOMITAPIDE.html	Risk of decrease of the plasma concentrations of the lomitapide	Not recommended	
1314	AMINOGLUTETHIMIDE	677					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	31-AMINOGLUTETHIMIDE.html	Described for warfarin and acenocoumarol. Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide.	Precaution for use	
1315	AMINOGLUTETHIMIDE	677			DEXAMETHASONE	3264			ANSM	31-AMINOGLUTETHIMIDE.html	Decrease of the effectiveness of the dexamethasone, due to increase of its hepatic metabolism	Precaution for use	
1316	LOMUSTINE	6466			CIMETIDINE	2541			ANSM	320-LOMUSTINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increased bone marrow toxicity (inhibition of the metabolism of the lomustine)	Not recommended	
1317	LOSARTAN	52175			FLUCONAZOLE	4450			ANSM	321-LOSARTAN.html	Risk of decrease of the effectiveness of the losartan, due to inhibition of the formation of its active metabolite by the fluconazole	Take into account	
1318	LUMEFANTRINE	847728			CLARITHROMYCIN	21212			ANSM	322-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1319	LUMEFANTRINE	847728			ERYTHROMYCIN	4053			ANSM	322-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1320	LUMEFANTRINE	847728					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	322-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1321	LUMEFANTRINE	847728			ITRACONAZOLE	28031			ANSM	322-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1322	LUMEFANTRINE	847728			KETOCONAZOLE	6135			ANSM	322-LUMEFANTRINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1323	LURASIDONE	1040028					ENZYMATIC INDUCERS	N03-J05-001	ANSM	323-LURASIDONE.html	Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
1324	LURASIDONE	1040028					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	323-LURASIDONE.html	Increase of the plasma concentrations of the lurasidone due to decrease of its hepatic metabolism by the inhibitor	CONTRANDICATION	
1325	LURASIDONE	1040028			ST JOHN'S WORT	258326			ANSM	323-LURASIDONE.html	Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1326	LURASIDONE	1040028			GRAGEFRUIT (JUICE AND FRUIT)				ANSM	323-LURASIDONE.html	Increase of the plasma concentrations of the lurasidone due to decrease of its metabolism by the grapefruit	Not recommended	
1327	MACITENTAN	1442132					ENZYMATIC INDUCERS	N03-J05-001	ANSM	324-MACITENTAN.html	Decrease of the plasma concentrations of macitentan due to increase of its metabolism by the inducer	Not recommended	
1328	MACITENTAN	1442132			ST JOHNS WORT	258326			ANSM	324-MACITENTAN.html	Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort	Not recommended	
1329			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Increase of the plasma concentrations of the dopaminergic with possible increase of its activity or appearance of signs of overdose.	Not recommended	
1330			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
1331			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	COLCHICINE	2683			ANSM	325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Increase of the undesirable effects of the colchicine, with potentially fatal consequences	CONTRAINDICATION	
1332			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	DIHYDROERGOTAMINE	3418			ANSM	325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye).	CONTRAINDICATION	
1333			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ERGOTAMINE	4025			ANSM	325-MACROLIDES-(EXCEPT-SPIRAMYCIN).html	Ergotism with possibility of necrosis of the extremeties (decrease of the hepatic elimination of the ergotamine).	CONTRAINDICATION	
1334	MANNITOL	6628			LITHIUM	6448			ANSM	326-MANNITOL.html	Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness	Precaution for use	
1335	MARAVIROC	620216			FOSAMPRENAVIR	358262			ANSM	327-MARAVIROC.html	Significant decrease of the concentrations of amprenavir that could lead to a loss of the virological response	Not recommended	
1336	MARAVIROC	620216					ENZYMATIC INDUCERS	N03-J05-001	ANSM	327-MARAVIROC.html	In the absence of the administration at the same time with a strong inhibitor of CYP3A4, decrease of the concentrations of maraviroc by the inducer	Precaution for use	
1337	MARAVIROC	620216					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	327-MARAVIROC.html	Increase of the concentrations of maraviroc by the inhibitor	Precaution for use	
1338	MARAVIROC	620216			ST JOHNS WORT	258326			ANSM	327-MARAVIROC.html	Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of the virological response	Not recommended	
1339			MEDICATIONS AT THE ORIGIN OF A SEROTONIN SYNDROME	N06A-002			OTHER MEDICATIONS AT THE ORIGIN OF A SEROTONIN SYNDROME	N06A-002	ANSM	328-MEDICATIONS-AT-THE-ORIGIN-OF-A-SEROTONIN-SYNDROME.html	Risk of appearance or of increased severity of a serotonin syndrome in case of administering any of these medications with any of the others.	Take into account	
1340			MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION	N05AA-001	DAPOXETINE	69394			ANSM	329-MEDICATIONS-AT-THE-ORIGIN-OF-ORTHOSTATIC-HYPOTENSION.html	Risk of increase of the undesirable effects, especially of the vertigo and fainting type	Not recommended	
1341			MEDICATIONS AT HE ORIGIN OF ORTHOSTATIC HYPOTENSION	N05AA-001			MEDICATIONS THAT LOWER BLOOD PRESSURE	MLBP	ANSM	329-MEDICATIONS-AT-THE-ORIGIN-OF-ORTHOSTATIC-HYPOTENSION.html	Risk of increase of hypotension, especially orthostatic	Take into account	
1342			AMINOGLYCOSIDES	J01GB-001			OTHER AMINOGLYCOSIDES	J01GB-001	ANSM	32-AMINOGLYCOSIDES.html	Increased risk of nephrotoxicity and ototoxicity (the ototoxicity is cumulative in cases of successive administrations of the aminoglycosides)	Contraindication	
1343			AMINOGLYCOSIDES	J01GB-001	AMPHOTERICIN B	732			ANSM	32-AMINOGLYCOSIDES.html	With the amphotericin B administered intravenously:increased risk of nephrotoxicity	Take into account	
1344			AMINOGLYCOSIDES	J01GB-001	ATALUREN				ANSM	32-AMINOGLYCOSIDES.html	Risk of increase of the renal toxicity of the aminoglycoside.	CONTRAINDICATION	
1345			AMINOGLYCOSIDES	J01GB-001	BOTULINUM TOXIN	1716			ANSM	32-AMINOGLYCOSIDES.html	Risk of increase of the effects of the botulinum toxin with the aminoglycosides (due to extrapolation from the effects observed during the course of the botulism)	Not recommended	
1346			AMINOGLYCOSIDES	J01GB-001	CEFALOTIN	2236			ANSM	32-AMINOGLYCOSIDES.html	Increase of the nephrotoxicity of the aminoglycosides by the cefalotin is under discussion	Precaution for use	
1347			AMINOGLYCOSIDES	J01GB-001	CICLOSPORIN	3008			ANSM	32-AMINOGLYCOSIDES.html	Larger increase of the creatinemia than with ciclosporin alone, with increase of the nephrotoxic risk	Take into account	
1348			AMINOGLYCOSIDES	J01GB-001			CURARES	M03A-001	ANSM	32-AMINOGLYCOSIDES.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	
1349			AMINOGLYCOSIDES	J01GB-001			LOOP DIURETICS	C03CA-001	ANSM	32-AMINOGLYCOSIDES.html	Increase of the nephrotoxic and ototoxic risks of the aminoglycoside (functional renal insufficiency linked to the dehydration caused by the diuretic)	Precaution for use	
1350			AMINOGLYCOSIDES	J01GB-001			PLATINUM-BASED ANTINEOPLASTIC DRUGS	ORGAPLA	ANSM	32-AMINOGLYCOSIDES.html	Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency	Take into account	
1351			AMINOGLYCOSIDES	J01GB-001	POLYMYXIN B	8536			ANSM	32-AMINOGLYCOSIDES.html	Addition of the nephrotoxic effects	Not recommended	
1352			AMINOGLYCOSIDES	J01GB-001	TACROLIMUS	42316			ANSM	32-AMINOGLYCOSIDES.html	Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
1353			MEDICATIONS AT RISK WHEN WITHDRAWING FROM TOBACCO	N0-R0-002			NICOTINE SUBSTITUTION TREATMENT	N07BA	ANSM	330-MEDICATIONS-AT-RISK-WHEN-WITHDRAWING-FROM-TOBACCO.html	Risk of overdose when replacing tobacco by the replacement therapy	Take into account	
1354			MEDICATIONS THAT LOWER BLOOD PRESSURE	MLBP			NITRATE DERIVATIVES AND RELATED	C01D-001	ANSM	331-MEDICATIONS-THAT-LOWER-BLOOD-PRESSURE.html	Increase of the risk of hypotension, especially orthostatic	Take into account	
1355			MEDICATIONS THAT LOWER BLOOD PRESSURE	MLBP			MEDICATIONS AT THE ORIGIN OF ORTHOSTATIC HYPOTENSION	N05AA-001	ANSM	331-MEDICATIONS-THAT-LOWER-BLOOD-PRESSURE.html	Risk of increase of hypotension, especially orthostatic	Take into account	
1356			MEDICATIONS THAT LOWER THE EPILEPTIC THRESHOLD	N05AA-002			OTHER MEDICATIONS THAT LOWER THE EPILEPTIC THRESHOLD	N05AA-002	ANSM	332-MEDICATIONS-THAT-LOWER-THE-EPILEPTIC-THRESHOLD.html	Accrued risk of convulsions	Take into account	
1357			ATROPINIC MEDICATIONS	R06AA			OTHER ATROPINIC MEDICATIONS	R06AA	ANSM	333-ATROPINIC-MEDICATIONS.html	Addition of the undesirable atropinic effects such as urinary retention, constipation, dry mouth	Take into account	
1358			METHEMOGLOBINIZING MEDICATIONS	METGL			OTHER METHEMOGLOBINIZING MEDICATIONS	METGL	ANSM	334-METHEMOGLOBINIZIN- MEDICATIONS.html	Risk of addition of the effects of the methomoglobinizing agents.	Take into account	
1359			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)				ANSM	335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precautions for use	
1360			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A			ORAL ANTICOAGULANTS	B01A-001	ANSM	335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Increase of the risk of hemorrhage	Precaution for use	
1361			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	CONTRAINDICATION	
1362			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, confusion, even coma	Not recommended	
1363			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ORLISTAT	37925			ANSM	335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1364			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	335-MIXED-ADRENERGIC-SEROTONINERGIC-MEDICATIONS.html	Paroxysmal hypertension with possibility of ventricular arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
1365			NEPHROTOXIC MEDICATIONS	J01-J05			OTHER NEPHROTOXIC MEDICATIONS	J01-J05	ANSM	336-NEPHROTOXIC-MEDICATIONS.html	Risk of increase of the nephrotoxicity	Take into account	
1366			OTOTOXIC MEDICATIONS	J01GB-J01XA			OTHER OTOTOXIC MEDICATIONS	J01GB-J01XA	ANSM	337-OTOTOXIC-MEDICATIONS.html	Increase of the ototoxicity	Take into account	
1367			SEDATIVE MEDICATIONS	N04-N05-N06	ALCOHOL (DRINK OR INGREDIENT)				ANSM	338-SEDATIVE-MEDICATIONS.html	Increase by the alcohol of the sedative effect of these substances. The alteration of alertness can make driving vehicles or using machines dangerous	Not recommended	
1368			SEDATIVE MEDICATIONS	N04-N05-N06			OTHER SEDATIVE MEDICATIONS	N04-N05-N06	ANSM	338-SEDATIVE-MEDICATIONS.html	Increase of central nervous center depression. The alteration of alertness can make driving vehicles or using machines dangerous	Not recommended	
1369	MEFLOQUINE	6694			QUININE	9071			ANSM	339-MEFLOQUINE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	
1370	AMIODARONE				AFATINIB	1430438			ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of afatinib by increase of its absorption by the amiodarone.	Precaution for use	
1371	AMIODARONE						VITAMIN K ANTAGONISTS	B01AA-001	ANSM	33-AMIODARONE.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
1372	AMIODARONE						BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001	ANSM	33-AMIODARONE.html	Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
1373	AMIODARONE						BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	33-AMIODARONE.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia	Precaution for use	
1374	AMIODARONE				CICLOSPORIN	3008			ANSM	33-AMIODARONE.html	Increase of the blood concentrations of ciclosporin, due to decrease of its hepatic metabolism, with risk of nephrotoxic effects	Not recommended	
1375	AMIODARONE				COBICISTAT	1306284			ANSM	33-AMIODARONE.html	Risk of increase of the undesirable effects of the amiodarone due to decrease of its metabolism by the cobicistat	CONTRAINDICATION	
1376	AMIODARONE				DABIGATRAN				ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of dabigatran, with greater risk of bleeding	Precaution for use	
1377	AMIODARONE				DACLATASVIR	1606218			ANSM	33-AMIODARONE.html	Only with the bitherapy daclatasvir/sofosbuvir:Appearance of bradycardia, possibly abrupt, that can have fatal consequences.	Not recommended	
1378	AMIODARONE				DIGOXIN	3407			ANSM	33-AMIODARONE.html	Depression of autoregulation (excessive bradycardia) and difficulties with atrioventricular conduction. Furthermore, increase of the blood concentrations of digoxin due to decrease of the clearance of the digoxin.	Precaution for use	
1379	AMIODARONE				DILTIAZEM	3443			ANSM	33-AMIODARONE.html	For diltiazem by injection: risk of bradycardia and of atrioventricular blockFor diltiazem by mouth: risk of bradycardia or of atrioventricular block, especially in older persons.	Not recommended	
1380	AMIODARONE				ESMOLOL	49737			ANSM	33-AMIODARONE.html	Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
1381	AMIODARONE				FIDAXOMICIN	1111103			ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
1382	AMIODARONE				FLUCONAZOLE	4450			ANSM	33-AMIODARONE.html	Risk of lengthening of the QT interval	Precaution for use	
1383	AMIODARONE				IBRUTINIB	1442981			ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of ibrutinib by decease of its hepatic metabolism by the amiodarone	Precaution for use	
1384	AMIODARONE				LEDIPASVIR	1591922			ANSM	33-AMIODARONE.html	Only with the ledipasvir/sofosbuvir bitherapy, appearance of bradycardia, possibly abrupt, that can have fatal consequences	Not recommended	
1385	AMIODARONE				LIDOCAINE	6387			ANSM	33-AMIODARONE.html	Risk of increase of the plasma concentrations of lidocaine, with possibility of undesirable neurological and cardiac effects, due to decrease of its hepatic metabolism by the amiodarone	Precaution for use	
1386	AMIODARONE				NINTEDANIB	1592737			ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of nintedanib due to increase of its absorption by the amiodarone.	Precaution for use	
1387	AMIODARONE				OLAPARIB	1597582			ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of olaparib by the amiodarone	Not recommended	
1388	AMIODARONE						OMBITASVIR + PARITAPEVIR	OMPA	ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of the amiodarone due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir	CONTRAINDICATION	
1389	AMIODARONE				ORLISTAT	37925			ANSM	33-AMIODARONE.html	Risk of decrease of the plasma concentrations of the amiodarone and of its active metabolite	Precaution for use	
1390	AMIODARONE						PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	33-AMIODARONE.html	Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)	Precaution for use	
1391	AMIODARONE				SIMVASTATIN	36567			ANSM	33-AMIODARONE.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin).	Precaution for use	
1392	AMIODARONE				SOFOSBUVIR	1484911			ANSM	33-AMIODARONE.html	Only when administered with the combinations daclatasvir/sofosbuvir or ledispasvir/sofosbuvir:Possibly abrupt appearance of bradycardia, which can have fatal consequences.	Not recommended	
1393	AMIODARONE				TACROLIMUS	42316			ANSM	33-AMIODARONE.html	Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone.	Precaution for use	
1394	AMIODARONE				TAMSULOSIN	77492			ANSM	33-AMIODARONE.html	Risk of increase of the undesirable effects of the tamsulosin due to inhibition of its hepatic metabolism	Precaution for use	
1395	AMIODARONE				TELAPREVIR	1102261			ANSM	33-AMIODARONE.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia	CONTRAINDICATION	
1396	AMIODARONE				VERAPAMIL	11170			ANSM	33-AMIODARONE.html	For verapamil by injection: -risk of bradycardia or of atrioventricular block. For verapamil by mouth:-risk of bradycardia or of atrioventricular block, especially with older patients	Not recommended with:	
1397	AMIODARONE	703			VORICONAZOLE	121243			ANSM	33-AMIODARONE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, due to possible decrease of the metabolism of the amiodarone	Precaution for use	
1398	MEQUITAZINE	29528			BUPROPION	42347			ANSM	340-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1399	MEQUITAZINE	29528			CINACALCET	407990			ANSM	340-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1400	MEQUITAZINE	29528			DULOXETINE	72625			ANSM	340-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1401	MEQUITAZINE	29528			FLUOXETINE	4493			ANSM	340-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1402	MEQUITAZINE	29528			PAROXETINE	32937			ANSM	340-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1403	MEQUITAZINE	29528			TERBINAFINE	37801			ANSM	340-MEQUITAZINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1404	METFORMIN	6809			ALCOHOL (DRINK OR INGREDIENT)				ANSM	341-METFORMIN.html	Increased risk of lactic acidosis when there is acute alcohol intoxication, particularly in cases of fasting or undernourishment, or in cases of liver failure	Not recommended	
1405	METFORMIN	6809					LOOP DIURETICS	C03CA-001	ANSM	341-METFORMIN.html	Lactic acidosis due to the metformin, set into action by a possible functional renal insufficiency, linked to the loop diuretics	Precaution for use	
1406	METFORMIN	6809			DOLUTEGRAVIR	1433868			ANSM	341-METFORMIN.html	Increase of the plasma concentrations of metformin by the dolutegravir and of its undesirable effects of the lactic acidosis type	Precaution for use	
1407	METFORMIN	6809					IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ANSM	341-METFORMIN.html	Lactic acidosis linked to elevated concentrations of metformin in relation to the functional renal insufficiency induced by the radiological exam.	CONTRAINDICATION	
1408	METHADONE	6813					MORPHINE LIKE ANTITUSSIVES	R05DA0-001	ANSM	342-METHADONE.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
1409	METHADONE	6813					TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	ANSM	342-METHADONE.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
1410	METHADONE	6813			BOCEPREVIR	1102129			ANSM	342-METHADONE.html	Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir	Precaution for use	
1411	METHADONE	6813			CIMETIDINE	2541			ANSM	342-METHADONE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes.	Precaution for use	
1412	METHADONE	6813			FLUVOXAMINE	42355			ANSM	342-METHADONE.html	Increase of the plasma concentrations of methadone with overdose and increased risk of lengthening of the QT interval and of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
1413	METHADONE	6813			FOSAMPRENAVIR	358262			ANSM	342-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the amprenavir	Precaution for use	
1414	METHADONE	6813					ENZYMATIC INDUCERS	N03-J05-001	ANSM	342-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism	Precaution for use	
1415	METHADONE	6813					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	342-METHADONE.html	Decrease of the plasma concentrations of methadone with risk of appearance of a withdrawal syndrome due to increase of its hepatic metabolism by the ritonavir	Precaution for use	
1416	METHADONE	6813					AGONIST-ANTAGONIST OPIOIDS	NO2A-001	ANSM	342-METHADONE.html	Decrease of the effect of the methadone due to competitive blockage of the receptors.	CONTRAINDICATION	
1417	METHADONE	6813					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	342-METHADONE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
1418	METHENAMINE	6832			SULFAMETHIZOLE	10179			ANSM	343-METHENAMINE.html	Precipitation of crystals in the urinary tract (due to the acidification of the urine)	Not recommended	
1419	METHOTREXATE	6851			ACETYLSALICYLIC ACID	1191			ANSM	344-METHOTREXATE.html	Increase of the toxicity, especially hematological, of the methotrezate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	
1420	METHOTREXATE	6851			ACITRETIN	16818			ANSM	344-METHOTREXATE.html	Risk of increase of the hepatoxicity of the methotrexate	Not recommended	
1421	METHOTREXATE	6851					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	344-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).	Not recommended	
1422	METHOTREXATE	6851					PROTON PUMP INHIBITORS	A02BC-001	ANSM	344-METHOTREXATE.html	Risk of increase of the toxicity of the methotrexate due to decrease of its elimination	Not recommended	
1423	METHOTREXATE	6851			CICLOSPORIN	3008			ANSM	344-METHOTREXATE.html	Increase of the toxicity of the methotrexate and of the ciclosporin with increase of the creatinemia: reciprocal decrease of the clearances of the two medications	Precaution for use	
1424	METHOTREXATE	6851			CIPROFLOXACIN	2551			ANSM	344-METHOTREXATE.html	Increase of the toxicity of the methotrexate due to inhibition of its renal tubular secretion by the ciprofloxacin	Not recommended	
1425	METHOTREXATE	6851					PENICILLINS	J01C	ANSM	344-METHOTREXATE.html	Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins	Not recommended	
1426	METHOTREXATE	6851			PROBENECID	8698			ANSM	344-METHOTREXATE.html	Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid	CONTRAINDICATION	
1427	METHOTREXATE	6851					ANTIBACTERIAL SULFONAMIDES	JO1E	ANSM	344-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate	Precaution for use	
1428	METHOTREXATE	6851			TRIMETHOPRIM	10829			ANSM	344-METHOTREXATE.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase)	CONTRAINDICATION	
1429	METHYLDOPA	6876			IRON	1431589			ANSM	345-METHYLDOPA.html	Decrease of the digestive absorption of the methyldopa (formation of complexes)	Precaution for use	
1430	METHYLDOPA	6876			LEVODOPA	6375			ANSM	345-METHYLDOPA.html	Increase of the effects of the levodopa but equally of its undesirable effects. Increase of the antihypertensive effect of the methyldopa	Precaution for use	
1431	METHYLDOPA	6876			LITHIUM	6448			ANSM	345-METHYLDOPA.html	Increase of the plasma concentrations of lithium which can attain toxic values, with signs of overdose of lithium	Precaution for use	
1432	METHYLPREDNISOLONE	6902					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	346-METHYLPREDNISOLONE.html	For doses of 0.5g to 1 g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
1433	METHYLPREDNISOLONE	6902			CICLOSPORIN	3008			ANSM	346-METHYLPREDNISOLONE.html	With the methylprednisolone administered by IV route: possible increase of the blood concentrations of ciclosporin and of the creatinemia Mecanism proposed: decrease of the hepatic elimination of the ciclosporin	Take into account	
1434	METHYLPREDNISOLONE	6902					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	346-METHYLPREDNISOLONE.html	In case of prolonged use, increase of the plasma concentrations of the corticoid, because of decrease of its hepatic metabolism by the inhibitor, with risk of appearance of cushing syndrome	Take into account	
1435	METOPROLOL	6918			ABIRATERONE	1100072			ANSM	347-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the abiraterone.	Precaution for use:	
1436	METOPROLOL	6918			BUPROPION	42347			ANSM	347-METOPROLOL.html	With the metoprolol used for heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
1437	METOPROLOL	6918			CIMETIDINE	2541			ANSM	347-METOPROLOL.html	With the metoprolol used for heart failure, and the cimetidine used at dosages greater than or equal to 800 mg/day: increase of the concentrations of the metoprolol, which can be dangerous in the case of treatment for heart failure, due to decrease of its hepatic metabolism by the cimetadine	Precaution for use	
1438	METOPROLOL	6918			CINACALCET	407990			ANSM	347-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	
1439	METOPROLOL	6918			DARIFENACIN	136198			ANSM	347-METOPROLOL.html	Increase of the plasma concentrations of the metoprolol, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use	
1440	METOPROLOL	6918			DULOXETINE	72625			ANSM	347-METOPROLOL.html	Increase of the plasma concentrations of metoprolol with risk of overdose, due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	
1441	METOPROLOL	6918			FLUOXETINE	4493			ANSM	347-METOPROLOL.html	Risk of increase of the undesirable effects of the metoprolol, with especially excessive bradycardia, due to inhibition of its metabolism by the fluoxetine	Precaution for use	
1442	METOPROLOL	6918			HYDROXYCHLOROQUINE	5521			ANSM	347-METOPROLOL.html	With the metoprolol used in heart failure: risk of increase of the undesirable effects of the metoprolol due to decrease of its hepatic metabolism by the hydroxychloroquine	Precaution for use	
1443	METOPROLOL	6918			MIRABEGRON	1300786			ANSM	347-METOPROLOL.html	With the metoprolol used in heart failure, increase of the plasma concentrations of the metoprolol due to decrease of its metabolism by the mirabegron	Precaution for use	
1444	METOPROLOL	6918			PAROXETINE	32937			ANSM	347-METOPROLOL.html	Risk of increase of the undesirable effects of the metoprolol, especially with excessive bradycardia, due to inhibition of its metabolism by the paroxetine	Precaution for use	
1445	METOPROLOL	6918					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	347-METOPROLOL.html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
1446	METOPROLOL	6918			RIFAMPICIN	9384			ANSM	347-METOPROLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
1447	METOPROLOL	6918			TERBINAFINE	37801			ANSM	347-METOPROLOL.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	
1448	METRONIDAZOLE	6922					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	348-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	
1449	METRONIDAZOLE	6922			BUSULFAN	1828			ANSM	348-METRONIDAZOLE.html	With the busulfan in large doses: doubling of the concentrations of busulfan by the metronidazole	Not recommended	
1450	METRONIDAZOLE	6922			DISULFIRAM	3554			ANSM	348-METRONIDAZOLE.html	Risk of episodes of acute psychosis or of confused state, reversible upon stopping the administration of the two substances together	Not recommended	
1451	METRONIDAZOLE	6922					FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ANSM	348-METRONIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
1452	METRONIDAZOLE	6922			LITHIUM	6448			ANSM	348-METRONIDAZOLE.html	Increase of the the plasma concentrations of lithium which can attain toxic values with signs of overdose of lithium.	Precaution for use	
1453	METRONIDAZOLE	6922			RIFAMPICIN	9384			ANSM	348-METRONIDAZOLE.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
1454	METYRAPONE	6923					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	349-METYRAPONE.html	Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of increase of its hepatic metabolism by the phenytoin.	Precaution for use	
1455	AMLODIPINE	17767			SIMVASTATIN	36567			ANSM	34-AMLODIPINE.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication).	Precaution for use	
1456	MEXILETINE	6926			CAFFEINE	1886			ANSM	350-MEXILETINE.html	Increase of the plasma concentrations of caffeine, due to inhibition of its hepatic metabolism by the mexiletine	Take into account	
1457	MEXILETINE	6926			FLUVOXAMINE	42355			ANSM	350-MEXILETINE.html	Risk of increase of the undesirable effects of the mexiletine, due to inhibition of its metabolism by the fluvoxamine	Precaution for use	
1458	MEXILETINE	6926					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	350-MEXILETINE.html	Decrease of the antiarrhythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)	Precaution for use	
1459	MEXILETINE	6926					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	350-MEXILETINE.html	Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	
1460	MIANSERIN	6929					ENZYMATIC INDUCERS	N03-J05-001	ANSM	351-MIANSERIN.html	Risk of ineffectiveness of the mianserin	Not recommended	
1461	MICONAZOLE	6932					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	352-MICONAZOLE.html	Unpredictable hemorrhages, possibly serious	CONTRAINDICATION	
1462	MICONAZOLE	6932					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	352-MICONAZOLE.html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	
1463	MICONAZOLE	6932					BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	352-MICONAZOLE.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	CONTRAINDICATION	
1464	MIDAZOLAM	6960					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	353-MIDAZOLAM.html	Risk of decrease of the plasma concentrations of the midazolam by the anticonvulsant	Take into account	
1465	MIDAZOLAM	6960			DILTIAZEM	3443			ANSM	353-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Precaution for use	
1466	MIDAZOLAM	6960			FLUCONAZOLE	4450			ANSM	353-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to reduction of its hepatic metabolism, with increase of sedation	Not recommended	
1467	MIDAZOLAM	6960					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	353-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam due to decrease of its hepatic metabolism, with increase of sedation	Not recommended:	
1468	MIDAZOLAM	6960			ST JOHNS WORT	258326			ANSM	353-MIDAZOLAM.html	Risk of decrease of the plasma concentrations of midazolam by the St Johns wort	Take into account	
1469	MIDAZOLAM	6960					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	353-MIDAZOLAM.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the ombitasvir+ paritaprevir	CONTRAINDICATION	
1470	MIDAZOLAM	6960			RIFAMPICIN	9384			ANSM	353-MIDAZOLAM.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
1471	MIDAZOLAM	6960			ROXITHROMYCIN	9478			ANSM	353-MIDAZOLAM.html	Slight increase of sedation	Take into account	
1472	MIDAZOLAM	6960			STIRIPENTOL	37119			ANSM	353-MIDAZOLAM.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation	Precaution for use	
1473	MIDAZOLAM	6960			VERAPAMIL	11170			ANSM	353-MIDAZOLAM.html	Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation)	Precaution for use	
1474	MIDECAMYCIN	30005			CICLOSPORIN	3008			ANSM	354-MIDECAMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	
1475	MIDODRINE	6963			DIGOXIN	3407			ANSM	355-MIDODRINE.html	Disorders of autoregulation (increase of the bradycardia inducing effect of the midodrine) and disorders of atrioventricular conduction	Not recommended	
1476	MIDODRINE	6963					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	355-MIDODRINE.html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped.	CONTRAINDICATION	
1477	ST JOHNS WORT	258326					METABOLIZED ANTICONVULSANTS	N03A-002	ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant.	CONTRAINDICATION	
1478	ST JOHNS WORT	258326					PROTON PUMP INHIBITORS	A02BC-001	ANSM	356-ST-JOHNS-WORT.html	Risk of ineffectiveness of the treatment by the proton pump inhibitor due to decrease of its metabolism by the St Johns wort	Take into account	
1479	ST JOHNS WORT	258326					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzymatic inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (thrombolitic event)	CONTRAINDICATION	
1480	ST JOHNS WORT	258326			BEDAQUILINE	1364504			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
1481	ST JOHNS WORT	258326			CARBAMAZEPINE	2002			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine	Not recommended	
1482	ST JOHNS WORT	258326			COBICISTAT	1306284			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	CONTRAINDICATION	
1483	ST JOHNS WORT	258326			CYPROTERONE	3014			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the effectiveness of the cyproterone, due to increase of its hepatic metabolism by the St Johns Wort	CONTRAINDICATION	
1484	ST JOHNS WORT	258326			DACLATASVIR	1606218			ANSM	356-ST-JOHNS-WORT.html	Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1485	ST JOHNS WORT	258326			DASABUVIR	1597381			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort	CONTRAINDICATION	
1486	ST JOHNS WORT	258326			DIGOXIN	3407			ANSM	356-ST-JOHNS-WORT.html	Decrease of the digoxinemia, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure).	CONTRAINDICATION	
1487	ST JOHNS WORT	258326			DOLUTEGRAVIR	1433868			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort	Not recommended	
1488	ST JOHNS WORT	258326			DRONEDARONE	233698			ANSM	356-ST-JOHNS-WORT.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite	Not recommended	
1489	ST JOHNS WORT	258326			ERIBULINE	1045453			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of eribuline by the St Johns wort	Not recommended	
1490	ST JOHNS WORT	258326					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect which can have possibly serious consequences (pregnancy).	CONTRAINDICATION	
1491	ST JOHNS WORT	258326			IDELALISIB	1544460			ANSM	356-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
1492	ST JOHNS WORT	258326					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	356-ST-JOHNS-WORT.html	Risk of appearance of a serotonin syndrome	Precaution for use	
1493	ST JOHNS WORT	258326					REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	356-ST-JOHNS-WORT.html	Risk of appearance of a serotonin syndrome	Precaution for use	
1494	ST JOHNS WORT	258326					IMMUNOSUPPRESSANTS	L04A	ANSM	356-ST-JOHNS-WORT.html	Decrease of the blood concentrations of the immunosuppressant, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (rejection of a graft)	CONTRAINDICATION	
1495	ST JOHNS WORT	258326					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)	CONTRAINDICATION	
1496	ST JOHNS WORT	258326					METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns Wort	CONTRAINDICATION	
1497	ST JOHNS WORT	258326					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	356-ST-JOHNS-WORT.html	Risk of appearance of a serotonin syndrome	Precaution for use	
1498	ST JOHNS WORT	258326			IRINOTECAN	51499			ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment	CONTRAINDICATION	
1499	ST JOHNS WORT	258326			ISAVUCONAZOLE	1720882			ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1500	ST JOHNS WORT	258326			ITRACONAZOLE	28031			ANSM	356-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1501	ST JOHNS WORT	258326			IVABRADINE	77417			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the effectiveness of the ivabradine due to increase of its metabolism by the St Johns wort	Not recommended	
1502	ST JOHNS WORT	258326			LEDIPASVIR	1591922			ANSM	356-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolidm by the St Johns wort	CONTRAINDICATION	
1503	ST JOHNS WORT	258326			LOMITAPIDE	1364479			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of the lomitapide	Not recommended	
1504	ST JOHNS WORT	258326			LURASIDONE	1040028			ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1505	ST JOHNS WORT	258326			MACITENTAN	1442132			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort	Not recommended	
1506	ST JOHNS WORT	258326			MARAVIROC	620216			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of virological response	Not recommended	
1507	ST JOHNS WORT	258326			MIDAZOLAM	6960			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of midazolam by the St Johns wort	Take into account	
1508	ST JOHNS WORT	258326			NEVIRAPINE	53654			ANSM	356-ST-JOHNS-WORT.html	Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1509	ST JOHNS WORT	258326			NINTEDANIB	1592737			ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the St Johns Wort	Not recommended	
1510	ST JOHNS WORT	258326			OXYCODONE	7804			ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the St Johns wort	Not recommended	
1511	ST JOHNS WORT	258326					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy)	CONTRAINDICATION	
1512	ST JOHNS WORT	258326			PROPAFENONE	8754			ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort	Precaution for use	
1513	ST JOHNS WORT	258326			QUETIAPINE	51272			ANSM	356-ST-JOHNS-WORT.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
1514	ST JOHNS WORT	258326			REGORAFENIB	1312397			ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort	Not recommended	
1515	ST JOHNS WORT	258326			RILPIVIRINE	1102270			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1516	ST JOHNS WORT	258326			SIMEPREVIR	1482790			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
1517	ST JOHNS WORT	258326			SIMVASTATIN	36567			ANSM	356-ST-JOHNS-WORT.html	Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
1518	ST JOHNS WORT	258326			SOFOSBUVIR				ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of sofobusvir due to decrease of its intestinal absorption by the St Johns wort	CONTRAINDICATION	
1519	ST JOHNS WORT	258326			TELAPREVIR	1102261			ANSM	356-ST-JOHNS-WORT.html	Risk of very large decrease of the concentrations of telaprevir	CONTRAINDICATION	
1520	ST JOHNS WORT	258326			TELITHROMYCIN	274786			ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort	Not recommended	
1521	ST JOHNS WORT	258326					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	356-ST-JOHNS-WORT.html	Decrease of the plasma concentrations of the theophylline, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome)	CONTRAINDICATION	
1522	ST JOHNS WORT	258326			TICAGRELOR	1116632			ANSM	356-ST-JOHNS-WORT.html	Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect	CONTRAINDICATION	
1523	ST JOHNS WORT	258326			ULIPRISTAL	1005921			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	
1524	ST JOHNS WORT	258326			VERAPAMIL	11170			ANSM	356-ST-JOHNS-WORT.html	Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect	CONTRAINDICATION	
1525	ST JOHNS WORT	258326			VISMODEGIB	1242987			ANSM	356-ST-JOHNS-WORT.html	Risk of decrease of the plasma concentrations of vismodegib	CONTRAINDICATION	
1526	ST JOHNS WORT	258326			VORICONAZOLE	121243			ANSM	356-ST-JOHNS-WORT.html	Large reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect	CONTRAINDICATION	
1527			MINERALOCORTICOIDS	H02AA0			ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	357-MINERALOCORTICOIDS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great in patients with AddisonÂ’s disease treated with the hydrocortisone and in the case of transplants.	Precaution for use	
1528			MINERALOCORTICOIDS	H02AA0	RIFAMPICIN	9384			ANSM	357-MINERALOCORTICOIDS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in the case of transplants	Precaution for use	
1529	MIRABEGRON	1300786			FLECAINIDE	4441			ANSM	358-MIRABEGRON.html	Increase of the plasma concentrations of the flecainide by decrease of its metabolism by the mirabegron	Precaution for use	
1530	MIRABEGRON	1300786			METOPROLOL	6918			ANSM	358-MIRABEGRON.html	With the metoprolol used in heart failure, increase of the plasma concentrations of the metoprolol due to decrease of its metabolism by the mirabegron	Precaution for use	
1531	MIRABEGRON	1300786			PROPAFENONE	8754			ANSM	358-MIRABEGRON.html	Increase of the plasma concentrations of the propafenone by decrease of its metabolism by the mirabegron	Precaution for use	
1532	MITOMYCIN C	632					VINCA ALKALOIDS	L01CA	ANSM	359-MITOMYCIN-C.html	Risk of increase of the pulmonary toxicity of the mitomycin and of the vinca-alkaloids	Take into account	
1533	AMPHOTERICIN B	732					AMINOGLYCOSIDES	J01GB-001	ANSM	35-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously: increased risk of nephrotoxicity	Take into account	
1534	AMPHOTERICIN B	732			CICLOSPORIN	3008			ANSM	35-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:greater increase of the creatinemia than with ciclosporin alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
1535	AMPHOTERICIN B	732			TACROLIMUS	42316			ANSM	35-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances).	Take into account	
1536	AMPHOTERICIN B	732			ZIDOVUDINE	11413			ANSM	35-AMPHOTERICIN-B.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	
1537	MITOTANE	7004			DASABUVIR	1597381			ANSM	360-MITOTANE.html	Risk of decrease of the plasma concentrations of the dasabuvir by the mitotane	CONTRAINDICATION	
1538	MITOTANE	7004			SPIRONOLACTONE	9997			ANSM	360-MITOTANE.html	Risk of blockage of the action of the mitotane by the spironolactone	CONTRAINDICATION	
1539	MIZOLASTINE	61455			CLARITHROMYCIN	21212			ANSM	361-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1540	MIZOLASTINE	61455			ERYTHROMYCIN	4053			ANSM	361-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1541	MIZOLASTINE	61455					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	361-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1542	MIZOLASTINE	61455			ITRACONAZOLE	28031			ANSM	361-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1543	MIZOLASTINE	61455			KETOCONAZOLE	6135			ANSM	361-MIZOLASTINE.html	Risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1544	MIZOLASTINE	61455			TELITHROMYCIN	274786			ANSM	361-MIZOLASTINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1545	MOCLOBEMIDE	30121			CIMETIDINE	2541			ANSM	362-MOCLOBEMIDE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the concentrations of the moclobemide, due to decrease of its hepatic metabolism	Precaution for use	
1546	MODAFINIL	30125			CICLOSPORIN	3008			ANSM	363-MODAFINIL.html	Risk of decrease of the blood concentrations and of the effectiveness of the immunosuppressant	Not recommended	
1547	MODAFINIL	30125					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	363-MODAFINIL.html	Risk of decrease of the contraceptive effectiveness, during the treatment and one cycle after the end of the treatment with the modafinil, due to its enzymatic inducer potential	Not recommended	
1548	MODAFINIL	30125			SOFOSBUVIR				ANSM	363-MODAFINIL.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil	Not recommended	
1549	MONTELUKAST	88249					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	364-MONTELUKAST.html	Risk of lower effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer	Precaution for use	
1550	MONTELUKAST	88249			RIFAMPICIN	9384			ANSM	364-MONTELUKAST.html	Risk of lower effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
1551	MORPHINE	7052			RIFAMPICIN	9384			ANSM	365-MORPHINE.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	
1552			OPIOIDS	N0-R0			BARBITURATES	N05CA-001	ANSM	366-OPIOIDS.html	Increased risk of respiratory depression, which could be fatal in case of overdose	Take into account	
1553			OPIOIDS	N0-R0			BENZODIAZEPINES AND RELATED	N05-001	ANSM	366-OPIOIDS.html	Increased risk of respiratory depression, which could be fatal in case of overdose	Take into account	
1554			AGONIST-ANTAGONIST OPIOIDS	NO2A-001			STEP II OPIOID ANALGESICS	N02A-003	ANSM	367-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome.	Not recommended	
1555			AGONIST-ANTAGONIST OPIOIDS	NO2A-001			STEP III OPIOID ANALGESICS	N02A-002	ANSM	367-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	CONTRAINDICATION	
1556			AGONIST-ANTAGONIST OPIOIDS	NO2A-001			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	ANSM	367-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Not recommended	
1557			AGONIST-ANTAGONIST OPIOIDS	NO2A-001	METHADONE	6813			ANSM	367-AGONIST-ANTAGONIST-OPIOIDS.html	Decrease of the effect of the methadone due to competitive blocking of the receptors	CONTRAINDICATION	
1558			AGONIST-ANTAGONIST OPIOIDS	NO2A-001			PARTIAL AGONIST OPIOIDS	PARAG	ANSM	367-AGONIST-ANTAGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect and/or of appearance of a withdrawal syndrome	CONTRAINDICATION	
1559			PARTIAL AGONIST OPIOIDS	PARAG			STEP II OPIOID ANALGESICS	N02A-003	ANSM	368-PARTIAL-AGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect	Not Recommended	
1560			PARTIAL AGONIST OPIOIDS	PARAG			STEP III OPIOID ANALGESICS	N02A-002	ANSM	368-PARTIAL-AGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect	CONTRAINDICATION	
1561			PARTIAL AGONIST OPIOIDS	PARAG			AGONIST-ANTAGONIST OPIOIDS	NO2A-001	ANSM	368-PARTIAL-AGONIST-OPIOIDS.html	Risk of decrease of the antalgic effect and/or appearance of a withdrawal syndrome	CONTRAINDICATION	
1562			PARTIAL AGONIST OPIOIDS	PARAG			OPIOIDS FOR REPLACEMENT THERAPY	N07BC	ANSM	368-PARTIAL-AGONIST-OPIOIDS.html	Risk of appearance of a withdrawal syndrome	CONTRAINDICATION	
1563			OPIOIDS FOR REPLACEMENT THERAPY	N07BC			PARTIAL AGONIST OPIOIDS	PARAG	ANSM	369-OPIOIDS-FOR-REPLACEMENT-THERAPY.html	Risk of appearance of a withdrawal syndrome	CONTRAINDICATION	
1564	ANAGRELIDE	596724			ACETYLSALICYLIC ACID	1191			ANSM	36-ANAGRELIDE.html	Increase of hemorrhagic events	Not recommended	
1565	ANAGRELIDE	596724					PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	36-ANAGRELIDE.html	Increase of hemorraghic events	Not recommended	
1566	ANAGRELIDE	596724					MEDICATIONS THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	36-ANAGRELIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
1567	MYCOPHENOLATE MOFETIL	7145					PROTON PUMP INHIBITORS	A02BC-001	ANSM	370-MYCOPHENOLATE-MOFETIL.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
1568	MYCOPHENOLATE MOFETIL	7145					FLUOROQUINOLONES	J01MA-001	ANSM	370-MYCOPHENOLATE-MOFETIL.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
1569	MYCOPHENOLATE MOFETIL	7145					AMINOPENICILLINS	J01CA	ANSM	370-MYCOPHENOLATE-MOFETIL.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
1570	MYCOPHENOLATE MOFETIL	7145					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	370-MYCOPHENOLATE-MOFETIL.html	Risk of general vaccine disease, possibly fatal.	CONTRAINDICATION	
1571	MYCOPHENOLATE SODIUM	408142					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	371-MYCOPHENOLATE-SODIUM.html	Risk of general vaccine disease, possibly fatal	CONTRAINDICATION	
1572	NEBIVOLOL	31555			FLUOXETINE	4493			ANSM	372-NEBIVOLOL.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	
1573	NEBIVOLOL	31555			PAROXETINE	32937			ANSM	372-NEBIVOLOL.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	
1574			NEUROLEPTICS	N05AA-003			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	373-NEUROLEPTICS.html	Vasidilator effect and risk of hypotension, especially orthostatic (additive effect)	Take into account	
1575			NEUROLEPTICS	N05AA-003	LITHIUM	6448			ANSM	373-NEUROLEPTICS.html	Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning	Precaution for use	
1576			NEUROLEPTICS	N05AA-003	ORLISTAT	37925			ANSM	373-NEUROLEPTICS.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1577			ANTIEMITIC NEUROLEPTICS	A03FA-001			DOPAMINERGICS	N04B-002	ANSM	374-ANTIEMETIC-NEUROLEPTICS.html	Reciprocal antagonism between the dopaminergic and the neuropleptic	CONTRAINDICATION	
1578			ANTIEMITIC NEUROLEPTICS	A03FA-001	LEVODOPA	6375			ANSM	374-ANTIEMETIC-NEUROLEPTICS.html	Reciprocal antagonism between the levodopa and the neuroleptic	CONTRAINDICATION	
1579			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001			ANTIPARKINSONIAN DOPAMINERGICS	N04B-001	ANSM	375-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or increase the psychotic disorders. When a treatment with neuroleptics is necessary for a parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of "neuroleptic malignant syndrome" (NMS)).	Not recommended	
1580			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001			DOPAMINERGICS, EXCEPT PARKINSON	G02CB-002	ANSM	375-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the dopamine agonist and the neuroleptics	CONTRAINDICATION	
1581			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	LEVODOPA	6375			ANSM	375-ANTIPSYCHOTIC-NEUROLEPTICS-(EXCEPT-CLOZAPINE).html	Reciprocal antagonism of the levodopa and the neuroleptics	Not recommended	
1582			NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES	N05A-002			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	376-NEUROLEPTICS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
1583	NEVIRAPINE	53654					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	377-NEVIRAPINE.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	
1584	NEVIRAPINE	53654			ATAZANAVIR	343047			ANSM	377-NEVIRAPINE.html	Risk of reduction of the effectiveness of the atanazavir due to increase of its hepatic metabolism	Not recommended	
1585	NEVIRAPINE	53654			FLUCONAZOLE	4450			ANSM	377-NEVIRAPINE.html	Doubling of the concentrations of nevirapine with risk of increase of its undesirable effects	Precaution for use	
1586	NEVIRAPINE	53654			FOSAMPRENAVIR	358262			ANSM	377-NEVIRAPINE.html	Risk of reduction of the effectiveness of the amprenavir	Precaution for use	
1587	NEVIRAPINE	53654			INDINAVIR	114289			ANSM	377-NEVIRAPINE.html	Risk of reduction of the effectiveness of the indinavir	Precaution for use	
1588	NEVIRAPINE	53654			KETOCONAZOLE	6135			ANSM	377-NEVIRAPINE.html	Increase of the plasma concentrations of nevirapine due to decrease of its hepatic metabolism by the ketoconazole, for one thing, and decrease of the plasma concentrations of the ketoconazole due to increase of its hepatic metabolism by the nevirapine, for another thing.	CONTRAINDICATION	
1589	NEVIRAPINE	53654			ST JOHNS WORT	258326			ANSM	377-NEVIRAPINE.html	Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
1590	NEVIRAPINE	53654			RIFAMPICIN	9384			ANSM	377-NEVIRAPINE.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
1591	NEVIRAPINE	53654			VORICONAZOLE	121243			ANSM	377-NEVIRAPINE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine.	Not recommended	
1592	NICARDIPINE	7396					IMMUNOSUPPRESSANTS	L04A	ANSM	378-NICARDIPINE.html	Increase of the blood concentrations of the immunosuppressant, due to inhibition of its hepatic metabolism	Precaution for use	
1593	NIFEDIPINE	7417			CICLOSPORIN	3008			ANSM	379-NIFEDIPINE.html	Risk of addition of undesirable effects of the gum disorders type	Not recommended	
1594	NIFEDIPINE	7417			CIMETIDINE	2541			ANSM	379-NIFEDIPINE.html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the hypotensive effect of the nifedipine due to inhibition of its hepatic metabolism by the cimetidine	Precaution for use	
1595	NIFEDIPINE	7417			DILTIAZEM	3443			ANSM	379-NIFEDIPINE.html	Large increase of the concentrations of nefedipine due to decrease of its hepatic metabolism by the diltiazem, with risk of severe hypotension	CONTRAINDICATION	
1596	ANAKINRA	72435					ANTI-TNF ALPHA	4ABO	ANSM	37-ANAKINRA.html	Increased risk of serious infections and of neutropenia.	Not recommended	
1597	ANAKINRA	72435			ETANERCEPT	214555			ANSM	37-ANAKINRA.html	Increased risk of serious infections and of neutropenia	Not recommended	
1598	NIMODIPINE	7426					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	380-NIMODIPINE.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer	Not recommended	
1599	NIMODIPINE	7426			RIFAMPICIN	9384			ANSM	380-NIMODIPINE.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	
1600	NIMODIPINE	7426					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	380-NIMODIPINE.html	With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid).	Take into account	
1601	NINTEDANIB	1592737			AMIODARONE	703			ANSM	381-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the amiodarone	Precaution for use	
1602	NINTEDANIB	1592737			CARBAMAZAPINE	2002			ANSM	381-NINTEDANIB.html	Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the carbamazepine	Precaution for use	
1603	NINTEDANIB	1592737			CICLOSPORIN	3008			ANSM	381-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ciclosporin	Precaution for use	
1604	NINTEDANIB	1592737			ERYTHROMYCIN				ANSM	381-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the erythromycin	Precaution for use	
1605	NINTEDANIB	1592737					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	381-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ritonavir boosted protease inhibitor	Precaution for use	
1606	NINTEDANIB	1592737			ITRACONAZOLE	28031			ANSM	381-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the itraconazole	Precaution for use	
1607	NINTEDANIB	1592737			KETOCONAZOLE	6135			ANSM	381-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ketoconazole	Precaution for use	
1608	NINTEDANIB	1592737			ST JOHN'S WORT	258326			ANSM	381-NINTEDANIB.html	Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the St Johns Wort	Not recommended	
1609	NINTEDANIB	1592737					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	381-NINTEDANIB.html	Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the phenytoin or the fosphenytoin	Precaution for use	
1610	NINTEDANIB	1592737			RIFAMPICIN	9384			ANSM	381-NINTEDANIB.html	Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the rifampicin	Precaution for use	
1611	NINTEDANIB	1592737			VERAPAMIL	11170			ANSM	381-NINTEDANIB.html	Increase of the plasma concentrations of the nintedanib by increase of its absorption by the verapamil	Precaution for use	
1612	NORFLOXACIN	7517			CAFFEINE	1886			ANSM	382-NORFLOXACIN.html	Increase of the plasma concentrations of caffeine, due to decrease of the hepatic metabolism of the caffeine	Take into account	
1613	NORFLOXACIN	7517					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	382-NORFLOXACIN.html	Increased risk of ventricular arrhythmias, especially of torsades de points.	Precaution for use	
1614	NORFLOXACIN	7517					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	382-NORFLOXACIN.html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	
1615	NORTRIPTYLINE	7531			BUPROPION	42347			ANSM	383-NORTRIPTYLINE.html	Risk of increase of the undesirable effects of the nortriptyline due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
1616	NOSCAPINE	7533					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	384-NOSCAPINE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	
1617	OLANZAPINE	61381			CARBAMAZEPINE	2002			ANSM	385-OLANZAPINE.html	Risk of decrease of the plasma concentrations of the olanzapine and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
1618	OLANZAPINE	61381			FLUVOXAMINE	42355			ANSM	385-OLANZAPINE.html	Increase of the concentrations of the olanzapine, with risk of increase of its undesirable effects, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	
1619	OLAPARIB	1597582			AMIODARONE	703			ANSM	386-OLAPARIB.html	Increase of the plasma concentrations of olaparib by the amiodarone	Not recommended	
1620	OLAPARIB	1597582			DILTIAZEM	3443			ANSM	386-OLAPARIB.html	Increase of the plasma concentrations of olaparib by the diltiazam	Not recommended	
1621	OLAPARIB	1597582			FLUCONAZOLE	4450			ANSM	386-OLAPARIB.html	Increase of the plasma concentrations of olaparib by the fluconazole	Not recommended	
1622	OLAPARIB	1597582					ENZYME INDUCERS	N03-J05-001	ANSM	386-OLAPARIB.html	Decrease, possibly very large depending on the inducer, of the plasma concentrations of the olaparib due to increase of its hepatique metabolism by the inducer	Not recommended	
1623	OLAPARIB	1597582					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	386-OLAPARIB.html	Increase of the plasma concentrations of olaparib by the inhibitor	Not recommended	
1624	OLAPARIB	1597582			VERAPAMIL	11170			ANSM	386-OLAPARIB.html	Increase of the plasma concentrations of olaparib by the verapamil.	Not recommended	
1625			OMBITASVIR + PARITAPREVIR	OMPA	FUSIDIC ACID	4608			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1626			OMBITASVIR + PARITAPREVIR	OMPA			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1627			OMBITASVIR + PARITAPREVIR	OMPA	ALFUZOSIN	17300			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the alfuzosin due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1628			OMBITASVIR + PARITAPREVIR	OMPA	AMIODARONE	703			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the amiodarone due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1629			OMBITASVIR + PARITAPREVIR	OMPA	ATORVASTATIN	83367			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1630			OMBITASVIR + PARITAPREVIR	OMPA	COLCHICINE	2683			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the bitherapy.	CONTRAINDICATION	
1631			OMBITASVIR + PARITAPREVIR	OMPA	ETHINYLESTRADIOL	4124			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the hepatotoxicity	CONTRAINDICATION	
1632			OMBITASVIR + PARITAPREVIR	OMPA			ENZYMATIC INDUCERS	N03-J05-001	ANSM	387-OMBITASVIR + PARITAPREVIR.html	Decrease of the plasma concentrations of the bitherapy due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
1633			OMBITASVIR + PARITAPREVIR	OMPA			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the bitherapy due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
1634			OMBITASVIR + PARITAPREVIR	OMPA	MIDAZOLAM	6960			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1635			OMBITASVIR + PARITAPREVIR	OMPA	PIMOZIDE	8331			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1636			OMBITASVIR + PARITAPREVIR	OMPA	QUETIAPINE	51272			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1637			OMBITASVIR + PARITAPREVIR	OMPA	QUINIDINE	9068			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the quinidine due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1638			OMBITASVIR + PARITAPREVIR	OMPA	SILDENAFIL	136411			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1639			OMBITASVIR + PARITAPREVIR	OMPA	SIMVASTATIN	36567			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1640			OMBITASVIR + PARITAPREVIR	OMPA	TICAGRELOR	1116632			ANSM	387-OMBITASVIR + PARITAPREVIR.html	Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the bitherapy	CONTRAINDICATION	
1641	OMEPRAZOLE	7646			DIGOXIN	3407			ANSM	388-OMEPRAZOLE.html	Moderate increase of the digoxinemia due to increase of its absorption by the omeprazole	Precaution for use	
1642	OMEPRAZOLE	7646			TACROLIMUS	42316			ANSM	388-OMEPRAZOLE.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	
1643	ONDANSETRON	26225			APOMORPHINE	1043			ANSM	389-ONDANSETRON.html	Severe hypotension and loss of consciousness have been reported when ondansetron is administered with apomorphine	CONTRAINDICATION	
1644	ONDANSETRON	26225					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	389-ONDANSETRON.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
1645	ONDANSETRON	26225			TRAMADOL	10689			ANSM	389-ONDANSETRON.html	Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemetic effect of the ondansetron	Take into account	
1646			AGONIST OPIOID ANALGESICS	N01A-N02A			OTHER AGONIST OPIOID ANALGESICS	N01A-N02A	ANSM	38-AGONIST-OPIOID-ANALGESICS.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
1647			AGONIST OPIOID ANALGESICS	N01A-N02A			MORPHINE LIKE ANTITUSSIVES	R05DA0-001	ANSM	38-AGONIST-OPIOID-ANALGESICS.html	Increased risk of respiratory depression, which can be fatal in cases of overdose	Take into account	
1648			AGONIST OPIOID ANALGESICS	N01A-N02A			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	ANSM	38-AGONIST-OPIOID-ANALGESICS.html	Increased risk of respiratory depression which can be fatal in cases of overdose	Take into account	
1649	GOLD	1311190					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	390-GOLD.html	With the gold salts administered by IV route: risk of "nitritoid" reaction when the ACE inhibitor is introduced (nausea, vomiting, vasomotor effects of the flushing type, hypotension, possibly sudden drop in blood pressure)	Take into account	
1650			PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS	L01XA			AMINOGLYCOSIDES	J01GB-001	ANSM	391-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html	Addition of the nephrotoxic and/or ototoxic effects, especially in the case of pre-existing renal insufficiency	Take into account	
1651			PLATINUM-BASED ANTINEOPLASTIC CANCER DRUGS	L01XA			LOOP DIURETICS	C03CA-001	ANSM	391-PLATINUM-BASED-ANTINEOPLASTIC-CANCER-DRUGS.html	Risk of addition of the ototoxic and/or nephrotoxic effects	Take into account	
1652	ORLISTAT	37925			AMIODARONE	703			ANSM	392-ORLISTAT.html	Risk of decrease of the plasma concentrations of the amiodarone and of its active metabolite	Precaution for use	
1653	ORLISTAT	37925					TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	392-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1654	ORLISTAT	37925					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	392-ORLISTAT.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
1655	ORLISTAT	37925			CICLOSPORIN	3008			ANSM	392-ORLISTAT.html	Decrease of the blood concentrations of ciclosporin due to decrease of its intestinal absorption, with risk of loss of the immunosuppressive activity	Not recommended	
1656	ORLISTAT	37925					THYROID HORMONES	H03AA	ANSM	392-ORLISTAT.html	Risk of disequilibrium of the thyroid replacement therapy when there is treatment with orlistat	Take into account	
1657	ORLISTAT	37925					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	392-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1658	ORLISTAT	37925			LITHIUM	6448			ANSM	392-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1659	ORLISTAT	37925					MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	392-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1660	ORLISTAT	37925					NEUROLEPTICS	N05AA-003	ANSM	392-ORLISTAT.html	Risk of therapeutic failure when there is concomitant treatment with orlistat	Take into account	
1661	ORLISTAT	37925					VITAMIN D	A11CC	ANSM	392-ORLISTAT.html	Decrease of the absorption of the vitamin D	Take into account	
1662	ORNIDAZOLE	7701					FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ANSM	393-ORNIDAZOLE.html	Increase of the toxicity of the fluorouracil due to decrease of its clearance	Take into account	
1663	OXCARBAZEPINE	32624					NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	394-OXCARBAZEPINE.html	Risk of decrease of the effectiveness of the hormonal treatment, due to increase of its hepatic metabolism by the oxcarbazepine.	Precaution for use	
1664	OXCARBAZEPINE	32624			LAMOTRIGINE	28439			ANSM	394-OXCARBAZEPINE.html	Decrease of the concentrations of the lamotrigine with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	
1665	OXCARBAZEPINE	32624			PERAMPANEL	1356552			ANSM	394-OXCARBAZEPINE.html	Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.	Take into account	
1666	OXCARBAZEPINE	32624			TOPIRAMATE	38404			ANSM	394-OXCARBAZEPINE.html	Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	
1667	OXPRENOLOL	7801			ERGOTAMINE	4025			ANSM	395-OXPRENOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	
1668	OXYCODONE	7804			FLUCONAZOLE	4450			ANSM	396-OXYCODONE.html	Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the fluconazole	Not recommended	
1669	OXYCODONE	7804					ENZYME INDUCERS	N03-J05-001	ANSM	396-OXYCODONE.html	Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the inducer	Not recommended	
1670	OXYCODONE	7804					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	396-OXYCODONE.html	Increase of the undesirable effects, especially respiratory ones, of the oxycodone due to decrease of its metabolism by the inhibitor	Not recommended	
1671	OXYCODONE	7804			ST JOHN'S WORT	258326			ANSM	396-OXYCODONE.html	Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the St Johns wort	Not recommended	
1672	PACLITAXEL	56946			CLOPIDOGREL	32968			ANSM	397-PACLITAXEL.html	Increase of the concentrations of the paclitaxel by the clopidogrel, with risk of increase of the undesirable effects.	Take into account	
1673	GRAPEFRUIT				ALISKIREN	325646			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Risk of decrease of the effectiveness of the aliskiren when grapefruit is consumed	Not recommended	
1674	GRAPEFRUIT				ATORVASTATIN	83367			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increase of the plasma concentrations of the cholesterol lowering medication, with risk of appearance of undesirable effects, especially muscular ones	Take into account	
1675	GRAPEFRUIT				AVANAFIL	1291301			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increase of the plasma concentrations of the avanafil, with risk of hypotension	Not recommended	
1676	GRAPEFRUIT				BUSPIRONE	1827			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Risk of increase of the undesirable effects of the buspirone due to decrease of its metabolism by the grapefruit	Take into account	
1677	GRAPEFRUIT				CARBAMAZEPINE	2002			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increase of the plasma concentrations of carbamazepine, with risk of overdose, due to inhibition of its metabolism by the grapefruit	Not recommended	
1678	GRAPEFRUIT				DRONEDARONE	233698			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increase of the concentrations of dronedarone due to inhibition of its metabolism by the grapefruit	Not recommended	
1679	GRAPEFRUIT				HALOFANTRINE	50749			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1680	GRAPEFRUIT						IMMUNOSUPPRESSANTS	L04A	ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increase of the bioavailability of the immunosuppressant and as a result of its undesirable effects	Not recommended	
1681	GRAPEFRUIT				IVABRADINE	77417			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects (inhibition of its intestinal metabolism by the grapefruit)	Not recommended	
1682	GRAPEFRUIT				LERCANIDIPINE	135056			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increased risk of undesirable effects, especially edema, due to decrease of the intestinal metabolism of the dihydropyridine	Take into account	
1683	GRAPEFRUIT				LURASIDONE	1040028			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increase of the plasma concentrations of the lurasidone due to decrease of its metabolism by the grapefruit	Not recommended	
1684	GRAPEFRUIT				REGORAFENIB	1312397			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the grapefruit	Not recommended	
1685	GRAPEFRUIT				SERTRALINE	36437			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Sometimes large increase of the plasma concentrations of the antidepressant with certain patients due to decrease of intestinal metabolism	Not recommended	
1686	GRAPEFRUIT				SIMVASTATIN	36567			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Large increase of the plasma concentrations of the cholesterol lowering medication, with risk of onset of undesirable effects, especially muscular ones.	Not recommended	
1687	GRAPEFRUIT				TICAGRELOR	1116632			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Doubling of the plasma concentrations of the platelet aggregation inhibitor, with risk of increase of the undesirable effects, especially hemorrhagic	Not recommended	
1688	GRAPEFRUIT				VARDENAFIL	306674			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increase of the plasma concentrations of the vardenafil, with risk of hypotension	Not recommended	
1689	GRAPEFRUIT				VERAPAMIL	11170			ANSM	398-GRAPEFRUIT-(JUICE -OR-FRUIT).html	Increase of the plasma concentrations of verapamil, with risk of onset of undesirable effects	Take into account	
1690	PANOBINOSTAT	1603350					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	399-PANOBINOSTAT.html	Risk of increase of the undesirable effects, especially cardiac ones, of the panobinostat due to decrease of its metabolism by the inhibitor	Precaution for use	
1691			STEP II OPIOID ANALGESICS	N02A-003			AGONIST-ANTAGONIST OPIOIDS	NO2A-001	ANSM	39-STEP II OPIOID ANALGESICS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Not recommended	
1692			STEP II OPIOID ANALGESICS	N02A-003			PARTIAL AGONIST OPIOIDS	PARAG	ANSM	39-STEP II OPIOID ANALGESICS.html	Risk of decrease of the antalgic effect	Not recommended	
1693	ACETAZOLAMIDE	167			ACETYLSALICYLIC ACID	1191			ANSM	3-ACETAZOLAMIDE.html	Increase of the undesirable effects, and especially of metabolic acidosis, of the acetylsalicylic acid in large doses and of the acetazolamide, due to decrease of the elimination of the acetylsalicylic acid by the acetazolamide	Not recommended	
1694	ACETAZOLAMIDE	167			CARBAMAZEPINE	2002			ANSM	3-ACETAZOLAMIDE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	
1695	ACETAZOLAMIDE	167			LITHIUM	6448			ANSM	3-ACETAZOLAMIDE.html	Decrease of the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness	Precaution for use	
1696	ACETAZOLAMIDE	167					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	3-ACETAZOLAMIDE.html	Increase of the hyperammonemia, with incresed risk of encephalopathy	Precaution for use	
1697	PARACETAMOL	161					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	400-PARACETAMOL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days	Precaution for use	
1698	PAROXETINE	32937			CARBAMAZEPINE	2002			ANSM	401-PAROXETINE.html	Increase of the plasma concentrations of carbamazepine with signs of overdose	Precaution for use	
1699	PAROXETINE	32937			MEQUITAZINE	29528			ANSM	401-PAROXETINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
1700	PAROXETINE	32937			METOPROLOL	6918			ANSM	401-PAROXETINE.html	Risk of increase of the undesirable effects of the metoprolol, with especially excessive bradycardia, due to inhibition of its metaboilsm by the paroxetine	Precaution for use	
1701	PAROXETINE	32937			NEBIVOLOL	31555			ANSM	401-PAROXETINE.html	Risk of increase of the undesirable effects of the nebivolol, with especially excessive bradycardia, due to inhibition of its metabolism by the antidepressant	Precaution for use	
1702	PAROXETINE	32937			PIMOZIDE	8331			ANSM	401-PAROXETINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	C0NTRAINDICATION	
1703	PAROXETINE	32937			RISPERIDONE	35636			ANSM	401-PAROXETINE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects.	Precaution for use	
1704	PAROXETINE	32937			TAMOXIFEN	10324			ANSM	401-PAROXETINE.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine	Not recommended	
1705	PAROXETINE	32937			VORTIOXETINE	1455099			ANSM	401-PAROXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	
1706	PEFLOXACIN	7960					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	402-PEFLOXACIN.html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	
1707	PEG-INTERFERON ALFA-2A	120608			TELBIVUDINE	474128			ANSM	403-PEG-INTERFERON-ALFA-2A.html	Increased risk of peripheral neuropathy	CONTRAINDICATION	
1708	PEMETREXED	68446			ACETYLSALICYLIC ACID	1191			ANSM	404-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not recommended	
1709	PEMETREXED	68446					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	404-PEMETREXED.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the NSAIs)	Not recommended	
1710			PENEMS	J01DH			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	405-PENEMS.html	Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable.	Not recommended	
1711	PENICILLAMINE	7975			IRON	1431589			ANSM	406-PENICILLAMINE.html	Decrease of the digestive absorption of the penicillamine	Precaution for use	
1712			PENICILLINS	J01C	METHOTREXATE	6851			ANSM	407-PENICILLINS.html	Increase of the effects and of the hematological toxicity of the methothrexate: inhibition of the renal tubular secretion of the methotrexate by the penicillins	Not recommended	
1713			AMINOPENICILLINS	J01CA	ALLOPURINOL	519			ANSM	408-AMINOPENICILLINS.html	Increased risk of cutaneous reactions	Take into account	
1714			AMINOPENICILLINS	J01CA	MYCOPHENOLATE MOFETIL	7145			ANSM	408-AMINOPENICILLINS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
1715	PENTAMIDINE	7994			DIDANOSINE	3364			ANSM	409-PENTAMIDINE.html	Increased risk of onset of pancreatitis due to addition of undesirable effects	Precaution for use	
1716	PENTAMIDINE	7994			FOSCARNET	33562			ANSM	409-PENTAMIDINE.html	Risk of severe hypocalcemia	Precaution for use	
1717	PENTAMIDINE	7994			STAVUDINE	59763			ANSM	409-PENTAMIDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
1718	PENTAMIDINE	7994			ZALCITABINE	3363			ANSM	409-PENTAMIDINE.html	Increased risk of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
1719			STEP III OPIOID ANALGESICS	N02A-002			AGONIST-ANTAGONIST OPIOIDS	NO2A-001	ANSM	40-STEP-III-OPIOID-ANALGESICS.html	Decrease of the antalgic effect due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	CONTRAINDICATION	
1720			STEP III OPIOID ANALGESICS	N02A-002			PARTIAL AGONIST OPIOIDS	PARAG	ANSM	40-STEP-III-OPIOID-ANALGESICS.html	Risk of decrease of the antalgic effect	CONTRAINDICATION	
1721	PENTOSTATIN	8011			CYCLOPHOSPHAMIDE	3002			ANSM	410-PENTOSTATIN.html	Increase of the risk of pulmonary toxicity which could be fatal	Not recommended	
1722	PENTOSTATIN	8011			FLUDARABINE	24698			ANSM	410-PENTOSTATIN.html	Increase of the risk of pulmonary toxicity which could be fatal	Not recommended	
1723	PENTOXIFYLLINE	8013					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	411-PENTOXIFYLLINE.html	Increase of the risk of hemorrhage	Take into account	
1724	PENTOXIFYLLINE	8013					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	411-PENTOXIFYLLINE.html	Increase of the risk of hemorrhage	Precaution for use	
1725	PENTOXIFYLLINE	8013					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	411-PENTOXIFYLLINE.html	Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline)	Precaution for use	
1726	PERAMPANEL	1356552					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	412-PERAMPANEL.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
1727	PERAMPANEL	1356552			CYPROTERONE	3014			ANSM	412-PERAMPANEL.html	For doses of perampanel > or = to 12 mg/day, risk of decrease of the effectiveness of the cyproterone	Not recommended	
1728	PERAMPANEL	1356552			OXCARBAZEPINE	32624			ANSM	412-PERAMPANEL.html	Decrease by half of the concentrations of perampanel and slight increase of those of the oxcarbazepine.	Take into account	
1729	PERAMPANEL	1356552					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	412-PERAMPANEL.html	For doses of perampanel >=12 mg/day: Risk of decrease of the contraceptive effectiveness	Not recommended	
1730	PERAMPANEL	1356552			RIFAMPICIN	9384			ANSM	412-PERAMPANEL.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
1731	PETHIDINE	6754					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	413-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
1732	PETHIDINE	6754					REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	413-PETHIDINE.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma.	CONTRAINDICATION	
1733	PETHIDINE	6754					MAOI-B	N04BD0-001	ANSM	413-PETHIDINE.html	Symptoms of central nervous system excitability evoking a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	CONTRAINDICATION	
1734			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	CHOLIC ACID	1440856			ANSM	414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Antagonist effect of the barbiturate	CONTRAINDICATION	
1735			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	CARBAMAZEPINE	2002			ANSM	414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Progressive decrease of the plasma concentrations of carbamazepine and of its active metabolite without apparent modification of its anticonvulsive effectiveness	Take into account	
1736			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	FELBAMATE	24812			ANSM	414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations and of the effectiveness of the felbamate and increase of the plasma concentrations of the phenobarbital, with risk of overdose.	Precaution for use	
1737			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001			FOLATES	V03-	ANSM	414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the phenobarbital, due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	
1738			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	IFOSFAMIDE	5657			ANSM	414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Risk of increase of the neurotoxicity of the ifosfamide due to increase of its hepatic metabolism by the phenobarbital	Not recommended	
1739			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	METOPROLOL	6918			ANSM	414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the metoprolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
1740			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)In cases of previous treatment with the pheyntoin and the addition of phenobarbital or of primidone, unpredictable changes:--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)	Take into account	
1741			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	PROPRANOLOL	8787			ANSM	414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
1742			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	414-PHENOBARBITAL (AND,-BY-EXTRAPOLATION,-PRIMIDONE).html	Increase of the hyperammonemia with increased risk of encephalopathy	Precaution for use	
1743			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	AMIODARONE	703			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of the phenytoin with signs of overdose, in particular neurological ones (decrease of the hepatic metabolism of the phenytoin)	Precaution for use	
1744			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	CARBAMAZEPINE	2002			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Reciprocal reduction of the plasma concentrations (increase of the metabolism without apparent modification of the anticonvulsive effectiveness)	Take into account	
1745			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	CIMETIDINE	2541			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the plasma concentrations of phenytoin with the possibility of appearance of the usual signs of overdose	Not recommended	
1746			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	CIPROFLOXACIN	2551			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Variation, possibly large, of the concentrations of phenytoin in the case of treatment with the ciprofloxacin	Precaution for use	
1747			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	CLOPIDOGREL	32968			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)	Precaution for use	
1748			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	CLOZAPINE	2626			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	
1749			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB			CYTOTOXICS	L01	ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Risk of onset of convulsions due to decrease of the digestive absorption of the phenytoin only [not the fosphenytoin] by the cytotoxic, or risk of increase of the toxicity or loss of the effectiveness of the cytotoxic due to the increase of its hepatic metabolism by the phenytoin or the fosphenytoin	Not recommended	
1750			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	DIAZEPAM	3322			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Unpredictable variations: the plasma concentrations of phenytoin can increase, with signs of overdose, but also decrease or remain stable.	Precaution for use	
1751			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	DISULFIRAM	3554			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Large and rapid increase of the plasma concentrations of phenytoin with signs of toxicity (inhibition of its metabolism)	Not recommended	
1752			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	FELBAMATE	24812			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with risk of overdose, due to inhibition of its metabolism by the felbamate	Precaution for use	
1753			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	FLUCONAZOLE	4450			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin that can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin	Precaution for use	
1754			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	FLUOXETINE	4493			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the metabolism of the phenytoin	Precaution for use	
1755			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	FLUVOXAMINE	42355			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose, due to inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	
1756			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB			FOLATES	V03-	ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the plasma concentrations of phenytoin due to increase of its metabolism of which the folates represent one of the cofactors	Precaution for use	
1757			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	FUROSEMIDE	460			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the diuretic effect which can reach 50%	Precaution for use	
1758			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ISONIAZID	6038			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Overdose of phenytoin (decrease of its metabolism)	Precaution for use	
1759			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	METYRAPONE	6923			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Risk of false negative results of the test with metyrapone, due to a decrease of its plasma concentrations, because of the increase of its hepatic metabolism by the phenytoin.	Precaution for use	
1760			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	MEXILETINE	6926			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the antiarrythmic activity, of the plasma concentrations, and of the half life of the mexiletine (increase of its hepatic metabolism)	Precaution for use	
1761			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	MICONAZOLE	6932			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin which can reach toxic values. Mechanism proposed: inhibition of the hepatic metabolism of the phenytoin.	Precaution for use	
1762			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	NINTEDANIB	1592737			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the phenytoin or the fosphenytoin.	Precaution for use	
1763			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	In cases of previous treatment with the phenobarbital or the primidone, and the addition of phenytoin, increase of the plasma concentrations of phenobarbital that can lead to toxic signs (inhibition of the metabolism by competition)In cases of previous treatment with the phenytoin and the addition of phenobarbital or of primidone, unpredictable changes:--the plasma concentrations of phenytoin are most often decreased (increase of the metabolism) without this decrease affecting the anticonvulsant activity unfavorably. When the phenobarbital or the primidone is stopped, possibility of toxic effects of the phenytoin.--it can happen that the concentrations of phenytoin are increased (inhibition of the metabolism due to competition)	Take into account	
1764			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	SUCRALFATE	10156			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Decrease of the digestive absorption of the phenytoin.	Precaution for use	
1765			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	SULFAFURAZOLE	10207			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	
1766			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	SULFAMETHIZOLE	10179			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	
1767			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	SULFAMETHOXAZOLE	10180			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism).	Not recommended	
1768			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	TICLOPIDINE	10594			ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin).	Precaution for use	
1769			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	415-PHENYTOIN-(AND,-BY-EXTRAPOLATION,-FOSPHENYTOIN).html	Increase of the hyperammoniemia, with increased risk of encephalopathy	Precaution for use	
1770	PILOCARPINE	8328					ACETYL-CHOLINESTERASE INHIBITORS	NO6DA-001	ANSM	416-PILOCARPINE.html	Risk of addition of the undesirable cholinergic effects, especially digestive	Take into account	
1771	PIMOZIDE	8331			APREPITANT	358255			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1772	PIMOZIDE	8331			DALFOPRISTIN	229369			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1773	PIMOZIDE	8331			DILTIAZEM	3443			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1774	PIMOZIDE	8331			EFAVIRENZ	195085			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1775	PIMOZIDE	8331			FLUCONAZOLE	4450			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1776	PIMOZIDE	8331					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1777	PIMOZIDE	8331			JOSAMYCIN	6084			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1778	PIMOZIDE	8331					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	417-PIMOZIDE.html	Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the combination ombitasvir + paritaprevir	CONTRAINDICATION	
1779	PIMOZIDE	8331			PAROXETINE	32937			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1780	PIMOZIDE	8331			QUINUPRISTINE	135098			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1781	PIMOZIDE	8331			SERTRALINE	36437			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1782	PIMOZIDE	8331			STIRIPENTOL	37119			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1783	PIMOZIDE	8331			TRICLABENDAZOLE	38608			ANSM	417-PIMOZIDE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the medication that tends to induce torsades de pointes).	CONTRAINDICATION	
1784	PIOGLITAZONE	33738					SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	418-PIOGLITAZONE.html	Risk of hyypoglycemia or hyperglycemia: decrease or increase of the need for glitazone, due to decrease of increase of the secretion of endogenous glucagon	Precaution for use	
1785	PIOGLITAZONE	33738			GEMFIBROZIL	4719			ANSM	418-PIOGLITAZONE.html	Risk of increase of the undesirable effects of the glitazone due to decrease of its hepatic metabolism by the gemfibrozil	Not recommended	
1786	PIOGLITAZONE	33738			RIFAMPICIN	9384			ANSM	418-PIOGLITAZONE.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampcin	Precaution for use	
1787	PIRFENIDONE	88221			FLUVOXAMINE	42355			ANSM	419-PIRFENIDONE.html	Increase of the plasma concentrations of pirfenidone with signs of overdose	CONTRAINDICATION	
1788			SOMATOSTATIN ANALOGS	H01CB0-001	CICLOSPORIN	3008			ANSM	41-SOMATOSTATIN-ANALOGS.html	With the ciclosporin administered orally:reduction of the blood concentrations of ciclosporin (decrease of its intestinal absorption).	Precaution for use	
1789			SOMATOSTATIN ANALOGS	H01CB0-001	INSULIN	5856			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for insulin, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	
1790			SOMATOSTATIN ANALOGS	H01CB0-001	PIOGLITAZONE	33738			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia: decrease of increase of the need for glitazone, due to decrease or increase of the secretion of endogenous glucogon	Precaution for use	
1791			SOMATOSTATIN ANALOGS	H01CB0-001	REPAGLINIDE	73044			ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for repaglinde due to decrease or increase of the secretion of endogenous glucagon .	Precaution for use	
1792			SOMATOSTATIN ANALOGS	H01CB0-001			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	41-SOMATOSTATIN-ANALOGS.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the needs for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	
1793	PITAVASTATIN	861634			CICLOSPORIN	3008			ANSM	420-PITAVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the pitavastatin	CONTRAINDICATION	
1794	POLYMYXIN B	8536					AMINOGLYCOSIDES	J01GB-001	ANSM	421-POLYMYXIN-B.html	Addition of the nephrotoxic effects.	Not recommended	
1795	POLYMYXIN B	8536					CURARES	M03A-001	ANSM	421-POLYMYXIN-B.html	Increase of the effects of the curares when the antibiotic is administered by parenteral and/or peritoneal route before, during, or after the curarizing agent.	Precaution for use	
1796	POSACONAZOLE	282446					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	422-POSACONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the posaconazole	Precaution for use	
1797	POSACONAZOLE	282446					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	422-POSACONAZOLE.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the H2 receptor antagonist	Not recommended	
1798	POSACONAZOLE	282446					PROTON PUMP INHIBITORS	A02BC-001	ANSM	422-POSACONAZOLE.html	Decrease of the absorption of the azole antifungal, due to increase of the gastric pH by the inhibitor	Not recommended	
1799	POSACONAZOLE	282446			ATORVASTATIN	83367			ANSM	422-POSACONAZOLE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)	CONTRAINDICATION	
1800	POSACONAZOLE	282446			DEXAMETHASONE	3264			ANSM	422-POSACONAZOLE.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of CushingÂ’s syndrome	Take into account	
1801	POSACONAZOLE	282446			DIGOXIN	3407			ANSM	422-POSACONAZOLE.html	Increase of the digoxinemia with nausea, vomiting, arrhythmias.	Precaution for use	
1802	POSACONAZOLE	282446					IMMUNOSUPPRESSANTS	L04A	ANSM	422-POSACONAZOLE.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
1803	POSACONAZOLE	282446			RIFABUTIN	55672			ANSM	422-POSACONAZOLE.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Not recommended	
1804	POSACONAZOLE	282446			RIFAMPICIN	9384			ANSM	422-POSACONAZOLE.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-infectives (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
1805	POSACONAZOLE	282446			SIMVASTATIN	36567			ANSM	422-POSACONAZOLE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)	CONTRAINDICATION	
1806	POSACONAZOLE	282446					VINCA ALKALOIDS	L01CA	ANSM	422-POSACONAZOLE.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole	Not recommended	
1807	POTASSIUM	8588					ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	423-POTASSIUM.html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).	Not recommended	
1808	POTASSIUM	8588			CICLOSPORIN	3008			ANSM	423-POTASSIUM.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
1809	POTASSIUM	8588					POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	423-POTASSIUM.html	Potentially lethal hyperkalemia, especially with patients having renal insufficiency (addition of the hyperkaliemia producing effects)	Contraindication:	
1810	POTASSIUM	8588					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	423-POTASSIUM.html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
1811	POTASSIUM	8588			TACROLIMUS	42316			ANSM	423-POTASSIUM.html	Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia producing effects)	Not recommended	
1812	POVIDONE-IODINE	8611					MERCURIAL ANTISEPTICS	D08AK0	ANSM	424-POVIDONE-IODINE.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurial and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
1813	PRAVASTATIN	42463			CLARITHROMYCIN	21212			ANSM	425-PRAVASTATIN.html	Increase of the plasma concentration of the pravastatin by the clarithromycin	Precaution for use	
1814	PRAVASTATIN	42463			ERYTHROMYCIN	4053			ANSM	425-PRAVASTATIN.html	With the erythromycin administered by oral route: increase of the plasma concentration of the pravastatin by the erythromycin	Precaution for use	
1815	PRAZIQUANTEL	8628					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	426-PRAZIQUANTEL.html	Very large decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment due to increase of its hepatic metabolism by the inducer	Not recommended	
1816	PRAZIQUANTEL	8628			DEXAMETHASONE	3264			ANSM	426-PRAZIQUANTEL.html	Decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the dexamethasone.	Precaution for use	
1817	PRAZIQUANTEL	8628			RIFAMPICIN	9384			ANSM	426-PRAZIQUANTEL.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	CONTRAINDICATION	
1818	PREDNISOLONE	8638			CICLOSPORIN	3008			ANSM	427-PREDNISOLONE.html	Increase of the effects of the prednisolone: characteristic CushingÂ’s appearance, reduction of tolerance of carbohydrates (decrease of the clearance of the prednisolone)	Take into account	
1819	LATEX CONDOMS						MINERAL OILS	A06AA-	ANSM	428-LATEX CONDOMS.html	Risk of rupture of the condom when used with lubricants containing mineral oils (paraffin oil, silicone oil, etc...)	CONTRAINDICATION	
1820	PRIMIDONE	8691			AFATINIB	1430438			ANSM	429-PRIMIDONE.html	Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the primidone	Precaution for use	
1821			ANDROGENS	A14AA0			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	42-ANDROGENS.html	Increase of the risk of hemorrhage due to the direct effect on coagulation and/or the fibrinolytic systems.	Precaution for use	
1822			ANDROGENS	A14AA0			ENZYME INDUCERS	N03-J05-001	ANSM	42-ANDROGENS.html	Risk of decrease of the plasma concentrations of the androgen and consequently of its effectiveness, due to increase of its hepatic metabolism by the inducer	Precaution for use	
1823	PRISTINAMYCIN	66958					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	430-PRISTINAMYCIN.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
1824	PRISTINAMYCIN	66958			COLCHICINE	2683			ANSM	430-PRISTINAMYCIN.html	Increase of the undesirable effects of the colchicine with potentially fatal consequences	CONTRAINDICATION	
1825	PRISTINAMYCIN	66958					IMMUNOSUPPRESSANTS	L04A	ANSM	430-PRISTINAMYCIN.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	
1826	PROBENECID	8698			ACETYLSALICYLIC ACID	1191			ANSM	431-PROBENECID.html	Decrease of the uricosuric effect due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
1827	PROBENECID	8698			DIPROPHYLLINE	3714			ANSM	431-PROBENECID.html	Risk of overdose due to increase of the plasma concentrations of diprophylline (inhibition of its renal tubular secretion)	Precaution for use	
1828	PROBENECID	8698			METHOTREXATE	6851			ANSM	431-PROBENECID.html	Increase of the toxicity of the methotrexate: inhibition of the renal tubular secretion of the methotrexate by the probenecid	CONTRAINDICATION	
1829	PROCARBAZINE	8702					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	432-PROCARBAZINE.html	Increase of the hypersensitivity reactions (hypereosinophilia, rash), due to increase of the metabolism of the procarbazine by the inducer	Take into account	
1830			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	ALDESLEUKIN	70223			ANSM	433-IODINATED-X-RAY-CONTRAST-MEDIA.html	Increase of the risk of reaction to the contrast media in cases of previous treatment with interleukin2: skin rash or more rarely low blood pressure, oliguria or even renal failure	Take into account	
1831			IODINATED X-RAY CONTRAST MEDIA	VO8A-001			DIURETICS	C0E-001	ANSM	433-IODINATED-X-RAY-CONTRAST-MEDIA.html	In case of dehydration caused by the diuretics, increased risk of acute functional renal insufficiency, in particular when large doses of the contrast media are used	Precaution for use	
1832			IODINATED X-RAY CONTRAST MEDIA	VO8A-001	METFORMIN	6809			ANSM	433-IODINATED-X-RAY-CONTRAST-MEDIA.html	Lactic acidosis linked to elevated concentrations of metformin in relation to functional renal insufficiency induced by the radiological exam.	CONTRAINDICATION	
1833			PROGESTIN CONTRACEPTIVES	G03-001	APREPITANT	358255			ANSM	434-PROGESTIN CONTRACEPTIVES.html	(Except IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness	Precaution for use	
1834			PROGESTIN CONTRACEPTIVES	G03-001	BOCEPREVIR	1102129			ANSM	434-PROGESTIN CONTRACEPTIVES.html	Aside from the combination ethinylestradiol (0.035mg)/norethisterone (1 mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir	Precaution for use	
1835			PROGESTIN CONTRACEPTIVES	G03-001	BOSENTAN	75207			ANSM	434-PROGESTIN CONTRACEPTIVES.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	
1836			PROGESTIN CONTRACEPTIVES	G03-001	GRISEOFULVIN	5021			ANSM	434-PROGESTIN CONTRACEPTIVES.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	
1837			PROGESTIN CONTRACEPTIVES	G03-001			ENZYME INDUCERS	N03-J05-001	ANSM	434-PROGESTIN CONTRACEPTIVES.html	Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer	Not recommended	
1838			PROGESTIN CONTRACEPTIVES	G03-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	434-PROGESTIN CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir	Not recommended	
1839			PROGESTIN CONTRACEPTIVES	G03-001	ST JOHNS WORT	258326			ANSM	434-PROGESTIN CONTRACEPTIVES.html	Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzyme inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy)	CONTRAINDICATION	
1840			PROGESTIN CONTRACEPTIVES	G03-001	PERAMPANEL	1356552			ANSM	434-PROGESTIN CONTRACEPTIVES.html	For doses of perampanel >=12 mg/day: Risk of decrease of the contraceptive effectiveness	Not recommended	
1841			PROGESTIN CONTRACEPTIVES	G03-001	ULIPRISTAL	1005921			ANSM	434-PROGESTIN CONTRACEPTIVES.html	Risk of antagonism of the effects of the progestin contraceptive	Not recommended	
1842			PROGESTIN CONTRACEPTIVES	G03-001	APREPITANT	358255			ANSM	434-PROGESTIN-CONTRACEPTIVES.html	(Except IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness	Precaution for use	
1843			PROGESTIN CONTRACEPTIVES	G03-001	BOCEPREVIR	1102129			ANSM	434-PROGESTIN-CONTRACEPTIVES.html	Aside from the combination ethinylestradiol (0.035mg)/norethisterone (1 mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir	Precaution for use	
1844			PROGESTIN CONTRACEPTIVES	G03-001	BOSENTAN	75207			ANSM	434-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	
1845			PROGESTIN CONTRACEPTIVES	G03-001	GRISEOFULVIN	5021			ANSM	434-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism	Precaution for use	
1846			PROGESTIN CONTRACEPTIVES	G03-001			ENZYME INDUCERS	N03-J05-001	ANSM	434-PROGESTIN-CONTRACEPTIVES.html	Decrease of the contraceptive effectiveness of the hormonal contraceptive, due to increase of its hepatic metabolism by the inducer	Not recommended	
1847			PROGESTIN CONTRACEPTIVES	G03-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	434-PROGESTIN-CONTRACEPTIVES.html	Risk of decrease of the contraceptive effectiveness because of decrease of the concentrations of hormonal contraceptive, due to the increase of its hepatic metabolism by the ritonavir	Not recommended	
1848			PROGESTIN CONTRACEPTIVES	G03-001	ST JOHNS WORT	258326			ANSM	434-PROGESTIN-CONTRACEPTIVES.html	Decrease of the plasma concentrations of the hormonal contraceptive, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy)	CONTRAINDICATION	
1849			PROGESTIN CONTRACEPTIVES	G03-001	PERAMPANEL	1356552			ANSM	434-PROGESTIN-CONTRACEPTIVES.html	For doses of perampanel >=12 mg/day: Risk of decrease of the contraceptive effectiveness	Not recommended	
1850			PROGESTIN CONTRACEPTIVES	G03-001	ULIPRISTAL	1005921			ANSM	434-PROGESTIN-CONTRACEPTIVES.html	Risk of antagonism of the effects of the progestin contraceptive	Not recommended	
1851			NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	BOSENTAN	75207			ANSM	435-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html	Risk of decrease of the effectiveness of the progestogen	Precaution for use	
1852			NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003			ENZYME INDUCERS	N03-J05-001	ANSM	435-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html	Decrease of the effectiveness of the progestogen	Precaution for use	
1853			NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	ULIPRISTAL	1005921			ANSM	435-NON-CONTRACEPTIVE-PROGESTOGENS,-COMBINED-WITH-AN-ESTROGEN-OR-NOT.html	Risk of antagonism of the effects of the progestogen	Not recommended	
1854	PROGUANIL	2382					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	436-PROGUANIL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
1855	PROGUANIL	2382					THYROID HORMONES	H03AA	ANSM	436-PROGUANIL.html	Risk of clinically low thyroid with patients having thyroid replacement therapy	Precaution for use	
1856	PROPAFENONE	8754			ABIRATERONE	1100072			ANSM	437-PROPAFENONE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the abiraterone	Precautions for use	
1857	PROPAFENONE	8754					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	437-PROPAFENONE.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the inducer	Precaution of use	
1858	PROPAFENONE	8754					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	437-PROPAFENONE.html	Increase of the anticoagulant effect and of the risk of hemorrhage. Mechanism proposed: inhibition of the metabolism of the vitamin K antagonist	Precaution for use	
1859	PROPAFENONE	8754					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	437-PROPAFENONE.html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
1860	PROPAFENONE	8754			BUPROPION	42347			ANSM	437-PROPAFENONE.html	Risk of increase of the undesirable effects of the propafenone due to decrease of its hepatic metabolism by the bupropion	Precaution for use	
1861	PROPAFENONE	8754			CINACALCET	407990			ANSM	437-PROPAFENONE.html	Increase of the plasma concentrations of propafenone with risk of overdose, due to decrease of its hepatic metabolism by the cinacalcet	Precaution for use	
1862	PROPAFENONE	8754			DARIFENACIN	136198			ANSM	437-PROPAFENONE.html	Increase of the plasma concentrations of propafenone, with risk of overdose, due to decrease of its hepatic metabolism by the darifenacin	Precaution for use.	
1863	PROPAFENONE	8754			DIGOXIN	3407			ANSM	437-PROPAFENONE.html	Risk of increase of the digoxinemia, especially with older patients	Precaution for use	
1864	PROPAFENONE	8754			DULOXETINE	72625			ANSM	437-PROPAFENONE.html	Increase of the plasma concentrations of propafenone with risk of overdosage due to decrease of its hepatic metabolism by the duloxetine	Precaution for use	
1865	PROPAFENONE	8754			ESMOLOL	49737			ANSM	437-PROPAFENONE.html	Disorders of contractility, autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
1866	PROPAFENONE	8754			ST JOHNS WORT	258326			ANSM	437-PROPAFENONE.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort	Precaution for use	
1867	PROPAFENONE	8754			MIRABEGRON	1300786			ANSM	437-PROPAFENONE.html	Increase of the plasma concentrations of the propafenone by decrease of its metabolism by the mirabegron	Precaution for use	
1868	PROPAFENONE	8754			RIFAMPICIN	9384			ANSM	437-PROPAFENONE.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
1869	PROPAFENONE	8754			TERBINAFINE	37801			ANSM	437-PROPAFENONE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	
1870	PROPAFENONE	8754			THEOPHYLLINE	10438			ANSM	437-PROPAFENONE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone.	Precaution for use	
1871	PROPRANOLOL	8787			ERGOTAMINE	4025			ANSM	438-PROPRANOLOL.html	Ergotism: some cases of arterial spasm with ischemia of the extremities have been observed (addition of vascular effects)	Precaution for use	
1872	PROPRANOLOL	8787			FLUVOXAMINE	42355			ANSM	438-PROPRANOLOL.html	Increase of the plasma concentrations of propranolol due to inhibition of its hepatic metabolism, with increase of the activity and of the undesirable effects, for example: significant bradycardia	Precaution for use	
1873	PROPRANOLOL	8787					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	438-PROPRANOLOL.html	Decrease of the plasma concentrations of the propranolol with reduction of its clinical effects (increase of its hepatic metabolism)	Take into account	
1874	PROPRANOLOL	8787			RIFAMPICIN	9384			ANSM	438-PROPRANOLOL.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
1875	PYRAZINAMIDE	8987			ISONIAZID	6038			ANSM	439-PYRAZINAMIDE.html	Addition of the hepatotoxic effects.	Precaution for use	
1876			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001			ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	A01AD	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increased cardiac sensitization	Precaution for use	
1877			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Reduction of the compensatory cardiovascular reactions by the beta blocking agents. The beta-andrenergic inhibition can be elevated by the beta-mimetics during surgery.	Precaution for use	
1878			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Reduction of the compensatory cardiovascular reactions by the beta blocking agents. The beta-adrenergic inhibition can be elevated during the surgery by the beta-stimulants.	Precaution for use	
1879			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ISONIAZID	6038			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites..	Precaution for use	
1880			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ISOPRENALINE	6054			ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
1881			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
1882			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	43-HALOGENATED-HYDROCARBON-ANESTHETICS.html	Perioperative hypertension	Precaution for use	
1883	PYRIMETHAMINE	9010			TRIMETHOPRIM	10829			ANSM	440-PYRIMETHAMINE.html	Megaloblastic anemia, more particularly with large doses of the two products (deficit of folic acid due to the combination of two 2-4 diaminopyrimidines)	Precaution for use	
1884	QUETIAPINE	51272					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	441-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
1885	QUETIAPINE	51272					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	441-QUETIAPINE.html	Large increase of the concentrations of quetiapine, with risk of overdose	CONTRAINDICATION	
1886	QUETIAPINE	51272			ST JOHNS WORT	258326			ANSM	441-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
1887	QUETIAPINE	51272					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	441-QUETIAPINE.html	Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination	CONTRAINDICATION	
1888	QUETIAPINE	51272			RIFAMPICIN	9384			ANSM	441-QUETIAPINE.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
1889	QUINIDINE	9068					URINARY ALKALIZERS	B05-001	ANSM	442-QUINIDINE.html	Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).	Precaution for use	
1890	QUINIDINE	9068			ALISKIREN	325646			ANSM	442-QUINIDINE.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.	CONTRAINDICATION	
1891	QUINIDINE	9068			COBICISTAT	1306284			ANSM	442-QUINIDINE.html	Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat	CONTRAINDICATION	
1892	QUINIDINE	9068			DABIGATRAN				ANSM	442-QUINIDINE.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	
1893	QUINIDINE	9068			DIGOXIN	3407			ANSM	442-QUINIDINE.html	Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)	Precaution for use	
1894	QUINIDINE	9068			DRONEDARONE	233698			ANSM	442-QUINIDINE.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine	Precaution for use	
1895	QUINIDINE	9068					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	442-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1896	QUINIDINE	9068			ITRACONAZOLE	28031			ANSM	442-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine	CONTRAINDICATION	
1897	QUINIDINE	9068					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	442-QUINIDINE.html	Increase of the plasma concentrations of the quidinine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination	CONTRAINDICATION	
1898	QUINIDINE	9068			STIRIPENTOL	37119			ANSM	442-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1899	QUINIDINE	9068			TAMOXIFEN	10324			ANSM	442-QUINIDINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine	Not recommended	
1900	QUINIDINE	9068			TRICLABENDAZOLE	38608			ANSM	442-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	CONTRAINDICATION	
1901	QUINIDINE	9068			VERAPAMIL	11170			ANSM	442-QUINIDINE.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
1902	QUINIDINE	9068			VORICONAZOLE	121243			ANSM	442-QUINIDINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
1903	QUINIDINE	9068			VORTIOXETINE	1455099			ANSM	442-QUINIDINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	
1904	QUININE	9071					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	443-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer.	Precaution for use	
1905	QUININE	9071			DIGOXIN	3407			ANSM	443-QUININE.html	Moderate increase of the digoxinemia	Precaution for use	
1906	QUININE	9071					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	443-QUININE.html	Risk of increase of the undesirable effects of the quinine, especially ventricular arrhythmias and neurosensory difficulties (cinchonism)	Not recommended	
1907	QUININE	9071			MEFLOQUINE	6694			ANSM	443-QUININE.html	For the quinine administered by IV route: increased risk of onset of epileptic crises due to addition of the convulsion producing effects	Not recommended	
1908	QUININE	9071			RIFAMPICIN	9384			ANSM	443-QUININE.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
1909	QUINUPRISTINE	135098			DIHYDROERGOTAMINE	3418			ANSM	444-QUINUPRISTINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
1910	QUINUPRISTINE	135098			ERGOTAMINE	4025			ANSM	444-QUINUPRISTINE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye).	CONTRAINDICATION	
1911	QUINUPRISTINE	135098					IMMUNOSUPPRESSANTS	L04A	ANSM	444-QUINUPRISTINE.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Precaution for use	
1912	QUINUPRISTINE	135098			PIMOZIDE	8331			ANSM	444-QUINUPRISTINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Not recommended	
1913	RACECADOTRIL	16738					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	445-RACECADOTRIL.html	Risk of increase of the undesirable effects of the angioedema type.	Contraindication	
1914	RALTEGRAVIR	719872			RIFAMPICIN	9384			ANSM	446-RALTEGRAVIR.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	
1915	RANOLAZINE	35829					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	447-RANOLAZINE.html	Risk of large decrease of the concentrations of ranolazine	Not recommended	
1916	RANOLAZINE	35829			ATORVASTATIN	83367			ANSM	447-RANOLAZINE.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine	Precaution for use	
1917	RANOLAZINE	35829			DIGOXIN	3407			ANSM	447-RANOLAZINE.html	Increase of the digoxinemia	Precaution for use	
1918	RANOLAZINE	35829					IMMUNOSUPPRESSANTS	L04A	ANSM	447-RANOLAZINE.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its metabolism by the ranolazine	Precaution for use	
1919	RANOLAZINE	35829					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	447-RANOLAZINE.html	Increase of the concentrations of ranolazine due to decrease of its metabolism by the inhibitor	CONTRAINDICATION	
1920	RANOLAZINE	35829			RIFAMPICIN	9384			ANSM	447-RANOLAZINE.html	Very large decrease of the concentrations of ranolazine.	Not recommended	
1921	RANOLAZINE	35829			SIMVASTATIN	36567			ANSM	447-RANOLAZINE.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine	Precaution for use	
1922	REGORAFENIB	1312397					ENZYME INDUCERS	N03-J05-001	ANSM	448-REGORAFENIB.html	Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the inducer	Not recommended	
1923	REGORAFENIB	1312397					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	448-REGORAFENIB.html	Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
1924	REGORAFENIB	1312397			ST JOHNS WORT	258326			ANSM	448-REGORAFENIB.html	Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort	Not recommended	
1925	REGORAFENIB	1312397			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	448-REGORAFENIB.html	Increase of the plasma concentrations of regorafenib due to decrease of its hepatic metabolism by the grapefruit	Not recommended	
1926	REPAGLINIDE	73044					SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	449-REPAGLINIDE.html	Risk of hypoglycemia or hyperglycemia:decrease or increase of the need for repaglinde due to decrease or increase of the secretion of endogenous glucagon.	Precaution for use	
1927	REPAGLINIDE	73044			CICLOSPORIN	3008			ANSM	449-REPAGLINIDE.html	Increase of more than double of the concentrations of the repaglinide due to increase of its absorption	Not recommended	
1928	REPAGLINIDE	73044			CLARITHROMYCIN	21212			ANSM	449-REPAGLINIDE.html	Risk of hypoglycemia due to increase of the plasma concentrations of the repaglinide	Precaution for use	
1929	REPAGLINIDE	73044			CLOPIDOGREL	32968			ANSM	449-REPAGLINIDE.html	Increase of the concentrations of repaglinide by the clopidogrel, with risk of increase of undesirable effects	Take into account	
1930	REPAGLINIDE	73044			DEFERASIROX	614373			ANSM	449-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide, due to inhibition of its hepatic metabolism by the deferasirox	Not recommended	
1931	REPAGLINIDE	73044			GEMFIBROZIL	4719			ANSM	449-REPAGLINIDE.html	Risk of severe hypoglycemia, even coma, due to large increase of the plasma concentrations of repaglinide by the gemfibrozil	CONTRAINDICATION	
1932	REPAGLINIDE	73044			TRIMETHOPRIM	10829			ANSM	449-REPAGLINIDE.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	
1933			ANTABUSE (REACTION)	123-ANT	ALCOHOL				ANSM	44-ANTABUSE-(MEDICATIONS-PROVOKING-A-REACTION).html	Antabuse effect (heat, redness, vomiting, tachycardia)	Not recommended	
1934	RESERPINE	9260					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	450-RESERPINE.html	Psychomotor agitation, convulsions, hypertension	CONTRAINDICATION	
1935	RESERPINE	9260			LEVODOPA	6375			ANSM	450-RESERPINE.html	Inhibition of the effects of the levodopa	CONTRAINDICATION	
1936			CHELATING RESINS	C10-V0	MEDICATIONS ADMINISTERED BY ORAL ROUTE				ANSM	451-CHELATING-RESINS.html	Taking chelating resins can decrease the intestinal absorption and, potentially, the effectiveness of other medications taken simultaneously	Precaution for use	
1937			CHELATING RESINS	C10-V0			THYROID HORMONES	H03AA	ANSM	451-CHELATING-RESINS.html	Decrease of the digestive absorption of the thyroid hormones	Precaution for use	
1938			RETINOIDS	D05-D10			OTHER RETINOIDS	D05-D10	ANSM	452-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	CONTRAINDICATION	
1939			RETINOIDS	D05-D10			TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	452-RETINOIDS.html	Risk of intracranial hypertension	CONTRAINDICATION	
1940			RETINOIDS	D05-D10	VITAMIN A	11246			ANSM	452-RETINOIDS.html	Risk of symptoms evocative of hypervitaminosis A	CONTRAINDICATION	
1941	RIBAVIRIN	9344					ANTIPURINES	ANTIPUR	ANSM	453-RIBAVIRIN.html	Increased risk of serious undesirable effects, due to inhibition of the metabolism of the immunomodulator by the ribavirin	Not recommended	
1942	RIBAVIRIN	9344			DIDANOSINE	3364			ANSM	453-RIBAVIRIN.html	Risk of increase of the mitochrondrial toxicity of the didanosine due to increase of its active metabolite	Not recommended	
1943	RIBAVIRIN	9344			STAVUDINE	59763			ANSM	453-RIBAVIRIN.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	
1944	RIBAVIRIN	9344			ZIDOVUDINE	11413			ANSM	453-RIBAVIRIN.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	
1945	RIFABUTIN	55672			ATOVAQUONE	60212			ANSM	454-RIFABUTIN.html	Moderate decrease of the plasma concentrations of atovaquone by the enzymatic inducer	Take into account	
1946	RIFABUTIN	55672			CLARITHROMYCIN	21212			ANSM	454-RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis) due to increase of its concentrations and of those of its active metabolite by the clarithromycin. In addition, increase of the metabolism of the clarithromycin by the rifabutin, with increase of the concentrations of its active metabolite	Precaution for use	
1947	RIFABUTIN	55672			COBICISTAT	1306284			ANSM	454-RIFABUTIN.html	Very large increase of the metabolite of the rifabutin, with risk of increase of its toxicity (uveitis, neutropenia). Furthermore, possible decrease of the concentrations of cobicistat	Precaution for use	
1948	RIFABUTIN	55672			EFAVIRENZ	195085			ANSM	454-RIFABUTIN.html	Decrease of the concentrations of rifabutin by about half, due to increase of its hepatic metabolism by the efavirenz	Precaution for use	
1949	RIFABUTIN	55672			ELVITEGRAVIR	1306286			ANSM	454-RIFABUTIN.html	Decrease of the minimal concentrations of elvitegravir	Take into account	
1950	RIFABUTIN	55672			FLUCONAZOLE	4450			ANSM	454-RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Precaution for use	
1951	RIFABUTIN	55672					THYROID HORMONES	H03AA	ANSM	454-RIFABUTIN.html	Described for phenytoin, rifampicin, and carbamazepine. Risk of clinical hypothyroidism in patients with low thyroid, due to increase of the metabolism of the T3 and T4	Precaution for use	
1952	RIFABUTIN	55672					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	454-RIFABUTIN.html	Risk of reduction of the effectiveness of the protease inhibitor (even more so when the dosage of the rifabutin is large) for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin for another.	Precaution for use	
1953	RIFABUTIN	55672			POSACONAZOLE	282446			ANSM	454-RIFABUTIN.html	Risk of increase of the undesirable effects of the rifabutin (uveitis), due to increase of its concentrations and of those of its active metabolite	Not recommended	
1954	RIFABUTIN	55672			VORICONAZOLE	121243			ANSM	454-RIFABUTIN.html	Decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifabutin for one thing; and risk of increase of the undesirable effects (uveitis) of the rifabutin for another	Not recommended	
1955	RIFAMPICIN	9384			ABIRATERONE	1100072			ANSM	455-RIFAMPICIN.html	Large decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
1956	RIFAMPICIN	9384			AFATINIB	1430438			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the afatinib due to increase of its metabolism by the rifampicin	Precaution for use	
1957	RIFAMPICIN	9384			ALBENDAZOLE	430			ANSM	455-RIFAMPICIN.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness	Precaution for use	
1958	RIFAMPICIN	9384					CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	
1959	RIFAMPICIN	9384					CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrythmic (increase of its hepatic metabolism).	Precaution for use	
1960	RIFAMPICIN	9384					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	455-RIFAMPICIN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	
1961	RIFAMPICIN	9384			APIXABAN	1364430			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
1962	RIFAMPICIN	9384			APREPITANT	358255			ANSM	455-RIFAMPICIN.html	Very large decrease of the concentrations of aprepitant	Not recommended	
1963	RIFAMPICIN	9384			ATORVASTATIN	83367			ANSM	455-RIFAMPICIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
1964	RIFAMPICIN	9384			ATOVAQUONE	60212			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of atorvaquone by the enzymatic inducer	Not recommended	
1965	RIFAMPICIN	9384			BOCEPREVIR	1102129			ANSM	455-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	
1966	RIFAMPICIN	9384			BOSENTAN	75207			ANSM	455-RIFAMPICIN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
1967	RIFAMPICIN	9384			BUSPIRONE	1827			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the buspirone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
1968	RIFAMPICIN	9384			CARBAMAZEPINE	2002			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the carbamazepine due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
1969	RIFAMPICIN	9384			CARVEDILOL				ANSM	455-RIFAMPICIN.html	Large decrease of the plasma concentrations of the carvedilol, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
1970	RIFAMPICIN	9384			CLARITHROMYCIN	21212			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and risk of lower effectiveness of the clarithromycin, especially with HIV patients, due to increase of its metabolism by the rifampicin	Precaution for use	
1971	RIFAMPICIN	9384			CLOZAPINE	2626			ANSM	455-RIFAMPICIN.html	Risk of ineffectiveness of the antipsychotic treatment (decrease of the plasma concentrations of clozapine due to increase of its hepatic metabolism)	Precaution for use	
1972	RIFAMPICIN	9384			COBICISTAT	1306284			ANSM	455-RIFAMPICIN.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	CONTRAINDICATION	
1973	RIFAMPICIN	9384			DABIGATRAN				ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
1974	RIFAMPICIN	9384			DEFERASIROX	614373			ANSM	455-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	
1975	RIFAMPICIN	9384			DELAMANID	1344662			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of delamanid due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
1976	RIFAMPICIN	9384			DRONEDARONE	233698			ANSM	455-RIFAMPICIN.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite.	Not recommended	
1977	RIFAMPICIN	9384			EFAVIRENZ	195085			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the efavirenz due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
1978	RIFAMPICIN	9384			EXEMESTANE	258494			ANSM	455-RIFAMPICIN.html	Risk of decrease of the effectiveness of the exemestane due to increase of its hepatic metabolism by the enzymatic inducer	Take into account	
1979	RIFAMPICIN	9384			FENTANYL	4337			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
1980	RIFAMPICIN	9384			FLUCONAZOLE	4450			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the fluconazole due to increase of its metabolism by the rifampicin	Not recommended	
1981	RIFAMPICIN	9384					GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in patients with Addisons disease treated with hydrocortisone and in cases of transplants	Precaution for use	
1982	RIFAMPICIN	9384			HALOPERIDOL	5093			ANSM	455-RIFAMPICIN.html	Risk of decrease of the plasma concentrations of the haloperidol and of its therapeutic effectiveness, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
1983	RIFAMPICIN	9384					THYROID HORMONES	H03AA	ANSM	455-RIFAMPICIN.html	Risk of clinically low thyroid in patients with already low thyroid, due to increase of the metabolism of the T3 and of the T4.	Precaution for use	
1984	RIFAMPICIN	9384			HYDROXYCHLOROQUINE	5521			ANSM	455-RIFAMPICIN.html	Risk of lower therapeutic effect of the hydroxychloroquine, due to increase of its metabolism by the rifampicin	Precaution for use	
1985	RIFAMPICIN	9384			IDELALISIB	1544460			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the inducer	Not recommended	
1986	RIFAMPICIN	9384					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	455-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the protease inhibitor, due to increase of its hepatic metabolism by the rifampicin.For the combination (saquinavir + ritonavir):risk of severe hepatocellular toxicity	CONTRAINDICATION	
1987	RIFAMPICIN	9384					METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
1988	RIFAMPICIN	9384			ISONIAZID	6038			ANSM	455-RIFAMPICIN.html	Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)	Precaution for use	
1989	RIFAMPICIN	9384			IVABRADINE	77417			ANSM	455-RIFAMPICIN.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the rifampicin	Precaution for use	
1990	RIFAMPICIN	9384			KETOCONAZOLE	6135			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two anti-antibiotics (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
1991	RIFAMPICIN	9384			LEDIPASVIR	1591922			ANSM	455-RIFAMPICIN.html	Large decrease of the plasma concentrations of ledipasvir due to increase of its hepatic metabolism by the rifampicin	CONTRAINDICATION	
1992	RIFAMPICIN	9384			LINEZOLIDE	190376			ANSM	455-RIFAMPICIN.html	Risk of decrease of the effectiveness of the linezolide due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	
1993	RIFAMPICIN	9384			METOPROLOL	6918			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta blocking agent (increase of its hepatic metabolism)	Take into account	
1994	RIFAMPICIN	9384			METRONIDAZOLE	6922			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
1995	RIFAMPICIN	9384			MIDAZOLAM	6960			ANSM	455-RIFAMPICIN.html	Risk of absence of effect of the midazolam, with very large decrease of its plasma concentrations, due to increase of its hepatic metabolism	Not recommended	
1996	RIFAMPICIN	9384					MINERALOCORTICOIDS	H02AA0	ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the rifampicin; the consequences are particularly great in persons with Addison's disease treated with the hydrocortisone and in cases of organ transplants	Precaution for use	
1997	RIFAMPICIN	9384			MONTELUKAST	88249			ANSM	455-RIFAMPICIN.html	Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
1998	RIFAMPICIN	9384			MORPHINE	7052			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the morphine and of its active metabolite	Precaution for use	
1999	RIFAMPICIN	9384			NEVIRAPINE	53654			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the rifampicin	Not recommended	
2000	RIFAMPICIN	9384			NIMODIPINE	7426			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	
2001	RIFAMPICIN	9384			NINTEDANIB	1592737			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the rifampicin	Precaution for use	
2002	RIFAMPICIN	9384			PERAMPANEL	1356552			ANSM	455-RIFAMPICIN.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
2003	RIFAMPICIN	9384			PIOGLITAZONE	33738			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the glitazone due to increase of its metabolism by the rifampicin	Precaution for use	
2004	RIFAMPICIN	9384			POSACONAZOLE	282446			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the two antibiotics (enzymatic induction by the rifampicin and decrease of the intestinal absorption by the azole antifungal)	Not recommended	
2005	RIFAMPICIN	9384			PRAZIQUANTEL	8628			ANSM	455-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the praziquantal, with risk of failure of the treatment, due to increase of the hepatic metabolism of the praziquantel by the rifampicin	CONTRAINDICATION	
2006	RIFAMPICIN	9384			PROPAFENONE	8754			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the propafanone, due to increase of its hepatic metabolism by the rifampicin	Precautions for use	
2007	RIFAMPICIN	9384			PROPRANOLOL	8787			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the beta-blocking agent (increase of its hepatic metabolism)	Take into account	
2008	RIFAMPICIN	9384			QUETIAPINE	51272			ANSM	455-RIFAMPICIN.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness	Not recommended	
2009	RIFAMPICIN	9384			QUININE	9071			ANSM	455-RIFAMPICIN.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer	Not recommended	
2010	RIFAMPICIN	9384			RALTEGRAVIR	719872			ANSM	455-RIFAMPICIN.html	Decrease of the concentrations of the raltegravir by the rifampicin	Not recommended	
2011	RIFAMPICIN	9384			RANOLAZINE	35829			ANSM	455-RIFAMPICIN.html	Very large decrease of the concentrations of ranolazine.	Not recommended	
2012	RIFAMPICIN	9384			RIVAROXABAN	1114195			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
2013	RIFAMPICIN	9384			SIMVASTATIN	36567			ANSM	455-RIFAMPICIN.html	Very large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
2014	RIFAMPICIN	9384			TELAPREVIR	1102261			ANSM	455-RIFAMPICIN.html	Very large decrease of the concentrations of telaprevir	CONTRAINDICATION	
2015	RIFAMPICIN	9384			TELITHROMYCIN	274786			ANSM	455-RIFAMPICIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin.	Not recommended	
2016	RIFAMPICIN	9384			TENOFOVIR ALAFENAMIDE	1721603			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the rifampicin	Not recommended	
2017	RIFAMPICIN	9384			TERBINAFINE	37801			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
2018	RIFAMPICIN	9384					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction)	Precaution for use	
2019	RIFAMPICIN	9384			TIAGABINE	31914			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	
2020	RIFAMPICIN	9384			TICAGRELOR	1116632			ANSM	455-RIFAMPICIN.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
2021	RIFAMPICIN	9384			ULIPRISTAL	1005921			ANSM	455-RIFAMPICIN.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer.	Not recommended	
2022	RIFAMPICIN	9384					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	455-RIFAMPICIN.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	
2023	RIFAMPICIN	9384					VITAMIN D	A11CC	ANSM	455-RIFAMPICIN.html	Decrease of the concentrations of vitamin D more marked than in the absence of the treatment with the rifampicin	Precaution for use	
2024	RIFAMPICIN	9384			VORICONAZOLE	121243			ANSM	455-RIFAMPICIN.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	CONTRAINDICATION	
2025	RIFAMPICIN	9384			ZOLPIDEM	39993			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
2026	RIFAMPICIN	9384			ZOPICLONE	40001			ANSM	455-RIFAMPICIN.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
2027	RILPIVIRINE	1102270					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	456-RILPIVIRINE.html	Risk of decrease of the plasma concentrations of the rilpivirine	Take into account	
2028	RILPIVIRINE	1102270					PROTON PUMP INHIBITORS	A02BC-001	ANSM	456-RILPIVIRINE.html	Decrease of the plasma concentrations of rilpivirine by the proton pump inhibitor (decreased absorption because of increase of the gastric pH)	CONTRAINDICATION	
2029	RILPIVIRINE	1102270			DEXAMETHASONE	3264			ANSM	456-RILPIVIRINE.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the dexamethasone	CONTRAINDICATION	
2030	RILPIVIRINE	1102270					ENZYME INDUCERS	N03-J05-001	ANSM	456-RILPIVIRINE.html	Large decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the inducer	CONTRAINDICATION	
2031	RILPIVIRINE	1102270			ST JOHNS WORT	258326			ANSM	456-RILPIVIRINE.html	Risk of decrease of the plasma concentratons of rilpivirine due to increase of its hepatic metabolism by the St Johns wort	CONTRAINDICATION	
2032	RIOCIGUAT	1439816					NITRATE DERIVATIVES AND RELATED	C01D-001	ANSM	457-RIOCIGUAT.html	Risk of serious hypotension (synergic effect)	CONTRAINDICATION	
2033	RIOCIGUAT	1439816					TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	457-RIOCIGUAT.html	Risk of serious hypotension (synergic effect)	CONTRAINDICATION	
2034	RIOCIGUAT	1439816					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	457-RIOCIGUAT.html	Increase of the plasma concentrations of riociguat due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
2035	RISPERIDONE	35636			CARBAMAZEPINE	2002			ANSM	458-RISPERIDONE.html	Risk of decrease of the active fraction of the risperidone and of its therapeutic effectiveness due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
2036	RISPERIDONE	35636			FLUOXETINE	4493			ANSM	458-RISPERIDONE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the fluoxetine, with risk of increase of the undesirable effects	Precaution for use	
2037	RISPERIDONE	35636			PAROXETINE	32937			ANSM	458-RISPERIDONE.html	Increase of the active fraction of the risperidone due to decrease of its hepatic metabolism by the paroxetine, with risk of increase of the undesirable effects.	Precaution for use	
2038	RIVAROXABAN	1114195					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	459-RIVAROXABAN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
2039	RIVAROXABAN	1114195			FLUCONAZOLE	4450			ANSM	459-RIVAROXABAN.html	Increase of the plasma concentrations of the rivaroxaban by the fluconazole, with increase of the risk of bleeding	Not recommended	
2040	RIVAROXABAN	1114195					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	459-RIVAROXABAN.html	Increase of the plasma concentrations of rivaroxaban, with increase of the risk of bleeding	Not recommended	
2041	RIVAROXABAN	1114195			RIFAMPICIN	9384			ANSM	459-RIVAROXABAN.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect	Not recommended	
2042			CALCIUM CHANNEL BLOCKERS	CO8CA-001			ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended:	
2043			CALCIUM CHANNEL BLOCKERS	CO8CA-001	IDELALISIB	1544460			ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Increase of the undesirable effects of the calcium channel blockers, of the orthostatic hypotension sort, especially with older patients	Precaution for use	
2044			CALCIUM CHANNEL BLOCKERS	CO8CA-001			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Increase of the undesirable effects of the calcium channel blockers, most often of the hypotension type, especially in older patients.	Precaution for use	
2045			CALCIUM CHANNEL BLOCKERS	CO8CA-001	RIFAMPICIN	9384			ANSM	45-CALCIUM-CHANNEL-BLOCKERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	
2046	ROPINIROLE	72302					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	460-ROPINIROLE.html	Increase of the risk of hemorrhage	Precaution for use	
2047	ROPINIROLE	72302			CIPROFLOXACIN	2551			ANSM	460-ROPINIROLE.html	Increase of the concentrations of ropinirole with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin	Precaution for use	
2048	ROPINIROLE	72302			ENOXACIN				ANSM	460-ROPINIROLE.html	Increase of the plasma concentrations of ropinirole with signs of overdose due to decrease of its hepatic metabolism	Precaution for use	
2049	ROPINIROLE	72302			FLUVOXAMINE	42355			ANSM	460-ROPINIROLE.html	Increase of the concentrations of ropinirole, with risk of overdose, due to decrease of its hepatic metabolism by the fluvoxamine	Precaution for use	
2050	ROSUVASTATIN	301542			CICLOSPORIN	3008			ANSM	461-ROSUVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, or of nephrotoxicity, due to decrease of the metabolism of the rosuvastatin	CONTRAINDICATION	
2051	ROSUVASTATIN	301542					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	461-ROSUVASTATIN.html	Increase of the plasma concentrations of the rosuvastatin due to increase of its absorption	Precaution for use	
2052	ROXITHROMYCIN	9478			ATORVASTATIN	83367			ANSM	462-ROXITHROMYCIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type	Precaution for use	
2053	ROXITHROMYCIN	9478			CICLOSPORIN	3008			ANSM	462-ROXITHROMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	
2054	ROXITHROMYCIN	9478			MIDAZOLAM	6960			ANSM	462-ROXITHROMYCIN.html	Slight increase of sedation	Take into account	
2055	ROXITHROMYCIN	9478			SIMVASTATIN	36567			ANSM	462-ROXITHROMYCIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type	Precaution for use	
2056	ROXITHROMYCIN	9478					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	462-ROXITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2057	ROXITHROMYCIN	9478					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	462-ROXITHROMYCIN.html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
2058	RUFINAMIDE	69036					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	463-RUFINAMIDE.html	Moderate decrease of the concentrations of ethinylestradiol	Precaution for use	
2059	RUFINAMIDE	69036					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	463-RUFINAMIDE.html	Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg.	Precaution for use	
2060	SACUBITRIL	1656328			ALISKIREN	325646			ANSM	464-SACUBITRIL.html	With diabetic patients or those with renal insufficiency, increase of the undesirable effects such as hypotension, hyperkaliemia	CONTRAINDICATION	
2061	SACUBITRIL	1656328					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	464-SACUBITRIL.html	Increase of the risk of angioedema	CONTRAINDICATION	
2062	SALMETEROL	36117			ITRACONAZOLE	28031			ANSM	465-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the itraconazole	Take into account	
2063	SALMETEROL	36117			KETOCONAZOLE	6135			ANSM	465-SALMETEROL.html	Large increase of the concentrations of salmeterol due to decrease of its hepatic metabolism by the ketoconazole	Take into account	
2064	SERTRALINE	36437					ENZYME INDUCERS	N03-J05-001	ANSM	466-SERTRALINE.html	Risk of ineffectiveness of the antidepressant treatment	Not recommended	
2065	SERTRALINE	36437			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	466-SERTRALINE.html	Increase, sometimes large, of the concentrations of the antidepressant with some patients due to decrease of its intestinal metabolism	Not recommended	
2066	SERTRALINE	36437			PIMOZIDE	8331			ANSM	466-SERTRALINE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
2067	SILDENAFIL	136411			JOSAMYCIN	6084			ANSM	467-SILDENAFIL.html	Increase of the plasma concentrations of sildenafil, with risk of hypotension	Precaution for use	
2068	SILDENAFIL	136411					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	467-SILDENAFIL.html	Increase of the plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the therapy with the ombitasvir+paritaprevir	CONTRAINDICATION	
2069	SIMEPREVIR	1482790			DEXAMETHASONE	3264			ANSM	468-SIMEPREVIR.html	With the dexamethasone for systemic use, risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the dexamethasone	Not recommended	
2070	SIMEPREVIR	1482790					ENZYME INDUCERS	N03-J05-001	ANSM	468-SIMEPREVIR.html	Decrease of he plasma concentrations of simeprevir due to increase of its hepatic metabolism by the inducer	Not recommended	
2071	SIMEPREVIR	1482790					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	468-SIMEPREVIR.html	Risk of increase of the plasma concentrations of simeprevir due to decrease of its heptatic metabolism by the inhibitor	Not recommended	
2072	SIMEPREVIR	1482790			ST JOHNS WORT	258326			ANSM	468-SIMEPREVIR.html	Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
2073	SIMVASTATIN	36567			AMIODARONE	703			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Precaution for use	
2074	SIMVASTATIN	36567			AMLODIPINE	17767			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (dose dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent).	Precaution for use	
2075	SIMVASTATIN	36567			AZITHROMYCIN	18631			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent.	Precaution for use	
2076	SIMVASTATIN	36567			BOCEPREVIR	1102129			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type, due to decrease of the metabolism of the simvastatin	CONTRAINDICATION	
2077	SIMVASTATIN	36567			CARBAMAZEPINE	2002			ANSM	469-SIMVASTATIN.html	Large decrease of the plasma concentrations of simvastatin, due to increase of its hepatic metabolism	Not recommended	
2078	SIMVASTATIN	36567			CICLOSPORIN	3008			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin	CONTRAINDICATION	
2079	SIMVASTATIN	36567			CLARITHROMYCIN	21212			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent.	CONTRAINDICATION	
2080	SIMVASTATIN	36567			DANAZOL	3102			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin	CONTRAINDICATION	
2081	SIMVASTATIN	36567			DILTIAZEM	3443			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent.	Precaution for use	
2082	SIMVASTATIN	36567			DRONEDARONE	233698			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	Not recommended	
2083	SIMVASTATIN	36567			ERYTHROMYCIN	4053			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	CONTRAINDICATION	
2084	SIMVASTATIN	36567					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	CONTRAINDICATION	
2085	SIMVASTATIN	36567			ITRACONAZOLE	28031			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	CONTRAINDICATION	
2086	SIMVASTATIN	36567			KETOCONAZOLE	6135			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	CONTRAINDICATION	
2087	SIMVASTATIN	36567			ST JOHNS WORT	258326			ANSM	469-SIMVASTATIN.html	Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort	Not recommended	
2088	SIMVASTATIN	36567					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	469-SIMVASTATIN.html	Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the therapy with ombitavir+paritaprevir	CONTRAINDICATION	
2089	SIMVASTATIN	36567			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	469-SIMVASTATIN.html	Significant increase of the plasma concentrations of the cholesterol lowering agent, with risk of onset of undesirable effects, especially muscular	Not recommended	
2090	SIMVASTATIN	36567			POSACONAZOLE	282446			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor).	CONTRAINDICATION	
2091	SIMVASTATIN	36567			RANOLAZINE	35829			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to inhibition of the metabolism of the simvastatin by the ranolazine	Precaution for use	
2092	SIMVASTATIN	36567			RIFAMPICIN	9384			ANSM	469-SIMVASTATIN.html	Very large decrease of the plasma concentrations of simvastatin due to increase of its hepatic metabolism by the rifampicin.	Not recommended	
2093	SIMVASTATIN	36567			ROXITHROMYCIN	9478			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type	Precaution for use	
2094	SIMVASTATIN	36567			STIRIPENTOL	37119			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	CONTRAINDICATION	
2095	SIMVASTATIN	36567			TELAPREVIR	1102261			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	CONTRAINDICATION	
2096	SIMVASTATIN	36567			TELITHROMYCIN	274786			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication)	CONTRAINDICATION	
2097	SIMVASTATIN	36567			VERAPAMIL	11170			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (dose-dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	Precaution for use	
2098	SIMVASTATIN	36567			VORICONAZOLE	121243			ANSM	469-SIMVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin	CONTRAINDICATION	
2099			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ACETYLSALICYLIC ACID	1191			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	For anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3 g per day) or for analgesic or antipyretic doses (>= 500 mg per dose and/or <=3 gr per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins.Furthermore, reduction of the antihypertensive effect.	Precaution for use	
2100			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ALISKIREN	325646			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Risk of hyperkalemia, of renal insufficiency, of increase of mortality from cardiovascular disease	Contraindication	
2101			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Acute renal insufficiency with patients at risk (older patient, dehydration, treatment with diuretics, changes in renal function), due to decrease of the glomerular filtration (inhibition of the vasodilater prostaglandins due to the non steroidal anti-inflammatories.) These effects are generally reversible. In addition, reduction of the antihypertensive effect.	Precaution for use	
2102			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001			POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Risk of hyperkalemia (potentially lethal) especially in case of renal insufficiancy (addition of the hyperkaliemia inducing effects)/	Not recommended	
2103			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001			POTASSIUM LOWERING DIURETICS	C03	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Risk of abrupt arterial hypotension and/or acute renal insufficiency at the beginning of or at an increase of the dosage of a treatment with an angiotensin II antagonist in cases where there is pre-existing fluid depletion.	Precaution for use	
2104			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	EPLERENONE	298869			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Increase of the risk of hyperkalemia, especially with older patients	Precaution for use	
2105			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	In indications where the administration of these substances together is possible, increased risk of degradation of renal function, even acute renal insufficiency, and increase of the hyperkalemia as well as hypotension and fainting or loss of consciousness.	Take into account	
2106			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	LITHIUM	6448			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Increase of the plasma concentrations of lithium that can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	
2107			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	POTASSIUM	8588			ANSM	46-ANGIOTENSIN-II-RECEPTOR-ANTAGONISTS.html	Hyperkalemia (potentially lethal) especially when there is renal insufficiency (addition of the hyperkalemia inducing effects).	Not recommended	
2108	SIROLIMUS	35302			CICLOSPORIN	3008			ANSM	470-SIROLIMUS.html	Increase of the blood concentrations of sirolimus by the ciclosporin. The nephrotoxicity of the ciclosporin is also increased when the two medications are administered together	Precaution for use	
2109	SIROLIMUS	35302			VERAPAMIL	11170			ANSM	470-SIROLIMUS.html	Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	
2110	SODIUM BICARBONATE				LITHIUM	6448			ANSM	471-SODIUM-BICARBONATE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts.	Precaution for use	
2111	SODIUM CHLORIDE	9863			LITHIUM	6448			ANSM	472-SODIUM-CHLORIDE.html	Risk of reduction of the effectiveness of the lithium due to increase of its renal elimination by the sodium salts	Precaution for use	
2112	SOFOSBUVIR				AMIODARONE	703			ANSM	473-SOFOSBUVIR.html	Only for interactions with the combinatons daclatasvir/sofosbuvir or ledispavir/sofosbuvir:Possibly abrupt onset of bradycardia, that can have fatal consequences	Not recommended	
2113	SOFOSBUVIR						ENZYME INDUCERS	N03-J05-001	ANSM	473-SOFOSBUVIR.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the enzymatic inducer	Contraindication	
2114	SOFOSBUVIR				ST JOHNS WORT	258326			ANSM	473-SOFOSBUVIR.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the St Johns wort	CONTRAINDICATION	
2115	SOFOSBUVIR				MODAFINIL	30125			ANSM	473-SOFOSBUVIR.html	Risk of decrease of the plasma concentrations of sofosbuvir due to decrease of its intestinal absorption by the modafinil	Not recommended	
2116	SORBITOL	9945			THE FRENCH DOCUMENT LISTS 'CATIORESINE SULFO CALCIQUE'				ANSM	474-SORBITOL.html	With the resin administered by oral and rectal route: risk of colonic necrosis, possibly fatal	CONTRAINDICATION	
2117	SORBITOL	9945			THE FRENCH DOCUMENT LISTS 'CATIORESINE SULFO SODIQUE'				ANSM	474-SORBITOL.html	With the resin administered by oral and rectal route: risk of colonic necrosis, possibly fatal.	Not recommended	
2118			SPERMICIDES	R02AA	MEDICATIONS USED BY VAGINAL ROUTE				ANSM	475-SPERMICIDES.html	All topical vaginal treatment is susceptible to disrupting the action of a topical spermicidal contraceptive	Not recommended	
2119	SPIRAMYCIN	9991			LEVODOPA	6375			ANSM	476-SPIRAMYCIN.html	In case of administration with the carbidopa: inhibition of the absorption of the carbidopa with decrease of the plasma concentrations of the levodopa	Precaution for use	
2120	SPIRONOLACTONE	9997					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	477-SPIRONOLACTONE.html	With the spironolactone in dosages from 12.5 to 50 mg per day, and with weak doses of the ACE inhibitor.In the treatment of class III or IV heart failure (NYHA) with an ejection fraction <35% and previous treatment with an ACE inhibitor + a loop diuretic: risk of hyperkalemia, potentially lethal, in case of failure to follow the prescription conditions for this combination of medications.	Precaution for use	
2121	SPIRONOLACTONE	9997			MITOTANE	7004			ANSM	477-SPIRONOLACTONE.html	Risk of blocking of the action of the mitotane by the spironolactone	CONTRAINDICATION	
2122	STAVUDINE	59763			ISONIAZID	6038			ANSM	478-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
2123	STAVUDINE	59763			PENTAMIDINE	7994			ANSM	478-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.	Precaution for use	
2124	STAVUDINE	59763			RIBAVIRIN	9344			ANSM	478-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	
2125	STAVUDINE	59763			THALIDOMIDE	10432			ANSM	478-STAVUDINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
2126	STAVUDINE	59763			ZALCITABINE	3363			ANSM	478-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites.	Not recommended	
2127	STAVUDINE	59763			ZIDOVUDINE	11413			ANSM	478-STAVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites.	Not recommended	
2128	STIRIPENTOL	37119					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	479-STIRIPENTOL.html	Increase of the plasma concentrations of the anticonvulsant, with risk of overdose, due to inhibition of its hepatic metabolism by the stiripentol	Precaution for use	
2129	STIRIPENTOL	37119			ATORVASTATIN	83367			ANSM	479-STIRIPENTOL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the chlosterol lowering medication)	CONTRAINDICATION	
2130	STIRIPENTOL	37119			CAFFEINE	1886			ANSM	479-STIRIPENTOL.html	Possible increase of the plasma concentrations of the caffeine, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	
2131	STIRIPENTOL	37119			CLOBAZAM	21241			ANSM	479-STIRIPENTOL.html	Increase of the plasma concentrations of these anticonvulsants, with risk of overdose, due to inhibition of their hepatic metabolism	Precaution for use	
2132	STIRIPENTOL	37119			DIAZEPAM	3322			ANSM	479-STIRIPENTOL.html	Increase of the plasma concentrations of the diazepam, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	
2133	STIRIPENTOL	37119			DIHYDROERGOTAMINE	3418			ANSM	479-STIRIPENTOL.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)	CONTRAINDICATION	
2134	STIRIPENTOL	37119			ERGOTAMINE	4025			ANSM	479-STIRIPENTOL.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic elimination of the alkaloid of ergot of rye)	CONTRAINDICATION	
2135	STIRIPENTOL	37119			HALOFANTRINE	50749			ANSM	479-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes.	Not recommended	
2136	STIRIPENTOL	37119					IMMUNOSUPPRESSANTS	L04A	ANSM	479-STIRIPENTOL.html	Increase of the blood concentrations of the immunosuppressant (decrease of its hepatic metabolism)	CONTRAINDICATION	
2137	STIRIPENTOL	37119			MIDAZOLAM	6960			ANSM	479-STIRIPENTOL.html	Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism with increase of sedation	Precaution for use	
2138	STIRIPENTOL	37119			PIMOZIDE	8331			ANSM	479-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
2139	STIRIPENTOL	37119			QUINIDINE	9068			ANSM	479-STIRIPENTOL.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
2140	STIRIPENTOL	37119			SIMVASTATIN	36567			ANSM	479-STIRIPENTOL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent)	CONTRAINDICATION	
2141	STIRIPENTOL	37119					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	479-STIRIPENTOL.html	Possible increase of the theophyllinemia, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	
2142			PLATELET AGGREGATION INHIBITORS	B01AC-001	ANAGRELIDE	596724			ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of hemorrhagic events	Not recommended	
2143			PLATELET AGGREGATION INHIBITORS	B01AC-001			ORAL ANTICOAGULANTS	B01A-001	ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of the risk of hemorrhage	Take into account	
2144			PLATELET AGGREGATION INHIBITORS	B01AC-001	DEFIBROTIDE	1311089			ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increased risk of hemorrhage	Not recommended	
2145			PLATELET AGGREGATION INHIBITORS	B01AC-001			HEPARINS	B01AB	ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of the risk of hemorrhage	Take into account	
2146			PLATELET AGGREGATION INHIBITORS	B01AC-001			THROMBOLYTICS	B01AD	ANSM	47-PLATELET-AGGREGATION-INHIBITORS.html	Increase of the risk of hemorrhage	Take into account	
2147	STRONTIUM	81638			CALCIUM	1428011			ANSM	480-STRONTIUM.html	With the calcium salts administered by oral route: decrease of the digestive absorption of the strontium	Precaution for use	
2148	STRONTIUM	81638					TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	480-STRONTIUM.html	Decrease of the digestive absorption of the strontium	Precaution for use	
2149	STRONTIUM	81638			IRON	1431589			ANSM	480-STRONTIUM.html	Decrease of the digestive absorption of the strontium	Precaution for use	
2150	STRONTIUM	81638					FLUOROQUINOLONES	J01MA-001	ANSM	480-STRONTIUM.html	Decrease of the digestive absorption of the strontium	Precaution for use	
2151	STRONTIUM	81638			ZINC	1431163			ANSM	480-STRONTIUM.html	Decrease of the digestive absorption of the strontium.	Precaution for use	
2152			SUBSTANCES WITH ABSORPTION REDUCED BY GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	RBGI			GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	A07BC-A02AD	ANSM	481-SUBSTANCES-WITH-ABSORPTION-REDUCED-BY-GASTRO-INTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html	Decrease of the absorption of these substances	Precaution for use	
2153			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANAGRELIDE	596724			ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2154			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES	P01B-001	ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
2155			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	AZITHROMYCIN	18631			ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2156			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2157			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			BRADYCARDIA INDUCING DRUGS	C0N0S0	ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2158			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	CIPROFLOXACIN	2551			ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2159			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	CLARITHROMYCIN	21212			ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2160			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	HYDROXYCHLOROQUINE	5521			ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
2161			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			POTASSIUM LOWERING AGENTS	C03-001	ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2162			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	LEVOFLOXACIN	82122			ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2163			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	METHADONE	6813			ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
2164			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			NEUROLEPTICS THAT TEND TO INDUCE TORSADES DE POINTES	N05A-002	ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
2165			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	NORFLOXACIN	7517			ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2166			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ONDANSETRON	26225			ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2167			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ROXITHROMYCIN	9478			ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Precaution for use	
2168			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05			TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)	C01B	ANSM	482-SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
2169			SUBSTRATES AT RISK OF CYP3A4	L01N01	CRIZOTINIB	1148495			ANSM	483-SUBSTRATES-AT-RISK-OF-CYP3A4.html	Risk of increase of the toxicity of these molecules due to decrease of their metabolism and/or increase of their bioavailability by the crizotinib	Not recommended	
2170			SUBSTRATES AT RISK OF CYP3A4	L01N01	IDELALISIB	1544460			ANSM	483-SUBSTRATES-AT-RISK-OF-CYP3A4.html	Increase of the plasma concentrations of the substrate due to decrease of its hepatic metabolism by the idealisib	Not recommended	
2171			SUBSTRATES AT RISK OF CYP3A4	L01N01			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	483-SUBSTRATES-AT-RISK-OF-CYP3A4.html	Increase of the undesirable effects particular to each substrate, with frequently severe consequences	Take into account	
2172	SUCRALFATE	10156					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	484-SUCRALFATE.html	Decrease of the digestive absorption of the vitamin K antagonist	Precaution for use	
2173	SUCRALFATE	10156			DIGOXIN	3407			ANSM	484-SUCRALFATE.html	Decrease of the digestive absorption of the digoxin	Precaution for use	
2174	SUCRALFATE	10156					FLUOROQUINOLONES	J01MA-001	ANSM	484-SUCRALFATE.html	Decrease of the digestive absorption of the fluorquinolones	Precaution for use	
2175	SUCRALFATE	10156					THYROID HORMONES	H03AA	ANSM	484-SUCRALFATE.html	Decrease of the digestive absorption of the thyroid hormones.	Precaution for use	
2176	SUCRALFATE	10156					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	484-SUCRALFATE.html	Decrease of the digestive absorption of the phenytoin	Precaution for use	
2177	SUCRALFATE	10156			SULPIRIDE	10239			ANSM	484-SUCRALFATE.html	Decrease of the digestive absorption of the sulpiride	Precaution for use	
2178	SUFENTANIL	56795					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	485-SUFENTANIL.html	Increase of the opioid analgesicÂ’s effect of respiratory depression due to decrease of its hepatic metabolism	Precaution for use	
2179	SULFAFURAZOLE	10207					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	486-SULFAFURAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution of use	
2180	SULFAFURAZOLE	10207					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	486-SULFAFURAZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	
2181	SULFAMETHIZOLE	10179					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	487-SULFAMETHIZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2182	SULFAMETHIZOLE	10179			METHENAMINE	6832			ANSM	487-SULFAMETHIZOLE.html	Precipitation of crystals in the urinary tract (due to the acidification of the urine)	Not recommended	
2183	SULFAMETHIZOLE	10179					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	487-SULFAMETHIZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	
2184	SULFAMETHOXAZOLE	10180					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	488-SULFAMETHOXAZOLE.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	
2185	SULFAMETHOXAZOLE	10180					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	488-SULFAMETHOXAZOLE.html	Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)	Not recommended	
2186			ANTIBACTERIAL SULFONAMIDES	JO1E	METHOTREXATE	6851			ANSM	489-ANTIBACTERIAL-SULFONAMIDES.html	Increase of the hematological toxicity of the methotrexate	Precaution for use	
2187			ANTIARRHYTHMIC AGENTS	C01B-001			OTHER ANTIARRHYTHMIC AGENTS	C01B-001	ANSM	48-ANTIARRHYTHMIC-AGENTS.html	The combination of two antiarrhythmic agents is very delicate. In the majority of cases, it is contraindicated or not recommended.	Contraindication	
2188			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ALCOHOL (DRINK OF INGREDIENT)				ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Antabuse effect, especially for glibenclamide, glipizide, tolbutamide. Increase of the hypoglycemic reaction (inhibition of the compensation reactions) that can make possible the onset of hypoglycemic coma	Not recommended	
2189			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB			SOMATOSTATIN ANALOGS	H01CB0-001	ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Risk of hypoglycemia or hyperglycemia: decrease or increase of the need for the blood glucose lowering sufonamide, due to decrease or increase of the secretion of endogenous glucagon	Precaution for use	
2190			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB			BETA-2 MIMETICS or BETA 2 ADRENERGIC AGONISTS	R03C-001	ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	
2191			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	All the beta blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
2192			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	All the beta blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
2193			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	CHLORPROMAZINE				ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With large doses (100mg per day of chlorpromazine): elevation of the glycemia (decrease of the release of the insulin)	Precaution for use	
2194			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	CLARITHROMYCIN	21212			ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Risk of hypoglycemia due to increase of the plasma concentrations of the antidiabetique	Precaution for use	
2195			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	DANAZOL	3102			ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Diabetes inducing effect of the danazol	Not recommended	
2196			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	FLUCONAZOLE	4450			ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	Increase of the half life of the sulfonamide with possible onset of manifestations of hypoglymemia	Precaution for use	
2197			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	The use of an ACE inhibitor can lead to an increase of the hypoglycemic effect in diabetic patients treated with glucose lowering sulfonamides. The onset of hypoglycemic difficulties seems exceptional (improvement of the tolerance for glucose that would have the result of a reduction of the need for the glucose lowering sulfonamides)	Precaution for use	
2198			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	MICONAZOLE	6932			ANSM	490-BLOOD-GLUCOSE-LOWERING-SULFONAMIDES.html	With the miconazole by general route or oral gel: increase of the hypoglycemic effect with possible onset of hypoglycemic manifestations, even coma	CONTRAINDICATION	
2199	SULFASALAZINE	9524			DIGOXIN	3407			ANSM	491-SULFASALAZINE.html	Decrease of the digoxinemia that can reach 50%	Precaution for use	
2200	SULFINPYRAZONE	10205			CICLOSPORIN	3008			ANSM	492-SULFINPYRAZONE.html	Decrease of the blood concentrations of ciclosporin due to increase of its metabolism by the sulfinpyrazone	Precaution for use	
2201	SULPIRIDE	10239			SUCRALFATE	10156			ANSM	493-SULPIRIDE.html	Decrease of the digestive absorption of the sulpiride	Precaution for use	
2202	SUNITINIB	357977					THYROID HORMONES	H03AA	ANSM	494-SUNITINIB.html	Risk of reduction of the effectiveness of the thyroid hormones	Take into account	
2203	SUXAMETHONIUM	10154					ACETYLCHOLINESTERASE INHIBITORS	ACETCHO	ANSM	495-SUXAMETHONIUM.html	Risk of lengthening of the motor block, increased in the case of partial deficit of pseudo-cholinesterase	Take into account	
2204			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	496-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Not recommended	
2205			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	496-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
2206			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	496-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Hypertensive crises (inhibition of the metabolism of the pressor amines). Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI is stopped	Not recommended	
2207			ALPHA-SYMPATHOMIMETICS-(ORAL-AND/OR-NASAL)	R01AA			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	496-ALPHA-SYMPATHOMIMETICS-(ORAL-AND-OR-NASAL).html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	CONTRAINDICATION	
2208			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES) .html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
2209			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES) .html	Paroxysmal hypertension with the possibility of arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
2210			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES) .html	Increase of the pressor action of the sympathomimetic, most often moderate.	Precaution for use	
2211			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES) .html	By extrapolation from the non selective MAOIs: risk of increase of the pressor action	Precaution for use	
2212			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	497-ALPHA-AND-BETA-SYMPATHOMIMETICS-(IM-AND-IV-ROUTES) .html	Paroxysmal hypertension with possibility of arrhythmias (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
2213			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			OTHER INDIRECT SYMPATHOMIMETICS	C01CA-R01BA	ANSM	498-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or of hypertensive crises.	CONTRAINDICATION	
2214			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	498-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
2215			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	498-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or of rapid elevation of blood pressure	Not recommended	
2216			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	498-INDIRECT-SYMPATHOMIMETICS.html	Perioperative hypertension	Precaution for use	
2217			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	498-INDIRECT-SYMPATHOMIMETICS.html	Paroxystic hypertension, hyperthermia that can be fatal. Because of the length of action of the MAOI, this interaction is still possible two weeks after the MAOI has been stopped	CONTRAINDICATION	
2218			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	498-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	Contraindication:	
2219			INDIRECT SYMPATHOMIMETICS	C01CA-R01BA			ALPHA-SYMPATHOMIMETICS (ORAL AND/OR NASAL)	R01AA	ANSM	498-INDIRECT-SYMPATHOMIMETICS.html	Risk of constriction of blood vessels and/or rapid elevation of blood pressure	CONTRAINDICATION	
2220	TACROLIMUS	42316					AMINOGLYCOSIDES	J01GB-001	ANSM	499-TACROLIMUS.html	Greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
2221	TACROLIMUS	42316			AMIODARONE	703			ANSM	499-TACROLIMUS.html	Increase of the blood concentrations of tacrolimus due to inhibition of its metabolism by the amiodarone	Precaution for use	
2222	TACROLIMUS	42316			AMPHOTERICIN B	732			ANSM	499-TACROLIMUS.html	With the amphotericin B administered by IV route: greater increase of the creatinemia than with tacrolimus alone (synergy of the nephrotoxic effects of the two substances)	Take into account	
2223	TACROLIMUS	42316					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	499-TACROLIMUS.html	Risk of addition of the nephrotoxic effects, especially with older patients	Precaution for use	
2224	TACROLIMUS	42316			CLINDAMYCIN	2582			ANSM	499-TACROLIMUS.html	Decrease of the blood concentrations of the immunosuppressant, with risk of loss of immunosuppressive activity.	Precaution for use	
2225	TACROLIMUS	42316			DABIGATRAN				ANSM	499-TACROLIMUS.html	Risk of increase of the plasma concentrations of dabigatran	Not recommended	
2226	TACROLIMUS	42316			DANAZOL	3102			ANSM	499-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus due to inhibition of its hepatic metabolism	Precaution for use	
2227	TACROLIMUS	42316					POTASSIUM SPARING DIURETICS (ALONE OR IN COMBINATION)	C0E-004	ANSM	499-TACROLIMUS.html	Potentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
2228	TACROLIMUS	42316			JOSAMYCIN	6084			ANSM	499-TACROLIMUS.html	Increase of the blood concentrations of tacrolimus and of the creatinemia, due to inhibition of the hepatic metabolism of the tacrolimus by the josamycin	Not recommended	
2229	TACROLIMUS	42316			LANSOPRAZOLE	17128			ANSM	499-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	
2230	TACROLIMUS	42316			OMEPRAZOLE	7646			ANSM	499-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus	Precaution for use	
2231	TACROLIMUS	42316			POTASSIUM	8588			ANSM	499-TACROLIMUS.html	Essentially lethal hyperkalemia, especially when there is renal insufficiency (addition of the hyperkalemia inducing effects)	Not recommended	
2232	TACROLIMUS	42316			VERAPAMIL	11170			ANSM	499-TACROLIMUS.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	
2233			CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003			BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001	ANSM	49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html	Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
2234			CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	49-CLASS-I-ANTIARRHYTHMICS-(EXCEPT-LIDOCAINE).html	Negative inotropic effect with risk of acute decompensated heart failure	CONTRAINDICATION	
2235	ACETOHYDROXAMIC ACID	16728			IRON	1431589			ANSM	4-ACETOHYDROXAMIC-ACID.html	Decrease of the digestive absorption of these two medications due to chelation of the iron	Take into account	
2236	TAMOXIFEN	10324					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	500-TAMOXIFEN.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2237	TAMOXIFEN	10324			BUPROPION	42347			ANSM	500-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine [sic]	Not recommended	
2238	TAMOXIFEN	10324			DULOXETINE	72625			ANSM	500-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the duloxetine	Not recommended	
2239	TAMOXIFEN	10324			FLUOXETINE	4493			ANSM	500-TAMOXIFEN.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the fluoxetine	Not recommended	
2240	TAMOXIFEN	10324			PAROXETINE	32937			ANSM	500-TAMOXIFEN.html	Reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the paroxetine	Not recommended	
2241	TAMOXIFEN	10324			QUINIDINE	9068			ANSM	500-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine	Not recommended	
2242	TAMOXIFEN	10324			TERBINAFINE	37801			ANSM	500-TAMOXIFEN.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine	Not recommended	
2243	TAMSULOSIN	77492			AMIODARONE	703			ANSM	501-TAMSULOSIN.html	Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism	Precaution for use	
2244	TAMSULOSIN	77492			DILTIAZEM	3443			ANSM	501-TAMSULOSIN.html	Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism	Precaution for use	
2245	TAMSULOSIN	77492					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	501-TAMSULOSIN.html	Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism	Not recommended	
2246	TAMSULOSIN	77492			VERAPAMIL	11170			ANSM	501-TAMSULOSIN.html	Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism	Precaution for use	
2247	TELAPREVIR	1102261			AMIODARONE	703			ANSM	502-TELAPREVIR.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia	CONTRAINDICATION	
2248	TELAPREVIR	1102261					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	502-TELAPREVIR.html	Risk of very large decrease of the concentrations of telaprevir.	CONTRAINDICATION	
2249	TELAPREVIR	1102261			ATORVASTATIN	83367			ANSM	502-TELAPREVIR.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
2250	TELAPREVIR	1102261			DIGOXIN	3407			ANSM	502-TELAPREVIR.html	Increase of the digoxinemia	Precaution for use	
2251	TELAPREVIR	1102261					NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	502-TELAPREVIR.html	Decrease of the effectiveness of the estrogen	Precaution for use	
2252	TELAPREVIR	1102261					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	502-TELAPREVIR.html	Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the telaprevir	Precaution for use	
2253	TELAPREVIR	1102261					IMMUNOSUPPRESSANTS	L04A	ANSM	502-TELAPREVIR.html	Increase of the plasma concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the telaprevir	Precaution for use	
2254	TELAPREVIR	1102261					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	502-TELAPREVIR.html	Decrease of the concentrations of the telaprevir and of the darunavir or of the fosamprenavir, with risk of therapeutic failure	Not recommended	
2255	TELAPREVIR	1102261			ITRACONAZOLE	28031			ANSM	502-TELAPREVIR.html	Risk of increase of the plasma concentrations of telaprevir and of the itraconazole	Precaution for use	
2256	TELAPREVIR	1102261			ST JOHNS WORT	258326			ANSM	502-TELAPREVIR.html	Risk of very large decrease of the concentrations of telaprevir	CONTRAINDICATION	
2257	TELAPREVIR	1102261			RIFAMPICIN	9384			ANSM	502-TELAPREVIR.html	Very large decrease of the concentrations of telaprevir	CONTRAINDICATION	
2258	TELAPREVIR	1102261			SIMVASTATIN	36567			ANSM	502-TELAPREVIR.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type (decrease of the hepatic metabolism of the simvastatin)	CONTRAINDICATION	
2259	TELAPREVIR	1102261			TENOFOVIR ALAFENAMIDE	1721603			ANSM	502-TELAPREVIR.html	Risk of decrease of the effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the telaprevir	Not recommended	
2260	TELBIVUDINE	474128			PEG-INTERFERON ALFA-2A	120608			ANSM	503-TELBIVUDINE.html	Increased risk of peripheral neuropathy	CONTRAINDICATION	
2261	TELITHROMYCIN	274786					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	504-TELITHROMYCIN.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of its hepatic metabolism by the inducer	Not recommended	
2262	TELITHROMYCIN	274786			ATORVASTATIN	83367			ANSM	504-TELITHROMYCIN.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering medication	CONTRAINDICATION	
2263	TELITHROMYCIN	274786			DEXAMETHASONE	3264			ANSM	504-TELITHROMYCIN.html	Increase of the plasma concentrations of the dexamethasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of Cushings syndrome	Take into account	
2264	TELITHROMYCIN	274786			DIGOXIN	3407			ANSM	504-TELITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	
2265	TELITHROMYCIN	274786					IMMUNOSUPPRESSANTS	L04A	ANSM	504-TELITHROMYCIN.html	Very large increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism	Not recommended	
2266	TELITHROMYCIN	274786					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	504-TELITHROMYCIN.html	Risk of increase of the undesirable effects, especially of the cardiac arrhythmia type	CONTRAINDICATION	
2267	TELITHROMYCIN	274786			ST JOHNS WORT	258326			ANSM	504-TELITHROMYCIN.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort	Not recommended	
2268	TELITHROMYCIN	274786			MIZOLASTINE	61455			ANSM	504-TELITHROMYCIN.html	Increased risk of ventricular arrhythmia, especially of torsades de pointes	CONTRAINDICATION	
2269	TELITHROMYCIN	274786			RIFAMPICIN	9384			ANSM	504-TELITHROMYCIN.html	Very large decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the rifampicin	Not recommended	
2270	TELITHROMYCIN	274786			SIMVASTATIN	36567			ANSM	504-TELITHROMYCIN.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering drug).	CONTRAINDICATION	
2271	TELITHROMYCIN	274786			VENLAFAXINE	39786			ANSM	504-TELITHROMYCIN.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2272	TELITHROMYCIN	274786					VINCA ALKALOIDS	L01CA	ANSM	504-TELITHROMYCIN.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the telithromycin	Precaution for use	
2273	TENOFOVIR ALAFENAMIDE	1721603			BOCEPREVIR	1102129			ANSM	505-TENOFOVIR-ALAFENAMIDE.html	Risk of lower effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the boceprevir	Not recommended	
2274	TENOFOVIR ALAFENAMIDE	1721603			CICLOSPORIN	3008			ANSM	505-TENOFOVIR-ALAFENAMIDE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	
2275	TENOFOVIR ALAFENAMIDE	1721603			COBICISTAT	1306284			ANSM	505-TENOFOVIR-ALAFENAMIDE.html	With the atazanavir, the darunavir or the lopinavir boosted with cobicistat, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	
2276	TENOFOVIR ALAFENAMIDE	1721603					ENZYME INDUCERS	N03-J05-001	ANSM	505-TENOFOVIR-ALAFENAMIDE.html	Decrease of the plasma concentrations of the tenofovir alafenamide due to decrease of its absorption by the inducer	Not recommended	
2277	TENOFOVIR ALAFENAMIDE	1721603					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	505-TENOFOVIR-ALAFENAMIDE.html	With the atazanavir, the darunavir or the lopinavir, increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	
2278	TENOFOVIR ALAFENAMIDE	1721603			ITRACONAZOLE	28031			ANSM	505-TENOFOVIR-ALAFENAMIDE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	
2279	TENOFOVIR ALAFENAMIDE	1721603			KETOCONAZOLE	6135			ANSM	505-TENOFOVIR-ALAFENAMIDE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	
2280	TENOFOVIR ALAFENAMIDE	1721603			RIFAMPICIN	9384			ANSM	505-TENOFOVIR-ALAFENAMIDE.html	Decrease of the plasma concentrations of tenofovir alafenamide due to decrease of its absorption by the rifampicin	Not recommended	
2281	TENOFOVIR ALAFENAMIDE	1721603			TELAPREVIR	1102261			ANSM	505-TENOFOVIR-ALAFENAMIDE.html	Risk of reduction of the effectiveness of the tenofovir alafenamide due to decrease of its intracellular activity by the telaprevir	Not recommended	
2282	TENOFOVIR ALAFENAMIDE	1721603			VERAPAMIL	11170			ANSM	505-TENOFOVIR-ALAFENAMIDE.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	
2283	TENOFOVIR DISOPROXIL	300195					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	506-TENOFOVIR-DISOPROXIL.html	Risk of increase of the nephrotoxicity of the tenofovir, especially with large doses of the anti-inflammatory or in the presence of factors of risk of renal insufficiency.	Precaution for use	
2284	TENOFOVIR DISOPROXIL	300195			ATAZANAVIR	343047			ANSM	506-TENOFOVIR-DISOPROXIL.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same substances together	Take into account	
2285	TENOFOVIR DISOPROXIL	300195			DIDANOSINE	3364			ANSM	506-TENOFOVIR-DISOPROXIL.html	Risk of failure of the antiretroviral treatment, even emergence of resistance. In addition, increase of the risk of the mitochondrial toxicity of the didanosine	Not recommended	
2286	TENOFOVIR DISOPROXIL	300195			LEDIPASVIR	1591922			ANSM	506-TENOFOVIR-DISOPROXIL.html	When co-administered with a protease inhibitor, increase of the plasma concentrations of the tenofovir by the ledipasvir	Precaution for use	
2287	TERBINAFINE	37801			CICLOSPORIN	3008			ANSM	507-TERBINAFINE.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	
2288	TERBINAFINE	37801			FLECAINIDE	4441			ANSM	507-TERBINAFINE.html	Risk of increase of the undesirable effects of the flecainide, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	
2289	TERBINAFINE	37801			MEQUITAZINE	29528			ANSM	507-TERBINAFINE.html	Risk of increase of the undesirable effects of the mequitazine, due to inhibition of its metabolism by the enzyme inhibitor	Not recommended	
2290	TERBINAFINE	37801			METOPROLOL	6918			ANSM	507-TERBINAFINE.html	With the patient having heart failure, risk of increase of the undesirable effects of the metoprolol, due to decrease of its hepatic metabolism by the terbinafine.	Precaution for use	
2291	TERBINAFINE	37801			PROPAFENONE	8754			ANSM	507-TERBINAFINE.html	Risk of increase of the undesirable effects of the propafenone, due to decrease of its hepatic metabolism by the terbinafine	Precaution for use	
2292	TERBINAFINE	37801			RIFAMPICIN	9384			ANSM	507-TERBINAFINE.html	Decrease of the plasma concentrations and of the effectiveness of the terbinafine, due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	
2293	TERBINAFINE	37801			TAMOXIFEN	10324			ANSM	507-TERBINAFINE.html	Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the terbinafine.	Nor recommended	
2294	TERBINAFINE	37801			VORTIOXETINE	1455099			ANSM	507-TERBINAFINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	
2295	TERIFLUNOMIDE	1310520					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	508-TERIFLUNOMIDE.html	Risk of general vaccine disease, possibly fatal	Not recommended	
2296	TETRABENAZINE	10390					DOPAMINERGICS	N04B-002	ANSM	509-TETRABENAZINE.html	Reciprocal antagonism between the dopaminergic and the tetrabenazine	Not recommended	
2297	TETRABENAZINE	10390					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	509-TETRABENAZINE.html	Risk of hypertensive crises. Because of the duration of the action of the MAOI, this interaction is still theoretically possible two weeks after the MAOI is stopped	CONTRAINDICATION	
2298	TETRABENAZINE	10390			LEVODOPA	6375			ANSM	509-TETRABENAZINE.html	Reciprocal antagonism between the levodopa and the tetrabenazine	Not recommended	
2299			CLASS IA ANTIARRHYTHMICS	C01B-002			ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic, due to increase of its hepatic metabolism by the inducer	Precaution for use	
2300			CLASS IA ANTIARRHYTHMICS	C01B-002	ESMOLOL	49737			ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Disorders of contractility, auto- regulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
2301			CLASS IA ANTIARRHYTHMICS	C01B-002	RIFAMPICIN	9384			ANSM	50-CLASS-IA-ANTIARRHYTHMICS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic (increase of its hepatic metabolism).	Precaution for use	
2302	THALIDOMIDE	10432			DIDANOSINE	3364			ANSM	510-THALIDOMIDE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
2303	THALIDOMIDE	10432			STAVUDINE	59763			ANSM	510-THALIDOMIDE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
2304	THALIDOMIDE	10432			ZALCITABINE	3363			ANSM	510-THALIDOMIDE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
2305	THEOPHYLLINE	10438			LITHIUM	6448			ANSM	511-THEOPHYLLINE.html	Decrease of the the plasma concentrations of lithium with risk of reduction of the therapeutic effectiveness	Precaution for use	
2306	THEOPHYLLINE	10438			PROPAFENONE	8754			ANSM	511-THEOPHYLLINE.html	Risk of increase of the theophyllinemia due to decrease of its hepatic metabolism by the propafenone	Precaution for use	
2307	THEOPHYLLINE	10438			VEMURAFENIB	1147220			ANSM	511-THEOPHYLLINE.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects.	Precaution for use	
2308			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA			ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations and of the effectiveness of the theophylline due to increase of its hepatic metabolism by the inducer	Precaution for use	
2309			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	CIMETIDINE	2541			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	With the cimetidine used in doses greater than or equal to 800 mg/day: increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	
2310			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	CIPROFLOXACIN	2551			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose, due to decrease of its hepatic metabolism by the ciprofloxacin.	Precaution for use	
2311			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	CLARITHROMYCIN	21212			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
2312			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	DIPYRIDAMOLE	3521			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	With the dipyridamole by injection: reduction of the vasodilator effect of the dipyridamole by the theophylline	Precaution for use	
2313			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ENOXACIN	3925			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Overdose of theophylline due to substantial decrease of its metabolism	CONTRAINDICATION	
2314			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ERYTHROMYCIN	4053			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Overdose of theophylline due to decrease of its hepatic elimination, more particularly dangerous with children	Not recommended	
2315			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	FLUCONAZOLE	4450			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the clearance of the theophylline)	Precaution for use	
2316			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	FLUVOXAMINE	42355			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with signs of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	
2317			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	HALOTHANE	5095			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Serious ventricular arrhythmias due to increase of cardiac sensitization	Not recommended	
2318			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA			XANTHINE OXYDASE INHIBITORS	M04AA0	ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	In case of large doses of the inhibitor, increase of the plasma concentrations of theophylline due to inhibition of its metabolism	Precaution for use	
2319			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations of the theophylline, due to increase of its hepatic metabolism	Precaution for use	
2320			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	JOSAMYCIN	6084			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children	Take into account	
2321			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	MEXILETINE	6926			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the hepatic metabolism of the theophylline)	Precaution for use	
2322			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ST JOHNS WORT	258326			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations of the theophylline, by reason of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome)	CONTRAINDICATION	
2323			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	NORFLOXACIN	7517			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	
2324			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	PEFLOXACIN	7960			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the metabolism of the theophylline)	Precaution for use	
2325			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	PENTOXIFYLLINE	8013			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (competition at the level of the hepatic metabolism of the theophylline)	Precaution for use	
2326			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	RIFAMPICIN	9384			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Decrease of the plasma concentrations and of the effectiveness of the theophylline (increase of its metabolism by enzymatic induction)	Precaution for use	
2327			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ROXITHROMYCIN	9478			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Risk of increase of the theophyllinemia, particularly with children.	Take into account	
2328			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	STIRIPENTOL	37119			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Possible increase of the theophyllinemia, with risk of overdose, due to inhibition of its hepatic metabolism	Precaution for use	
2329			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	TIABENDAZOLE	10450			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline	Precaution for use	
2330			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	TICLOPIDINE	10594			ANSM	512-THEOPHYLLINE-AND,-BY-EXTRAPOLATION,-AMINOPHYLLINE).html	Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline)	Precaution for use	
2331			THROMBOLYTICS	B01AD	ACETYLSALICYLIC ACID	1191			ANSM	513-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
2332			THROMBOLYTICS	B01AD			PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	513-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
2333			THROMBOLYTICS	B01AD			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	513-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
2334			THROMBOLYTICS	B01AD	DEFIBROTIDE	1311089			ANSM	513-THROMBOLYTICS.html	Accrued risk of hemorrhage	CONTRAINDICATION	
2335			THROMBOLYTICS	B01AD			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	513-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
2336			THROMBOLYTICS	B01AD			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	513-THROMBOLYTICS.html	Increase of the risk of hemorrhage	Take into account	
2337	TIABENDAZOLE	10450					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	514-TIABENDAZOLE.html	Increase of the theophyllinemia with risk of overdose, due to decrease of the hepatic metabolism of the theophylline	Precaution for use	
2338	TIAGABINE	31914					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	515-TIAGABINE.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism by the inducer	Precaution for use	
2339	TIAGABINE	31914			RIFAMPICIN	9384			ANSM	515-TIAGABINE.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism	Precaution for use	
2340	TIANEPTINE	38252					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	516-TIANEPTINE.html	Risk of drop in blood pressure, paroxystic hypertension, hyperthermia, convulsions, death	Not recommended	
2341	TIBOLONE	38260					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	517-TIBOLONE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2342	TICAGRELOR	1116632			ACETYLSALICYLIC ACID	1191			ANSM	518-TICAGRELOR.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities	Not recommended	
2343	TICAGRELOR	1116632					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	518-TICAGRELOR.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the anticonvulsant enzyme inducer, with risk of decrease of the therapeutic effect	Not recommended	
2344	TICAGRELOR	1116632			DABIGATRAN				ANSM	518-TICAGRELOR.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Take into account	
2345	TICAGRELOR	1116632			DILTIAZEM	3443			ANSM	518-TICAGRELOR.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
2346	TICAGRELOR	1116632					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	518-TICAGRELOR.html	Increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism by the inhibitor	CONTRAINDICATION	
2347	TICAGRELOR	1116632			ST JOHNS WORT	258326			ANSM	518-TICAGRELOR.html	Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect.	CONTRAINDICATION	
2348	TICAGRELOR	1116632					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	518-TICAGRELOR.html	Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the therapy with ombitasvir+paritaprevir	CONTRAINDICATION	
2349	TICAGRELOR	1116632			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	518-TICAGRELOR.html	Doubling of the plasma concentrations of the antiagregant, with risk of increase of its undesirable effects, especially hemorrhagic ones	Not recommended	
2350	TICAGRELOR	1116632			RIFAMPICIN	9384			ANSM	518-TICAGRELOR.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
2351	TICAGRELOR	1116632			VERAPAMIL	11170			ANSM	518-TICAGRELOR.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
2352	TICLOPIDINE	10594			ACETYLSALICYLIC ACID	1191			ANSM	519-TICLOPIDINE.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation action	Not recommended	
2353	TICLOPIDINE	10594			CICLOSPORIN	3008			ANSM	519-TICLOPIDINE.html	Decrease of the blood concentrations of ciclosporin	Precaution for use	
2354	TICLOPIDINE	10594					PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	519-TICLOPIDINE.html	Increase of the plasma concentrations of phenytoin with signs of overdose (inhibition of the metabolism of the phenytoin)	Precaution for use	
2355	TICLOPIDINE	10594					THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	519-TICLOPIDINE.html	Increase of the theophyllinemia with risk of overdose (decrease of the plasma clearance of the theophylline).	Precaution for use	
2356			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of excessive bradycardia (addition of the bradycardia inducing effects)	Precaution for use	
2357			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	PILOCARPINE	8328			ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of addition of the undesirable cholinergic effects, especially digestive ones	Take into account	
2358			ACETYL-CHOLINESTERASE INHIBITORS	ACETCHO	SUXAMETHONIUM	10154			ANSM	51-ACETYLCHOLINESTERASE-INHIBITORS.html	Risk of lengthening of the motor block, increased in the case of partial deficit of pseudocholinesterase	Take into account	
2359			GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	A07BC-A02AD	MEDICATIONS ADMINISTERED BY ORAL ROUTE				ANSM	520-GASTROINTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html	Decrease of the absorption of certain other medications ingested simultaneously	Precaution for use	
2360			GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	A07BC-A02AD			SUBSTANCES WITH ABSORPTION REDUCED BY GASTRO-INTESTINAL TARGETED MEDICATIONS, ANTACIDS, AND ABSORBANTS	RBGI	ANSM	520-GASTROINTESTINAL-TARGETED-MEDICATIONS,-ANTACIDS,-AND-ABSORBANTS.html	Decrease of the absorption of these substances	Precaution for use	
2361	TOPIRAMATE	38404			CARBAMAZEPINE	2002			ANSM	521-TOPIRAMATE.html	Decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
2362	TOPIRAMATE	38404					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	521-TOPIRAMATE.html	For doses of topiramate >= 200 mg/day: Risk of decrease of the contraceptive effectiveness due to decrease of the concentrations of estrogen	Not recommended	
2363	TOPIRAMATE	38404			LITHIUM	6448			ANSM	521-TOPIRAMATE.html	For doses of topiramate >=200mg/day: increase of the the plasma concentrations of lithium that can reach toxic levels, with signs of overdose of lithium	Precaution for use	
2364	TOPIRAMATE	38404			OXCARBAZEPINE	32624			ANSM	521-TOPIRAMATE.html	Risk of decrease of the concentrations of the topiramate with risk of lower effectiveness, due to increase of its hepatic metabolism by the oxcarbazepine	Precaution for use	
2365	TOPIRAMATE	38404					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	521-TOPIRAMATE.html	Increase of the hyperammonemia, with increased risk of encephalopathy	Precaution for use	
2366			TORSADES DE POINTES INDUCING MEDICATIONS (EXCEPT ANTIPARASITICS, NEUROLEPTICS, METHADONE)	C01B			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	522-TORSADES-DE-POINTES-INDUCING-MEDICATIONS-(EXCEPT-ANTIPARASITICS,-NEUROLEPTICS,-METHADONE).html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
2367	TRABECTEDINE	397736			ITRACONAZOLE	28031			ANSM	523-TRABECTEDINE.html	Risk of increase of the plasma concentrations of the trabectedine by the itraconazole	Not recommended	
2368			NICOTINE SUBSTITUION TREATMENT	N07BA			MEDICATIONS AT RISK WHEN WITHDRAWING FROM TOBACCO	N0-R0-002	ANSM	524-NICOTINE-SUBSTITUTION-TREATMENT.html	Risk of overdose when replacing tobacco by the substitution treatment	Take into account	
2369	TRAMADOL	10689					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	525-TRAMADOL.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2370	TRAMADOL	10689			BUPROPION	42347			ANSM	525-TRAMADOL.html	Increase of the plasma concentrations of the tramadol due to decrease of its hepatic metabolism by the bupropion. In addition, risk of convulsions due to addition of the effects of the two medications	Take into account	
2371	TRAMADOL	10689					IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	525-TRAMADOL.html	Risk of appearance of a serotonin syndrome: diarrhea, sweats, trembling, confusion, even coma	CONTRAINDICATION	
2372	TRAMADOL	10689					REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	525-TRAMADOL.html	Risk of appearance of a serotonin syndrome: diarrhea, tachycardia, sweats, trembling, confusion, even coma	Not recommended	
2373	TRAMADOL	10689					MAOI-B	N04BD0-001	ANSM	525-TRAMADOL.html	Risk of appearance of a serotonin syndrome	Take into account	
2374	TRAMADOL	10689					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	525-TRAMADOL.html	Risk of appearance of convulsions and/or a serotonin syndrome	Take into account	
2375	TRAMADOL	10689			ONDANSETRON	26225			ANSM	525-TRAMADOL.html	Decrease of the intensity and of the duration of the analgesic effect of the tramadol and risk of decrease of the antiemitic effect of the ondansetron	Take into account	
2376	TRAMADOL	10689			VENLAFAXINE	39786			ANSM	525-TRAMADOL.html	Risk of appearance of convulsions and/or of a serotonin syndrome	Take into account	
2377	TRASTUZUMAB EMTANSINE						STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	526-TRASTUZUMAB-EMTANSINE.html	Increase of the plasma concentrations of the DM1, a component of the trastuzumab emtansine, due to inhibition of its metabolism by the inhibitor	Not recommended	
2378	TRICLABENDAZOLE	38608			DIHYDROERGOTAMINE	3418			ANSM	527-TRICLABENDAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	CONTRAINDICATION	
2379	TRICLABENDAZOLE	38608			ERGOTAMINE	4025			ANSM	527-TRICLABENDAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	CONTRAINDICATION	
2380	TRICLABENDAZOLE	38608			PIMOZIDE	8331			ANSM	527-TRICLABENDAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	CONTRAINDICATION	
2381	TRICLABENDAZOLE	38608			QUINIDINE	9068			ANSM	527-TRICLABENDAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)	CONTRAINDICATION	
2382	TRIMETHOPRIM	10829			CICLOSPORIN	3008			ANSM	528-TRIMETHOPRIM.html	With the trimethoprim (alone or in combination) by oral route: increase of the creatinemia with possible decrease of the blood concentrations of ciclosporinWith trimethoprime (alone or in combination) by IV route: the decrease of the blood concentrations of ciclosporin can be very large with possible loss of all immunosuppressant capacity	Take into account	
2383	TRIMETHOPRIM	10829			METHOTREXATE	6851			ANSM	528-TRIMETHOPRIM.html	Increase of the hematological toxicity of the methotrexate (decrease of its renal excretion as well as inhibition of the dihydrofolate reductase).	CONTRAINDICATION	
2384	TRIMETHOPRIM	10829			PYRIMETHAMINE	9010			ANSM	528-TRIMETHOPRIM.html	Megaloblastic anemia, more particularly with strong doses of the two products (deficit of folic acid due to the combination of the two 2-4 diaminopyrimidines)	Precaution for use	
2385	TRIMETHOPRIM	10829			REPAGLINIDE	73044			ANSM	528-TRIMETHOPRIM.html	Risk of increase of the plasma concentrations of repaglinide due to inhibition of its hepatic metabolism by the trimethoprim	Not recommended	
2386			TRIPTANS	N02CC-001			VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE	N02CA0-001	ANSM	529-TRIPTANS .html	Risk of arterial hypertension, of constriction of coronary arteries	CONTRAINDICATION	
2387			TRIPTANS	N02CC-001			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	529-TRIPTANS .html	Risk of appearance of a serotonin syndrome	Take into account	
2388			ORAL ANTICOAGULANTS	B01A-001			OTHER ORAL ANTICOAGULANTS	B01A-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Risk of increase of hemorrhagic events when one oral anticoagulant is replaced with another.	Take into account	
2389			ORAL ANTICOAGULANTS	B01A-001	ACETYLSALICYLIC ACID	1191			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage, especially in cases with a previous gastroduodenal ulcer	Contraindication with:	
2390			ORAL ANTICOAGULANTS	B01A-001			PLATELET AGGREGATION INHIBITORS	B01AC-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage	Take into account	
2391			ORAL ANTICOAGULANTS	B01A-001			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the oral anticoagulant's risk of hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories)	Not recommended	
2392			ORAL ANTICOAGULANTS	B01A-001	DEFIBROTIDE	1311089			ANSM	52-ORAL-ANTICOAGULANTS.html	Increased risk of hemorrhage	Not recommended	
2393			ORAL ANTICOAGULANTS	B01A-001			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Glucocorticoids (general and rectal routes): possible impact of the corticotherapy on the metabolism of the vitamin K antagonist and on that of the factors of coagulation. Risk of hemorrhage specific to the corticotherapy (digestive mucosa, vascular fragility) with large doses or in treatment prolonged beyond 10 days.	Precaution for use	
2394			ORAL ANTICOAGULANTS	B01A-001			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage	Precaution for use	
2395			ORAL ANTICOAGULANTS	B01A-001			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hemorrhage	Precaution for use	
2396			ORAL ANTICOAGULANTS	B01A-001	IPILIMUMAB	1094833			ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of digestive system hemorrhage	Precaution for use	
2397			ORAL ANTICOAGULANTS	B01A-001			MIXED ADRENERGIC-SEROTONINERGIC MEDICATIONS	N06A	ANSM	52-ORAL-ANTICOAGULANTS.html	Increase of the risk of hermorrhage.	Precaution for use	
2398			TRIPTANS METABOLIZED BY THE MAO	N02CC-002			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	530-TRIPTANS-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	CONTRAINDICATION	
2399			TRIPTANS METABOLIZED BY THE MAO	N02CC-002			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	530-TRIPTANS-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	CONTRAINDICATION	
2400			TRIPTANS METABOLIZED BY THE MAO	N02CC-002			MAOI-B	N04BD0-001	ANSM	530-TRIPTANS-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	CONTRAINDICATION	
2401			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003			IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)	N06AF0	ANSM	531-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
2402			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003			REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE	NO6AG-001	ANSM	531-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
2403			TRIPTANS NOT METABOLIZED BY THE MAO	NO2CC-003			MAOI-B	N04BD0-001	ANSM	531-TRIPTANS-NOT-METABOLIZED-BY-THE-MAO.html	Risk of arterial hypertension, of constriction of the coronary arteries	Not recommended	
2404	ULIPRISTAL	1005921					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	532-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	
2405	ULIPRISTAL	1005921					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	532-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to decrease of its absorption	Take into account	
2406	ULIPRISTAL	1005921					PROTON PUMP INHIBITORS	A02BC-001	ANSM	532-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to decrease of its absorption	Take into account	
2407	ULIPRISTAL	1005921			CYPROTERONE	3014			ANSM	532-ULIPRISTAL.html	Risk of antagonism of the effects of the progestin	Not recommended	
2408	ULIPRISTAL	1005921					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	532-ULIPRISTAL.html	Risk of antagonism of the effects of the estrogen-progestin contraceptive	Not recommended	
2409	ULIPRISTAL	1005921					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	532-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the ritonavir	Not recommended	
2410	ULIPRISTAL	1005921			ST JOHNS WORT	258326			ANSM	532-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	
2411	ULIPRISTAL	1005921					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	532-ULIPRISTAL.html	Risk of antagonism of the effects of the progestin contraceptive	Not recommended	
2412	ULIPRISTAL	1005921					NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	ANSM	532-ULIPRISTAL.html	Risk of antagonism of the effects of the progestin contraceptive	Not recommended	
2413	ULIPRISTAL	1005921			RIFAMPICIN	9384			ANSM	532-ULIPRISTAL.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	
2414			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ABATACEPT	614391			ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of general vaccine disease, possibly fatal	Not recommended	
2415			ATTENUATED LIVE VIRUS VACCINES	J07B-001			MONOCLONAL ANTIBODIES (EXCEPT ANTI-TNF ALPHA)	MONANT	ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of general vaccine disease, possibly fatal.	Not recommended with	
2416			ATTENUATED LIVE VIRUS VACCINES	J07B-001			ANTI-TNF ALPHA	LO4AB	ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease	CONTRAINDICATION	
2417			ATTENUATED LIVE VIRUS VACCINES	J07B-001	BELATACEPT	1112973			ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of general vaccine disease, possibly fatal	Not recommended	
2418			ATTENUATED LIVE VIRUS VACCINES	J07B-001			CYTOTOXICS	L01	ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease	CONTRAINDICATION	
2419			ATTENUATED LIVE VIRUS VACCINES	J07B-001	DIMETHYL (FUMERATE OF)	1373478			ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Possible increase of the risk of infection	Take into account	
2420			ATTENUATED LIVE VIRUS VACCINES	J07B-001			ANTI-LYMPHOCYTE GLOBULINS	L04AA0-001	ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease. This risk is increased in older patients already immunodepressed by the underlying disease.	Take into account	
2421			ATTENUATED LIVE VIRUS VACCINES	J07B-001			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	With the exception of inhaled and local routes and for dosages greater than 10mg/day of prednisone equivalent (or >2mg/kg/day with children or >20 mg/day for children weighing more than 10 kg) for more than two weeks and for administration in "bolus" of the corticoids:risk of possibly fatal general vaccine disease.	CONTRAINDICATION	
2422			ATTENUATED LIVE VIRUS VACCINES	J07B-001	HYDROXYCARBAMIDE	5552			ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	In its indication for the patient with drepanocytosis, theoretic risk of general fatal vaccine disease.	Not recommended	
2423			ATTENUATED LIVE VIRUS VACCINES	J07B-001			IMMUNOSUPPRESSANTS	L04A	ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease.	CONTRAINDICATION	
2424			ATTENUATED LIVE VIRUS VACCINES	J07B-001	MYCOPHENOLATE MOFETIL				ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease.	CONTRAINDICATION	
2425			ATTENUATED LIVE VIRUS VACCINES	J07B-001	MYCOPHENOLATE SODIUM	408142			ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of possibly fatal general vaccine disease	CONTRAINDICATION	
2426			ATTENUATED LIVE VIRUS VACCINES	J07B-001	TERIFLUNOMIDE	1310520			ANSM	533-ATTENUATED-LIVE-VIRUS-VACCINES.html	Risk of general vaccine disease, possibly fatal	Not recommended	
2427			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ACETAZOLAMIDE	167			ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the hyperammonemia, with accrued risk of encephalopathy	Precaution for use	
2428			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	AZTREONAM	1272			ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid	Precaution for use	
2429			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	CARBAMAZEPINE	2002			ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the plasma concentrations of the active metabolite of the carbamazepine with signs of overdose. In addition, decrease of the plasma concentrations of valproic acid due to increase of its hepatic metabolism by the carbamazepine	Precaution for use	
2430			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	FELBAMATE	24812			ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the plasma concentrations of the valproic acid, with risk of overdose.	Precaution for use	
2431			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	LAMOTRIGINE	28439			ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increased risk of serious cutaneous reactions (Lyell's syndorme). In addition, increase of the plasma concentrations of lamotrigine (decrease of its hepatic metabolism by the sodium valproate)	Not recommended	
2432			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	NIMODIPINE	7426			ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	With the nimodipine by oral route, and by extrapolation, by injection: risk of increase of the hypotensive effect of the nimodipine due to increase of its plasma concentrations (decrease of its metabolism by the valproic acid)	Take into account	
2433			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0			PENEMS	J01DH	ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to rapid decrease of the plasma concentrations of the valproic acid, that can become undetectable	Not recommended	
2434			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0			PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the hyperammonemia, with accrued risk of encephalopathy	Precaution for use	
2435			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0			PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)	N03AB	ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the hyperammonemia, with accrued risk of encephalopathy	Precaution for use	
2436			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	RIFAMPICIN	9384			ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of onset of convulsive crises, due to increase of the hepatic metabolism of the valproate by the rifampicin	Precaution for use	
2437			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	RUFINAMIDE	69036			ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Possible increase of the concentrations of rufinamide, especially with children who weigh less than 30 kg	Precaution for use	
2438			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	TOPIRAMATE	38404			ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the hyperammonemia with accrued risk of encephalopathy	Precaution for use	
2439			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ZIDOVUDINE (AZT)	11413			ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid.	Precaution for use	
2440			VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ZONISAMIDE				ANSM	534-VALPROIC-(ACID)-AND,-BY-EXTRAPOLATION,-VALPROMIDE.html	Increase of the hyperammonemia, with accrued risk of encephalopathy	Precaution for use	
2441	VARDENAFIL	306674			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	535-VARDENAFIL.html	Increase of the plasma concentrations of the vardenafil, with risk of hypotension.	Not recommended	
2442	VEMURAFENIB	1147220			BUPROPION	42347			ANSM	536-VEMURAFENIB.html	Risk of decrease of the concentrations of the bupropion, with increase of its active metabolite and increased toxicity	Take into account	
2443	VEMURAFENIB	1147220					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	536-VEMURAFENIB.html	Risk of decrease of the concentrations of the combined estrogen-progestin contraceptive with the consequence of a risk of ineffectiveness	Not recommended	
2444	VEMURAFENIB	1147220			IFOSFAMIDE	5657			ANSM	536-VEMURAFENIB.html	Risk of decrease of the concentrations of the ifosfamide, with increase of its active metabolite and increased toxicity	Take into account	
2445	VEMURAFENIB	1147220					IMMUNOSUPPRESSANTS	L04A	ANSM	536-VEMURAFENIB.html	Risk of decrease of the concentrations of the immunosuppressants, with the consequence of a risk of ineffectiveness	Not recommended	
2446	VEMURAFENIB	1147220					ENZYME INDUCERS	N03-J05-001	ANSM	536-VEMURAFENIB.html	Risk of decrease of the concentrations of the vemurafenib, with lower effectiveness	Not recommended	
2447	VEMURAFENIB	1147220			THEOPHYLLINE	10438			ANSM	536-VEMURAFENIB.html	Large increase of the concentrations of theophylline, with risks of increase of its undesirable effects	Precaution for use	
2448	VENLAFAXINE	39786			CLARITHROMYCIN	21212			ANSM	537-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2449	VENLAFAXINE	39786			ERYTHROMYCIN	4053			ANSM	537-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2450	VENLAFAXINE	39786					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	537-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose.	Take into account	
2451	VENLAFAXINE	39786			ITRACONAZOLE	28031			ANSM	537-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2452	VENLAFAXINE	39786			KETOCONAZOLE	6135			ANSM	537-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2453	VENLAFAXINE	39786			TELITHROMYCIN	274786			ANSM	537-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2454	VENLAFAXINE	39786			TRAMADOL	10689			ANSM	537-VENLAFAXINE.html	Risk of appearance of convulsions and/or of a serotonin syndrome	Take into account	
2455	VENLAFAXINE	39786			VORICONAZOLE	121243			ANSM	537-VENLAFAXINE.html	Increase of the concentrations of venlafaxine with risk of overdose	Take into account	
2456	VERAPAMIL	11170			AFATINIB	1430438			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of afatinib due to increase of its absorption by the verapamil	Precaution for use	
2457	VERAPAMIL	11170			ALISKIREN	325646			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects	Precaution for use	
2458	VERAPAMIL	11170			AMIODARONE	703			ANSM	538-VERAPAMIL.html	For verapamil by injection:--risk of bradycardia or of atrioventricular blockFor verapamil by mouth:--risk of bradycardia or of atrioventricular block, especially with older persons	Not recommended with	
2459	VERAPAMIL	11170			ATORVASTATIN	83367			ANSM	538-VERAPAMIL.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication	Precaution for use	
2460	VERAPAMIL	11170					BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	538-VERAPAMIL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	
2461	VERAPAMIL	11170					BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	538-VERAPAMIL.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction	CONTRAINDICATION	
2462	VERAPAMIL	11170			BUSPIRONE	1827			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of the buspirone due to decrease of its hepatic metabolism by the verapamil, with increase of its undesirable effects	Precaution for use	
2463	VERAPAMIL	11170			CICLOSPORIN	3008			ANSM	538-VERAPAMIL.html	Increase of the blood concentrations of the ciclosporin (decrease of its hepatic metabolism), and increase of the risk of gum disorders.	Precaution for use	
2464	VERAPAMIL	11170			CLONIDINE	2599			ANSM	538-VERAPAMIL.html	Disorders of autoregulation (disorders of atrioventricular conduction due to addition of the negative effects on conduction)	Take into account	
2465	VERAPAMIL	11170			COLCHICINE	2683			ANSM	538-VERAPAMIL.html	Risk of increase of the undesirable effects of the colchicine, due to increase of its plasma concentrations by the verapamil	Not recommended	
2466	VERAPAMIL	11170			DABIGATRAN				ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding	Precaution for use	
2467	VERAPAMIL	11170			DANTROLENE	3105			ANSM	538-VERAPAMIL.html	With the dantrolene administered by IV: with animals, fatal cases of ventricular fibrillations are constantly observed when verapamil and dantrolene are administered by IV route. The administration of a calcium channel blocker and dantrolene together is thus potentially dangerous. However, some patients have received nifedipine and dantrolene together without incident.	CONTRAINDICATION	
2468	VERAPAMIL	11170			DIGOXIN	3407			ANSM	538-VERAPAMIL.html	Excessive bradycardia and atrioventricular block due to increase of the effects of the digoxin on autoregulation and conduction and due to decrease of the renal and extrarenal elimination of the digoxin	Precaution for use	
2469	VERAPAMIL	11170			DOXORUBICIN	3639			ANSM	538-VERAPAMIL.html	Risk of increase of the toxicity of the doxorubicin due to increase of its plasma concentrations	Take into account	
2470	VERAPAMIL	11170			DRONEDARONE	233698			ANSM	538-VERAPAMIL.html	Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the calcium channel blocker	Precaution for use	
2471	VERAPAMIL	11170			ERIBULINE	1045453			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of eribuline by the verapamil.	Not recommended	
2472	VERAPAMIL	11170			ERYTHROMYCIN	4053			ANSM	538-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the erythromycin	Precaution for use	
2473	VERAPAMIL	11170			ESMOLOL	49737			ANSM	538-VERAPAMIL.html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and cardiac failure	Not recommended	
2474	VERAPAMIL	11170			EVEROLIMUS	141704			ANSM	538-VERAPAMIL.html	Increase of the blood concentrations of the everolimus due to decrease of its hepatic metabolism by the verapamil	Precaution for use	
2475	VERAPAMIL	11170			FIDAXOMICIN	1111103			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of the fidaxomicin	Not recommended	
2476	VERAPAMIL	11170			IBRUTINIB	1442981			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of ibrutinib due to decrease of its hepatic metabolism by the verapamil	Precaution for use	
2477	VERAPAMIL	11170					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	538-VERAPAMIL.html	Bradycardia and/or disorders of atrioventricular conduction, due to decrease of the hepatic metabolism of the verapamil by the inhibitor	Precaution for use	
2478	VERAPAMIL	11170			IVABRADINE	77417			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of the ivabradine and of its undesirable effects, especially cardiac ones (inhibition of its hepatic metabolism by the verapamil), that add to the bradycardia inducing effects of these molecules.	CONTRAINDICATION	
2479	VERAPAMIL	11170			MIDAZOLAM	6960			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of midazolam (decrease of its hepatic metabolism with increase of sedation).	Precaution for use	
2480	VERAPAMIL	11170			ST JOHNS WORT	258326			ANSM	538-VERAPAMIL.html	Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect.	CONTRAINDICATION	
2481	VERAPAMIL	11170			NINTEDANIB	1592737			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of the nintedanib due to increase of it absorption by the verapamil	Precaution for use	
2482	VERAPAMIL	11170			OLAPARIB	1597582			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of olaparib by the verapamil	Not recommended	
2483	VERAPAMIL	11170			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of verapamil, with risk of the appearance of undesirable effects	Take into account	
2484	VERAPAMIL	11170			QUINIDINE	9068			ANSM	538-VERAPAMIL.html	Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia	Not recommended	
2485	VERAPAMIL	11170			SIMVASTATIN	36567			ANSM	538-VERAPAMIL.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	
2486	VERAPAMIL	11170			SIROLIMUS	35302			ANSM	538-VERAPAMIL.html	Increase of the blood concentrations of the sirolimus (decrease of its hepatic metabolism by the verapamil).	Precaution for use	
2487	VERAPAMIL	11170			TACROLIMUS	42316			ANSM	538-VERAPAMIL.html	Increase of the blood concentrations of the tacrolimus (decrease of its hepatic metabolism by the verapamil)	Precaution for use	
2488	VERAPAMIL	11170			TAMSULOSIN	77492			ANSM	538-VERAPAMIL.html	Risk of increase of the undesirable effects of the tamsulosin, due to inhibition of its hepatic metabolism	Precaution for use	
2489	VERAPAMIL	11170			TENOFOVIR ALAFENAMIDE	1721603			ANSM	538-VERAPAMIL.html	Increase of the plasma concentrations of the tenofovir alafenamide due to increase of its absorption	Precaution for use	
2490	VERAPAMIL	11170			TICAGRELOR	1116632			ANSM	538-VERAPAMIL.html	Risk of increase of the plasma concentrations of ticagrelor due to decrease of its hepatic metabolism	Take into account	
2491	VIDARABINE	11194			ALLOPURINOL	519			ANSM	539-VIDARABINE.html	Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral	Not recommended	
2492			ANTICONVULSANT ENZYME INDUCERS	N03A-001	ABIRATERONE	1100072			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Significant decrease of the plasma concentrations of the abiraterone, with risk of lower effectiveness	Not recommended	
2493			ANTICONVULSANT ENZYME INDUCERS	N03A-001	AFATINIB	1430438			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of afatinib due to increase of its metabolism by these substances	Precaution for use	
2494			ANTICONVULSANT ENZYME INDUCERS	N03A-001	ALBENDAZOLE	430			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Large decrease of the plasma concentrations of the albendazole and of its active metabolite by the inducer, with risk of reduction of its effectiveness.	Precaution for use	
2495			ANTICONVULSANT ENZYME INDUCERS	N03A-001			CALCIUM CHANNEL BLOCKERS	CO8CA-001	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism	Not recommended	
2496			ANTICONVULSANT ENZYME INDUCERS	N03A-001			CLASS IA ANTIARRHYTHMICS	C01B-002	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the antiarrhythmic, due to increase of its hepatic metabolism by the inducer.	Precaution for use	
2497			ANTICONVULSANT ENZYME INDUCERS	N03A-001			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer	Precaution for use	
2498			ANTICONVULSANT ENZYME INDUCERS	N03A-001	APIXABAN	1364430			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decreased of the plasma concentrations of the apixaban by the anticonvulsant enzyme inducer, with risk of lower therapeutic effect.	Not recommended	
2499			ANTICONVULSANT ENZYME INDUCERS	N03A-001	APREPITANT	358255			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of very large decrease of the concentrations of aprepitant	Not recommended	
2500			ANTICONVULSANT ENZYME INDUCERS	N03A-001	BOCEPREVIR	1102129			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	
2501			ANTICONVULSANT ENZYME INDUCERS	N03A-001	BOSENTAN	75207			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of decrease of the plasma concentrations of bosentan	Not recommended	
2502			ANTICONVULSANT ENZYME INDUCERS	N03A-001	COBICISTAT	1306284			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer	CONTRAINDICATION	
2503			ANTICONVULSANT ENZYME INDUCERS	N03A-001	DABIGATRAN				ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of dabigatran, with risk of decrease of the therapeutic effect	Not recommended	
2504			ANTICONVULSANT ENZYME INDUCERS	N03A-001	DEFERASIROX	614373			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of decrease of the plasma concentrations of deferasirox	Precaution for use	
2505			ANTICONVULSANT ENZYME INDUCERS	N03A-001	DELAMANID	1344662			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentratioins of delamanid due to increase of its hepatic metabolism by the inducer.	CONTRAINDICATION	
2506			ANTICONVULSANT ENZYME INDUCERS	N03A-001	DOXYCYCLINE	3640			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of the doxycycline due to increase of its hepatic metabolism by the inducer	Precaution for use	
2507			ANTICONVULSANT ENZYME INDUCERS	N03A-001	DRONEDARONE	233698			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Large decrease of the concentrations of dronedarone due to increase of its metabolism, without notable modification of the active metabolite	Not recommended	
2508			ANTICONVULSANT ENZYME INDUCERS	N03A-001			NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the effectiveness of the estrogen .	Precaution for use	
2509			ANTICONVULSANT ENZYME INDUCERS	N03A-001	FENTANYL	4337			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of fentanyl due to increase of its hepatic metabolism by the anticonvulsant	Not recommended	
2510			ANTICONVULSANT ENZYME INDUCERS	N03A-001			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great with patients who have AddisonÂ’s disease treated with hydrocortisone and in cases of organ transplants	Precaution for use	
2511			ANTICONVULSANT ENZYME INDUCERS	N03A-001	HALOPERIDOL	5093			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Clinical monitoring and, if needed, dosage adjustment during the treatment with carbamazepine and after it is stopped.	Precaution for use	
2512			ANTICONVULSANT ENZYME INDUCERS	N03A-001			THYROID HORMONES	H03AA	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of clinically low thyroid in patients with hypothyroidism, due to increase of the metabolism of the T3 and of the T4	Precaution for use	
2513			ANTICONVULSANT ENZYME INDUCERS	N03A-001	IDELALISIB	1544460			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the anticonvulsant enzyme inducer	Not recommended	
2514			ANTICONVULSANT ENZYME INDUCERS	N03A-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of reduction of the effectiveness of the protease inhibitor due to increase of its hepatic metabolism by the inducer	Precaution for use	
2515			ANTICONVULSANT ENZYME INDUCERS	N03A-001			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the tyrosine kinase inhibitor, due to increase of its metabolism by the inducer	Not recommended	
2516			ANTICONVULSANT ENZYME INDUCERS	N03A-001	IVABRADINE	77417			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of decrease of the effectiveness of the ivabradine, due to increase of its metabolism by the inducer	Precaution for use	
2517			ANTICONVULSANT ENZYME INDUCERS	N03A-001	LEDIPASVIR	1591922			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolism by the anticonvulsant enzyme inducer.	CONTRAINDICATION	
2518			ANTICONVULSANT ENZYME INDUCERS	N03A-001	METRONIDAZOLE	6922			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of the metronidazole due to increase of its hepatic metabolism by the inducer	Precaution for use	
2519			ANTICONVULSANT ENZYME INDUCERS	N03A-001	MIDAZOLAM	6960			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of decrease of the plasma concentration of the midazolam by the anticonvulsant	Take into account	
2520			ANTICONVULSANT ENZYME INDUCERS	N03A-001			MINERALOCORTICOIDS	H02AA0	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the corticoids due to increase of their hepatic metabolism by the inducer: the consequences are particularly great in patients with AddisonÂ’s disease treated with the hydrocortisone and in the case of transplants.	Precaution for use	
2521			ANTICONVULSANT ENZYME INDUCERS	N03A-001	MONTELUKAST	88249			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of reduction of the effectiveness of the montelukast due to increase of its hepatic metabolism by the inducer	Precaution for use	
2522			ANTICONVULSANT ENZYME INDUCERS	N03A-001	NIMODIPINE	7426			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of the calcium channel blocker due to increase of its hepatic metabolism by the inducer	Not recommended	
2523			ANTICONVULSANT ENZYME INDUCERS	N03A-001	PERAMPANEL	1356552			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Large decrease (up to two thirds) of the concentrations of perampanel	Take into account	
2524			ANTICONVULSANT ENZYME INDUCERS	N03A-001	POSACONAZOLE	282446			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the posaconazole	Precaution for use	
2525			ANTICONVULSANT ENZYME INDUCERS	N03A-001	PRAZIQUANTEL	8628			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Very large decrease of the plasma concentrations of the praziquantel, with risk of failure of the treatment due to increase of its hepatic metabolism by the inducer	Not recommended	
2526			ANTICONVULSANT ENZYME INDUCERS	N03A-001	PROCARBAZINE	8702			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Increase of the hypersensitivity reactions (hypereosinophilia, rash), due to increase of the metabolism of the procarbazine by the inducer	Take into account	
2527			ANTICONVULSANT ENZYME INDUCERS	N03A-001	PROPAFENONE	8754			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the inducer	Precaution of use	
2528			ANTICONVULSANT ENZYME INDUCERS	N03A-001	QUETIAPINE	51272			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness.	Not recommended	
2529			ANTICONVULSANT ENZYME INDUCERS	N03A-001	QUININE				ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of loss of the effectiveness of the quinine due to increase of its hepatic metabolism by the inducer.	Precaution for use	
2530			ANTICONVULSANT ENZYME INDUCERS	N03A-001	RANOLAZINE	35829			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of large decrease of the concentrations of ranolazine	Not recommended	
2531			ANTICONVULSANT ENZYME INDUCERS	N03A-001	RIVAROXABAN	1114195			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of rivaroxaban, with risk of decrease of the therapeutic effect.	Not recommended	
2532			ANTICONVULSANT ENZYME INDUCERS	N03A-001	STIRIPENTOL	37119			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Increase of the plasma concentrations of the anticonvulsant, with risk of overdose, due to inhibition of its hepatic metabolism by the stiripentol.	Precaution for use	
2533			ANTICONVULSANT ENZYME INDUCERS	N03A-001	TELAPREVIR	1102261			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of very large decrease of the concentrations of telaprevir	CONTRAINDICATION	
2534			ANTICONVULSANT ENZYME INDUCERS	N03A-001	TELITHROMYCIN	274786			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment due to increase of its hepatic metabolism by the inducer	Not recommended	
2535			ANTICONVULSANT ENZYME INDUCERS	N03A-001			THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)	R03DA	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations and of the effectiveness of the theophylline due to increase of its hepatic metabolism by the inducer	Precaution for use	
2536			ANTICONVULSANT ENZYME INDUCERS	N03A-001	TIAGABINE	31914			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the plasma concentrations of the tiagabine due to increase of its hepatic metabolism by the inducer	Precaution for use	
2537			ANTICONVULSANT ENZYME INDUCERS	N03A-001	TICAGRELOR	1116632			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolsim by the anticonvulsant enzyme inducer, with risk of decrease of the therapeutic effect.	Not recommended	
2538			ANTICONVULSANT ENZYME INDUCERS	N03A-001	ULIPRISTAL	1005921			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer	Not recommended	
2539			ANTICONVULSANT ENZYME INDUCERS	N03A-001			VITAMIN D	A11CC	ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	Decrease of the concentrations of vitamin D more marked than in the absence of the inducer.	Precaution for use	
2540			ANTICONVULSANT ENZYME INDUCERS	N03A-001	VORICONAZOLE	121243			ANSM	53-ANTICONVULSANT-ENZYME-INDUCERS.html	-for carbamazipine, phenobarbital, primidone: Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the inducerFor phenytoin, fosphenytoin: Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the phenytoin, for one thing; and increase of the plasma concentrations of the phenytoin due to decrease of its hepatic metabolism by the voriconazole for another thing	Contraindication	
2541			VINCA ALKALOIDS	L01CA	CLARITHROMYCIN	21212			ANSM	540-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the clarithromycin	Precaution for use	
2542			VINCA ALKALOIDS	L01CA	COBICISTAT	1306284			ANSM	540-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic due to decrease of its hepatic metabolism by the cobicistat	Precaution for use	
2543			VINCA ALKALOIDS	L01CA	ERYTHROMYCIN	4053			ANSM	540-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the erythromycin	Precaution for use	
2544			VINCA ALKALOIDS	L01CA			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	540-VINCA-ALKALOIDS.html	Increase of the toxicity of the antimitotic, due to decrease of its hepatic metabolism by the protease inhibitor.	Precaution for use	
2545			VINCA ALKALOIDS	L01CA	ITRACONAZOLE	28031			ANSM	540-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the itraconazole	Not recommended	
2546			VINCA ALKALOIDS	L01CA	KETOCONAZOLE	6135			ANSM	540-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the ketoconazole	Not recommended	
2547			VINCA ALKALOIDS	L01CA	MITOMYCIN C	632			ANSM	540-VINCA-ALKALOIDS.html	Risk of increase of the pulmonary toxicity of the mitomycin and of the vinca alkaloids	Take into account	
2548			VINCA ALKALOIDS	L01CA	POSACONAZOLE	282446			ANSM	540-VINCA-ALKALOIDS.html	Increase of the neurotoxicity of the antimitotic, due to decrease of its hepatic metabolism by the posaconazole	Not recommended	
2549			VINCA ALKALOIDS	L01CA	TELITHROMYCIN	274786			ANSM	540-VINCA-ALKALOIDS.html	Risk of increase of the toxicity of the antimitotic due to decrease of its hepatic metabolism by the telithromycin	Precaution for use	
2550	VISMODEGIB	1242987					ENZYME INDUCERS	N03-J05-001	ANSM	541-VISMODEGIB.html	Risk of decrease of the plasma concentrations of vismodegib due to increase of its hepatic metabolism by the inducer	Not recommended	
2551	VISMODEGIB	1242987			ST JOHNS WORT	258326			ANSM	541-VISMODEGIB.html	Risk of decrease of the plasma concentrations of vismodegib	CONTRAINDICATION	
2552	VITAMIN A	11246					TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	542-VITAMIN-A.html	In case of intake of 10,000 IU/day and more: risk of intracranial hypertension	CONTRAINDICATION	
2553	VITAMIN A	11246					RETINOIDS	D05-D10	ANSM	542-VITAMIN-A.html	Risk of symptoms evocative of hypervitaminosis A	CONTRAINDICATION	
2554			VITAMIN D	A11CC			ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	543-VITAMIN-D.html	Decrease of the concentrations of vitamin D more noticeable than in the absence of the inducer	Precaution for use	
2555			VITAMIN D	A11CC	ORLISTAT	37925			ANSM	543-VITAMIN-D.html	Decrease of the absorption of the vitamin D	Take into account	
2556			VITAMIN D	A11CC	RIFAMPICIN	9384			ANSM	543-VITAMIN-D.html	Decrease of the concentrations of vitamin D more noticeable than in the absence of treatment with the rifampacin	Precaution for use	
2557	VORICONAZOLE	121243			AMIODARONE	703			ANSM	544-VORICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes, due to possible decrease of the metabolism of the amiodarone.	Precaution for use	
2558	VORICONAZOLE	121243					ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	544-VORICONAZOLE.html	--for carbamazepine, phenobarbital, primidone: Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the inducer--for phenytoin, fosphenytoin: Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the phenytoin, for one thing; and increase of the plasma concentrations of the phenytoin due to decrease of its hepatic metabolism by the voriconazole, for another.	Contraindication	
2559	VORICONAZOLE	121243					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	544-VORICONAZOLE.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism	Precaution for use	
2560	VORICONAZOLE	121243					OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ANSM	544-VORICONAZOLE.html	In case of prolonged use by oral or inhaled route:increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the voriconazole, with risk of appearance of CushingÂ’s syndrome even of adrenal insufficiency	Take into account	
2561	VORICONAZOLE	121243			DEXAMETHASONE	3264			ANSM	544-VORICONAZOLE.html	Increase of the plasma concentrations of the dexamthasone due to decrease of its hepatic metabolism by the enzyme inhibitor, with risk of appearance of CushingÂ’s syndrome	Take into account	
2562	VORICONAZOLE	121243			DIHYDROERGOTAMINE	3418			ANSM	544-VORICONAZOLE.html	Ergotism with possibility of necrosis of the extremities (inhibition of the hepatic metabolism of the alkaloid of ergot of rye)	CONTRAINDICATION	
2563	VORICONAZOLE	121243			EFAVIRENZ	195085			ANSM	544-VORICONAZOLE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the efavirenz	Not recommended	
2564	VORICONAZOLE	121243			GLIPIZIDE	4821			ANSM	544-VORICONAZOLE.html	Risk of increase of the plasma concentrations of the glipizide at the origin of potentially severe hypoglycemia	Precaution for use	
2565	VORICONAZOLE	121243					IMMUNOSUPPRESSANTS	L04A	ANSM	544-VORICONAZOLE.html	Increase of the blood concentrations of the immunosuppressant due to inhibition of its hepatic metabolism by the voriconazole.	Not recommended	
2566	VORICONAZOLE	121243					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	544-VORICONAZOLE.html	Very large reduction of the concentrations of the antifungal due to increase of its metabolism by the ritonavir, with risk of failure of the treatment	Not recommended	
2567	VORICONAZOLE	121243			ST JOHNS WORT	258326			ANSM	544-VORICONAZOLE.html	Significant reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect	CONTRAINDICATION	
2568	VORICONAZOLE	121243			NEVIRAPINE	53654			ANSM	544-VORICONAZOLE.html	Risk of reduction of the effectiveness of the voriconazole due to increase of its hepatic metabolism by the nevirapine	Not recommended	
2569	VORICONAZOLE	121243			QUINIDINE	9068			ANSM	544-VORICONAZOLE.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
2570	VORICONAZOLE	121243			RIFABUTIN	55672			ANSM	544-VORICONAZOLE.html	Decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifabutin for one thing, and risk of increase of the undesirable effects (uveitis) of the rifabutin for another.	Not recommended	
2571	VORICONAZOLE	121243			RIFAMPICIN	9384			ANSM	544-VORICONAZOLE.html	Large decrease of the plasma concentrations of the voriconazole with risk of loss of effectiveness, due to increase of its hepatic metabolism by the rifampicin	CONTRAINDICATION	
2572	VORICONAZOLE	121243			SIMVASTATIN	36567			ANSM	544-VORICONAZOLE.html	Increased risk of undesirable effects (concentration dependent) of the rhabdomyolysis type due to decrease of the hepatic metabolism of the simvastatin	CONTRAINDICATION	
2573	VORICONAZOLE	121243			VENLAFAXINE	39786			ANSM	544-VORICONAZOLE.html	Increase of the concentrations of venlafaxine with risk of overdose.	Take into account	
2574	VORTIOXETINE	1455099			CINACALCET	407990			ANSM	545-VORTIOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	
2575	VORTIOXETINE	1455099			FLUOXETINE	4493			ANSM	545-VORTIOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine by decrease of its hepatic metabolism	Precaution for use	
2576	VORTIOXETINE	1455099					ENZYMATIC INDUCERS	N03-J05-001	ANSM	545-VORTIOXETINE.html	Reduction of the plasma concentrations of the vortioxetine	Precaution for use	
2577	VORTIOXETINE	1455099			PAROXETINE	32937			ANSM	545-VORTIOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	
2578	VORTIOXETINE	1455099			QUINIDINE	9068			ANSM	545-VORTIOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	
2579	VORTIOXETINE	1455099			TERBINAFINE	37801			ANSM	545-VORTIOXETINE.html	Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism	Precaution for use	
2580	YOHIMBINE	220982			CLONIDINE	2599			ANSM	546-YOHIMBINE.html	Possible inhibition of the antihypertensive activity due to antagonism at the level of the receptors	Not recommended	
2581	ZALCITABINE	3363			DIDANOSINE	3364			ANSM	547-ZALCITABINE.html	Increased risk of onset of pancreatitis and of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
2582	ZALCITABINE	3363			GANCICLOVIR	4678			ANSM	547-ZALCITABINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
2583	ZALCITABINE	3363			LAMIVUDINE	68244			ANSM	547-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
2584	ZALCITABINE	3363			PENTAMIDINE	7994			ANSM	547-ZALCITABINE.html	Increased risk of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
2585	ZALCITABINE	3363			STAVUDINE	59763			ANSM	547-ZALCITABINE.html	Risk of decrease of the effectiveness of each antiviral, due to inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
2586	ZALCITABINE	3363			THALIDOMIDE	10432			ANSM	547-ZALCITABINE.html	Increased risk of onset of peripheral neuropathy due to addition of undesirable effects	Precaution for use	
2587	ZIDOVUDINE	11413			AMPHOTERICIN B	732			ANSM	548-ZIDOVUDINE.html	With the amphotericin B administered intravenously:increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	
2588	ZIDOVUDINE	11413			DAPSONE	3108			ANSM	548-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	
2589	ZIDOVUDINE	11413			FLUCYTOSINE	4451			ANSM	548-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	
2590	ZIDOVUDINE	11413			GANCICLOVIR	4678			ANSM	548-ZIDOVUDINE.html	Increase of the hematological toxicity (addition of effects of bone marrow toxicity)	Precaution for use	
2591	ZIDOVUDINE	11413			RIBAVIRIN	9344			ANSM	548-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Precaution for use	
2592	ZIDOVUDINE	11413			STAVUDINE	59763			ANSM	548-ZIDOVUDINE.html	Risk of decrease of the effectiveness of each antiviral, due to reciprocal inhibition of the phosphorylation reaction at the origin of the active metabolites	Not recommended	
2593	ZIDOVUDINE	11413					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	548-ZIDOVUDINE.html	Risk of increase of the undesirable effects, especially hematological ones, of the zidovudine due to decrease of its metabolism by the valproic acid	Precaution for use	
2594	ZINC	1431163			CALCIUM	1428011			ANSM	549-ZINC.html	Decrease of the digestive absorption of the zinc by the calcium	Precaution for use	
2595	ZINC	1431163					TETRACYCLINE ANTIBIOTICS	J01AA	ANSM	549-ZINC.html	Decrease of the digestive absorption of the tetracycline antibiotics	Precaution for use	
2596	ZINC	1431163			IRON	1431589			ANSM	549-ZINC.html	Decrease of the digestive absorption of the zinc by the iron	Precaution for use	
2597	ZINC	1431163					FLUOROQUINOLONES	J01MA-001	ANSM	549-ZINC.html	Decrease of the digestive absorption of the fluoroquinolones	Precaution for use	
2598	ZINC	1431163			STRONTIUM	81638			ANSM	549-ZINC.html	Decease of the digestive absorption of the strontium	Precaution for use	
2599			METABOLIZED ANTICONVULSANTS	N03A-002	ST JOHNS WORT				ANSM	54-METABOLIZED-ANTICONVULSANTS.html	Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant.	CONTRAINDICATION	
2600	ZOLPIDEM	39993					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	550-ZOLPIDEM.html	Slight increase of the sedative effect of the zolpidem	Take into account	
2601	ZOLPIDEM	39993			RIFAMPICIN	9384			ANSM	550-ZOLPIDEM.html	Decrease of the plasma concentrations and of the effectiveness of the zolpidem due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
2602	ZONISAMIDE						VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	551-ZONISAMIDE.html	Increase of the hyperammonemia, with increased risk of encephalopathy	Precaution for use	
2603	ZOPICLONE	40001					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	552-ZOPICLONE.html	Slight increase of the sedative effect of the zopiclone	Take into account	
2604	ZOPICLONE	40001			RIFAMPICIN	9384			ANSM	552-ZOPICLONE.html	Decrease of the plasma concentrations and of the effectiveness of the zopiclone due to increase of its hepatic metabolism by the rifampicin	Precaution for use	
2605			MONOCLONAL ANTIBODIES (EXCEPT ANTI-TNF ALPHA)	MONANT			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	55-MONOCLONAL-ANTIBODIES-(EXCEPT-ANTI-TNF-ALPHA).html	Risk of general vaccine disease, possibly fatal.	Not recommended with:	
2606			TRICYCLIC ANTIDEPRESSANTS	N06AA-001			ADRENALINE (ORAL-DENTAL OR SUB-CUTANEOUS)	A01AD	ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Serious ventricular arrhythmias due to increased cardiac sensitization.	Precaution for use	
2607			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	BACLOFEN	1292			ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Risk of increase of the muscular hypotonia.	Take into account	
2608			TRICYCLIC ANTIDEPRESSANTS	N06AA-001			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)	Take into account	
2609			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	CLONIDINE	2599			ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Described for desipramine, imipramine:inhibition of the antihypertensive effect of the clonidine (antagonism at the level of the adrenergic receptors)	Not recommended	
2610			TRICYCLIC ANTIDEPRESSANTS	N06AA-001			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Increase of the plasma concentrations of the tricyclic antidepressant with risk of convulsions and increase of the undesirable effects	Precaution for use	
2611			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ORLISTAT	37925			ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Risk of therapeutic failure in cases of concomitant treatment with orlistat	Take into account	
2612			TRICYCLIC ANTIDEPRESSANTS	N06AA-001			ALPHA AND BETA SYMPATHOMIMETICS (IM AND IV ROUTES)	C01CA	ANSM	56-TRICYCLIC-ANTIDEPRESSANTS.html	Paroxysmal hypertension with the possibility of arrhythmia (inhibition of the entry of the sympathomimetic into the sympathic fiber)	Not recommended	
2613			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001	ANSM	57-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Risk of severe orthostatic hypotension	Not recommended	
2614			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001			ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001	ANSM	57-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Greater risk of orthostatic hypotension.	Take into account	
2615			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001			TYPE 5 PHOSPHODIESTERASE INHIBITORS	G04BE	ANSM	57-ANTIHYPERTENSIVE-ALPHA-BLOCKERS.html	Risk of orthostatic hypotension, especially with older patients	Not recommended	
2616			CENTRAL ANTIHYPERTENSIVES	C02AC-001			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	58-CENTRAL-ANTIHYPERTENSIVES.html	Large increase of blood pressure in cases of sudden termination of the treatment with the central antihypertensive	Precaution for use	
2617			CENTRAL ANTIHYPERTENSIVES	C02AC-001			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	ANSM	58-CENTRAL-ANTIHYPERTENSIVES.html	Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in case of heart failure treated with a beta-blocking agent and vasodilator	Not recommended	
2618			ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001			ALPHA BLOCKERS FOR UROLOGICAL USE	G04CA-001	ANSM	59-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Greater risk of orthostatic hypotension	Take into account	
2619			ANTIHYPERTENSIVES EXCEPT ALPHA BLOCKERS	C0-001			ANTIHYPERTENSIVE ALPHA BLOCKERS	C02CA0-001	ANSM	59-ANTIHYPERTENSIVES-EXCEPT-ALPHA-BLOCKERS.html	Increase of the hypotensive effect. Greater risk of orthostatic hypotension	Take into account	
2620	ACETYLSALICYLIC ACID	1191			ACETAZOLAMIDE	167			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the undesirable effects, and especially of metabolic acidosis, of the acetylsalicylic acid in large doses and of the acetazolamide, due to decrease of the elimination of the acetylsalicylic acid by the acetazolamide	Not recommended	
2621	ACETYLSALICYLIC ACID	1191			ANAGRELIDE	596724			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of hemorrhagic events	Not recommended	
2622	ACETYLSALICYLIC ACID	1191					ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory dosages of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500mg by dose and/or <3g per day):Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	
2623	ACETYLSALICYLIC ACID	1191					ORAL ANTICOAGULANTS	B01A-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage, especially in cases with a previous gastro duodenal ulcer.	Contraindication with:	
2624	ACETYLSALICYLIC ACID	1191					NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of digestive system ulceration and hemorrhage.	Not recommended	
2625	ACETYLSALICYLIC ACID	1191			CLOPIDOGREL	32968			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet aggregation activities.	Not recommended	
2626	ACETYLSALICYLIC ACID	1191			DEFERASIROX	614373			ANSM	5-ACETYLSALICYLIC-ACID.html	With anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 g per day):increase of the risk of digestive ulceration and hemorrhage	Take into account	
2627	ACETYLSALICYLIC ACID	1191					DIURETICS	C0E-001	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 g per day):Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	
2628	ACETYLSALICYLIC ACID	1191					GLUCOCORTICOIDS (EXCEPT FOR HYDROCORTISONE)	A0-H0-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Not recommended	
2629	ACETYLSALICYLIC ACID	1191					LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastro duodenal mucosa by the acetylsalicylic acid)	Not recommended	
2630	ACETYLSALICYLIC ACID	1191					LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.	Take into account	
2631	ACETYLSALICYLIC ACID	1191			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)				ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastro duodenal mucosa by the acetylsalicylic acid)	Not recommended	
2632	ACETYLSALICYLIC ACID	1191			UNFRACTIONATED HEPARIN (PREVENTIVE DOSES)				ANSM	5-ACETYLSALICYLIC-ACID.html	The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring	Take into account	
2633	ACETYLSALICYLIC ACID	1191					ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	5-ACETYLSALICYLIC-ACID.html	For anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day) or for analgesic or antipyretic doses (>=500 mg per dose and/or <3 g per day):Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.	Precaution for use	
2634	ACETYLSALICYLIC ACID	1191					SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)	N06AB	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
2635	ACETYLSALICYLIC ACID	1191			METHOTREXATE	6851			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the toxicity, especially hematological, of the methotrexate (decrease of its renal clearance by the acetylsalicylic acid)	With doses of methotrexate > 20 mg/week	
2636	ACETYLSALICYLIC ACID	1191			PEMETREXED	68446			ANSM	5-ACETYLSALICYLIC-ACID.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).	Not Recommended	
2637	ACETYLSALICYLIC ACID	1191			PROBENECID	8698			ANSM	5-ACETYLSALICYLIC-ACID.html	Decrease of the uricosuric effect due to competition of the elimination of the uric acid at the level of the renal tubules	Not recommended	
2638	ACETYLSALICYLIC ACID	1191					THROMBOLYTICS	B01AD	ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage	Take into account	
2639	ACETYLSALICYLIC ACID	1191			TICAGRELOR	1116632			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation actions	Not recommended	
2640	ACETYLSALICYLIC ACID	1191			TICLOPIDINE	10594			ANSM	5-ACETYLSALICYLIC-ACID.html	Increase of the risk of hemorrhage due to addition of the platelet antiagregation actions	Not recommended	
2641			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			OTHER NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	With the other non steroidal anti-inflammatory drugs: increase of the risk of causing ulcers and digestive hemorrhage	Not recommended	
2642			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ACETYLSALICYLIC ACID	1191			ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of digestive system ulceration and hemorrhage	Not recommended with	
2643			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)	C09CA0-001	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Acute renal insufficiency with patients at risk (older patient, dehydration, treatment with diuretics, changes in renal function), due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the non-steroidal anti-inflammatories). These effects are generally reversible. In addition, reduction of the antihypertensive effect.	Precaution for use	
2644			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			ORAL ANTICOAGULANTS	B01A-001	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the oral anticoagulantÂ’s risk of hemorrhage (irritation of the gastroduodenal mucosa by the non-steroidal anti-inflammatories)	Not recommended	
2645			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Reduction of the antihypertensive effect (inhibition of the vasodilating prostaglandins by the non steroidal anti-inflammatories	Take into account	
2646			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	CICLOSPORIN	3008			ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of addition of the nephrotoxic effects, especially with older patients.	Precaution for use	
2647			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	DEFERASIROX	614373			ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
2648			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			DIURETICS	C0E-001	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Acute renal insufficiency with the patient at risk (older patient and/or dehydrated one) due to decrease of the glomerular filtration (inhibition of the vasodilator prostaglandins due to the NSAIs). Furthermore, reduction of the antihypertensive effect	Precaution for use	
2649			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)	A0-H0-001	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of ulceration and of gastrointestinal hemorrhage	Take into account	
2650			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-001	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	
2651			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES)	B01AB-002	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage	Take into account	
2652			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)	B01AB-003	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage (irritation of the gastroduodenal mucosa by the NSAIs)	Not recommended	
2653			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			UNFRACTIONATED-HEPARIN-(PREVENTIVE-DOSES)	B01AB-004	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage	Take into account	
2654			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)	C09AA	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Acute renal insufficiency with patients at risk (older patients, dehydrated ones, those taking diuretics, those with altered renal function) due to decrease of the glomerular filtration (inhibition of the vasodilating prostaglandins due to the NSAIs). These effects are generally reversible. Furthermore, reduction of the antihypertensive effect.	Precaution for use	
2655			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002			SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSR1s)	NO6AB	ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrhage	Take into account	
2656			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	LITHIUM	6448			ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the plasma concentrations of lithium that can reach toxic values (decrease of the renal excretion of the lithium)	Not recommended	
2657			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	METHOTREXATE	6851			ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the hematological toxicity of the methotrexate (decrease of the renal clearance of the methotrexate by the NSAIs).	Not recommended	
2658			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	PEMETREXED	68446			ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the NSAIs)	Not recommended	
2659			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	PENTOXIFYLLINE	8013			ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Increase of the risk of hemorrage	Take into account	
2660			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	TACROLIMUS	42316			ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of addition of the nephrotoxic effects, especially with older patients	Precaution for use	
2661			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	TENOFOVIR DISOPROXIL	300195			ANSM	60-NON-STEROIDAL-ANTI-INFLAMMATORY-DRUGS.html	Risk of increase of the nephrotoxicity of the tenofovir, especially with large doses of the anti-inflammatory or in the presence of factors of risk of renal insufficiency	Precaution for use	
2662			ANTIPARASITICS THAT TEND TO INDUCE TORSADES DE POINTES	P01B-001			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	61-ANTIPARASITICS-THAT-TEND-TO-INDUCE-TORSADES-DE-POINTES.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	Contraindication	
2663			ANTIPARKINSONIAN ANTICHOLINERGICS	N04AA-001			DOPAMINERGIC ALKALOIDS OF ERGOT OF RYE	G02CB-001	ANSM	62-ANTIPARKINSONIAN-ANTICHOLINERGICS.html	Risk of increase of neuropsychological disorders.	Precaution for use	
2664			ANTIPARKINSONIAN DOPAMINERGICS	N04B-001			ANTIPSYCHOTIC NEUROLEPTICS (EXCEPT CLOZAPINE)	N05A-001	ANSM	63-ANTIPARKINSONIAN-DOPAMINERGICS.html	Reciprocal antagonism of the dopaminergic and the neuroleptics. The dopaminergic can cause or aggravate the psychotic disorders. When a treatment with neuroleptics is necessary for a Parkinsons patient treated with dopaminergics, these latter must be decreased progressively until they are stopped (their abrupt discontinuation exposes the patient to a risk of "neuroleptic malignant syndrome" (NMS)).	Not recommended	
2665			ANTIPURINES	ANTIPUR			VITAMIN K ANTAGONISTS	B01AA-001	ANSM	64-ANTIPURINES.html	Decrease of the effect of the Vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	
2666			ANTIPURINES	ANTIPUR			DERIVATIVES OF AMINOSALICYLIC ACID (ASA)	A07EC-001	ANSM	64-ANTIPURINES.html	Risk of increase of the myelotoxicity of the immunoinhibitor, by inhibition of its hepatic metabolism by the ASA derivative, especially with patients presenting a partial deficit of thiopurine methyltransferase (TPMT)	Take into account	
2667			ANTIPURINES	ANTIPUR			XANTHINE OXYDASE INHIBITORS	M04AA0	ANSM	64-ANTIPURINES.html	Possibly serious medullary insufficiency	CONTRAINDICATION	
2668			ANTIPURINES	ANTIPUR	RIBAVIRIN	9344			ANSM	64-ANTIPURINES.html	Increased risks of serious undesirable effects, due to inhibition of the metabolism of the immunoinhibitor by the ribavirin	Not recommended	
2669			H2 RECEPTOR ANTAGONISTS	A02BA-001	ATAZANAVIR	343047			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the plasma concentrations of the atazanavir	Take into account	
2670			H2 RECEPTOR ANTAGONISTS	A02BA-001	CYANOCOBALAMIN	11248			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of vitamin B12	Take into account	
2671			H2 RECEPTOR ANTAGONISTS	A02BA-001			METABOLIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the bioavailabilty of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption	Take into account	
2672			H2 RECEPTOR ANTAGONISTS	A02BA-001	ITRACONAZOLE	28031			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
2673			H2 RECEPTOR ANTAGONISTS	A02BA-001	KETOCONAZOLE	6135			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
2674			H2 RECEPTOR ANTAGONISTS	A02BA-001	POSACONAZOLE	282446			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Not recommended	
2675			H2 RECEPTOR ANTAGONISTS	A02BA-001	RILPIVIRINE	1102270			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the plasma concentrations of the rilpivirine	Take into account	
2676			H2 RECEPTOR ANTAGONISTS	A02BA-001	ULIPRISTAL	1005921			ANSM	65-H2-RECEPTOR-ANTAGONISTS.html	Risk of decrease of the effect of the ulipristal due to decrease of its absorption	Take into account	
2677			PROTON PUMP INHIBITORS	A02BC-001	ATAZANAVIR	343047			ANSM	66-PROTON-PUMP-INHIBITORS.html	Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure	Not recommended	
2678			PROTON PUMP INHIBITORS	A02BC-001	CYANOCOBALAMIN	11248			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of deficiency of cyanocobalamin after prolonged treatment (several years), the reduction of gastric acidity by these medications can diminish the digestive absorption of the vitamin B12.	Take into account	
2679			PROTON PUMP INHIBITORS	A02BC-001			METABLOIZED TYROSINE-KINASE INHIBITORS	L01XE	ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of decrease of the bioavailability of the tyrosine kinase inhibitor, by reason of its pH-dependent absorption	Take into account	
2680			PROTON PUMP INHIBITORS	A02BC-001	ITRACONAZOLE	28031			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal due to increase of the gastric pH by the antisecretory	Take into account	
2681			PROTON PUMP INHIBITORS	A02BC-001	KETOCONAZOLE	6135			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal due to increase of the intragastric pH by the antisecretory	Take into account	
2682			PROTON PUMP INHIBITORS	A02BC-001	LEDIPASVIR	1591922			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of ledipasvir when the proton pump inhibitor is administered before the ledipasvir	Precaution for use	
2683			PROTON PUMP INHIBITORS	A02BC-001	METHOTREXATE	6851			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of increase of the toxicity of the methotrexate due to decrease of its elimination	Not recommended	
2684			PROTON PUMP INHIBITORS	A02BC-001	ST JOHN'S WORT	258326			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of ineffectiveness of the treatment by the antisecretory due to increase of its metabolism by the St Johns wort	Take into account	
2685			PROTON PUMP INHIBITORS	A02BC-001	MYCOPHENOLATE MOFETIL				ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the concentrations of the mycophenolic acid by about a third, with potential risk of reduction of effectiveness	Take into account	
2686			PROTON PUMP INHIBITORS	A02BC-001	POSACONAZOLE	282446			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the absorption of the azole antifungal, due to increase of the intragastric pH by the antisecretory	Not recommended	
2687			PROTON PUMP INHIBITORS	A02BC-001	RILPIVIRINE	1102270			ANSM	66-PROTON-PUMP-INHIBITORS.html	Decrease of the plasma concentrations of rilpivirine by the proton pump inhibitor (decreased absorption due to the increase of the gastric pH).	CONTRAINDICATION	
2688			PROTON PUMP INHIBITORS	A02BC-001	ULIPRISTAL	1005921			ANSM	66-PROTON-PUMP-INHIBITORS.html	Risk of decrease of the effect of the ulipristal, due to decrease of its absorption	Take into account	
2689			MERCURIAL ANTISEPTICS	D08AK0	POVIDONE-IODINE	8611			ANSM	67-MERCURIAL-ANTISEPTICS.html	Erythema, blisters, even necrosis of skin and mucosa (formation of a caustic complex in the case of concomitant use of mercurials and iodine antiseptics). The interaction depends on the stability of the organo-mercurial at the cutaneous level and on individual sensitivity.	Not recommended	
2690			URINARY ANTISPASMODICS	DFST			STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	68-URINARY-ANTISPASMODICS.html	Risk of increase of undesirable effects	Contraindication	
2691			ANTI-TNF ALPHA	LO4AB	ABATACEPT	614391			ANSM	69-ANTI-TNF-ALPHA.html	Increase of the immunodepression	Not recommended	
2692			ANTI-TNF ALPHA	LO4AB	ANAKINRA	72435			ANSM	69-ANTI-TNF-ALPHA.html	Increased risk of serious infections and neutropenia	Not recommended	
2693			ANTI-TNF ALPHA	LO4AB	CANAKINUMAB	853491			ANSM	69-ANTI-TNF-ALPHA.html	Risk of increase of serious infections	Not recommended	
2694			ANTI-TNF ALPHA	LO4AB			ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	69-ANTI-TNF-ALPHA.html	Risk of general vaccine disease possibly fatal	CONTRAINDICATION	
2695	ASCORBIC ACID	1151			DEFEROXAMINE	3131			ANSM	6-ASCORBIC-ACID.html	With large doses of ascorbic acid and by intravenous route: cardiac function anomalies, even acute heart failure (generally reversible by ending the administration of the Vitamin C).	Precaution for use	
2696			MORPHINE LIKE ANTITUSSIVES	R05DA0-001			AGONIST OPIOID ANALGESICS	N01A-N02A	ANSM	70-MORPHINE-LIKE-ANTITUSSIVES.html	Increased risk of respiratory depression, which can be fatal in cases of overdose	Take into account	
2697			MORPHINE LIKE ANTITUSSIVES	R05DA0-001	METHADONE	6813			ANSM	70-MORPHINE-LIKE-ANTITUSSIVES.html	Increased risk of respiratory depression, which can be fatal in cases of overdose	Take into account	
2698			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002			AGONIST OPIOID ANALGESICS	N01A-N02A	ANSM	71-TRUE-MORPHINE-ANTITUSSIVES.html	Increased risk of respiratory depression which can be fatal in cases of overdose	Take into account	
2699			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002	METHADONE	6813			ANSM	71-TRUE-MORPHINE-ANTITUSSIVES.html	Increased risk of respiratory depression which can be fatal in case of overdose	Take into account	
2700			TRUE MORPHINE ANTITUSSIVES	R0GDA0-002			AGONIST-ANTAGONIST OPIOIDS	NO2A-001	ANSM	71-TRUE-MORPHINE-ANTITUSSIVES.html	Decrease of the antalgic or antitussive effect of the opioid, due to competitive blocking of the receptors, with risk of appearance of a withdrawal syndrome	Not recommended	
2701			VITAMIN K ANTAGONISTS	B01AA-001	ALCOHOL (DRINK OR INGREDIENT)				ANSM	72-VITAMIN-K;ANTAGONISTS.html	Possible variations of the anticoagulating effect, with increase in case of acute intoxication or decrease in case of chronic alcoholism (increased metabolism)	Take into account	
2702			VITAMIN K ANTAGONISTS	B01AA-001	ALLOPURINOL	519			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	
2703			VITAMIN K ANTAGONISTS	B01AA-001	ALPHA-TOCOPHEROL	11256			ANSM	72-VITAMIN-K;ANTAGONISTS.html	With the vitamin E used in doses greater than or equal to 500 mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2704			VITAMIN K ANTAGONISTS	B01AA-001	AMINOGLUTETHIMIDE	677			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Described for warfarin and acenocoumarol.Decrease of the effect of the vitamin K antagonist, due to increase of its hepatic metabolism by the aminoglutethimide	Precaution for use	
2705			VITAMIN K ANTAGONISTS	B01AA-001	AMIODARONE	703			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2706			VITAMIN K ANTAGONISTS	B01AA-001			ANDROGENS	A14AA0	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the risk of hemorrhage due to direct effect on the coagulation and/or the fibrinolytic systems	Precaution for use	
2707			VITAMIN K ANTAGONISTS	B01AA-001			ANTICONVULSANT ENZYME INDUCERS	N03A-001	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Decrease (or, infrequently, increase with the phenytoin) of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the anticonvulsant inducer	Precaution for use	
2708			VITAMIN K ANTAGONISTS	B01AA-001			ANTIPURINES	ANTIPUR	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Decrease of the effect of the Vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	
2709			VITAMIN K ANTAGONISTS	B01AA-001	APREPITANT	358255			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant	Precaution for use	
2710			VITAMIN K ANTAGONISTS	B01AA-001	BOSENTAN	75207			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	
2711			VITAMIN K ANTAGONISTS	B01AA-001	CEFAMANDOLE	2178			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2712			VITAMIN K ANTAGONISTS	B01AA-001	CEFOPERAZONE	2184			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2713			VITAMIN K ANTAGONISTS	B01AA-001	CEFOTETAN	2184			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution of use	
2714			VITAMIN K ANTAGONISTS	B01AA-001	CEFTRIAXONE	2193			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2715			VITAMIN K ANTAGONISTS	B01AA-001	CIMETIDINE	2541			ANSM	72-VITAMIN-K;ANTAGONISTS.html	With the cimetidine used in doses greater than or equal to 800mg/day: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)	Precaution for use	
2716			VITAMIN K ANTAGONISTS	B01AA-001	CLINDAMYCIN	2582			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2717			VITAMIN K ANTAGONISTS	B01AA-001	COLCHICINE	2683			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2718			VITAMIN K ANTAGONISTS	B01AA-001			TETRACYCLINE ANTIBIOTICS	D06AA-J01AA	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2719			VITAMIN K ANTAGONISTS	B01AA-001			CYTOTOXICS	L01	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the risk of thrombosis and hemorrhage accompanying tumors. In addition, possible interaction between the vitamin K antagonist and the chemotherapy	Precaution for use	
2720			VITAMIN K ANTAGONISTS	B01AA-001	DANAZOL	3102			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the risk of hemorrhage due to direct effect on coagulation and/or the fibrinolytic systems.	Precaution for use	
2721			VITAMIN K ANTAGONISTS	B01AA-001	DEFERASIROX	614373			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the risk of causing ulcers and digestive hemorrhage	Take into account	
2722			VITAMIN K ANTAGONISTS	B01AA-001	DISULFIRAM	3554			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2723			VITAMIN K ANTAGONISTS	B01AA-001	DRONEDARONE	233698			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2724			VITAMIN K ANTAGONISTS	B01AA-001	ECONAZOLE	3743			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Regardless of the route of administration of the econazole:increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2725			VITAMIN K ANTAGONISTS	B01AA-001	EFAVIRENZ	195085			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	
2726			VITAMIN K ANTAGONISTS	B01AA-001			FIBRATES	C01AB-001	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2727			VITAMIN K ANTAGONISTS	B01AA-001	FLUCONAZOLE	4450			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2728			VITAMIN K ANTAGONISTS	B01AA-001			FLUOROQUINOLONES	J01MA-001	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2729			VITAMIN K ANTAGONISTS	B01AA-001			FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	
2730			VITAMIN K ANTAGONISTS	B01AA-001	GLUCOSAMINE	4845			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the risk of hemorrhage	Precaution for use	
2731			VITAMIN K ANTAGONISTS	B01AA-001	GRISEOFULVINE	5021			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the griseofulvine	Precaution for use	
2732			VITAMIN K ANTAGONISTS	B01AA-001			UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENT)	B01AB-003	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the risk of hemorrhage	Precaution for use	
2733			VITAMIN K ANTAGONISTS	B01AA-001	IMATINIB	282388			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the risk of hemorrhage	Not recommended	
2734			VITAMIN K ANTAGONISTS	B01AA-001			HMG-COA REDUCTASE INHIBITORS (STATINS)	C10AA	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2735			VITAMIN K ANTAGONISTS	B01AA-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Variation of the effect of the vitamin K antagonist, most often by decreasing it	Precaution for use	
2736			VITAMIN K ANTAGONISTS	B01AA-001	ITRACONAZOLE	28031			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2737			VITAMIN K ANTAGONISTS	B01AA-001	LEVOCARNITINE	42955			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2738			VITAMIN K ANTAGONISTS	B01AA-001			MACROLIDES (EXCEPT SPIRAMYCIN)	J01FA	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2739			VITAMIN K ANTAGONISTS	B01AA-001	METHYLPREDNISOLONE				ANSM	72-VITAMIN-K;ANTAGONISTS.html	For doses of 0.5g to 1g of methylprednisolone administered in bolus: increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2740			VITAMIN K ANTAGONISTS	B01AA-001	MICONAZOLE	6932			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Unpredictable hemorrhage, possibly serious	CONTRAINDICATION	
2741			VITAMIN K ANTAGONISTS	B01AA-001	ST JOHN'S WORT	258326			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzyme inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have serious consequences (thrombolitic event)	CONTRAINDICATION	
2742			VITAMIN K ANTAGONISTS	B01AA-001	NEVIRAPINE	53654			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	
2743			VITAMIN K ANTAGONISTS	B01AA-001	NOSCAPINE	7533			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	
2744			VITAMIN K ANTAGONISTS	B01AA-001	ORLISTAT	37925			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2745			VITAMIN K ANTAGONISTS	B01AA-001	PARACETAMOL	161			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage when taking paracetamol in maximal doses (4g/day) for at least 4 days	Precaution for use	
2746			VITAMIN K ANTAGONISTS	B01AA-001	PENTOXIFYLLINE	8013			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the risk of hemorrhage	Precaution for use	
2747			VITAMIN K ANTAGONISTS	B01AA-001	PRISTINAMYCIN	66958			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2748			VITAMIN K ANTAGONISTS	B01AA-001	PROGUANIL	2382			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2749			VITAMIN K ANTAGONISTS	B01AA-001	PROPAFENONE	8754			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the anticoagulant effect and of the risk of hemorrhage. Mecanism proposed: inhibition of the metabolism of the vitamin K antagonist	Precaution for use	
2750			VITAMIN K ANTAGONISTS	B01AA-001	RIFAMPICIN	9384			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the rifampicin.	Precaution for use	
2751			VITAMIN K ANTAGONISTS	B01AA-001	ROPINIROLE	72302			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the risk of hemorrhage	Precaution for use	
2752			VITAMIN K ANTAGONISTS	B01AA-001	SUCRALFATE	10156			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Decrease of the digestive absorption of the vitamin K antagonist	Precaution for use	
2753			VITAMIN K ANTAGONISTS	B01AA-001	SULFAFURAZOLE	10207			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2754			VITAMIN K ANTAGONISTS	B01AA-001	SULFAMETHIZOLE	10179			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2755			VITAMIN K ANTAGONISTS	B01AA-001	SULFAMETHOXAZOLE	10180			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Large increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Not recommended	
2756			VITAMIN K ANTAGONISTS	B01AA-001	TAMOXIFEN	10324			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2757			VITAMIN K ANTAGONISTS	B01AA-001			THROMBOLYTICS	B01AD	ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the risk of hemorrhage	Take into account	
2758			VITAMIN K ANTAGONISTS	B01AA-001	TIBOLONE	38260			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2759			VITAMIN K ANTAGONISTS	B01AA-001	TRAMADOL	10689			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Risk of increase of the effect of the vitamin K antagonist and of the risk of hemorrhage	Precaution for use	
2760			VITAMIN K ANTAGONISTS	B01AA-001	VORICONAZOLE	121243			ANSM	72-VITAMIN-K;ANTAGONISTS.html	Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage due to decrease of its hepatic metabolism	Precaution for use	
2761	APIXABAN	1364430					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	73-APIXABAN.html	Decrease of the plasma concentrations of the apixaban by the anticonvulsant enzymatic inducer, with risk of decrease of the therapeutic effect.	Not recommended	
2762	APIXABAN	1364430			FLUCONAZOLE	4450			ANSM	73-APIXABAN.html	Increase of the plasma concentrations of the apixiban by the fluconazole, with increase of the risk of bleeding	Not recommended	
2763	APIXABAN	1364430					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	73-APIXABAN.html	Increase of the plasma concentrations of the apixaban by the inhibitor, with increase of the risk of bleeding.	Not recommended	
2764	APIXABAN	1364430			RIFAMPICIN	9384			ANSM	73-APIXABAN.html	Decrease of the plasma concentrations of the apixaban by the rifampicin, with risk of decrease of the therapeutic effect.	Not recommended	
2765	APOMORPHINE	1043			ONDANSETRON	26225			ANSM	74-APOMORPHINE.html	Severe hypotension and loss of consciousness have been reported when ondansetron and apomorphine were taken together.	CONTRAINDICATION	
2766	APREPITANT	358255					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	75-APREPITANT.html	Risk of very large decrease of the concentrations of aprepitant	Not recommended	
2767	APREPITANT	358255					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	75-APREPITANT.html	Risk of decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism by the aprepitant	Precaution for use	
2768	APREPITANT	358255			CYPROTERONE	3014			ANSM	75-APREPITANT.html	Risk of decrease of the concentrations of the cyproterone with risk of lower contraceptive effectiveness	Precaution for use	
2769	APREPITANT	358255					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	75-APREPITANT.html	Decrease of the concentrations of the estrogen-progestin or of the progestin, with risk of lower contraceptive effectiveness.	Precaution for use	
2770	APREPITANT	358255			IFOSFAMIDE	5657			ANSM	75-APREPITANT.html	Risk of increase of the neurotoxicity of the ifosfamide	Take into account	
2771	APREPITANT	358255			ITRACONAZOLE	28031			ANSM	75-APREPITANT.html	Increase of the concentrations of aprepitant due to decrease of its hepatic metabolism by the itraconazole.	Take into account	
2772	APREPITANT	358255			PIMOZIDE	8331			ANSM	75-APREPITANT.html	Increased risk of ventricular arrhythmias, especially of torsades de pointes	CONTRAINDICATION	
2773	APREPITANT	358255					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	75-APREPITANT.html	(Except for IUD), decrease of the concentrations of progestin, with risk of lower contraceptive effectiveness.	Precaution for use	
2774	APREPITANT	358255			RIFAMPICIN	9384			ANSM	75-APREPITANT.html	Very large decrease of the concentrations of aprepitant	Not recommended	
2775	ARIPIPRAZOLE	89013					ENZYMATIC INDUCERS	N03-J05-001	ANSM	76-ARIPIPRAZOLE.html	Decrease of the plasma concentrations of the aripiprazole	Precaution for use	
2776	ATALUREN						AMINOGLYCOSIDES	J01GB-001	ANSM	77-ATALUREN.html	Risk of increase of the renal toxicity of the aminoglycoside	CONTRAINDICATIOIN	
2777	ATAZANAVIR	343047					H2 RECEPTOR ANTAGONISTS	A02BA-001	ANSM	78-ATAZANAVIR.html	Risk of decrease of the plasma concentrations of the atazanavir	Take into account	
2778	ATAZANAVIR	343047					PROTON PUMP INHIBITORS	A02BC-001	ANSM	78-ATAZANAVIR.html	Very large decrease of the plasma concentrations of the atazanavir, with risk of therapeutic failure	Not recommended	
2779	ATAZANAVIR	343047			BUPRENORPHINE	1819			ANSM	78-ATAZANAVIR.html	Risk of increase or decrease of the effects of the buprenorphine, due to simultaneous inhibition and acceleration of its metabolism by the protease inhibitor	Take into account	
2780	ATAZANAVIR	343047			CLARITHROMYCIN	21212			ANSM	78-ATAZANAVIR.html	Increase of the plasma concentrations of clarithromycin and inhibition of the formation of its active metabolite	Precaution for use	
2781	ATAZANAVIR	343047			EFAVIRENZ	195085			ANSM	78-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism	Not recommended	
2782	ATAZANAVIR	343047			NEVIRAPINE	53654			ANSM	78-ATAZANAVIR.html	Risk of reduction of the effectiveness of the atazanavir due to increase of its hepatic metabolism	Not recommended	
2783	ATAZANAVIR	343047			TENOFOVIR DISOPROXIL	300195			ANSM	78-ATAZANAVIR.html	Decrease by about a third of the exposure to the atazanavir in patients who are also taking tenofovir, compared to a healthy subject receiving the same two substances together [sic]	Take into account	
2784	ATORVASTATIN	83367			AZITHROMYCIN	18631			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication	Precaution for use	
2785	ATORVASTATIN	83367			BOCEPREVIR	1102129			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type, due to decrease of the hepatic metabolism of the atorvastatin	Precaution for use	
2786	ATORVASTATIN	83367			CICLOSPORIN	3008			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the metabolism of the cholesterol-lowering medication)	Precaution for use	
2787	ATORVASTATIN	83367			CLARITHROMYCIN	21212			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering drug	Precaution for use	
2788	ATORVASTATIN	83367			DILTIAZEM	3443			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent	Precaution for use	
2789	ATORVASTATIN	83367			ERYTHROMYCIN	4053			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to decrease of the hepatic metabolism of the cholesterol-lowering agent	Precaution for use	
2790	ATORVASTATIN	83367					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	Not recommended	
2791	ATORVASTATIN	83367			ITRACONAZOLE	28031			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
2792	ATORVASTATIN	83367			KETOCONAZOLE				ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
2793	ATORVASTATIN	83367					OMBITASVIR + PARITAPREVIR	OMPA	ANSM	79-ATORVASTATIN.html	Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the therapy with the two drug combination	CONTRAINDICATION	
2794	ATORVASTATIN	83367			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	79-ATORVASTATIN.html	Increase of the plasma concentrations of the hypokaliemiant, with risk of undesirable effects, especially muscular ones	Take into account	
2795	ATORVASTATIN	83367			POSACONAZOLE	282446			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type (decrease of the hepatic metabolism of the HMG-CoA reductase inhibitor)	CONTRAINDICATION	
2796	ATORVASTATIN	83367			RANOLAZINE	35829			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabodmyolysis type due to inhibition of the metabolism of the atorvastatin by the ranolazine	Precaution for use	
2797	ATORVASTATIN	83367			RIFAMPICIN	9384			ANSM	79-ATORVASTATIN.html	Very large decrease of the plasma concentrations of atorvastastatin, due to increase of its hepatic metabolism by the rifampicin	Not recommended	
2798	ATORVASTATIN	83367			ROXITHROMYCIN	9478			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration dependant) of the rhabdomyolysis type	Precaution for use	
2799	ATORVASTATIN	83367			STIRIPENTOL	37119			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (dose dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)	CONTRAINDICATION	
2800	ATORVASTATIN	83367			TELAPREVIR	1102261			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the atorvastatin)	CONTRAINDICATION	
2801	ATORVASTATIN	83367			TELITHROMYCIN	274786			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (dose-dependent) of the rhabdomyolysis type (decrease of the hepatic metabolism of the cholesterol-lowering medication)	CONTRAINDICATION	
2802	ATORVASTATIN	83367			VERAPAMIL	11170			ANSM	79-ATORVASTATIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol-lowering medication	Precaution for use	
2803	CHOLIC ACID	1440856					PHENOBARBITAL (AND, BY EXTRAPOLATION, PRIMIDONE)	N03AA-001	ANSM	7-CHOLIC-ACID.html	Antagonist effect of the barbiturate	CONTRAINDICATION	
2804	ATOVAQUONE	60212			EFAVIRENZ	195085			ANSM	80-ATOVAQUONE.html	Decrease of the plasma concentrations of atovaquone by the enzyme inducer	Not recommended	
2805	ATOVAQUONE	60212					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	80-ATOVAQUONE.html	Decrease, possibly very large, of the plasma concentrations of the atovaquone due to increase of its metabolism	Not recommended	
2806	ATOVAQUONE	60212			RIFABUTIN	55672			ANSM	80-ATOVAQUONE.html	Moderate decrease of the plasma concentrations of atovaquone by the enzyme inducer	Take into account	
2807	ATOVAQUONE	60212			RIFAMPICIN	9384			ANSM	80-ATOVAQUONE.html	Decrease of the plasma concentrations of atovaquone by the enzyme inducer	Not recommended	
2808			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001			RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	81-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the protease inhibitor, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency	Take into account	
2809			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	ITRACONAZOLE	28031			ANSM	81-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the itraconazole, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency	Take into account	
2810			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	KETOCONAZOLE	6135			ANSM	81-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the ketoconazole, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency	Take into account	
2811			OTHER CORTICOIDES, ESPECIALLY INHALED ONES	D07AC-001	VORICONAZOLE	121243			ANSM	81-OTHER-CORTICOIDES,-ESPECIALLY-INHALED-ONES.html	In case of prolonged use by oral or inhaled route: increase of the plasma concentrations of the corticoid due to decrease of its hepatic metabolism by the voriconazole, with risk of appearance of Cushing's syndrome, even of adrenal insufficiency	Take into account	
2812	AVANAFIL	1291301			GRAPEFRUIT (JUICE AND FRUIT)				ANSM	82-AVANAFIL.html	Increase of the plasma concentrations of the avanafil, with risk of hypotension	Not recommended	
2813	AZITHROMYCIN	18631			ATORVASTATIN	83367			ANSM	83-AZITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependant) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the cholesterol lowering medication	Precaution for use	
2814	AZITHROMYCIN	18631			CICLOSPORIN	3008			ANSM	83-AZITHROMYCIN.html	Risk of increase of the blood concentrations of ciclosporin and of the creatinemia	Precaution for use	
2815	AZITHROMYCIN	18631			DIGOXIN	3407			ANSM	83-AZITHROMYCIN.html	Increase of the digoxinemia due to increase of its absorption	Precaution for use	
2816	AZITHROMYCIN	18631			IVABRADINE	77417			ANSM	83-AZITHROMYCIN.html	Increased risk of problems with ventricular rhythm, especially of torsades de pointes. In addition, increase of the plasm concentrations of the ivabradine due to decrease of its metabolism by the azithromycin.	Precaution for use	
2817	AZITHROMYCIN	18631			SIMVASTATIN	36567			ANSM	83-AZITHROMYCIN.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolosis type, due to decrease of the hepatic metabolism of the cholesterol lowering agent	Precaution for use	
2818	AZITHROMYCIN	18631					SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	83-AZITHROMYCIN.html	Increased risk of ventricular arrhythmias, especially torsades de pointes	Precaution for use	
2819	AZTREONAM	1272					VALPROIC (ACID) AND, BY EXTRAPOLATION, VALPROMIDE	N03AG0	ANSM	84-AZTREONAM.html	Risk of onset of convulsive crises, due to decrease of the plasma concentrations of the valproic acid	Precaution for use	
2820	BACLOFEN	1292					TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	85-BACLOFEN.html	Risk of increase of hypotonia	Take into account	
2821	BACLOFEN	1292			LEVODOPA	6375			ANSM	85-BACLOFEN.html	Risk of aggravation of the ParkinsonÂ’s syndrome or of undesirable central effects (visual hallucinations, confusion, headaches)	Take into account	
2822			BARBITURATES	N05CA-001			BENZODIAZEPINES AND RELATED	N05-001	ANSM	86-BARBITURATES.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
2823			BARBITURATES	N05CA-001			OPIOIDS	N0-R0	ANSM	86-BARBITURATES.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
2824	BEDAQUILINE	1364504					ENZYMATIC INDUCERS	N03-J05-001	ANSM	87-BEDAQUILINE.html	Decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
2825	BEDAQUILINE	1364504					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	87-BEDAQUILINE.html	Increase of the plasma concentrations of bedaquiline due to decrease of its hepatic metabolism by the inhibitor	Not recommended	
2826	BEDAQUILINE	1364504			ST JOHNS WORT	258326			ANSM	87-BEDAQUILINE.html	Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer	Not recommended	
2827	BELATACEPT	1112973					ATTENUATED LIVE VIRUS VACCINES	J07B-001	ANSM	88-BELATACEPT.html	Risk of general vaccine disease, possibly fatal.	Not recommended	
2828			BENZODIAZEPINES AND RELATED	N05-001			BARBITURATES	N05CA-001	ANSM	89-BENZODIAZEPINES-AND-RELATED.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
2829			BENZODIAZEPINES AND RELATED	N05-001	BUPRENORPHINE	1819			ANSM	89-BENZODIAZEPINES-AND-RELATED.html	With the buprenorphine used in replacement therapy: increased risk of respiratory depression, which can be fatal.	Take into account	
2830			BENZODIAZEPINES AND RELATED	N05-001	CLOZAPINE	2626			ANSM	89-BENZODIAZEPINES-AND-RELATED.html	Accrued risk of drop in blood pressure with respiratory and/or cardiac arrest.	Take into account	
2831			BENZODIAZEPINES AND RELATED	N05-001			OPIOIDS	N0-R0	ANSM	89-BENZODIAZEPINES-AND-RELATED.html	Increased risk of respiratory depression, which can be fatal in case of overdose	Take into account	
2832	CLODRONIC ACID	3350			ESTRAMUSTINE	4089			ANSM	8-CLODRONIC-ACID.html	Risk of increase of the plasma concentrations of estrasmustine by the clodronate	Precaution for use	
2833			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	HALOTHANE	5095			ANSM	90-BETA-2-MIMETICS-or-BETA2-ADRENERGIC-AGONISTS.html	In cases of obstetrical surgery, increased uterine inertia with risk of hemorrhage; furthermore serious ventricular arrhythmias, due to increase of the cardiac reactivity	Not recommended	
2834			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001	INSULIN	5856			ANSM	90-BETA-2-MIMETICS-or-BETA2-ADRENERGIC-AGONISTS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	
2835			BETA-2 MIMETICS or BETA2 ADRENERGIC AGONISTS	R03C-001			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	90-BETA-2-MIMETICS-or-BETA2-ADRENERGIC-AGONISTS.html	Elevation of the glycemia by the beta-2 mimetic	Precaution for use	
2836			BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001	AMIODARONE	703			ANSM	91-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL-AND-SOTALOL).html	Disorders of autoregulation and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
2837			BETA BLOCKING AGENTS (EXCEPT ESMOLOL AND SOTALOL)	C07AB-001			CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003	ANSM	91-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL-AND-SOTALOL).html	Disorders of contractility, autoregulation, and electrical conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
2838			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated during the surgical procedure by the beta-mimetics	Precaution for use	
2839			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			CENTRAL ANTIHYPERTENSIVES	C02AC-001	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Large increase of blood pressure in cases of sudden discontinuation of the treatment with the central hypertensive	Precaution for use	
2840			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			NON STEROIDAL ANTI-INFLAMMATORY DRUGS	M01A-002	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Reduction of the antihypertensive effect (inhibition of the vasodilator prostaglandins by the non steroidal anti-inflammatories)	Take into account	
2841			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			DIHYDROPYRIDINES	C08CA-002	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (addition of the negative inotropic effects). The beta-blocking agent can furthermore minimize the sympathetic reflex reaction brought into play in the case of excessive hemodynamic repercussion	Take into account	
2842			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	DILTIAZEM	3443			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure	Not recommended	
2843			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	DIPYRIDAMOLE	3521			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With the dipyridamole by injection: increase of the antihypertensive effect	Take into account	
2844			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			GLINIDES	A10BX-001	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
2845			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			GLIPTINS	A10B-001	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
2846			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	INSULIN	5856			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
2847			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	LIDOCAINE	6387			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	With lidocaine administered by IV route: increase of the plasma concentrations of lidocaine with possibility of undesirable neurological and cardiac effects (decrease of the hepatic clearance of the lidocaine)	Precaution for use	
2848			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	PROPAFENONE	8754			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Disorders of contractility, autoregulation, and conduction (suppression of the compensatory sympathetic mechanisms)	Precaution for use	
2849			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
2850			BETA BLOCKING AGENTS (EXCEPT ESMOLOL)	C07AB-002	VERAPAMIL	11170			ANSM	92-BETA-BLOCKING-AGENTS-(EXCEPT-ESMOLOL).html	Disorders of autoregulation (excessive bradycardia, sinus arrest), disorders of sinoatrial and atrioventricular conduction, and heart failure	Not recommended	
2851			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	AMIODARONE	703			ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Disorders of autoregulation and of cardiac conduction with risk of excessive bradycardia.	Precaution for use	
2852			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			HALOGENATED HYDROCARBON ANESTHETICS	N01AB0-001	ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Reduction of the compensatory cardiovascular reactions by the beta-blocking agents. The beta-adrenergic inhibition can be elevated by the beta-stimulants during the surgery	Precaution for use	
2853			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			CLASS I ANTIARRHYTHMICS (EXCEPT LIDOCAINE)	C01B-003	ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	CONTRAINDICATION	
2854			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			ACETYLCHOLINESTERASE INHIBITORS	ACETCHO	ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Risk of excessive bradycardia (addition of the bradycardia inducing effects)	Precaution for use	
2855			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			TRICYCLIC ANTIDEPRESSANTS	N06AA-001	ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)	Take into account	
2856			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			CENTRAL ANTIHYPERTENSIVES	C02AC-001	ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Central decrease of the sympathetic tone and vasodilator effect of the central antihypertensives, dangerous in cases of heart failure treated with a beta-blocking agent and vasodilator	Not recommended	
2857			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	DIGOXIN	3407			ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Difficulties of autoregulation (bradycardia, sinus arrest) and of sinoatrial and atrioventricular conduction	Take into account	
2858			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			DIHYDROPYRIDINES	C08CA-002	ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Hypotension, heart failure in patients with latent or uncontrolled cardiac insufficiency (negative iotropic effect of the dihydropyridines in vitro more or less marked and susceptible of adding to the negative inotropic effects of the beta-blocking agents). The presence of a beta-blocking treatment can furthermore minimize the sympathetic reflex reaction put into play in cases of excessive hemodynamic repercussion	Take into account	
2859			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	DILTIAZEM	3443			ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest), and disorders of sinoatrial and atrioventricular conduction	CONTRAINDICATION	
2860			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			GLINIDES	A10BX-001	ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
2861			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	INSULIN	5856			ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
2862			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	LIDOCAINE	6387			ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure	Take into account	
2863			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			NEUROLEPTICS	N05AA-003	ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Vasodilator effect and risk of hypotension, especially orthostatic (additive effect)	Take into account	
2864			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			SUBSTANCES THAT TEND TO INDUCE TORSADES DE POINTES	C01-N05	ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Increased risk of ventricular arrythmias, especially of torsades de pointes	Precaution for use	
2865			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003			BLOOD GLUCOSE LOWERING SULFONAMIDES	A10BB	ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	All the beta-blocking agents can mask certain symptoms of hypoglycemia: palpitations and tachycardia	Precaution for use	
2866			BETA-BLOCKING AGENTS IN HEART FAILURE	C07AB-003	VERAPAMIL	11170			ANSM	93-BETA-BLOCKING-AGENTS- IN-HEART- FAILURE.html	Negative inotropic effect with risk of acute decompensated heart failure, disorders of autoregulation (bradycardia, sinus arrest) and disorders of sinoatrial and atrioventricular conduction	CONTRAINDICATION	
2867			BISPHOSPHONATES	M05B-001	CALCIUM	1428011			ANSM	94-BISPHOSPHONATES.html	For calcium salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	
2868			BISPHOSPHONATES	M05B-001	IRON	1431589			ANSM	94-BISPHOSPHONATES.html	For the iron salts administered via oral route: decrease of the digestive absorption of the bisphosphonates	Precaution for use	
2869	BLEOMYCIN	1622			BRENTUXIMAB	1147320			ANSM	95-BLEOMYCIN.html	Risk of increase of pulmonary toxicity	CONTRAINDICATION	
2870	BOCEPREVIR	1102129					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	96-BOCEPREVIR.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	
2871	BOCEPREVIR	1102129			ATORVASTATIN	83367			ANSM	96-BOCEPREVIR.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type, due to decrease of the hepatic metabolism of the atorvastatin	Precaution for use	
2872	BOCEPREVIR	1102129			DROSPIRENONE	840781			ANSM	96-BOCEPREVIR.html	Increase by more than double of the concentrations of drosperinone when taken with the boceprevir	Nor recommended	
2873	BOCEPREVIR	1102129					NON-CONTRACEPTIVE ESTROGENS	G03C-001	ANSM	96-BOCEPREVIR.html	Decrease of the effectiveness of the estrogen.	Precaution for use	
2874	BOCEPREVIR	1102129					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	96-BOCEPREVIR.html	Aside from the combination with ethinylestradiol (0.035mg)/noresthisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir	Precaution for use	
2875	BOCEPREVIR	1102129					IMMUNOSUPPRESSANTS	L04A	ANSM	96-BOCEPREVIR.html	Increase of the blood concentrations of the immunosuppressant (substantial for the ciclosporin, extremely large for the tacrolimus)	Precaution for use	
2876	BOCEPREVIR	1102129					RITONAVIR BOOSTED PROTEASE INHIBITORS	J05AE-002	ANSM	96-BOCEPREVIR.html	Decrease of the concentrations of the boceprevir and of the lopinavir (or darunavir or fosamprenavir), with risk of therapeutic failure	Not recommended	
2877	BOCEPREVIR	1102129			METHADONE	6813			ANSM	96-BOCEPREVIR.html	Decrease of the plasma concentrations of methadone, with risk of appearance of a withdrawal syndrome, due to increase of its hepatic metabolism by the boceprevir	Precaution for use	
2878	BOCEPREVIR	1102129					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	96-BOCEPREVIR.html	Aside from the combination with ethinylestradiol (0.035mg)/noresthisterone (1mg), risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive by the boceprevir	Precaution for use	
2879	BOCEPREVIR	1102129			RIFAMPICIN	9384			ANSM	96-BOCEPREVIR.html	Risk of decrease of the plasma concentrations of boceprevir	Not recommended	
2880	BOCEPREVIR	1102129			SIMVASTATIN	36567			ANSM	96-BOCEPREVIR.html	Increased risk of undesirable effects (concentration-dependent) of the rhabdomyolysis type due to decrease of the metabolism of the simvastatin	CONTRAINDICATION	
2881	BOCEPREVIR	1102129			TENEFOVIR ALAFENAMIDE	1721603			ANSM	96-BOCEPREVIR.html	Risk of decrease of the effectiveness of the tenefovir alafenamide by decrease of its intracellular activity by the boceprevir	Not recommended	
2882	BORTEZOMIB	358258					ENZYMATIC INDUCERS	N03-J05-001	ANSM	97-BORTEZOMIB.html	Decrease of the concentrations of the cytotoxic due to increase of its metabolism by the inducer, with risk of lower effectiveness	Take into account	
2883	BORTEZOMIB	358258					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	97-BORTEZOMIB.html	Risk of increase of the undesirable effects, especially neurological, of the bortezomib due to decrease of its metabolism.	Precaution for use	
2884	BOSENTAN	75207					ANTICONVULSANT ENZYMATIC INDUCERS	N03A-001	ANSM	98-BOSENTAN.html	Risk of decrease of the plasma concentrations of bosentan	Not recommended	
2885	BOSENTAN	75207					VITAMIN K ANTAGONISTS	B01AA-001	ANSM	98-BOSENTAN.html	Decrease of the effect of the vitamin K antagonist due to increase of its hepatic metabolism	Precaution for use	
2886	BOSENTAN	75207			CICLOSPORIN	3008			ANSM	98-BOSENTAN.html	Large decrease of the blood concentrations of the ciclosporin and increase of the plasma concentrations of bosentan	CONTRAINDICATION	
2887	BOSENTAN	75207			CYPROTERONE	3014			ANSM	98-BOSENTAN.html	Risk of decrease of the effectiveness of the cyproterone	Precaution for use	
2888	BOSENTAN	75207					COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES	G03AB-001	ANSM	98-BOSENTAN.html	Risk of decrease of the contraceptive effectiveness due to increase of the hepatic metabolism of the hormonal contraceptive	Precaution for use	
2889	BOSENTAN	75207			GLIBENCLAMIDE	4815			ANSM	98-BOSENTAN.html	Risk of reduced effectiveness of the glibenclamide due to decrease of its plasma concentrations, because of the inducer effect of the bosentan. Furthermore, cases of hepotoxicity have been reported with these two substances administered together.	Precaution for use	
2890	BOSENTAN	75207					STRONG INHIBITORS OF CYP3A4	J02-J05	ANSM	98-BOSENTAN.html	Increased risk of the undesirable effects of the bosantan, especially hepatic attacks, due to decrease of its metabolism by the inhibitor	Precaution for use	
2891	BOSENTAN	75207					PROGESTIN CONTRACEPTIVES	G03-001	ANSM	98-BOSENTAN.html	Risk of decrease of the effectiveness of the hormonal contraceptive due to increase of its hepatic metabolism.	Precaution for use	
2892	BOSENTAN	75207					NON-CONTRACEPTIVE PROGESTOGENS, COMBINED WITH AN ESTROGEN OR NOT	G03-003	ANSM	98-BOSENTAN.html	Risk of decrease of the effectiveness of the progestogen	Precaution for use	
2893	BOSENTAN	75207			RIFAMPICIN	9384			ANSM	98-BOSENTAN.html	Risk of decrease, large for the rifampicin, of the plasma concentrations of bosentan	Not recommended	
2894	BOTULINUM TOXIN	1716					AMINOGLYCOSIDES	J01GB-001	ANSM	99-BOTULINUM-TOXIN.html	Risk of increase of the effects of the botulinum toxin with the aminoglycosides (by extrapolation from the effects observed during the course of the botulism)	Not recommended	
2895	FOLINIC ACID	6313					FLUOROURACIL (AND, BY EXTRAPOLATION, OTHER FLUOROPYRIMIDINES)	L01BC-001	ANSM	9-FOLINIC-ACID.html	Strengthening of the effects, both cytostatic and undesirable, of the fluorouracil.	Take into account	
